Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	May 12	EXTEND option available in structure searching
NEWS	4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS	6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:16:34 ON 14 AUG 2004

```
=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:16:43 ON 14 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   12 AUG 2004  HIGHEST RN 726125-61-7
DICTIONARY FILE UPDATES:  12 AUG 2004  HIGHEST RN 726125-61-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10823809.6

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```



G1 Cb,Hy

G2 N,CH

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
FULL SEARCH INITIATED 10:17:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  39580 TO ITERATE
```

100.0% PROCESSED 39580 ITERATIONS 152 ANSWERS
SEARCH TIME: 00.00.02

L2 152 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'CAPLUS' ENTERED AT 10:17:15 ON 14 AUG 2004

FILE COVERS 1907 - 14 Aug 2004 VOL 141 ISS 8
FILE LAST UPDATED: 13 Aug 2004 (20040813/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 32 L2

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:41461 CAPLUS
DN 140:93789
TI Preparation of substituted anthranilic amide derivatives as VEGF modulators and methods of use against cancer and other disorders
IN Huang, Qi; Chen, Guoqing; Li, Aiwen; Riahi, Babak; Tasker, Andrew; Yang, Kevin; Yuan, Chester Chenguang
PA Amgen Inc., USA
SO PCT Int. Appl., 204 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004005279	A2	20040115	WO 2003-US21601	20030709
	WO 2004005279	A3	20040311		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-395144P P	20020709
				US 2003-615809 A	20030708
	US 2004087568	A1	20040506	US 2003-615809	20030708
				US 2002-395144P P	20020709

OS MARPAT 140:93789
IT **645418-48-0P**, N-(1-Acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(4-fluorobenzylamino)benzamide **645418-50-4P**, 2-(4-Fluorobenzylamino)-N-[4-[1-methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide **645418-56-0P**, N-[3,3-Dimethyl-1-[(4-methylpiperazin-1-yl)carbonyl]-2,3-dihydro-1H-indol-6-yl]-2-(4-fluorobenzylamino)benzamide **645418-64-0P**, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-(4-fluorobenzylamino)benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted anthranilic amide derivs. as
VEGF modulators and methods of use against cancer and other disorders)
RN 645418-48-0 CAPLUS
CN Benzamide, N-(1-acetyl-2,3-dihydro-3,3 dimethyl-1H-indol-6-yl)-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 645418-64-0 CAPLUS
CN Benzamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)



IT **645418-65-1P**, 7-[[2-(4-Fluorobenzylamino)benzoyl]amino]-4,4-dimethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted anthranilic amide derivs. as VEGF modulators and
methods of use against cancer and other disorders)
RN 645418-65-1 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-[[2-[[(4-fluorophenyl)methyl]amino]benzoyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 645418-50-4 CAPLUS
CN Benzamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl 4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 645418-56-0 CAPLUS
CN Benzamide, N-[2,3-dihydro-3,3-dimethyl-1-[(4-methyl-1-piperazinyl)carbonyl]-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

GI



I



II

AB Selected substituted anthranilic amide derivs. (shown as I; variables defined below; e.g. II) are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving cancer and the like. Although the methods of preparation are not
claimed, .apprx.139 example prepns. of I and .apprx.80 of intermediates are included. For example, II was prepared in 3 steps starting from 2-nitrobenzoic acid and [4-[1-Methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]amine and involving intermediates
2-nitro-N-[4-[1-methyl 1-(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide and
2-amino-N-[4-[1-methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide. Compds. I showed inhibition of KDR at doses <50 μM. Some of the exemplified I inhibit VEGF-stimulated HUVEC proliferation <1 μM. Compds. I are active at doses <150 mpk in a tumor model. For I: R = (un)substituted 9- or 10-membered fused heterocyclyl, -(CH2)1-2-R3; R1 = (un)substituted 5-6 membered saturated or partially saturated heterocyclyl, 9-10 membered bicyclic and
13-14 membered tricyclic saturated or partially saturated heterocyclyl, and
phenyl; R2 is ≥1 substituents = H, halo, hydroxy, amino, C1-6-alkyl, C1-6-haloalkyl, C1-6-alkoxy, C1-2-alkylamino, aminosulfonyl, C3-6-cycloalkyl, cyano, C1-2-hydroxyalkyl, nitro, C2-3-alkenyl, C2-3-alkynyl, C1-6-haloalkoxy, C1-6-carboxyalkyl, 4-6-membered heterocyclyl-C1-6-alkylamino, (un)substituted Ph and (un)substituted 4-6 membered heterocyclyl; Ra = H, C1-2-alkyl; addnl. details are given in the
claims.

L3 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:950836 CAPLUS
DN 140:16722
TI Preparation of 1,1-disubstituted cycloalkyl derivatives as factor Xa inhibitors for treating a thromboembolic disorder
IN Qiao, Jennifer X.; Pinto, Donald J.; Orwat, Michael J.; Han, Wei; Friedrich, Sarah R.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 686 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003099276	A1	20031204	WO 2003-US13893	20030505
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-379357P	P 20020510
			US 2002-415367P	P 20021002

OS MARPAT 140:16722
IT **630385-55-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 1,1-disubstituted cycloalkyl derivs. as factor Xa inhibitors for treating thromboembolic disorder)
RN 630385-55-6 CAPLUS
CN Benzeneacetic acid, 4-[[[2-[[(5-chloro-2-pyridinyl)amino]carbonyl]phenyl]amino]methyl]-α,α-dimethyl-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





GI



AB The present application describes 1,1-disubstituted cycloalkyl compds. and derivs. thereof (P4-P-M-M4; variables defined below; most of the examples contain 1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, e.g. the trifluoroacetate of I), or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa for treatment of a thromboembolic disorder. Although the methods of preparation are not claimed, .apprx.240 example prepns. are included. A number of I exhibit Ki's of <10 μM towards factor Xa; also some I are direct acting inhibitors (Ki < 10 μM) of the serine protease thrombin as indicated by their ability to inhibit the cleavage of small mol. substrates by thrombin in a purified system; the specific compds. are not stated. For I: M is a 3-10 membered carbocycle or a 4-10 membered heterocycle, consisting of: C atoms and 1-3 heteroatoms = O, S(O)p, N, and NZ2; ring M is substituted with 0-3 R1a and

L3 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
0-2 carbonyl groups, and there are 0-3 ring double bonds; P is fused onto ring M and is a 5, 6, or 7 membered carbocycle or a 5, 6, or 7 membered heterocycle, consisting of: C atoms and 1-3 heteroatoms = O, S(O)p, and N; ring P is substituted with 0-3 R1a and 0-2 carbonyl groups, and there are 0-3 ring double bonds; alternatively, ring P is absent and P4 is directly attached to ring M, provided that when ring P is absent, P4 and M4 are attached to the 1,2, 1,3, or 1,4 positions of ring M. One of P4 and M4 is -Z-A-B and the other -G1-G, provided that P4 and M4 are attached to different rings when ring P is present; G is consists of 2 fused rings D and E (ring D, including the two atoms of Ring E to which it is attached, is a 5-6 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O)p; E is selected from (un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl; alternatively, ring D is absent and ring E is selected from (un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, thienyl, and thiazolyl); G1 is absent or = (CR3R3a)1-5, etc. A = (un)substituted C3-10 carbocycle and 5-12 membered heterocycle consisting of: C atoms and 1-4 heteroatoms N, O, and S(O)p; B is Y-R4a or X-Y-R4a, provided that Z and B are attached to different atoms on A and A and R4a or X and R4a are attached to the same atom on Y; Z = a bond, -(CR3R3e)1-4-, etc. Addnl. details including provisos are given in the claims.
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:913147 CAPLUS
DN 139:381477
TI Preparation of 4,5-dihydro-1H-benzo[g]indazole-3 carboxamides as IKK2 inhibitors for the treatment of cancer and inflammation
IN Lennon, Patrick; Bonafoux, Dominique; Oburn, David S.; Wolfson, Serge G.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 312 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003095430	A1	20031120	WO 2003-US8917	20030319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-379090P	P 20020509
			WO 2002-US29774	A 20020919
WO 2003024935	A2	20030327	WO 2002-US29774	20020919
WO 2003024935	A3	20030821		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509

PATENT FAMILY INFORMATION:
FAN 2003:242305

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003024935	A2	20030327	WO 2002-US29774	20020919
WO 2003024935	A3	20030821		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

L3 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 2001-323423P	P	20010919
				US 2002-379090P	P	20020509
US 2004110741		A1	20040610	US 2002-247096		20020919
				US 2001-323423P	P	20010919
				US 2002-379090P	P	20020509
EP 1444207		A2	20040811	EP 2002-775879		20020919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK						
				US 2001-323423P	P	20010919
				US 2002-379090P	P	20020509
				WO 2002-US29774	W	20020919
WO 2003095430		A1	20031120	WO 2003-US8917		20030319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
				US 2002-379090P	P	20020509
				WO 2002-US29774	A	20020919

OS MARPAT 139:381477

IT **503535-09-7P**, 1-(1,3-Benzodioxol-5-yl)-8-{[[2-[(4-methoxybenzyl)amino]pyridin-3-yl]carbonyl]amino}-4,5-dihydro-1H-benzo[g]indazole 3-carboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides as IKK2 inhibitors for treatment of cancer and inflammation)

RN 503535-09-7 CAPLUS

CN 1H-Benz[g]indazole-3-carboxamide, 1-(1,3-benzodioxol-5-yl)-4,5-dihydro-8-[[[2-[[(4-methoxyphenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

GI





I



II

L3 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AB The present invention relates to substituted pyrazolyl derivs., compns. comprising such, intermediates, methods of making substituted pyrazolyl derivs., and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis. 4,5-Dihydro-1H-benzo[g]indazole-3-carboxamides (shown as I; variables defined below; e.g. II) were prepared via conventional and solid phase synthetic methods as IκB protein kinase β (IKKβ or IKK2) inhibitors. Although the methods of preparation are not claimed, 480 example prepns. and/or characterization data are included. For example, reaction of 7-nitro-1 tetralone with Et acetate in the presence of Li bis(trimethylsilyl)amide in ether gave the 1,3-diketone (87%), which was cyclized with 4-sulfonamidophenylhydrazine•HCl with HCl in MeOH to give the Et 1H-dihydrobenzo[g]indazolecarboxylate (69%). Amidation with NH4OH in MeOH provided II. In IKKβ resin enzyme assays, I exhibited IKKβ activity with IC50 values ranging from ≤ 1 μM to > 100 μM. Thus, I are useful for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis (no data). For I: B is a 5 or 6 membered heteroaryl, aryl, (un)saturated heterocyclic (un)substituted with R1, R2, and R12; W is a 5 or 6 membered heteroaryl, aryl, (un)saturated heterocyclic. R1 = hydrido, halo, alkyl, aryl, heteroaryl, alkenyl, alkynyl, haloalkyl, CN, NO2, OR5, OCOOR5, CO2R7, CON(R6)R7, COR6, SR6, SOR6, SO2R6, NR6R7, NR6COR7, NR6CONHR7, NR6SO2R7, NR6SO2NHR7, and SO2N(R6)R7; R2 = halo, hydrido, hydroxyalkyl, alkyl, OR6, CN, NO2, SR6, NHR6, CON(R6)R7, NHCONHR6, CO2H, and haloalkyl; R1 and R2 may be taken together to form a 5 to 7 membered (un)saturated carbocyclic ring optionally containing 0 to 3 heteroatoms N, O, or S, and wherein said ring is (un)substituted with R1. R12 = hydrido, halo, alkyl, and alkoxy; R15 = alkylsulfonamide, sulfamyl, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, halo, acyloxy, oxy, formyl, haloalkyl, cyano, haloalkoxy, acyl, carboxy, hydroxy, hydroxyalkyloxy, phenoxy, nitro, azido, benzyloxy, dialkylaminoacyl, thioalkyl, aminoacyloxy, thiocyanate, isothiocyanate, alkyldioxy, hydroxyalkyl, alkylamino, alkyloxycarbonyl, alkoxyalkyl, alkenylamino, alkynylamino, alkenyl, alkynyl, dialkylaminoalkyloxy, and heterocyclic; addnl. details are given in the claims.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:665525 CAPLUS

DN 139:345320

TI Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching

AU Furet, Pascal; Bold, Guido; Hofmann, Francesco; Manley, Paul; Meyer, Thomas; Altmann, Karl-Heinz

CS Oncology Research, Novartis Pharma AG, Basel, CH-4002, Switz.

SO Bioorganic & Medicinal Chemistry Letters (2003), 13(18), 2967-2971
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science B.V.

DT Journal

LA English

OS CASREACT 139:345320

IT **618359-41-4**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(identification, synthesis and structure-activity relationship studies on a new chemical class of potent angiogenesis inhibitors (anthranilamides)-based on conformational considerations and database searching)

RN 618359-41-4 CAPLUS

CN Benzamide, N-(2-fluorophenyl)-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



AB The vascular endothelial growth factor (VEGF) tyrosine kinase receptors KDR and Flt-1 are targets of current interest in anticancer drug research. PTK787/ZK222584 is a potent inhibitor of these enzymes in clin. evaluation as an antiangiogenic agent. The development of a hypothesis concerning the bioactive conformation of this compound has led to the discovery of a new class of potent inhibitors of KDR and Flt-1, the anthranilamides. This could be achieved with a limited exptl. effort, which only involved the testing of one archive compound and the synthesis and testing of one appropriate analog.

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:551370 CAPLUS
DN 139:111679
TI Combination of microsomal triglyceride transfer protein (MTP) inhibitors or apoB secretion inhibitors with fibrates for use as drugs
IN Thomas, Leo; Mark, Michael
PA Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
SO PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003057205	A2	20030717	WO 2003-EP57	20030107
WO 2003057205	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			DE 2002-10200633 A 20020110	
			DE 2002-10256184 A 20021202	
DE 10200633	A1	20030724	DE 2002-10200633	20020110
DE 10256184	A1	20040609	DE 2002-10256184	20021202
US 2003162788	A1	20030828	US 2003-339088	20030109
			DE 2002-10200633 A 20020110	
			US 2002-353397P P 20020201	
			DE 2002-10256184 A 20021202	
			US 2002-435386P P 20021220	

OS MARPAT 139:111679
IT **486436-62-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)
RN 486436-62-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 1-methyl N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]-4-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (continued)



AB The invention discloses the use of fibrates for reducing the hepatic toxicity of MTP inhibitors, as well as pharmaceutical compns. that contain
an MTP inhibitor and a fibrate. Compound preparation is included.

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:551181 CAPLUS
DN 139:117339
TI Preparation of substituted arylamine derivatives as antitumor agents
IN Elbaum, Daniel; Askew, Benny; Booker, Shon; Germain, Julie; Habgood, Gregory; Handley, Michael; Kim, Tae-Seong; Li, Aiwen; Nishimura, Nobuko; Patel, Vinod F.; Yuan, Chester Chenguang; Kim, Joseph L.
PA Amgen Inc., USA
SO U.S. Pat. Appl. Publ., 106 pp., Cont.-in-part of U.S. Ser. No. 46,526.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003134836	A1	20030717	US 2002-197960	20020717
			US 2001-261360P P	20010112
			US 2001-323686P P	20010919
			US 2002-46526 A2	20020110
US 2002147198	A1	20021010	US 2002-46526	20020110
			US 2001-261360P P	20010112
			US 2001-323686P P	20010919
WO 2004007457	A2	20040122	WO 2003-US22276	20030715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-197960 A 20020717	

PATENT FAMILY INFORMATION:
FAN 2002:539663

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002055501	A2	20020718	WO 2002-US742	20020111
WO 2002055501	A3	20021219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-261360P P	20010112
			US 2001-323686P P	20010919
			US 2002-46526 A	20020110
US 2002147198	A1	20021010	US 2002-46526	20020110
			US 2001-261360P P	20010112
			US 2001-323686P P	20010919
EP 1358161	A2	20031105	EP 2002-717324	20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2001-261360P P	20010112

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 2001-323686P	P	20010919
US 2002-46526	A	20020110
WO 2002-US742	W	20020111

OS MARPAT 139:117339
IT **561297-65-2P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted aminopyridines as antitumor agents)
RN 561297-65-2 CAPLUS
CN 1-Azetidinecarboxylic acid, 3-[[2-chloro-5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **561297-60-7P 561297-61-8P 561297-62-9P**
561297-63-0P 561297-64-1P 561297-66-3P
561297-68-5P 561297-70-9P 561297-71-0P
561297-72-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted aminopyridines as antitumor agents)
RN 561297-60-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(methylsulfonyl)-1H-indol-6-yl]-2-[[[4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 561297-61-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[[(dimethylamino)acetyl]amino]-4-(1,1-dimethylethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 561297-62-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 561297-63-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[(methylsulfonyl)amino]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 561297-64-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 561297-66-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-(3-azetidinylmethoxy)-4-chlorophenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 561297-68-5 CAPLUS
CN 4-Pyridazinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-3-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 561297-70-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-(3-azetidinylmethoxy)-5-(trifluoromethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 561297-71-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-hydroxy-3-nitrophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 561297-72-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-amino-4-hydroxyphenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **442847-21-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted aminopyridines as antitumor agents)
RN 442847-21-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinylmethyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **442845-77-4P 442846-13-1P 442846-17-5P**
442846-22-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation of substituted aminopyridines as antitumor agents)
RN 442845-77-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442846-13-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-17-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[6-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3 dimethyl-1H-indol-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-22-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-acetyl-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **442845-71-8P 442845-72-9P 442845-73-0P**
442845-78-5P 442845-79-6P 442845-80-9P
442845-81-0P 442845-82-1P 442845-83-2P
442845-84-3P 442845-85-4P 442845-86-5P
442845-87-6P 442845-88-7P 442845-89-8P
442845-90-1P 442845-91-2P 442845-92-3P
442845-93-4P 442845-94-5P 442845-95-6P
442845-96-7P 442845-97-8P 442845-99-0P
442846-00-6P 442846-01-7P 442846-02-8P
442846-03-9P 442846-04-0P 442846-05-1P
442846-06-2P 442846-07-3P 442846-08-4P
442846-09-5P 442846-10-8P 442846-12-0P
442846-14-2P 442846-15-3P 442846-16-4P
442846-18-6P 442846-19-7P 442846-20-0P
442846-21-1P 442846-23-3P 442846-24-4P
442846-25-5P 442846-26-6P 442846-27-7P
442846-28-8P 442846-29-9P 442846-30-2P
442846-31-3P 442846-32-4P 442846-33-5P
442846-34-6P 442846-35-7P 442846-36-8P
442846-38-0P 442846-39-1P 442846-40-4P
442846-42-6P 442846-44-8P 442847-23-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of substituted aminopyridines as antitumor agents)
RN 442845-71-8 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 442845-72-9 CAPLUS
CN 2-Pyridinecarboxamide, [illegible]nitrophenyl)methyl]amino]-

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



RN 442845-73-0 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-fluoro-4-methylphenyl)-3-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-78-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-81-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2-bromophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442845-82-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-(trifluoromethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-83-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-difluorophenyl)methyl]amino]-N-(4-

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-79-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442845-80-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442845-84-3 CAPLUS
CN 3-Pyridinecarboxamide,
N-(4-chlorophenyl)-2-[[(4-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-85-4 CAPLUS
CN 3-Pyridinecarboxamide,
N-(4-chlorophenyl)-2-[[(2-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 442845-86-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(2-methylpropyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-87-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-88-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-methoxyphenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-91-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-92-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-89-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-aminophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-90-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 442845-93-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-94-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-95-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-96-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-97-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-99-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 442846-02-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,6-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-03-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-04-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-00-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-01-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-05-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[3-(dimethylamino)propyl]-5-(trifluoromethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-06-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-07-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-08-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-bromo-2-fluorophenyl)-2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-12-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-14-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[2-(1,1-dimethylethyl)-5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-09-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-10-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-fluoro-3-[3-(4-morpholinyl)-1-propynyl]phenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-15-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(1-methyl-4-piperidinyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-16-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-[(dimethylamino)acetyl]-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-18-6 CAPLUS
CN Carbamic acid, [2-[6-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl 1H-indol-1-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-19-7 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-20-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[3-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-21-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[2-(1,1-dimethylethyl)-5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-23-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-24-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-25-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[(2R)-2-pyrrolidinylmethoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-26-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-piperidinylmethoxy)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-27-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-28-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-29-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-(aminoacetyl)-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-30-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-31-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-(4-piperidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-32-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-33-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-34-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-[(1-methyl-4-piperidinyl)methyl]-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-35-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 442846-36-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-2-oxo-7-quinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 442846-40-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3,4-difluorophenyl)methyl]amino]-N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 442846-42-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 442846-44-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(1-piperidinylmethyl)amino]phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-38-0 CAPLUS
CN 3-Pyridinecarboxamide, N-5-benzofuranyl-2-[[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-39-1 CAPLUS
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl 2-[[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442847-23-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 442845-77-4
CMF C25 H20 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

GI

L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I II

AB The title compds. I [R2 = (un)substituted Ph, 9-10 membered bicyclic and 11-14 membered tricyclic (un)saturated heterocyclyl; R8 = halo, NH2, NO2, etc.], and their pharmaceutically acceptable derivs., are prepared and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. E.g., a multi-step synthesis of II, starting from 1-dimethylamino-2-propyne and 3-bromo-5-trifluoromethylaniline, was given. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

L3 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 536759-14-5 CAPLUS
CN Benzamide,
N-(5 chloro-2-pyridinyl)-2-[[[4-[[(dimethylamino)acetyl]methyla mino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



GI



I

AB Compds. P4-P-M-M4 [M is a 3-10 membered carbocycle or a 4-10 membered heterocycle; P is null or a 5-7 membered carbocycle or heterocycle fused to ring M; one of P4 and M4 is -Z-A-B and the other is -G1 G, where G is (un)substituted (fused) (hetero)aryl or (hetero)cyclyl; G1 is null or (un)substituted optionally-functionalized alk(en)(yn)yl; Z is a bond or (hetero)alkylene; A is (substituted) 3 10 membered carbocyclyl or 5-12 membered heterocyclyl; B is a functionalized amino group (with provisos)] or their pharmaceutically-acceptable salts were prepared for use as inhibitors of factor Xa. Thus, 1H-pyrazolo[3,4-c]pyridine derivative I.TFA was prepared by reactions of 3-aminobenzamide, 3-hydroxy-1-(4-iodophenyl)-4-(trifluoroacetyl)-5,6-dihydro-2(1H) pyridinone, chloroacetyl chloride, and dimethylamine.
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:454323 CAPLUS
DN 139:22501
TI Preparation of glycinamide heterocyclic derivatives as factor Xa inhibitors
IN Pinto, Donald J. P.; Han, Wei; Hu, Zilun
PA Bristol-Myers Squibb Company, USA; Qiao, Jennifer
SO PCT Int. Appl., 451 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048158	A1	20030612	WO 2002-US38239	20021127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-336994P	P 20011204
	US 2003232804	A1	20031218	US 2002-304070	20021125
				US 2001-336994P	P 20011204

PATENT FAMILY INFORMATION:
FAN 2003:454257

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048081	A2	20030612	WO 2002-US37212	20021118
	WO 2003048081	A3	20030912		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-336994P	P 20011204
	US 2003232804	A1	20031218	US 2002-304070	20021125
				US 2001-336994P	P 20011204

OS MARPAT 139:22501
IT **536759-14-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of glycinamide heterocyclic derivs. as factor Xa inhibitors)

L3 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:454257 CAPLUS
DN 139:7167
TI Preparation of glycinamide heterocyclic derivatives as factor Xa inhibitors
IN Pinto, Donald J. P.; Han, Wei; Hu, Zilun
PA Bristol-Myers Squibb Company, USA; Qiao, Jennifer
SO PCT Int. Appl., 448 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048081	A2	20030612	WO 2002-US37212	20021118
	WO 2003048081	A3	20030912		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-336994P	P 20011204
	US 2003232804	A1	20031218	US 2002-304070	20021125
				US 2001-336994P	P 20011204

PATENT FAMILY INFORMATION:
FAN 2003:454323

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048158	A1	20030612	WO 2002-US38239	20021127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-336994P	P 20011204
	US 2003232804	A1	20031218	US 2002-304070	20021125
				US 2001-336994P	P 20011204

OS MARPAT 139:7167
IT **536759-14-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of glycinamide heterocyclic derivs. as factor Xa inhibitors)
RN 536759-14-5 CAPLUS
CN Benzamide,
N-(5-chloro-2-pyridinyl)-2-[[[4-[[(dimethylamino)acetyl]methyla mino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I

AB Compds. P4-P-M-M4 [M is a 3-10 membered carbocycle or a 4-10 membered heterocycle; P is null or a 5-7 membered carbocycle or heterocycle fused to ring M; one of P4 and M4 is -Z-A-B and the other is -G1-G, where G is (un)substituted (fused) (hetero)aryl or (hetero)cyclyl; G1 is null or (un)substituted optionally-functionalized alk(en)(yn)yl; Z is a bond or (hetero)alkylene; A is (substituted) 3-10 membered carbocyclyl or 5-12 membered heterocyclyl; B is a functionalized amino group (with provisos)] or their pharmaceutically-acceptable salts were prepared for use as inhibitors of factor Xa. Thus, 1H-pyrazolo[3,4-c]pyridine derivative I.TFA was prepared by reactions of 3-aminobenzamide, 3-hydroxy-1-(4-iodophenyl)-4-(trifluoroacetyl)-5,6-dihydro-2(1H)-pyridinone, chloroacetyl chloride, and dimethylamine.

L3 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I



II

AB The title compds. [I; Ar = II (wherein Ra = H, alkyl; and R1 = H, perfluoroalkyl; R2 = H, halo, alkyl, alkenyl, alkynyl); or Ar = 4-pyridyl and R1 = perfluoroalkyl; R2 = Br, I, alkyl, alkenyl, alkynyl; or R1 = H, and R2 = F, Br, I, Et, alkyl, alkenyl or alkynyl] and their N-oxides and salts, useful for the treatment especially of a neoplastic disease, such as a tumor disease, of retinopathy or age-related macular degeneration in the human or animal body, were prepared and formulated. Thus, reductive amination of 4-pyridinecarboxaldehyde with 2-amino-N-(4-bromo-3-trifluoromethylphenyl)benzamide (preparation given) in the presence of NaBH3CN afforded I [Ar = 4-pyridyl; R1 = CF3; R2 = Br]. The IC50-values that can be found for the compds. I are in range of 0.001 to 1 μM in test for activity against VEGF-receptor tyrosine kinase.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:376824 CAPLUS

DN 138:368777

TI Preparation of pyridyl-substituted anthranilic acid amides for treating neoplastic disease

IN Bold, Guido; Furet, Pascal; Manley, Paul William

PA Novartis AG, Switz.; Novartis Pharma Gmbh

SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003040101	A1	20030515	WO 2002-EP12445	20021107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
			GB 2001-26901	A 20011108
			GB 2002-12917	A 20020605

OS MARPAT 138:368777

IT **524729-00-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridyl-substituted anthranilic acid amides for treating neoplastic disease)

RN 524729-00-8 CAPLUS

CN Benzamide, 2-[[[3-[(methylamino)carbonyl]phenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:242305 CAPLUS

DN 138:271675

TI Preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides for the treatment of inflammation

IN Bergmanis, Arija A.; Bonafoux, Dominique; Clare, Michael; Crich, Joyce Z.; Fletcher, Theresa R.; Geng, Lifeng; Hagen, Timothy J.; Hamper, Bruce C.; Hanson, Gunnar J.; Houdek, Stephen C.; Huang, He; Iula, Donna M.; Koszyk, Francis J.; Lennon, Patrick J.; Liao, Shuyuan; Liao, Subo; Metz, Suzanne; Mohler, Scott B.; Nguyen, Maria; Oburn, David S.; Owen, Thomas J.; Partis, Richard A.; Scates, Angela M.; Stealey, Michael A.; Tollefson, Michael B.; Vazquez, Michael L.; Weier, Richard M.; Wolfson, Serge G.; Xu, Xiangdong

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 331 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003024935	A2	20030327	WO 2002-US29774	20020919
WO 2003024935	A3	20030821		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509
US 2004110741	A1	20040610	US 2002-247096	20020919
			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509
EP 1444207	A2	20040811	EP 2002-775879	20020919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509
			WO 2002-US29774	W 20020919
WO 2003095430	A1	20031120	WO 2003-US8917	20030319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-379090P	P 20020509

L3 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				WO 2002-US29774	A 20020919

PATENT FAMILY INFORMATION:

FAN 2003:913147

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003095430	A1	20031120	WO 2003-US8917	20030319
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-379090P	P 20020509
				WO 2002-US29774	A 20020919
	WO 2003024935	A2	20030327	WO 2002-US29774	20020919
	WO 2003024935	A3	20030821		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001 323423P	P 20010919
				US 2002-379090P	P 20020509

OS MARPAT 138:271675

IT **503555-09-7P**, 1-(1,3-Benzodioxol-5-yl)-8-[[[2-[(4-methoxybenzyl)amino]pyridin-3-yl]carbonyl]amino]-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(IKK2 inhibitor; preparation of benzo[g]carboxamides as IKK2 inhibitors for
treatment of cancer, inflammation, and inflammation-associated disorders)

RN 503555-09-7 CAPLUS

CN 1H Benz[g]indazole-3-carboxamide, 1-(1,3-benzodioxol-5-yl)-4,5-dihydro-8-[[[2-[[(4-methoxyphenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I II

AB The present invention relates to substituted pyrazolyl derivs., compns. comprising such, intermediates, methods of making substituted pyrazolyl derivs., and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis. Title compds. I [wherein A = (un)substituted (CH2)m; m = 0-3; B = (un)substituted (hetero)aryl; X = N or C; Y and Z = independently N, C, CH, CR3, S, or O; R1 = H, halo, (halo)alkyl, (hetero)aryl, alkenyl, alkynyl, CN, NO2, alkoxy(carbonyl), carbamoyl, acyl, alkylthio, sulfamoyl, ureido, etc.; R2 = H, halo, (halo)alkyl, hydroxyalkyl, alkoxy, CN, NO2, alkylthio, amino, carbamoyl, ureido, CO2H, etc.; R3 = (un)substituted amidine, alkylamino, aminoalkyl, carbamoyl, NH2, or acylamino(methyl); R4 = H, halo, alkylsulfinyl, alkylsulfonyl, CN, alkoxycarbonyl, (halo)alkyl, hydroxyalkyl, haloalkoxy, heterocyclyl, NO2, acylamino, (hetero)aryl, alkenyl, alkoxy, alkylthio, sulfamoyl, acyl, ureido, carbamoyl, etc.; R5 =

L3 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

H, or (un)substituted (aryl)alkyl, (hetero)aryl, heterocyclylalkyl, or heteroarylalkyl; R11 = H, halo, (halo)alkyl, CN, alkoxycarbonyl, alkenyl, alkynyl, alkoxy, carbamoyl, etc.; R12 = H, halo, alkyl, or alkoxy; with provisos; and isomers, tautomers, carriers, esters, prodrugs, and pharmaceutically acceptable salts thereof] were prepd. via conventional and solid phase synthetic methods as IκB protein kinase β (IKKβ or IKK2) inhibitors. For example, reaction of 7-nitro 1-tetralone with Et acetate in the presence of Li bis(trimethylsilyl)amide in ether gave the 1,3-diketone (87%), which was cyclized with 4-sulfonamidophenylhydrazine•HCl with HCl in MeOH to give the Et 1H-dihydrobenzo[g]indazolecarboxylate (69%). Amidation with NH3OH in MeOH provided II. In IKKβ resin enzyme assays, I exhibited IKKβ activity with IC50 values ranging from ≤ 1 μM to > 100 μM. Thus, I are useful for treating cancer, inflammation, and inflammation-assocd. disorders, such as arthritis (no data).

L3 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:42101 CAPLUS

DN 138:106502

TI Preparation of biphenylcarboxylic acid amides as inhibitors of microsomal triglyceride transfer protein (MTP)

IN Priepke, Henning; Hauel, Norbert; Dahmann, Georg; Thomas, Leo; Mark, Michael

PA Boehringer Ingelheim Pharma K.-G., Germany

SO PCT Int. Appl., 193 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003004020	A1	20030116	WO 2002-EP7215	20020629
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DE 2001-10132686	A 20010705
	DE 10132686	A1	20030116	DE 2001-10132686	20010705
	US 2003073836	A1	20030417	US 2002-187860	20020702
				DE 2001-10132686	A 20010705
				US 2001-304584P	P 20010711

OS MARPAT 138:106502

IT **486436-62-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of biphenylcarboxylic acid amides as microsomal
triglyceride transfer protein (MTP) inhibitors)

RN 486436-62-8 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]-4-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I

AB Title compds. I [X1 = CR1; X2 = CR2; X3 = CR3; X4 = CR4; with 1-2 of the groups being a N-atom; R1, R2, R3, R4 = H, halo, alkyl, etc.; A = O, S, NH, etc.; R8 = (un)substituted Ph, 1-naphthyl, 2-naphthyl, etc.; R5 = H, (un)substituted alkyl; R6 = H, alkyl; R7 = (un)substituted alkyl; Y = 1-2 carbon atom(s) bound to (un)substituted 5-membered heteroaryl] and their pharmaceutically acceptable salts were prepared. For example, coupling of acid II, e.g., prepared from 4-hydrazinobenzonitrile in 5-steps, and 4-phenylbenzylamine afforded biphenylcarboxylic acid amide III in 86% yield. In triglyceride transfer protein inhibition studies, compds. I exhibited IC50 values ≤ 100μM. Compds. I are claimed useful as inhibitors of microsomal triglyceride transfer protein (MTP) for the treatment of atherosclerosis.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:22869 CAPLUS
DN 138:89806
TI Preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for treatment of cardiovascular disease.
IN Ingraham, Richard H.; Proudfoot, John R.
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003002555	A1	20030109	WO 2002-US18752	20020614
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-302066P	P 20010629
US 2003022929	A1	20030130	US 2002-172457	20020614
			US 2001-302066P	P 20010629
EP 1406892	A1	20040414	EP 2002-739870	20020614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2001-302066P	P 20010629
			WO 2002-US18752	W 20020614
US 2004092567	A1	20040513	US 2003-670668	20030925
			US 2001-302066P	P 20010629
			US 2002-172457	A1 20020614

OS MARPAT 138:89806
IT **483342-21-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for treatment of cardiovascular disease)
RN 483342-21-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I

AB A method of treating cardiovascular disease comprises administration of title compds. [I; R1, R3 = CF3, halo, cyano, alkyl, alkenyl, alkynyl, (substituted) cycloalkyl, heterocyclyl, etc.; R2 = H, halo, Me; L = NHCO, NHCS, NH, NHCH2, NHCOCO, etc.; R4 = (substituted) alkyl, alkoxy, alkylthio, alkylamino, alkoxyalkyl, alkylthioalkyl, carbocyclyl, heterocyclyl, etc.; R8 = H, NH2] (no data). Thus, 2-chloronicotinic acid in MeCN was treated with EDC and then with 1-(4-aminophenyl)-3-(3-pyridyl)-5-trifluoromethylpyrazole under ice cooling followed by stirring for 1 h to give I (R1 = 3-pyridyl; R2, R8 = H; R3 = CF3; L = NHCO; R4 = 2-chloropyridin-3-yl).

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:603273 CAPLUS
DN 138:122629
TI Synthesis of 1,4-benzodiazepine-2,5-dione derivatives
AU Ho, Tong-Ing; Chen, Wen-Shiong; Hsu, Chi-Wei; Tsai, Yeun-Min; Fang, Jim-Min
CS Dep. of Chem., National Taiwan Univ., Taipei, Taiwan
SO Heterocycles (2002), 57(8), 1501-1506
CODEN: HTCYAM; ISSN: 0385-5414
PB Japan Institute of Heterocyclic Chemistry
DT Journal
LA English
OS CASREACT 138:122629
IT **489446-50-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2,5-dioxo-1H-1,4-benzodiazepine-3-carboxylate derivs.)
RN 489446-50-6 CAPLUS
CN Benzamide, N-(4-methoxyphenyl)-2-[[(3-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



AB A synthesis of a series of 1,4-benzodiazepine-2,5-dione derivs. with a carboxy group at the 3-position is realized in good yields by using Me malonylchloride as a key reagent and intramol. nucleophilic substitution as ring closure reaction. The synthesis of 4-(4-Methoxyphenyl)-1-[(3-methoxyphenyl)methyl]-2,5-dioxo-1H-1,4-benzodiazepine-3-carboxylic acid Me ester was described.

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:539663 CAPLUS
DN 137:109210
TI Preparation of substituted arylamine derivatives and methods of use as antitumor agents
IN Chen, Guoqing; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Huang, Qi; Kim, Joseph L.; Kim, Tae-Seong; Patel, Vinod F.; Smith, Leon M.; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang
PA Amgen Inc., USA
SO PCT Int. Appl., 253 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055501	A2	20020718	WO 2002-US742	20020111
	WO 2002055501	A3	20021219		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-261360P P	20010112
				US 2001-323686P P	20010919
				US 2002-46526 A	20020110
	US 2002147198	A1	20021010	US 2002-46526	20020110
				US 2001-261360P P	20010112
				US 2001-323686P P	20010919
	EP 1358161	A2	20031105	EP 2002-717324	20020111
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2001-261360P P	20010112
				US 2001-323686P P	20010919
				US 2002-46526 A	20020110
				WO 2002-US742 W	20020111

PATENT FAMILY INFORMATION:
FAN 2003:551181

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003134836	A1	20030717	US 2002-197960	20020717
				US 2001-261360P P	20010112
				US 2001-323686P P	20010919
				US 2002-46526 A2	20020110
	US 2002147198	A1	20021010	US 2002-46526	20020110
				US 2001-261360P P	20010112
				US 2001-323686P P	20010919
	WO 2004007457	A2	20040122	WO 2003-US22276	20030715
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2002-197960 A 20020717
OS MARPAT 137:109210
IT **442847-21-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted aminopyridines as antitumor agents)
RN 442847-21-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinylmethyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



IT **442845-77-4P 442846-13-1P 442846-17-5P**
442846-22-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation of substituted aminopyridines as antitumor agents)
RN 442845-77-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-13-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-17-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[6-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-22-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-acetyl-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



IT **442845-71-8P 442845-72-9P 442845-73-0P**
442845-78-5P 442845-79-6P 442845-80-9P
442845-81-0P 442845-82-1P 442845-83-2P
442845-84-3P 442845-85-4P 442845-86-5P
442845-87-6P 442845-88-7P 442845-89-8P
442845-90-1P 442845-91-2P 442845-92-3P
442845-93-4P 442845-94-5P 442845-95-6P
442845-96-7P 442845-97-8P 442845-99-0P
442846-00-6P 442846-01-7P 442846-02-8P
442846-03-9P 442846-04-0P 442846-05-1P
442846-06-2P 442846-07-3P 442846-08-4P

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
442846-09-5P 442846-10-8P 442846-12-0P
442846-14-2P 442846-15-3P 442846-16-4P
442846-18-6P 442846-19-7P 442846-20-0P
442846-21-1P 442846-23-3P 442846-24-4P
442846-25-5P 442846-26-6P 442846-27-7P
442846-28-8P 442846-29-9P 442846-30-2P
442846-31-3P 442846-32-4P 442846-33-5P
442846-34-6P 442846-35-7P 442846-36-8P
442846-38-0P 442846-39-1P 442846-40-4P
442846-42-6P 442846-44-8P 442846-46-0P
442846-48-2P 442846-50-6P 442846-52-8P
442846-53-9P 442847-23-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of substituted aminopyridines as antitumor agents)

RN 442845-71-8 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 442845-72-9 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[[(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-73-0 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-fluoro-4-methylphenyl)-3-[[(4-

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-78-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-79-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-80-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-81-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2-bromophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442845-82-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(trifluoromethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-83-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-difluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442845-84-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[(4-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-85-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[(2-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-86-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(2-methylpropyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-87-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-88-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-methoxyphenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-89-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-aminophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-90-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-91-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-92-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-93-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-94-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-95-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-96-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-97-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-99-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-00-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-01-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-02-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,6-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl] (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-03-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-04-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-05-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[3-(dimethylamino)propyl]-5-

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(trifluoromethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-06-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-07-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-10-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-fluoro-3-[3-(4-morpholinyl)-1-propynyl]phenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-12-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-08-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-bromo-2-fluorophenyl)-2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-09-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-14-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[2-(1,1-dimethylethyl)-5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-15-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(1-methyl-4-piperidinyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-16-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-[(dimethylamino)acetyl]-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-18-6 CAPLUS
CN Carbamic acid, [2-[6-[[[2-[[(4 fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-21-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[2-(1,1-dimethylethyl)-5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-23-3 CAPLUS
CN 1-Piperidinecarboxylic acid,
4-[[3-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846 19 7 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid,
7-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-20-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid,
2-[[3-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-24-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-25-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[(2R)-2-pyrrolidinylmethoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-26-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-piperidinylmethoxy)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-27-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-28-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 442846-29-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-(aminoacetyl)-2,3 dihydro 3,3-dimethyl-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-30-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-31-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-(4-piperidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-32-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-33-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-34-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-[(1-methyl-4-piperidinyl)methyl]-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-35-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-39-1 CAPLUS
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-2-[[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-40-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3,4-difluorophenyl)methyl]amino]-N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-36-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-2-oxo-7-quinolinyl)- (9CI) (CA INDEX NAME)



RN 442846-38-0 CAPLUS
CN 3 Pyridinecarboxamide, N-5-benzofuranyl-2-[[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 442846-42-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 442846-44-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(1-piperidinylmethyl)amino]phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-46-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-48-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-(2-pyrrolidinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-50-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-(2-pyrrolidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-52-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(2-pyrrolidinylmethoxy)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-53-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[(1-methyl-2-pyrrolidinyl)methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442847-23-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 442845-77-4
CMF C25 H20 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [B1 and B2 independently equal C or N, wherein B1B2 form part of 5-6 membered heteroaryl ring A; R1 = one or more substituents selected from H, halo, oxo, (un)substituted cycloalkyl, phenylalkyl, etc.; R2 = (un)substituted cycloalkyl, cycloalkenyl, 6-10 membered aryl or 5-6 membered heterocyclyl, etc.; R3 = (un)substituted aryl; R4 = H, alkyl, (un)substituted Ph or aralkyl; X1 = bond, alkylenyl, alkenylenyl and alkynylenyl, where one of the CH2 groups may be substituted with O or NH, wherein X1 is optionally substituted with OH; X2 = (un)substituted N containing linker, e.g., -NHCH2-], and there pharmaceutically acceptable derivs., are prepared and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. Thus, II was prepared via arylation of 1-dimethylamino-2-propyne with 3-bromo-5-trifluoromethylaniline, hydrogenation, amidation with 2-chloropyridine-3-carbonyl chloride and chloro-substitution with 4-fluorobenzylamine. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

L3 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:171853 CAPLUS
DN 136:232201
TI Preparation of cyclic amine derivatives as CCR3 antagonists
IN Morihira, Koichiro; Inami, Hiroshi; Kubota, Hirokazu; Yokoyama, Kazuhiro; Morokata, Tatsuaki; Takeuchi, Makoto; Takahashi, Toshiya; Kaneko, Masayuki; Imaoka, Takayuki; Torii, Yuichi; Iura, Yosuke
PA Yamanouchi Pharmaceutical Co., Ltd., Japan; Toray Industries, Inc.
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002018335	A1	20020307	WO 2001-JP7321	20010827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			JP 2000-257451	A 20000828
AU 2001080187	A5	20020313	AU 2001-80187	20010827
			JP 2000-257451	A 20000828
			WO 2001-JP7321	W 20010827

OS MARPAT 136:232201
IT **403477-79-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic amine derivs. as CCR3 antagonists)
RN 403477-79-2 CAPLUS
CN Benzamide, 2-[[(2-chlorophenyl)methyl]amino]-N-[8-[(6-fluoro-2-naphthalenyl)methyl]-8-azabicyclo[3.2.1]oct-3-yl]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB The title compds. I [ring A = (un)substituted heterocyclic ring, etc.; X = bond, O, CO, etc.; ring B = Q1, etc.; ring V3 = hydrocarbon ring, etc.; W = CH, N; Y = CO, etc.; R21, R22 = H, halo, etc.; T1 = (CH2)n; n = 0 - 2; ring D = (un)substituted aryl, etc.] are prepared In an in vitro test (for CCR3 antagonism) using cells, compds. of this invention showed IC50 values of 0.001 μM to 0.45 μM.
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:11104 CAPLUS
DN 136:69743
TI Preparation of pyridyl benzamides and related compounds as Factor Xa inhibitors.
IN Zhu, Bing-Yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick A.; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
PA USA
SO U.S. Pat. Appl. Publ., 259 pp., Cont.-in-part of U.S. Ser. No. 663,420.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002002183	A1	20020103	US 2001-794225	20010228
US 6376515	B2	20020423		
			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
US 2003162690	A1	20030828	US 2002-126976	20020422
			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
			US 2001-794225	A1 20010228
US 2004097561	A1	20040520	US 2003-687334	20031015
			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
			US 2001-794225	A1 20010228
			US 2002-126976	A1 20020422

PATENT FAMILY INFORMATION:
FAN 2001:208239

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001019788	A2	20010322	WO 2000-US25196	20000915
WO 2001019788	A3	20010809		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
AU 2000074867	A5	20010417	AU 2000-74867	20000915
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			WO 2000-US25196	W 20000915
EP 1216228	A2	20020626	EP 2000-963452	20000915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			WO 2000-US25196	W 20000915
BR 2000014076	A	20021015	BR 2000-14076	20000915
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			WO 2000-US25196	W 20000915

L3 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

JP 2003509406	T2	20030311	JP 2001-523368	20000915
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			WO 2000-US25196	W 20000915
NO 2002001229	A	20020521	NO 2002-1229	20020312
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			WO 2000-US25196	W 20000915

FAN 2001:208248

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001019798	A2	20010322	WO 2000-US25195	20000915
WO 2001019798	A3	20011025		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 1999-154332P	P 19990917
AU 2000074866	A5	20010417	AU 2000-74866	20000915
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915
EP 1216231	A2	20020626	EP 2000-963451	20000915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915
BR 2000014078	A	20021231	BR 2000-14078	20000915
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915
TR 200200413	T2	20030221	TR 2002-200200413	20000915
			US 1999-154332P	P 19990917
JP 2003509412	T2	20030311	JP 2001-523378	20000915
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915
NZ 517828	A	20031031	NZ 2000-517828	20000915
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915
NO 2002001230	A	20020521	NO 2002-1230	20020312
			US 1999-154332P	P 19990917
			WO 2000 US25195	W 20000915

FAN 2001:661391

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001064642	A2	20010907	WO 2001-US6247	20010228
WO 2001064642	A3	20020502		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

L3 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915

FAN 2001:661392

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001064643	A2	20010907	WO 2001-US6255	20010228
WO 2001064643	A3	20020404		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915
	EP 1259485	A2	20021127	EP 2001-918257	20010228

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915
				WO 2001-US6255	W 20010228

FAN 2002:522631

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002091116	A1	20020711	US 2001-794214	20010228
US 6632815	B2	20031014		
			US 1999-154332P	P 19990917
			US 2000-662807	A2 20000915
US 6720317	B1	20040413	US 2000-662807	20000915
			US 1999-154332P	P 19990917
US 6686368	B1	20040203	US 2003-387927	20030312
			US 1999-154332P	P 19990917
			US 2000-662807	A3 20000915
US 2004116399	A1	20040617	US 2003-600695	20030620
			US 1999-154332P	P 19990917
			US 2000-662807	A2 20000915
			US 2001-794214	A1 20010228

OS MARPAT 136:69743

IT **358659-62-8P 358659-63-9P 358659-64-0P 358659-65-1P 358659-74-2P 358659-75-3P 358659-76-4P 358659-77-5P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridyl benzamides and related compds. as Factor Xa inhibitors)

RN 358659-62-8 CAPLUS

CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





RN 358659-63-9 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(methylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-64-0 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-65-1 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-74-2 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-75-3 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-76-4 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(4-methyl-1-piperazinyl)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-77-5 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(hexahydro-1H-azepin-1-yl)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R2C(:NR3), (substituted) Ph, naphthyl, heterocyclyl, etc.; R1-R3 = H, OR5, NR5R6, alkyl, alkenyl, etc.;

R1R2 or R2R3 = atoms to form (substituted) cycloalkyl, heterocyclyl; R5, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) alkylphenyl, alkylnaphthyl; R5R6 = atoms to form a 3-8 membered (substituted) ring; Q = bond, CH2, CO, O, S, SO, SO2, NR7, SO2NR7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, (substituted) alkylphenyl, alkylnaphthyl; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, O, S, SO, SO2, alkylcarbonyl, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, 3-8 membered (fused) (aromatic) heterocyclyl; J = bond, NR9CO, O, S, SO, SO2, CH2, NR9SO2,

L3 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
= (substituted) Ph, naphthyl, (fused) heteroaryl], were prepd. as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-aminophenylcarboxamide (prepn. given), 4-cyanobenzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-cyanophenylcarbonyl)amino]phenylcarboxamide. The latter in MeOH at 0° was satd. with HCl and stirred overnight followed by solvent evapn. The residue was refluxed 2 h with NH4OAc in MeOH to give 70%
N-(5-bromo-2-pyridinyl)-[2-(4-amidinophenylcarbonyl)amino]phenylcarboxamide.

L3 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	BR 2000014076	A	20021015	BR 2000-14076	20000915
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	JP 2003509406	T2	20030311	JP 2001-523368	20000915
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	NO 2002001229	A	20020521	NO 2002-1229	20020312
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915

FAN 2001:208248

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001019798	A2	20010322	WO 2000-US25195	20000915
WO 2001019798	A3	20011025		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 1999-154332P	P 19990917
AU 2000074866	A5	20010417	AU 2000-74866	20000915
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915
EP 1216231	A2	20020626	EP 2000-963451	20000915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915
BR 2000014078	A	20021231	BR 2000-14078	20000915
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915
TR 200201413	T2	20030221	TR 2002-200201413	20000915
			US 1999-154332P	P 19990917
JP 2003509412	T2	20030311	JP 2001-523378	20000915
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915
NZ 517828	A	20031031	NZ 2000-517828	20000915
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915
NO 2002001230	A	20020521	NO 2002-1230	20020312
			US 1999-154332P	P 19990917
			WO 2000-US25195	W 20000915

FAN 2001:661391

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001064642	A2	20010907	WO 2001-US6247	20010228
WO 2001064642	A3	20020502		

L3 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:661392 CAPLUS
DN 135:226888
TI Preparation of pyridyl benzamides and related compounds as Factor Xa inhibitors.
IN Zhu, Bing-yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
PA Cor Therapeutics, Inc., USA
SO PCT Int. Appl., 322 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001064643	A2	20010907	WO 2001-US6255	20010228
WO 2001064643	A3	20020404		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 2000-185746P	P 20000229
			US 2000-663420	A 20000915
EP 1259485	A2	20021127	EP 2001-918257	20010228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2000-185746P	P 20000229
			US 2000-663420	A 20000915
			WO 2001-US6255	W 20010228

PATENT FAMILY INFORMATION:
FAN 2001:208239

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001019788	A2	20010322	WO 2000-US25196	20000915
WO 2001019788	A3	20010809		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
AU 2000074867	A5	20010417	AU 2000-74867	20000915
			US 1999-154332P	P 19990917
			US 2000-185746P	P 20000229
			WO 2000-US25196	W 20000915
EP 1216228	A2	20020626	EP 2000-963452	20000915

L3 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915

FAN 2002:11104

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002002183	A1	20020103	US 2001-794225	20010228
US 6376515	B2	20020423		
			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
US 2003162690	A1	20030828	US 2002-126976	20020422
			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
			US 2001-794225	A1 20010228
US 2004097561	A1	20040520	US 2003-687334	20031015
			US 2000-185746P	P 20000229
			US 2000-663420	A2 20000915
			US 2001-794225	A1 20010228
			US 2002-126976	A1 20020422

FAN 2002:522631

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002091116	A1	20020711	US 2001-794214	20010228
US 6632815	B2	20031014		
			US 1999-154332P	P 19990917
			US 2000-662807	A2 20000915
US 6720317	B1	20040413	US 2000-662807	20000915
			US 1999-154332P	P 19990917
US 6686368	B1	20040203	US 2003-387927	20030312
			US 1999-154332P	P 19990917
			US 2000-662807	A3 20000915
US 2004116399	A1	20040617	US 2003-600695	20030620
			US 1999-154332P	P 19990917
			US 2000-662807	A2 20000915
			US 2001-794214	A1 20010228

OS MARPAT 135:226888
IT **358659-62-8P 358659-63-9P 358659-64-0P 358659-65-1P 358659-74-2P 358659-75-3P 358659-76-4P 358659-77-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridyl benzamides and related compds. as Factor Xa inhibitors)
RN 358659-62-8 CAPLUS
CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-63-9 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(methylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-64-0 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659 76-4 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(4-methyl-1-piperazinyl)methyl]phenyl]methyl]amino] (9CI) (CA INDEX NAME)



RN 358659-77-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(hexahydro-1H-azepin-1-yl)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



L3 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-65-1 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-74-2 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-75-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino] (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R2C(:NR3), (substituted) Ph, naphthyl, heterocyclyl, etc.; R1-R3 = H, OR5, NR5R6, alkyl, alkenyl, etc.;
R1R2 or R2R3 = atoms to form (substituted) cycloalkyl, heterocyclyl; R5, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) alkylphenyl, alkylnaphthyl; R5R6 = atoms to form a 3-8 membered (substituted) ring; Q =
bond, CH2, CO, O, S, SO, SO2, NR7, SO2NR7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, (substituted) alkylphenyl, alkylnaphthyl; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, O, S, SO, SO2, alkylcarbonyl, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, 3-8 membered (fused) (arom.) heterocyclyl; J = bond, NR9CO, O, S, SO, SO2, CH2, NR9SO2, etc.;
X
= (substituted) Ph, naphthyl, (fused) heteroaryl], were prepd. as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-aminophenylcarboxamide (prepn. given), 4-cyanobenzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-cyanophenylcarbonyl)amino]phenylcarboxamide. The latter in MeOH at 0° was satd. with HCl and stirred overnight followed by solvent evapn. The residue was refluxed 2 h with NH4OAc in MeOH to give 70%
N-(5-bromo-2-pyridinyl)-[2-(4-amidinophenylcarbonyl)amino]phenylcarboxamide.

L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:661391 CAPLUS
DN 135:210946
TI Preparation of pyridylamides as Factor Xa inhibitors.
IN Zhu, Bing-Yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
PA Cor Therapeutics, Inc., USA
SO PCT Int. Appl., 306 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064642	A2	20010907	WO 2001-US6247	20010228
	WO 2001064642	A3	20020502		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915

PATENT FAMILY INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FAN 2001:208239					
PI	WO 2001019788	A2	20010322	WO 2000-US25196	20000915
	WO 2001019788	A3	20010809		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
	AU 2000074867	A5	20010417	AU 2000-74867	20000915
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	EP 1216228	A2	20020626	EP 2000-963452	20000915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	BR 2000014076	A	20021015	BR 2000-14076	20000915
				US 1999-154332P	P 19990917

L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	JP 2003509406	T2	20030311	JP 2001-523368	20000915
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	NO 2002001229	A	20020521	NO 2002-1229	20020312
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
FAN	2001:208248				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019798	A2	20010322	WO 2000-US25195	20000915
	WO 2001019798	A3	20011025		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-154332P	P 19990917
	AU 2000074866	A5	20010417	AU 2000-74866	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	EP 1216231	A2	20020626	EP 2000-963451	20000915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	BR 2000014078	A	20021231	BR 2000-14078	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	TR 200201413	T2	20030221	TR 2002-200201413	20000915
				US 1999-154332P	P 19990917
	JP 2003509412	T2	20030311	JP 2001-523378	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	NZ 517828	A	20031031	NZ 2000-517828	20000915
				US 1999 154332P	P 19990917
				WO 2000-US25195	W 20000915
	NO 2002001230	A	20020521	NO 2002-1230	20020312
				US 1999 154332P	P 19990917
				WO 2000-US25195	W 20000915
FAN	2001:661392				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064643	A2	20010907	WO 2001-US6255	20010228
	WO 2001064643	A3	20020404		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				

L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
				RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915
	EP 1259485	A2	20021127	EP 2001-918257	20010228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000 185746P	P 20000229
				US 2000-663420	A 20000915
				WO 2001-US6255	W 20010228
FAN	2002:11104				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002002183	A1	20020103	US 2001-794225	20010228
	US 6376515	B2	20020423		
				US 2000-185746P	P 20000229
				US 2000-663420	A2 20000915
	US 2003162690	A1	20030828	US 2002-126976	20020422
				US 2000-185746P	P 20000229
				US 2000-663420	A2 20000915
				US 2001-794225	A1 20010228
	US 2004097561	A1	20040520	US 2003-687334	20031015
				US 2000-185746P	P 20000229
				US 2000-663420	A2 20000915
				US 2001-794225	A1 20010228
				US 2002-126976	A1 20020422
FAN	2002:522631				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002091116	A1	20020711	US 2001-794214	20010228
	US 6632815	B2	20031014		
				US 1999 154332P	P 19990917
				US 2000-662807	A2 20000915
	US 6720317	B1	20040413	US 2000-662807	20000915
				US 1999-154332P	P 19990917
	US 6686368	B1	20040203	US 2003-387927	20030312
				US 1999-154332P	P 19990917
				US 2000-662807	A3 20000915
	US 2004116399	A1	20040617	US 2003-600695	20030620
				US 1999-154332P	P 19990917
				US 2000-662807	A2 20000915
				US 2001-794214	A1 20010228

OS MARPAT 135:210946
IT **358659-62-8P 358659-63-9P 358659-64-0P 358659-65-1P 358659-74-2P 358659-75-3P 358659-76-4P 358659-77-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridylamides as Factor Xa inhibitors)
RN 358659-62-8 CAPLUS
CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





RN 358659-63-9 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(methylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 358659-64-0 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-65-1 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-74-2 CAPLUS
CN Benzamide, N-(5-chloro 2 pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-75-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659 76-4 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(4-methyl-1-piperazinyl)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-77-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(hexahydro-1H-azepin-1-yl)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R1C(:NR3), (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl, etc.; R1-R3 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (alkyl)aryl, (alkyl)heteroaryl, etc.; R1R2 or R2R3 = atoms to form a 3-8 membered (substituted) (heterocyclic) ring; Q = bond, CH2, CO, O, NR7, etc.; R7 = H, alkyl, (alkyl)aryl, (alkyl)heteroaryl, etc.; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, S, SO, SO2, alkoxy, etc.; G = (substituted)

L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
alkenyl, cycloalkenyl, phenylene, heterocyclyl, fused cyclic system; J = bond, NR9CO, O, S, SO, SO2, SO2NR9, CH2, NR9, etc.; R9 = H, alkyl, (alkyl)aryl, etc.; X = (substituted) Ph, naphthyl, heteroaryl, fused bicyclyl], were prepd. as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl) 2-aminophenylcarboxamide (prepn. given), 4-[(2-tert-butylaminosulfonyl)phenyl]benzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 85% N-(5-bromo-2-pyridinyl)-[2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino]phenylcarboxamide.

L3 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:565010 CAPLUS
DN 135:137407
TI Preparation of 2-aminonicotinamides as VEGF receptor tyrosine kinase inhibitors
IN Manley, Paul William; Bold, Guido
PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001055114	A1	20010802	WO 2001-EP835	20010125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			GB 2000-1930	A 20000127
AU 2001028499	A5	20010807	AU 2001-28499	20010125
AU 771626	B2	20040401		
			GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
BR 2001007805	A	20021022	BR 2001-7805	20010125
			GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
EP 1259487	A1	20021127	EP 2001-946854	20010125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
JP 2003520853	T2	20030708	JP 2001-555056	20010125
			GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
NZ 520005	A	20040227	NZ 2001-520005	20010125
			GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
NO 2002003218	A	20020916	NO 2002-3218	20020702
			GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
US 2003032656	A1	20030213	US 2002-181005	20020711
US 6624174	B2	20030923		
			GB 2000-1930	A 20000127
			WO 2001-EP835	W 20010125
ZA 2002005988	A	20030728	ZA 2002-5988	20020726
			GB 2000-1930	A 20000127

OS MARPAT 135:137407
IT **62636-33-3P 352227-86-2P 352227-92-0P 352228-00-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L3 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(prepn. of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors)
RN 62636-33-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 352227-86-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-[(methylamino)carbonyl]phenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl] (9CI) (CA INDEX NAME)



RN 352227-92-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-hydroxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 352228-00-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-hydroxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; n = 1-6; W = O, S; R1, R3 = H, alkyl, acyl; R2 = (un)substituted cycloalkyl, aryl, mono- or bicyclic heteroaryl comprising

L3 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
one or more ring N atoms and 0-2 heteroatoms selected from O and S; R, R' = H, alkyl; X = (un)substituted aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S] and their pharmaceutically acceptable salts, useful for therapy of a disease which responds to an inhibition of the VEGF-receptor tyrosine kinase activity (such as neoplastic disease), were prepd. and formulated. Thus, amidation of 3-aminobenzotrifluoride with 2-chloronicotinoyl chloride followed by reacting 4-pyridineethanamine with the resulting carboxamide afforded I [n = 2; R, R' = H; X = 4-pyridyl; W = O; R1, R3 = H; R2 = 3-(F3C)C6H4].
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:409260 CAPLUS
DN 131:73440
TI Preparation of aromatic amide derivatives as ACC inhibitor
IN Igawa, Hiroshi; Nishimura, Masato; Okada, Keiji; Nakamura, Takashi
PA Fujirebio, Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 72 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 11171848	A2	19990629	JP 1998-270721	19980925
			JP 1997-277942	19970926

OS MARPAT 131:73440
IT **228580-60-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aromatic amide derivs. as ACC inhibitor)
RN 228580-60-7 CAPLUS
CN Benzoic acid, 2-[[2-[(phenylmethyl)amino]benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



IT **228580-61-8P 228580-84-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of aromatic amide derivs. as ACC inhibitor)
RN 228580-61-8 CAPLUS
CN Benzoic acid, 2-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 228580-84-5 CAPLUS
CN Benzoic acid, 2-[[2-[(3-phenylpropyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



AB Title compds. [I; R = 3-CF3C6H4, C6H5(CH2)2, C6H5, CH3(CH2)5, CH3(CH2)3, CH3(CH2)2, CH3CH2, CH3, C6H5(CH2)3, etc.; R1 = H, CH3(CH2)4, 5-CH3(CH2)5CC, 5-CH3CH2CC, 5-(CH3)3CCC, 4-C6H5CH2O, 4-C6H5CC, 3-C6H5CC, 3-C6H5CC, 3-(4-NO2C6H4)CC, 3-(4-NCC6H4)CC, 3-(4-HOC6H4)CC, etc.; R2 = 5-OH, 5-Cl, 5-OMe, 5-Me, 5-Br, etc.; R3 = H, CH3, etc.; R4 = CO2H, AcNHSO2, CH3(CH2)4CONHSO2, 4-CF3C6H4CONHSO2, PHCONHSO2, (CH3)3CONHSO2, CH3(CH2)2NHCONHSO2, etc.; X = CH, N; dotted bond = single, double] are prepared and tested as ACC (acetyl-CoA carboxylase) inhibitors in treatment of lipids oxidation related diseases, such as myocardial infarction, cerebral infarction, and diabetes. The title compound I (R = 3-CF3C6H4; R1 = H; R2 = H; R3 = H; X = CH; dotted bonds were double bonds) was prepared with 72% yield from 3-EtO2CC6H4NH2 and 3-(2-HO2CC6H4NH)C6H4CF3.

L3 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:236274 CAPLUS
DN 128:282780
TI Preparation of heterocyclic inhibitors of microsomal triglyceride transfer protein
IN Biller, Scott A.; Dickson, John K.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Sulsky, Richard B.; Tino, Joseph A.
PA Bristol-Myers Squibb Co., USA
SO U.S., 185 pp., Cont.-in-part of U.S. Ser. No. 391,901, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5739135	A	19980414	US 1995-472067	19950606
				US 1993-117362 A2	19930903
				US 1994-284808 B2	19940805
				US 1995-391901 B2	19950221
	CA 2091102	AA	19930907	CA 1993-2091102	19930305
				US 1992-847503 A	19920306
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503 A	19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503 A	19920306
	EP 584446	A2	19940302	EP 1993-103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1992-847503 A	19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503 A	19920306
	PT 584446	T	20020930	PT 1993-103697	19930308
				US 1992-847503 A	19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308
				US 1992-847503 A	19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992-847503 A	19920306
	US 5595872	A	19970121	US 1993-117362	19930903
				US 1992-847503 B2	19920306
				US 1993-15449 B2	19930222
	US 5789197	A	19980804	US 1995-486924	19950607
				US 1992-847503 B2	19920306
				US 1993-15449 B2	19930222
				US 1993-117362 A3	19930903
	US 6492365	B1	20021210	US 1995-486929	19950607
				US 1992-847503 B2	19920306
				US 1993-15449 B2	19930222
				US 1993-117362 A3	19930903
	US 5712279	A	19980127	US 1996-548811	19960111
				US 1995-391901 B2	19950221
				US 1995-472067 A2	19950606

L3 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	IL 116917	A1	20000831	IL 1996-116917	19960126
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
	TW 486469	B	20020511	TW 1996-85100978	19960126
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
	CA 2213466	AA	19960829	CA 1996-2213466	19960201
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
	WO 9626205	A1	19960829	WO 1996-US824	19960201
	W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
	AU 9647631	A1	19960911	AU 1996-47631	19960201
	AU 699865	B2	19981217		
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
				WO 1996-US824 W	19960201
	CN 1176640	A	19980318	CN 1996-192015	19960201
	CN 1108301	B	20030514		
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
	EP 886637	A1	19981230	EP 1996-903604	19960201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
				WO 1996-US824 W	19960201
	JP 11500442	T2	19990112	JP 1996-525679	19960201
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
				WO 1996-US824 W	19960201
	NZ 302055	A	20000228	NZ 1996-302055	19960201
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
				WO 1996-US824 W	19960201
	PL 185443	B1	20030530	PL 1996-322003	19960201
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
				WO 1996-US824 W	19960201
	ZA 9601340	A	19970911	ZA 1996-1340	19960220
				US 1995-391901 A	19950221
	US 5883099	A	19990316	US 1997-896872	19970721
				US 1993-117362 A2	19930903
				US 1994-284808 B2	19940805
				US 1995-391901 B2	19950221
				US 1995-472067 A3	19950606
	US 6034098	A	20000307	US 1997-898304	19970721
				US 1993-117362 A2	19930903
				US 1994-284808 B2	19940805
				US 1995-391901 B2	19950221
				US 1995-472067 A3	19950606
	US 6066650	A	20000523	US 1997-898303	19970721
				US 1993-117362 A2	19930903
				US 1994-284808 B2	19940805
				US 1995-391901 B2	19950221
				US 1995-472067 A1	19950606

L3 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	FI 9703416	A	19970820	FI 1997-3416	19970820
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
				WO 1996-US824 W	19960201
	NO 9703821	A	19970820	NO 1997-3821	19970820
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
				WO 1996-US824 W	19960201
	LT 4367	B	19980825	LT 1997-152	19970919
				US 1995-391901 A	19950221
	LV 11951	B	19981120	LV 1997-171	19970919
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
	US 2003166590	A1	20030904	US 2001-933593	20010821
				US 1992-847503 B2	19920306
				US 1993-15449 B2	19930222
				US 1993-117362 A3	19930903
				US 1995-486929 A3	19950607

PATENT FAMILY INFORMATION:
FAN 1995:568500

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 643057	A1	19950315	EP 1994-113800	19940902
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1993-117362 A	19930903
	CA 2091102	AA	19930907	CA 1993-2091102	19930305
				US 1992-847503 A	19920306
	ZA 9301601	A	19931005	ZA 1993-1601	19930305
				US 1993-117362 A	19930903
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503 A	19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503 A	19920306
	EP 584446	A2	19940302	EP 1993-103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1992-847503 A	19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503 A	19920306
	PT 584446	T	20020930	PT 1993-103697	19930308
				US 1992-847503 A	19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308
				US 1992-847503 A	19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992-847503 A	19920306
	US 5595872	A	19970121	US 1993-117362	19930903
				US 1992-847503 B2	19920306
				US 1993-15449 B2	19930222
	CA 2131430	AA	19950304	CA 1994-2131430	19940902
				US 1993-117362 A	19930903
	FI 9404048	A	19950304	FI 1994-4048	19940902
				US 1993-117362 A	19930903
	NO 9403260	A	19950306	NO 1994-3260	19940902
				US 1993-117362 A	19930903

L3 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	AU 9471642	A1	19950316	AU 1994-71642	19940902
	AU 690125	B2	19980423		
				US 1993-117362	A 19930903
	ZA 9406772	A	19950403	ZA 1994-6772	19940902
				US 1993-117362	A 19930903
	JP 07165712	A2	19950627	JP 1994-210057	19940902
				US 1993-117362	A 19930903
	CN 1106003	A	19950802	CN 1994-115640	19940902
				US 1993-117362	A 19930903
	HU 70613	A2	19951030	HU 1994-2542	19940902
				US 1993-117362	A 19930903
	US 5789197	A	19980804	US 1995-486924	19950607
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
	US 6492365	B1	20021210	US 1995-486929	19950607
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
	US 2003166590	A1	20030904	US 2001-933593	20010821
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
				US 1995-486929	A3 19950607

FAN 1996:641305

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9626205	A1	19960829	WO 1996-US824	19960201

W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
	CA 2091102	AA	19930907	CA 1993-2091102	19930305
				US 1992-847503	A 19920306
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503	A 19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503	A 19920306
	EP 584446	A2	19940302	EP 1993-103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

				US 1992-847503	A 19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503	A 19920306
	PT 584446	T	20020930	PT 1993-103697	19930308
				US 1992-847503	A 19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308
				US 1992-847503	A 19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992-847503	A 19920306

L3 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	US 5739135	A	19980414	US 1995-472067	19950606
				US 1993-117362	A2 19930903
				US 1994-284808	B2 19940805
				US 1995-391901	B2 19950221
	ZA 9601340	A	19970911	ZA 1996-1340	19960220
				US 1995-391901	A 19950221
	LT 4367	B	19980825	LT 1997-152	19970919
				US 1995-391901	A 19950221

OS MARPAT 128:282780

IT **182429-79-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic inhibitors of microsomal triglyceride transfer protein)

RN 182429-79-4 CAPLUS

CN 9H-Fluorene 9-carboxamide, 9-[4-[4-[[2-[(phenylmethyl)amino]benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L3 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	US 5739135	A	19980414	US 1995-472067	19950606
				US 1993-117362	A2 19930903
				US 1994-284808	B2 19940805
				US 1995-391901	B2 19950221
	AU 9647631	A1	19960911	AU 1996-47631	19960201
	AU 699865	B2	19981217		
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	EP 886637	A1	19981230	EP 1996-903604	19960201

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE

				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	JP 11500442	T2	19990112	JP 1996-525679	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	NZ 302055	A	20000228	NZ 1996-302055	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	PL 185443	B1	20030530	PL 1996-322003	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	ZA 9601340	A	19970911	ZA 1996-1340	19960220
				US 1995-391901	A 19950221
	FI 9703416	A	19970820	FI 1997-3416	19970820
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	NO 9703821	A	19970820	NO 1997-3821	19970820
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	LT 4367	B	19980825	LT 1997-152	19970919
				US 1995-391901	A 19950221

FAN 1998:115356

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5712279	A	19980127	US 1996-548811	19960111
			US 1995-391901	B2 19950221
			US 1995-472067	A2 19950606
CA 2091102	AA	19930907	CA 1993-2091102	19930305
			US 1992-847503	A 19920306
HU 67962	A2	19950529	HU 1993-627	19930305
HU 218419	B	20000828		
			US 1992-847503	A 19920306
JP 06038761	A2	19940215	JP 1993-46499	19930308
			US 1992-847503	A 19920306
EP 584446	A2	19940302	EP 1993-103697	19930308
EP 584446	A3	19950426		
EP 584446	B1	20020619		

L3 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I-V; Q = C(O), S(O)2; X = CHR8, C(O), CHR9CHR10, CR9:CR10 (wherein R8-R10 = H, alkyl, alkenyl, etc.); Y = (CH2)m, C(O) (m = 2-3); R1 = alkyl, alkenyl, alkynyl, etc.; R2-R4 = H, halo, alkyl, etc.; R5 = alkyl, alkenyl, alkynyl, etc.; R6 = H, C1-4 alkyl, C1-4 alkenyl] which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases such as hyperglycemia and obesity, were prepared Thus, reaction of 1-(3,3-diphenylpropyl)-4-piperidinamine.HCl (preparation described) with benzoyl chloride in the presence of Et3N in CH2Cl2 afforded 84% the title compound III.HCl [Q = C(O); R1 = 3,3-diphenylpropyl; R5 = Ph; R6 = H]. Compds. I-V are effective at 5-500 mg/day.

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:641305 CAPLUS
DN 125:275663
TI Preparation of 9-(piperidinoalkyl)fluorene-9-carboxamides and analogs as microsomal triglyceride transfer protein inhibitors
IN Wetterau, John R. II; Sharp, Daru Young; Gregg, Richard E.; Biller, Scott A.; Dickson, John A.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Robl, Jeffrey A.; et al.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 427 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9626205	A1	19960829	WO 1996-US824	19960201
	W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
	CA 2091102	AA	19930907	CA 1993-2091102	19930305
				US 1992-847503	A 19920306
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503	A 19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503	A 19920306
	EP 584446	A2	19940302	EP 1993-103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1992-847503	A 19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503	A 19920306
	PT 584446	T	20020930	PT 1993-103697	19930308
				US 1992-847503	A 19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308
				US 1992-847503	A 19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992-847503	A 19920306
	US 5739135	A	19980414	US 1995-472067	19950606
				US 1993-117362	A2 19930903
				US 1994-284808	B2 19940805
				US 1995-391901	B2 19950221
	AU 9647631	A1	19960911	AU 1996-47631	19960201
	AU 699865	B2	19981217		
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	EP 886637	A1	19981230	EP 1996-903604	19960201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				

L3 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	JP 11500442	T2	19990112	JP 1996-525679	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	NZ 302055	A	20000228	NZ 1996-302055	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	PL 185443	B1	20030530	PL 1996-322003	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	ZA 9601340	A	19970911	ZA 1996-1340	19960220
				US 1995-391901	A 19950221
	FI 9703416	A	19970820	FI 1997-3416	19970820
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	NO 9703821	A	19970820	NO 1997-3821	19970820
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	LT 4367	B	19980825	LT 1997-152	19970919
				US 1995-391901	A 19950221

PATENT FAMILY INFORMATION:

FAN 1995:568500

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 643057	A1	19950315	EP 1994-113800	19940902
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1993-117362	A 19930903
	CA 2091102	AA	19930907	CA 1993-2091102	19930305
				US 1992-847503	A 19920306
	ZA 9301601	A	19931005	ZA 1993-1601	19930305
				US 1993-117362	A 19930903
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503	A 19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503	A 19920306
	EP 584446	A2	19940302	EP 1993-103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1992-847503	A 19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503	A 19920306
	PT 584446	T	20020930	PT 1993-103697	19930308
				US 1992-847503	A 19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308

L3 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1992-847503	A 19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992-847503	A 19920306
	US 5595872	A	19970121	US 1993-117362	19930903
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
	CA 2131430	AA	19950304	CA 1994-2131430	19940902
				US 1993-117362	A 19930903
	FI 9404048	A	19950304	FI 1994-4048	19940902
				US 1993-117362	A 19930903
	NO 9403260	A	19950306	NO 1994-3260	19940902
				US 1993-117362	A 19930903
	AU 9471642	A1	19950316	AU 1994-71642	19940902
	AU 690125	B2	19980423		
				US 1993-117362	A 19930903
	ZA 9406772	A	19950403	ZA 1994-6772	19940902
				US 1993-117362	A 19930903
	JP 07165712	A2	19950627	JP 1994-210057	19940902
				US 1993-117362	A 19930903
	CN 1106003	A	19950802	CN 1994-115640	19940902
				US 1993-117362	A 19930903
	HU 70613	A2	19951030	HU 1994-2542	19940902
				US 1993-117362	A 19930903
	US 5789197	A	19980804	US 1995-486924	19950607
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
	US 6492365	B1	20021210	US 1995-486929	19950607
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
	US 2003166590	A1	20030904	US 2001-933593	20010821
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
				US 1995-486929	A3 19950607

FAN 1998:115356

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5712279	A	19980127	US 1996-548811	19960111
				US 1995-391901	B2 19950221
				US 1995-472067	A2 19950606
	CA 2091102	AA	19930907	CA 1993-2091102	19930305
				US 1992-847503	A 19920306
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503	A 19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503	A 19920306
	EP 584446	A2	19940302	EP 1993-103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1992-847503	A 19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503	A 19920306
	PT 584446	T	20020930	PT 1993-103697	19930308

L3 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1992-847503	A 19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308
				US 1992-847503	A 19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992-847503	A 19920306
	US 5739135	A	19980414	US 1995-472067	19950606
				US 1993-117362	A2 19930903
				US 1994-284808	B2 19940805
				US 1995-391901	B2 19950221
	ZA 9601340	A	19970911	ZA 1996-1340	19960220
				US 1995-391901	A 19950221
	LT 4367	B	19980825	LT 1997-152	19970919
				US 1995-391901	A 19950221

FAN 1998:236274

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5739135	A	19980414	US 1995-472067	19950606
				US 1993-117362	A2 19930903
				US 1994-284808	B2 19940805
				US 1995-391901	B2 19950221
	CA 2091102	AA	19930907	CA 1993-2091102	19930305
				US 1992-847503	A 19920306
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503	A 19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503	A 19920306
	EP 584446	A2	19940302	EP 1993-103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1992-847503	A 19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503	A 19920306
	PT 584446	T	20020930	PT 1993-103697	19930308
				US 1992-847503	A 19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308
				US 1992-847503	A 19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992-847503	A 19920306
	US 5595872	A	19970121	US 1993-117362	19930903
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
	US 5789197	A	19980804	US 1995-486924	19950607
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
	US 6492365	B1	20021210	US 1995-486929	19950607
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
	US 5712279	A	19980127	US 1996-548811	19960111
				US 1995-391901	B2 19950221
				US 1995-472067	A2 19950606
	IL 116917	A1	20000831	IL 1996-116917	19960126
				US 1995-391901	A 19950221

L3 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

			US 1995-472067	A 19950606
TW 486469	B	20020511	TW 1996-85100978	19960126
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
CA 2213466	AA	19960829	CA 1996-2213466	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
WO 9626205	A1	19960829	WO 1996-US824	19960201
W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
AU 9647631	A1	19960911	AU 1996-47631	19960201
AU 699865	B2	19981217		
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
CN 1176640	A	19980318	CN 1996-192015	19960201
CN 1108301	B	20030514		
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
EP 886637	A1	19981230	EP 1996-903604	19960201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
JP 11500442	T2	19990112	JP 1996-525679	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
NZ 302055	A	20000228	NZ 1996-302055	19960201
			US 1995 391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
PL 185443	B1	20030530	PL 1996-322003	19960201
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
ZA 9601340	A	19970911	ZA 1996-1340	19960220
			US 1995-391901	A 19950221
US 5883099	A	19990316	US 1997-896872	19970721
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805
			US 1995-391901	B2 19950221
			US 1995-472067	A3 19950606
US 6034098	A	20000307	US 1997-898304	19970721
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805
			US 1995-391901	B2 19950221
			US 1995-472067	A3 19950606
US 6066650	A	20000523	US 1997-898303	19970721
			US 1993-117362	A2 19930903
			US 1994-284808	B2 19940805

L3 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

			US 1995-391901	B2 19950221
			US 1995-472067	A1 19950606
FI 9703416	A	19970820	FI 1997-3416	19970820
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
NO 9703821	A	19970820	NO 1997-3821	19970820
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
			WO 1996-US824	W 19960201
LT 4367	B	19980825	LT 1997-152	19970919
			US 1995-391901	A 19950221
LV 11951	B	19981120	LV 1997-171	19970919
			US 1995-391901	A 19950221
			US 1995-472067	A 19950606
US 2003166590	A1	20030904	US 2001-933593	20010821
			US 1992-847503	B2 19920306
			US 1993-15449	B2 19930222
			US 1993-117362	A3 19930903
			US 1995-486929	A3 19950607

OS MARPAT 125:275663

IT **182429-79-4P 182433-96-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 9-(piperidinoalkyl)fluorene-9-carboxamides and analogs as microsomal triglyceride transfer protein inhibitors)

RN 182429-79-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[[2-[(phenylmethyl)amino]benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 182433-96-1 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[1-oxido-4-[[2-[(phenylmethyl)amino]benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



GI

L3 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB R5Z3NRR6 [R = piperidyl group Q1; R5 = alkyl, alkoxy, (hetero)aryl, etc.; R6 = H, alk(en)yl; R5R6 = atoms to form a benzanellated ring; Z3 = CO or SO2; 1 of Z4,Z5 = NR1 and the other = CH2; R1 = e.g., (un)substituted aryl group Q2; R12 = H, (halo)alkyl, heteroaryl, etc.; Z = bond, O, S, alkylimino, etc.; Z1,Z2 = bond, O, SO0-2, CO, etc.; Z11 = bond, alkylene, arylene, etc.] were prepared as microsomal triglyceride transfer protein inhibitors (no data). Thus, N-propyl 9-fluorenecarboxamide (preparation given) was alkylated by 1(CH2)4OSiMe2CMe3 (preparation given) and the deprotected and iodinated product aminated by 2-(4-piperidinyl)-2,3-dihydro-1H-isoindol-1-one (preparation given) to give title compound I.

L3 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:571361 CAPLUS
DN 117:171361
TI Synthesis of biologically active 4(3H)-quinazolinonium perchlorates
AU Chernobrovin, N. I.; Kozhevnikov, Yu. V.; Morozova, G. E.; Chernobrovina, T. A.
CS Perm. Farm. Inst., Perm, Russia
SO Khimiko-Farmatsevticheskii Zhurnal (1992), 26(3), 48-51
CODEN: KHFZAN; ISSN: 0023-1134
DT Journal
LA Russian
IT **139602-64-5P 139602-66-7P 139602-67-8P**
139602-68-9P 139602-69-0P 139602-71-4P
139602-72-5P 139602-73-6P 143424-22-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acetylation of)
RN 139602-64-5 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 139602-66-7 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)





RN 139602-67-8 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4 methylphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139602-68-9 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-2-[[(2,4-dimethoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 139602-69-0 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 139602-71-4 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 139602-72-5 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(4 methylphenyl)- (9CI) (CA INDEX NAME)



RN 139602-73-6 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-2-[[(3,4-dimethoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 143424-22-0 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB Title salts I (R = H, 3-Me, 4-Me, 4-MeO, 4-Cl; R1 = OMe, R2 = H; R1 = H, R2 = OMe) were prepared by condensation of anthranilanilides with dimethoxybenzaldehydes, followed by borohydride reduction of the imine group, N-acetylation, and acid cyclization. The acute toxicity and anticonvulsant, analgesic, and antimicrobial activities of some I were tested.

L3 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1992:128388 CAPLUS
DN 116:128388
TI Arylamides of N-(p-2',4'- or -3',4'-dimethoxybenzyl)anthranilic acid
IN Chernobrovin, N. I.; Kozhevnikov, Yu. V.; Zalesov, V. S.; Semenova, Z. N.
PA Perm Pharmaceutical Institute, USSR
SO U.S.S.R.
From: Otkrytiya, Izobret. 1991, (28), 258.
CODEN: URXXAF
DT Patent
LA Russian
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	SU 1156362	A1	19910730	SU 1983-3573020	19830217
				SU 1983-3573020	19830217

IT **139602-64-5 139602-65-6 139602-66-7 139602-67-8 139602-68-9 139602-69-0 139602-70-3 139602-71-4 139602-72-5 139602-73-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(intermediate for quinazolinonium perchlorate deriva.)

RN 139602-64-5 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 139602-65-6 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 139602-66-7 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





RN 139602-67-8 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 139602-68-9 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-2-[[(2,4-dimethoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 139602-69-0 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)

L3 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139602-70-3 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 139602-71-4 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 139602-72-5 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139602-73-6 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-2-[[(3,4-dimethoxyphenyl)methyl]amino]-(9CI) (CA INDEX NAME)



GI



AB The title compds. (I; R = H, Me, p-Cl; R1 o-OMe, m-OMe) are intermediates for biol. active 1-(2',4'- or -3',4'-dimethoxybenzyl) 2-methyl-3-aryl-4(3H)-quinazolinonium perchlorates.

L3 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:514559 CAPLUS
DN 115:114559
TI Preparation of 5,11-dihydro-6H-dipyrido [3,2-b:2',3'-e](1,4) diazepines and their use in the prevention or treatment of HIV infection
IN Hargrave, Karl D.; Schmidt, Guenther; Engel, Wolfhard; Trummlitz, Guenther; Eberlein, Wolfgang
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl, G.m.b.H.
SO Eur. Pat. Appl., 42 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 429987	A2	19910605	EP 1990-121954	19901116
EP 429987	A3	19920122		
EP 429987	B1	19990317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
			US 1989-438923 A	19891117
			US 1990-579001 A	19900906
			US 1990-600390 A	19901019
CA 2030056	AA	19910518	CA 1990-2030056	19901115
CA 2030056	C	19951017		
			US 1989-438923 A	19891117
			US 1990-579001 A	19900906
FI 9005674	A	19910518	FI 1990-5674	19901116
FI 94529	B	19950615		
FI 94529	C	19950925		
			US 1989-438923 A	19891117
			US 1990-579001 A	19900906
			US 1990-600390 A	19901019
NO 9004986	A	19910521	NO 1990-4986	19901116
NO 175478	B	19940711		
NO 175478	C	19941019		
			US 1989-438923 A	19891117
			US 1990-579001 A	19900906
			US 1990-600390 A	19901019
HU 56103	A2	19910729	HU 1990-7186	19901116
HU 208139	B	19930830		
			US 1989-438923 A	19891117
JP 04178386	A2	19920625	JP 1990-311230	19901116
JP 2912007	B2	19990628		
			US 1989-438923 A	19891117
IL 96367	A1	19970218	IL 1990-96367	19901116
			US 1989-438923 A	19891117
			IL 1990-94883 A0	19900627
			US 1990-579001 A	19900906
			US 1990-600390 A	19901019
AT 177744	E	19990415	AT 1990-121954	19901116
			US 1989-438923 A	19891117
			US 1990-579001 A	19900906
			US 1990-600390 A	19901019
ES 2130114	T3	19990701	ES 1990-121954	19901116
			US 1989-438923 A	19891117

L3 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

			US 1990-579001 A	19900906
			US 1990-600390 A	19901019
AU 9066732	A1	19910523	AU 1990-66732	19901119
AU 630251	B2	19921022		
			US 1989-438923 A	19891117
			US 1990-579001 A	19900906
			US 1990-600390 A	19901019
ZA 9009246	A	19920729	ZA 1990-9246	19901119
			US 1989-438923 A	19891117
JP 04257584	A2	19920911	JP 1991-211068	19910822
JP 2539116	B2	19961002		
			US 1990-579001 A	19900906
			US 1990-600390 A	19901019
HU 59407	A2	19920528	HU 1991-2865	19910904
HU 214595	B	19980428		
			US 1990-579001 A	19900906
			US 1990-600390 A	19901019
RU 2040527	C1	19950725	RU 1992-5011559	19920506
			US 1989-438923 A	19891117
			US 1990-579001 A	19900906
			US 1990-600390 A	19901019
US 5366972	A	19941122	US 1993-91418	19930713
			US 1989-340970 B2	19890420
			US 1989-372974 B2	19890628
			US 1989-438923 B2	19891117
			US 1990-579001 B2	19900906
			US 1990-600390 B2	19901019
			US 1991-740828 B1	19910805
US 5620974	A	19970415	US 1994-279464	19940722
			US 1989-340970 B2	19890420
			US 1989-372974 B2	19890628
			US 1989-438923 B2	19891117
			US 1990-579001 B2	19900906
			US 1990-600390 B2	19901019
			US 1991-740828 B1	19910805
			US 1993-91418 A3	19930713
HK 1011025	A1	20000420	HK 1998-112090	19981117
			US 1989-438923 A	19891117
			US 1990-579001 A	19900906
			US 1990-600390 A	19901019

PATENT FAMILY INFORMATION:

FAN 1991:102069

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 393529	A1	19901024	EP 1990-107098	19900412
EP 393529	B1	19930630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
			US 1989-340970 A	19890420
AT 91128	E	19930715	AT 1990-107098	19900412
			US 1989-340970 A	19890420
			EP 1990-107098 A	19900412
ES 2058656	T3	19941101	ES 1990-107098	19900412
			US 1989-340970 A	19890420
CA 2014771	AA	19901020	CA 1990-2014771	19900418
CA 2014771	C	20000801		
			US 1989-340970 A	19890420
JP 03063276	A2	19910319	JP 1990-104379	19900419
JP 2851913	B2	19990127		
			US 1989-340970 A	19890420

L3 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 5366972	A	19941122	US 1993-91418	19930713
			US 1989-340970 B2	19890420
			US 1989-372974 B2	19890628
			US 1989-438923 B2	19891117
			US 1990-579001 B2	19900906
			US 1990-600390 B2	19901019
			US 1991-740828 B1	19910805
US 5620974	A	19970415	US 1994-279464	19940722
			US 1989-340970 B2	19890420
			US 1989-372974 B2	19890628
			US 1989-438923 B2	19891117
			US 1990-579001 B2	19900906
			US 1990-600390 B2	19901019
			US 1991-740828 B1	19910805
			US 1993-91418 A3	19930713

FAN 1991:449732

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 410148	A1	19910130	EP 1990-112072	19900626
EP 410148	B1	19940406		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
			US 1989-372974 A	19890628
CA 2019812	AA	19901228	CA 1990-2019812	19900626
CA 2019812	C	20001121		
			US 1989-372974 A	19890628
DD 295849	A5	19911114	DD 1990-342100	19900626
			US 1989-372974 A	19890628
AT 103918	E	19940415	AT 1990-112072	19900626
			US 1989-372974 A	19890628
			EP 1990-112072 A	19900626
ES 2063202	T3	19950101	ES 1990-112072	19900626
			US 1989-372974 A	19890628
NO 9002851	A	19910102	NO 1990-2851	19900627
NO 174468	B	19940131		
NO 174468	C	19940518		
			US 1989-372974 A	19890628
HU 55017	A2	19910429	HU 1990-4021	19900627
HU 206504	B	19921130		
			US 1989-372974 A	19890628
JP 03115283	A2	19910516	JP 1990-169663	19900627
JP 2911967	B2	19990628		
			US 1989-372974 A	19890628
ZA 9004991	A	19920325	ZA 1990-4991	19900627
			US 1989-372974 A	19890628
FI 92828	B	19940930	FI 1990-3225	19900627
FI 92828	C	19950110		
			US 1989-372974 A	19890628
IL 94883	A1	19941007	IL 1990-94883	19900627
			US 1989-372974 A	19890628
AU 9057921	A1	19910103	AU 1990-57921	19900628
AU 620724	B2	19920220		
			US 1989-372974 A	19890628
RU 2024522	C1	19941215	RU 1992-5011432	19920427
			US 1989-372974 A	19890628
US 5366972	A	19941122	US 1993-91418	19930713
			US 1989-340970 B2	19890420
			US 1989-372974 B2	19890628
			US 1989-438923 B2	19891117
			US 1990-579001 B2	19900906

L3 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1990-600390	B2 19901019
				US 1991-740828	B1 19910805
US 5620974	A	19970415		US 1994-279464	19940722
				US 1989-340970	B2 19890420
				US 1989-372974	B2 19890628
				US 1989-438923	B2 19891117
				US 1990-579001	B2 19900906
				US 1990-600390	B2 19901019
				US 1991-740828	B1 19910805
				US 1993-91418	A3 19930713

OS MARPAT 115:114559

IT **132312-45-9P 132362-76-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antiviral dihydrodipyridodiazepines)

RN 132312-45-9 CAPLUS

CN 3 Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)





RN 132362-76-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



GI



AB Title compds. I (Z = O, S, :NCN, :NOR9; R1-R8 = various subsets of groups selected from H, alkyl, cycloalkyl, fluoroalkyl, aryl, tetrahydrofuryl, alkanoyl, trihalomethyl, alkoxycarbonyl, halo, amino, and many more; R9 = C1-3 alkyl; numerous provisions and exceptions) were prepared for prevention and treatment of HIV-1 infection. For example, 2-hydroxy-4-methyl-3-nitropyridine was converted by chlorination with POCl3 and reduction to 3-amino-2-chloro-4-methylpyridine, which underwent amidation with 2-chloronicotinoyl chloride and condensation with EtNH2 to give (chloromethylpyridinyl)(ethylamino)pyridinecarboxamide II. Cyclization of II by NaH in DMF at reflux temperature gave I (Z = O, R1 = R3 =R4 = R6-R8 = H, R2 = Et, R5 = Me) (III). At 3 μg/mL, III gave 100% inhibition of HIV-1 replication in a human T-cell culture assay. III also gave 100% inhibition of HIV-1 reverse transcriptase at 10 μg/mL in vitro; no activity was seen for I against 2 related enzymes, indicating high specificity. Three formulations, 77 synthetic examples, and addnl. test results including cytotoxicity are given.

L3 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:449732 CAPLUS

DN 115:49732

TI Preparation of 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-ones and thiones and their use in the prevention or treatment of AIDS

IN Schmidt, Guenther; Engel, Wolfhard; Trummlitz, Guenter; Eberlein, Wolfgang; Hargrave, Karl D.

PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl, G.m.b.H.

SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 410148	A1	19910130	EP 1990-112072	19900626
EP 410148	B1	19940406		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
			US 1989-372974 A	19890628
CA 2019812	AA	19901228	CA 1990-2019812	19900626
CA 2019812	C	20001121		
			US 1989-372974 A	19890628
DD 295849	A5	19911114	DD 1990-342100	19900626
			US 1989-372974 A	19890628
AT 103918	E	19940415	AT 1990-112072	19900626
			US 1989-372974 A	19890628
			EP 1990-112072 A	19900626
ES 2063202	T3	19950101	ES 1990-112072	19900626
			US 1989-372974 A	19890628
NO 9002851	A	19910102	NO 1990-2851	19900627
NO 174468	B	19940131		
NO 174468	C	19940518		
			US 1989-372974 A	19890628
HU 55017	A2	19910429	HU 1990-4021	19900627
HU 206504	B	19921130		
			US 1989-372974 A	19890628
JP 03115283	A2	19910516	JP 1990-169663	19900627
JP 2911967	B2	19990628		
			US 1989-372974 A	19890628
ZA 9004991	A	19920325	ZA 1990-4991	19900627
			US 1989-372974 A	19890628
FI 92828	B	19940930	FI 1990-3225	19900627
FI 92828	C	19950110		
			US 1989-372974 A	19890628
IL 94883	A1	19941007	IL 1990-94883	19900627
			US 1989-372974 A	19890628
AU 9057921	A1	19910103	AU 1990-57921	19900628
AU 620724	B2	19920220		
			US 1989-372974 A	19890628
RU 2024522	C1	19941215	RU 1992-5011432	19920427
			US 1989-372974 A	19890628
US 5366972	A	19941122	US 1993-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805

L3 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 5620974	A	19970415		US 1994-279464	19940722
				US 1989-340970	B2 19890420
				US 1989-372974	B2 19890628
				US 1989-438923	B2 19891117
				US 1990-579001	B2 19900906
				US 1990-600390	B2 19901019
				US 1991-740828	B1 19910805
				US 1993-91418	A3 19930713

PATENT FAMILY INFORMATION:

FAN 1991:102069

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 393529	A1	19901024	EP 1990-107098	19900412
EP 393529	B1	19930630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
			US 1989-340970 A	19890420
AT 91128	E	19930715	AT 1990-107098	19900412
			US 1989-340970 A	19890420
			EP 1990-107098 A	19900412
ES 2058656	T3	19941101	ES 1990-107098	19900412
			US 1989-340970 A	19890420
CA 2014771	AA	19901020	CA 1990-2014771	19900418
CA 2014771	C	20000801		
			US 1989-340970 A	19890420
JP 03063276	A2	19910319	JP 1990-104379	19900419
JP 2851913	B2	19990127		
			US 1989-340970 A	19890420
US 5366972	A	19941122	US 1993-91418	19930713
			US 1989-340970 B2	19890420
			US 1989-372974 B2	19890628
			US 1989-438923 B2	19891117
			US 1990-579001 B2	19900906
			US 1990-600390 B2	19901019
US 5620974	A	19970415	US 1991-740828 B1	19910805
			US 1994-279464	19940722
			US 1989-340970 B2	19890420
			US 1989-372974 B2	19890628
			US 1989-438923 B2	19891117
			US 1990-579001 B2	19900906
			US 1990-600390 B2	19901019
			US 1991-740828 B1	19910805
			US 1993-91418 A3	19930713

FAN 1991:514559

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 429987	A2	19910605	EP 1990-121954	19901116
EP 429987	A3	19920122		
EP 429987	B1	19990317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
			US 1989-438923 A	19891117
			US 1990-579001 A	19900906
			US 1990-600390 A	19901019
CA 2030056	AA	19910518	CA 1990-2030056	19901115
CA 2030056	C	19951017		
			US 1989-438923 A	19891117
			US 1990-579001 A	19900906
FI 9005674	A	19910518	FI 1990-5674	19901116
FI 94529	B	19950615		
FI 94529	C	19950925		

L3 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	NO 9004986	A	19910521	NO 1990-4986	19901116
	NO 175478	B	19940711		
	NO 175478	C	19941019		
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	HU 56103	A2	19910729	HU 1990-7186	19901116
	HU 208139	B	19930830		
				US 1989-438923	A 19891117
	JP 04178386	A2	19920625	JP 1990-311230	19901116
	JP 2912007	B2	19990628		
				US 1989-438923	A 19891117
	IL 96367	A1	19970218	IL 1990-96367	19901116
				US 1989-438923	A 19891117
				IL 1990-94883	A0 19900627
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	AT 177744	E	19990415	AT 1990-121954	19901116
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	ES 2130114	T3	19990701	ES 1990-121954	19901116
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	AU 9066732	A1	19910523	AU 1990-66732	19901119
	AU 630251	B2	19921022		
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	ZA 9009246	A	19920729	ZA 1990-9246	19901119
				US 1989-438923	A 19891117
	JP 04257584	A2	19920911	JP 1991-211068	19910822
	JP 2539116	B2	19961002		
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	HU 59407	A2	19920528	HU 1991-2865	19910904
	HU 214595	B	19980428		
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	RU 2040527	C1	19950725	RU 1992-5011559	19920506
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970	B2 19890420
				US 1989-372974	B2 19890628
				US 1989-438923	B2 19891117
				US 1990-579001	B2 19900906
				US 1990-600390	B2 19901019
				US 1991-740828	B1 19910805
	US 5620974	A	19970415	US 1994-279464	19940722

L3 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1989-340970	B2 19890420
				US 1989-372974	B2 19890628
				US 1989-438923	B2 19891117
				US 1990-579001	B2 19900906
				US 1990-600390	B2 19901019
				US 1991-740828	B1 19910805
				US 1993 91418	A3 19930713
	HK 1011025	A1	20000420	HK 1998-112090	19981117
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019

OS MARPAT 115:49732

IT **132312-45-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of drug for treatment of AIDS)

RN 132312-45-9 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)





GI



I

AB The title compds. I [Z = O, S; R1 = H, (substituted) alkyl, arylmethyl,

L3 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

etc.; R2 = H, (substituted) alkyl, alkenyl, etc.; R3-R8 = H, or 1 of R3-R8 is alkyl, alkoxy, alkylthio, etc., and the remaining 5 of R3-R8 are each H, or R3 R5 are H, alkyl with the proviso that at least one is H or 1 of R3 R5 is Bu with the remaining 2 being H; and R6-R8 are H, alkyl with the proviso that at least 1 is H, or 1 of R6-R8 is Bu with the remaining 2 being H; with the proviso that when R1 and R2 are H, alkyl and R3-R8 are all H then Z is S] were prepd. A mixt. of 5,11-dihydro-11-ethyl-5-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one and Lawesson's reagent in toluene was refluxed for 2.5 h to give I (R1 = Me; Z = S; R2 = Et; R3 = R4 = R5 = R6 = R7 = R8 = H), which at 10 μg/mL gave 100% in vitro inhibition of reverse transcriptase.

L3 ANSWER 27 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:449642 CAPLUS

DN 115:49642

TI Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones

AU Hargrave, Karl D.; Proudfoot, John R.; Grozinger, Karl G.; Cullen, Ernest; Kapadia, Suresh R.; Patel, Usha R.; Fuchs, Victor U.; Mauldin, Scott C.; Vitous, Jana; et al.

CS Boehringer Ingelheim Pharm., Inc., Ridgefield, CT, 06877, USA

SO Journal of Medicinal Chemistry (1991), 34(7), 2231-41
CODEN: JMCMAR; ISSN: 0022 2623

DT Journal

LA English

OS CASREACT 115:49642

IT **132312-45-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and reductive intramol. cyclocondensation of, dipyridodiazepinone from)

RN 132312-45-9 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)





GI



I II

AB Novel pyrido[2,3-b][1,4]benzodiazepinones, pyrido[2,3-b][1,5]benzodiazepinones, and dipyrido[3,2-b:2',3'-e][1,4]diazepinones e.g., I (X = N, X1 = CH; X = CH; X1 = N) and II inhibited human immunodeficiency virus type 1 reverse transcriptase in vitro at concns.

L3 ANSWER 27 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

low as 35 nM. In all three series, small substituents (e.g., Me, Et, Ac) are preferred at the lactam nitrogen, whereas slightly larger alkyl moieties (e.g., Et, cyclopropyl) are favored at the other (N-11) diazepinone nitrogen. In general, lipophilic substituents are preferred on the A ring, whereas substitution on the C ring generally reduces potency relative to the corresponding compds. with no substituents on the arom. ring. Max. potency is achieved with Me substitution at the position

ortho to the lactam nitrogen atom; however, in this case an unsubstituted lactam nitrogen is preferred. Addnl. substituents on the A ring can be readily tolerated. II (BI-RG-587) is a potent (IC50 = 84 nM) and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, and has

been chosen for preclin. development. II is noncytotoxic except at high doses and effective against all clin. isolates of HIV-1, including those which are AZT-resistant. It is specific for HIV-1, ineffective against HIV-2, inactive against simian and feline reverse transcriptase, and does not inhibit DNA polymerases.

L3 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:102069 CAPLUS

DN 114:102069

TI Preparation of 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-ones as drugs for prevention or treatment of AIDS

IN Schmidt, Guenther; Engel, Wolfhard; Trummlitz, Guenter; Eberlein, Wolfgang; Hargrave, Karl D.

PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl, G.m.b.H.

SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 393529	A1	19901024	EP 1990-107098	19900412
	EP 393529	B1	19930630		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1989-340970 A	19890420
	AT 91128	E	19930715	AT 1990-107098	19900412
				US 1989-340970 A	19890420
				EP 1990-107098 A	19900412
	ES 2058656	T3	19941101	ES 1990-107098	19900412
				US 1989-340970 A	19890420
	CA 2014771	AA	19901020	CA 1990-2014771	19900418
	CA 2014771	C	20000801		
				US 1989-340970 A	19890420
	JP 03063276	A2	19910319	JP 1990-104379	19900419
	JP 2851913	B2	19990127		
				US 1989-340970 A	19890420
	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
	US 5620974	A	19970415	US 1994-279464	19940722
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
				US 1993-91418 A3	19930713

PATENT FAMILY INFORMATION:

FAN 1991:449732

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 410148	A1	19910130	EP 1990-112072	19900626
	EP 410148	B1	19940406		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1989-372974 A	19890628
	CA 2019812	AA	19901228	CA 1990-2019812	19900626

L3 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	CA 2019812	C	20001121		
				US 1989-372974 A	19890628
	DD 295849	A5	19911114	DD 1990-342100	19900626
				US 1989-372974 A	19890628
	AT 103918	E	19940415	AT 1990-112072	19900626
				US 1989-372974 A	19890628
				EP 1990-112072 A	19900626
	ES 2063202	T3	19950101	ES 1990-112072	19900626
				US 1989-372974 A	19890628
	NO 9002851	A	19910102	NO 1990-2851	19900627
	NO 174468	B	19940131		
	NO 174468	C	19940518		
				US 1989-372974 A	19890628
	HU 55017	A2	19910429	HU 1990-4021	19900627
	HU 206504	B	19921130		
				US 1989-372974 A	19890628
	JP 03115283	A2	19910516	JP 1990-169663	19900627
	JP 2911967	B2	19990628		
				US 1989-372974 A	19890628
	ZA 9004991	A	19920325	ZA 1990-4991	19900627
				US 1989-372974 A	19890628
	FI 92828	B	19940930	FI 1990-3225	19900627
	FI 92828	C	19950110		
				US 1989-372974 A	19890628
	IL 94883	A1	19941007	IL 1990-94883	19900627
				US 1989-372974 A	19890628
	AU 9057921	A1	19910103	AU 1990-57921	19900628
	AU 620724	B2	19920220		
				US 1989-372974 A	19890628
	RU 2024522	C1	19941215	RU 1992-5011432	19920427
				US 1989-372974 A	19890628
	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
	US 5620974	A	19970415	US 1994-279464	19940722
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
				US 1993-91418 A3	19930713

FAN 1991:514559

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 429987	A2	19910605	EP 1990-121954	19901116
	EP 429987	A3	19920122		
	EP 429987	B1	19990317		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	CA 2030056	AA	19910518	CA 1990-2030056	19901115
	CA 2030056	C	19951017		
				US 1989-438923 A	19891117

L3 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1990-579001	A 19900906
	FI 9005674	A	19910518	FI 1990-5674	19901116
	FI 94529	B	19950615		
	FI 94529	C	19950925		
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	NO 9004986	A	19910521	NO 1990-4986	19901116
	NO 175478	B	19940711		
	NO 175478	C	19941019		
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	HU 56103	A2	19910729	HU 1990-7186	19901116
	HU 208139	B	19930830		
				US 1989-438923	A 19891117
	JP 04178386	A2	19920625	JP 1990-311230	19901116
	JP 2912007	B2	19990628		
				US 1989-438923	A 19891117
	IL 96367	A1	19970218	IL 1990-96367	19901116
				US 1989-438923	A 19891117
				IL 1990-94883	A0 19900627
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	AT 177744	E	19990415	AT 1990-121954	19901116
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	ES 2130114	T3	19990701	ES 1990-121954	19901116
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	AU 9066732	A1	19910523	AU 1990-66732	19901119
	AU 630251	B2	19921022		
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	ZA 9009246	A	19920729	ZA 1990-9246	19901119
				US 1989-438923	A 19891117
	JP 04257584	A2	19920911	JP 1991-211068	19910822
	JP 2539116	B2	19961002		
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	HU 59407	A2	19920528	HU 1991-2865	19910904
	HU 214595	B	19980428		
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	RU 2040527	C1	19950725	RU 1992-5011559	19920506
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970	B2 19890420
				US 1989-372974	B2 19890628
				US 1989-438923	B2 19891117
				US 1990-579001	B2 19900906
				US 1990-600390	B2 19901019
				US 1991-740828	B1 19910805
	US 5620974	A	19970415	US 1994-279464	19940722

L3 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

			US 1989-340970	B2	19890420
			US 1989-372974	B2	19890628
			US 1989-438923	B2	19891117
			US 1990-579001	B2	19900906
			US 1990-600390	B2	19901019
			US 1991-740828	B1	19910805
			US 1993-91418	A3	19930713
HK 1011025	A1	20000420	HK 1998-112090		19981117
			US 1989-438923	A	19891117
			US 1990-579001	A	19900906
			US 1990-600390	A	19901019

OS MARPAT 114:102069
IT **132312-45-9P 132362-76-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for dipyridodiazepinone reverse transcriptase inhibitor)
RN 132312-45-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)





RN 132362-76-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I



II

AB The title compds. (I; R1, R2 = H, C1-5 alkyl), were prepared Thus, N-(2-chloro-3-pyridinyl)-2-[[(4-methoxyphenyl)methyl]amino]-3-pyridinecarboxamide (preparation given) was refluxed 8 h with NaH in DMF to give 50% 5,11-dihydro-11-[(4-methoxyphenyl)methyl]-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, which was converted to title compound II in 3 steps.
II at 10 μg/mL gave 100% inhibition of HIV-I reverse transcriptase. Dosage formulations were prepared containing I (R1 = H, R2 = Pr).

L3 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1984:611088 CAPLUS
DN 101:211088
TI Studies of 4[3H]-quinazolone. XII. Synthesis and biological activity of 1-benzyl(4'-nitrobenzyl)-2 methyl-3-alkyl(aryl)-4(3H)-quinazolinone perchlorates
AU Chernobrovin, N. I.; Kozhevnikov, Yu. V.; Zalesov, V. S.; Gradel, I. I.
CS Perm. Farm. Inst., Perm, USSR
SO Khimiko-Farmatsevticheskii Zhurnal (1984), 18(7), 830-3
CODEN: KHFZAN; ISSN: 0023-1134
DT Journal
LA Russian
IT **92944-76-8P 92944-77-9P 92944-78-0P**
92944-79-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acetylation of)
RN 92944-76-8 CAPLUS
CN Benzamide, N-(2,4-dimethylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 92944-77-9 CAPLUS
CN Benzamide, N-(4-methoxyphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 92944-78-0 CAPLUS
CN Benzamide, N-(4-methoxyphenyl)-2-[[(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 92944-79-1 CAPLUS
CN Benzamide, N-(4-ethoxyphenyl)-2-[[(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



GI



I

L3 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
AB The title compds. I (R = 2,4-xylyl, 4-MeOC6H4, Bu, hexyl, R1 = H; R = 4-MeOC6H4, 4-EtOC6H4, R1 = NO2) were prepared in 58.6-83.4% yields by acetylation of o-RNHCOC6H4NR2CH2C6H4R1-p (II, R2 = H) to give 61.3-98.1% II (R2 = Ac) which were cyclized by refluxing in MeOH containing 57% HClO4. I (R = 4-MeOC6H4, R1 = NO2) was an effective antispasmodic for white mice at 150 mg/kg dosage.

L3 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1984:34516 CAPLUS
DN 100:34516
TI New synthesis of 11-acyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones and related studies
AU Kovac, T.; Oklobdzija, M.; Comisso, G.; Decorte, E.; Fajdiga, T.; Moimas, F.; Angeli, C.; Zonno, F.; Toso, R.; Sunjic, V.
CS Chem. Res. Co., San Giovanni, Italy
SO Journal of Heterocyclic Chemistry (1983), 20(5), 1339-49
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 100:34516
IT **88369-73-7P 88369-74-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 88369-73-7 CAPLUS
CN Benzamide, N-(2-chloro-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 88369-74-8 CAPLUS
CN Benzamide, N-(2-chloro-1-oxido-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI)
(CA INDEX NAME)



GI

L3 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB 11-Acyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones I (R = 4-methylpiperazino, imidazolo, 2-methylimidazolo) were prepared via N-α-chloroacetylation and aminolysis. Other attempts at cyclization to form I are also reported.

L3 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1977:171214 CAPLUS
DN 86:171214
TI Synthesis and pharmacological properties of 2-aminonicotinamide derivatives
AU Zhmurenko, L. A.; Borisenko, S. A.; Salimov, R. M.; Glozman, O. M.; Zagorevskii, V. A.
CS Nauchno-Issled. Inst. Farmakol., Moscow, USSR
SO Fiziologicheski Aktivnye Veshchestva (1976), 8, 89-92
CODEN: FAVUAI; ISSN: 0533-1153
DT Journal
LA Russian
IT **62636-33-3P 62636-39-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and pharmacol. properties of)
RN 62636-33-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 62636-39-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-methoxyphenyl)-2-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

GI



I

AB The title compds. I (R = H, m-F3CC6H4, o-MeOC6H4, NR21 = HOCH2CH2NH,

L3 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
PhCH2NH, 4-methyl-1-piperazinyl, 4-(2-hydroxyethyl)-1-piperazinyl, piperidino], useful as sedatives and muscle relaxants, were obtained in 56-98% yields by amination of chloronicotinamides with R21NH.

L3 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Et3N; after 30 min, ice-cold 6-aminopenicillanic acid and Et3N in CHCl3 was added and the soln. kept 12 hr to give, after alk. addn., Na 6-(3-benzyloxy-2-picolinamido)penicillanate. Prepd. similarly were: Na 7-(3-benzyloxy-2-picolinamido)cephalosporanate, Na 6-(3-hydroxy-2-picolinamido)penicillanate, and Na 7-(3-hydroxy-2-picolinamido)-cephalosporanate.

L3 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1971:76431 CAPLUS
DN 74:76431
TI 3-Substituted picolinyl penicillins and cephalosporins, useful as animal feed supplements and in germicidal preparations employed as surface disinfectants
IN Schwarz, J. S. Paul; Sheehan, John T.
PA E. R. Squibb and Sons, Inc.
SO U.S., 11 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3553203	A	19710105	US 1969-834157	19690617
	BR 6915314	A0	19730419	BR 1969-215314	19691219
				US 1969-834157	19690617
	CA 963003	A1	19750218	CA 1970-85025	19700609
				US 1969-834157	19690617
	DE 2028830	A	19710107	DE 1970-2028830	19700611
				US 1969-834157	19690617
	CH 517116	A	19711231	CH 1970-517116	19700616
				US 1969-834157	19690617
	FR 2052982	A1	19710416	FR 1970-22345	19700617
	FR 2052982	A5	19710416		
				US 1969-834157	19690617

IT **30861-03-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 30861-03-1 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[3-(benzylamino)picolinamido]-3,3-dimethyl-7-oxo-, monosodium salt (8CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

AB The title compds. were prepared Thus, ClCO2Et was added to an ice-cold solution of 3-benzyloxy-2-picolinic acid-HCl sesquihydrate in CHCl3 containing

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	253.01	408.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-23.52	-23.52

STN INTERNATIONAL LOGOFF AT 10:17:57 ON 14 AUG 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	May 12	EXTEND option available in structure searching
NEWS	4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS	6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:10:15 ON 14 AUG 2004

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:10:31 ON 14 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2004 HIGHEST RN 726125-61-7
DICTIONARY FILE UPDATES: 12 AUG 2004 HIGHEST RN 726125-61-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10823809.4

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Cb,Hy
G2 N,CH

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

```
FULL SEARCH INITIATED 10:10:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 525425 TO ITERATE

 76.1% PROCESSED  400000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.07

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       525425 TO   525425
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS FUL L1

=> log y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               155.42     155.63

STN INTERNATIONAL LOGOFF AT 10:11:06 ON 14 AUG 2004
```

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	May 12	EXTEND option available in structure searching
NEWS	4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS	6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:01:02 ON 14 AUG 2004

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:01:13 ON 14 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2004 HIGHEST RN 726125-61-7
DICTIONARY FILE UPDATES: 12 AUG 2004 HIGHEST RN 726125-61-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10823809.2

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Cb,Hy
G2 N,CH

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 10:01:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 40288 TO ITERATE

100.0% PROCESSED 40288 ITERATIONS 239 ANSWERS
SEARCH TIME: 00.00.01

L2 239 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'CAPLUS' ENTERED AT 10:01:41 ON 14 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Aug 2004 VOL 141 ISS 8
FILE LAST UPDATED: 13 Aug 2004 (20040813/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 49 L2

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:589247 CAPLUS
TI Preparation of heterocyclic compounds as selective phosphodiesterase V inhibitors
IN Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohei
PA Japan
SO U.S. Pat. Appl. Publ., 116 pp., Cont.-in-part of U.S. Ser. No. 258,545.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2004142930	A1	20040722	US 2003-699804		20031104
				JP 2000-130371	A	20000428
				JP 2000-277652	A	20000913
				WO 2001-JP2034	W	20010315
				US 2002-258545	A2	20021025
	JP 2002012587	A2	20020115	JP 2000-277652		20000913
				JP 1999-261852	A	19990916
				JP 2000-130371	A	20000428
	WO 2001083460	A1	20011108	WO 2001-JP2034		20010315
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
				JP 2000-130371	A	20000428
	US 2003229089	A1	20031211	US 2002-258545		20021025
				JP 2000-130371	A	20000428
				WO 2001-JP2034	W	20010315

PATENT FAMILY INFORMATION:
FAN 2001:208252

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2001019802	A1	20010322	WO 2000-JP6258		20000913
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
				JP 1999-261852	A	19990916
				JP 2000-130371	A	20000428
	AU 2000073118	A5	20010417	AU 2000-73118		20000913
	AU 767558	B2	20031113			
				JP 1999-261852	A	19990916
				JP 2000-130371	A	20000428
				WO 2000-JP6258	W	20000913

L3 ANSWER 1 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	BR 2000014526	A	20020618	BR 2000-14526	20000913
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	W 20000918
	TR 200200701	T2	20020621	TR 2002-200200701	20000913
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
	EP 1219609	A1	20020703	EP 2000-960979	20000913
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	W 20000913
	RU 2233273	C2	20040727	RU 2002-109792	20000913
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	W 20000913
	US 2003032647	A1	20030213	US 2001-925892	20010810
	US 6656935	B2	20031202		
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	A1 20000913
	ZA 2002001499	A	20020902	ZA 2002-1499	20020222
				JP 1999-261852	A 19990916
	NO 2002001308	A	20020424	NO 2002-1308	20020315
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	W 20000913
	BG 106566	A	20030228	BG 2002-106566	20020402
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	W 20000913
	US 2003229095	A1	20031211	US 2003-426884	20030501
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	A1 20000913
				US 2001-925892	A3 20010810

FAN 2001:816647

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2001083460	A1	20011108	WO 2001-JP2034		20010315
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
				JP 2000-130371	A	20000428
	AU 2001041142	A5	20011112	AU 2001-41142		20010315
				JP 2000-130371	A	20000428
				WO 2001-JP2034	W	20010315
	EP 1277741	A1	20030122	EP 2001-912373		20010315

L3 ANSWER 1 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

				JP 2000-130371	A 20000428
				WO 2001-JP2034	W 20010315
	NZ 522217	A	20040430	NZ 2001-522217	20010315
				JP 2000-130371	A 20000428
				WO 2001-JP2034	W 20010315
	US 2003229089	A1	20031211	US 2002-258545	20021025
				JP 2000-130371	A 20000428
				WO 2001-JP2034	W 20010315
	US 2004142930	A1	20040722	US 2003-699804	20031104
				JP 2000-130371	A 20000428
				JP 2000-277652	A 20000913
				WO 2001-JP2034	W 20010315
				US 2002-258545	A2 20021025

IT **372115-86-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as selective phosphodiesterase V inhibitors for treating various diseases due to functional disorders on cGMP-signaling)
RN 372115-86-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-chloro-4-methoxyphenyl]methyl]amino]-N-(trans-4-hydroxycyclohexyl)-6-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI

L3 ANSWER 1 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title compds. (I) [X = CH, N; Y = NH, NR, S, O, CH:N, N:CH, N:N, CH:CHC(:R5)N, CH:C(R5), N:C(R7); R1 = each (un)substituted lower alkoxy, amino, heterocyclyl containing N atom(s), HO, or heterocyclyloxy containing N atom(s), cyano; R2 = lower alkylamino or lower alkoxy each optionally substituted by an (un)substituted aryl, lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), lower alkylamino group substituted by a (un)substituted heterocyclic ring, (un)substituted arylamino; R3 = each (un)substituted aryl, heterocyclyl containing N atom(s), lower alkyl, lower alkoxy, lower cycloalkoxy, heterocyclyloxy containing N atom(s), or NH2; R4-R7 = each (un)substituted aryl, heterocyclyl containing N atom(s), lower alkoxy, or NH2; R4, R5, R6 or R7 may combine with R3 to form a lactone ring Q or Q1; when X = N, Y = CH:N, or N:CH, R2 = an amino group monosubstituted by an (un)substituted arylmethyl, and R3 = (un)substituted lower alkyl, amino monosubstituted by an (un)substituted heterocyclyl-lower alkyl containing N atom(s) in the ring, heterocyclylamino containing N atom(s) in the ring, or (un)substituted lower cycloalkylamino, R1 = each (un)substituted lower alkoxy, amino, heterocyclyloxy containing N atom(s) in the ring, or cyano group] or pharmacol. acceptable salts thereof are prepared. These compds. have excellent selective PDE V inhibitory activity and therefore, are useful as therapeutic or prophylactic drugs for treating various diseases due to functional disorders on cGMP-signaling, such as erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis. Thus, 2-(hydroxymethyl)pyridine was treated with NaH in THF and etherified with 2-chloro-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine to give 2-(2-pyridylmethoxy)-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine.

L3 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:41461 CAPLUS
DN 140:93789
TI Preparation of substituted anthranilic amide derivatives as VEGF modulators and methods of use against cancer and other disorders
IN Huang, Qi; Chen, Guoqing; Li, Aiwen; Riahi, Babak; Tasker, Andrew; Yang, Kevin; Yuan, Chester Chenguang
PA Amgen Inc., USA
SO PCT Int. Appl., 204 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004005279	A2	20040115	WO 2003-US21601	20030709
WO 2004005279	A3	20040311		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2002-395144P	P 20020709
			US 2003-615809	A 20030708
US 2004087568	A1	20040506	US 2003-615809	20030708
			US 2002-395144P	P 20020709

OS MARPAT 140:93789
IT **645418-48-0P**, N-(1-Acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(4-fluorobenzylamino)benzamide **645418-50-4P**, 2-(4-Fluorobenzylamino)-N-[4-[1-methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide **645418-56-0P**, N-[3,3-Dimethyl-1-[(4-methylpiperazin-1-yl)carbonyl]-2,3-dihydro 1H-indol-6-yl]-2-(4-fluorobenzylamino)benzamide **645418-64-0P**, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-(4-fluorobenzylamino)benzamide **645418-68-4P**, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-fluoro-6-(4-fluorobenzylamino)benzamide **645418-69-5P**, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-fluoro-6-(4-fluorobenzylamino)benzamide **645418-70-8P**, N (4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3,4-difluoro-6-(4-fluorobenzylamino)benzamide **645418-98-0P**, 4,4-Dimethyl-7 [[2-[[(quinoxalin-5-yl)methyl]amino]benzoyl]amino]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester **645418-99-1P**, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-[[(quinoxalin-5-yl)methyl]amino]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted anthranilic amide derivs. as

L3 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
VEGF modulators and methods of use against cancer and other disorders)
RN 645418-48-0 CAPLUS
CN Benzamide, N-(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 645418-50-4 CAPLUS
CN Benzamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1 (1 methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 645418-56-0 CAPLUS
CN Benzamide, N-[2,3-dihydro-3,3-dimethyl-1-[(4-methyl-1-piperazinyl)carbonyl]-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 645418-64-0 CAPLUS
CN Benzamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 645418-68-4 CAPLUS
CN Benzamide, 5-fluoro-2 [[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 645418-69-5 CAPLUS
CN Benzamide, 4-fluoro-2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 645418-70-8 CAPLUS
CN Benzamide, 4,5-difluoro-2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 645418-98-0 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-4,4-dimethyl-7-[[2-[(5-quinoxalinylmethyl)amino]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 645418-99-1 CAPLUS
CN Benzamide, 2-[(5-quinoxalinylmethyl)amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **645418-65-1P**, 7-[[2-(4-Fluorobenzylamino)benzoyl]amino]-4,4-dimethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted anthranilic amide derivs. as VEGF modulators and
methods of use against cancer and other disorders)
RN 645418-65-1 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-[[2-[[(4-fluorophenyl)methyl]amino]benzoyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



GI

L3 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



II

AB Selected substituted anthranilic amide derivs. (shown as I; variables defined below; e.g. II) are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving cancer and the like. Although the methods of preparation are not
claimed, .apprx.139 example prepns. of I and .apprx.80 of intermediates are included. For example, II was prepared in 3 steps starting from 2-nitrobenzoic acid and [4-[1-Methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]amine and involving intermediates
2-nitro-N-[4-[1-methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide and
2-amino-N-[4-[1-methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide. Compds. I showed inhibition of KDR at doses <50 μM. Some of the exemplified I inhibit VEGF-stimulated HUVEC proliferation <1 μM. Compds. I are active at doses <150 mpk in a tumor model. For I: R = (un)substituted 9- or 10-membered fused heterocyclyl, -(CH2)1-2-R3; R1 = (un)substituted 5-6 membered saturated or partially saturated heterocyclyl, 9-10 membered bicyclic and
13-14 membered tricyclic saturated or partially saturated heterocyclyl, and
phenyl; R2 is ≥1 substituents = H, halo, hydroxy, amino, C1-6-alkyl, C1-6-haloalkyl, C1-6-alkoxy, C1-2-alkylamino, aminosulfonyl, C3-6-cycloalkyl, cyano, C1-2-hydroxyalkyl, nitro, C2-3-alkenyl, C2-3-alkynyl, C1-6-haloalkoxy, C1-6-carboxyalkyl, 4-6-membered heterocyclyl-C1-6-alkylamino, (un)substituted Ph and (un)substituted 4-6 membered heterocyclyl; Ra = H, C1-2-alkyl; addnl. details are given in the
claims.

L3 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:950836 CAPLUS
DN 140:16722
TI Preparation of 1,1-disubstituted cycloalkyl derivatives as factor Xa inhibitors for treating a thromboembolic disorder
IN Qiao, Jennifer X.; Pinto, Donald J.; Orwat, Michael J.; Han, Wei; Friedrich, Sarah R.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 686 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003099276	A1	20031204	WO 2003-US13893	20030505
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-379357P	P 20020510
			US 2002-415367P	P 20021002

OS MARPAT 140:16722
IT **630385-55-6P 630385-58-9P 630385-59-0P 630388-70-4P 630388-71-5P 630388-72-6P 630388-73-7P 630388-74-8P 630388-75-9P 630388-76-0P 630388-77-1P 630388-84-0P 630388-85-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 1,1-disubstituted cycloalkyl derivs. as
factor Xa inhibitors for treating thromboembolic disorder)
RN 630385-55-6 CAPLUS
CN Benzeneacetic acid, 4-[[[2-[[(5-chloro-2-pyridinyl)amino]carbonyl]phenyl]amino]methyl]-α,α-dimethyl-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





RN 630385-58-9 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(2-hydroxy-1,1-dimethylethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 630385-59-0 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[2-(dimethylamino)-1,1-dimethylethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 630388-70-4 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[(2-oxo-1-

L3 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
pyrrolidinyl]methyl]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 630388-71-5 CAPLUS
CN Benzamide,
2-[[[4-[1-[(acetylmethylamino)methyl]cyclopropyl]phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 630388-72-6 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[[methyl[(methylamino)carbonyl]amino]methyl]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 630388-75-9 CAPLUS
CN Benzamide, 2-[[[4-[1-(acetylamino)cyclopropyl]phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 630388-76-0 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[[(2-hydroxyethyl)amino]methyl]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 630388-77-1 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[[(2-hydroxyethyl)methylamino]methyl]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 630388-73-7 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[[methyl(methylsulfonyl)amino]methyl]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 630388-74-8 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[(methylsulfonyl)amino]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 630388-84-0 CAPLUS
CN Benzamide,
5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[2-(dimethylamino)-2-oxoethyl]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 630388-85-1 CAPLUS
CN Benzamide,
2-[[[4-[1-(2-amino-2-oxoethyl)cyclopropyl]phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB The present application describes 1,1-disubstituted cycloalkyl compds. and
derivs. thereof (P4-P M-M4; variables defined below; most of the examples
contain 1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, e.g. the
trifluoroacetate of I), or pharmaceutically acceptable salt forms thereof,
which are useful as inhibitors of factor Xa for treatment of a
thromboembolic disorder. Although the methods of preparation are not claimed,
.apprx.240 example prepns. are included. A number of I exhibit Ki's of <10
μM towards factor Xa; also some I are direct acting inhibitors (Ki < 10
μM) of the serine protease thrombin as indicated by their ability to
inhibit the cleavage of small mol. substrates by thrombin in a purified
system; the specific compds. are not stated. For I: M is a 3-10 membered
carbocycle or a 4-10 membered heterocycle, consisting of: C atoms and 1-3
heteroatoms = O, S(O)p, N, and NZ2; ring M is substituted with 0-3 R1a and
0-2 carbonyl groups, and there are 0-3 ring double bonds; P is fused onto
ring M and is a 5, 6, or 7 membered carbocycle or a 5, 6, or 7 membered
heterocycle, consisting of: C atoms and 1-3 heteroatoms = O, S(O)p, and N;
ring P is substituted with 0-3 R1a and 0-2 carbonyl groups, and there are
0-3 ring double bonds; alternatively, ring P is absent and P4 is directly
attached to ring M, provided that when ring P is absent, P4 and M4 are
attached to the 1,2, 1,3, or 1,4 positions of ring M. One of P4 and M4 is
Z A-B and the other -G1-G, provided that P4 and M4 are attached to
different rings when ring P is present; G is consists of 2 fused rings D
and E (ring D, including the two atoms of Ring E to which it is attached,
is a 5-6 membered ring consisting of carbon atoms and 0-2 heteroatoms
selected from the group consisting of N, O, and S(O)p; E is selected from
(un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl;
alternatively, ring D is absent and ring E is selected from
(un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl,

L3 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, thienyl, and
thiazolyl); G1 is absent or = (CR3R3a)1-5, etc. A = (un)substituted C3-10
carbocycle and 5-12 membered heterocycle consisting of: C atoms and 1-4
heteroatoms N, O, and S(O)p; B is Y-R4a or X-Y-R4a, provided that Z and B
are attached to different atoms on A and A and R4a or X and R4a are
attached to the same atom on Y; Z = a bond, -(CR3R3e)1-4-, etc. Addnl.
details including provisos are given in the claims.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:950057 CAPLUS
DN 140:16647
TI Preparation of 2 aminopyridine-3-carboxamides as remedies for angiogenesis
mediated diseases
IN Askew, Benny; Adams, Jeffrey; Booker, Shon; Chen, Guoqing; Dipietro, Lucian V.; Elbaum, Daniel; Germain, Julie; Geuns-Meyer, Stephanie D.; Habgood, Gregory J.; Handley, Michael; Huang, Qi; Kim, Tae-seong; Li, Aiwen; Nishimura, Nobuko; Nomak, Rana; Patel, Vinod P.; Riahi, Babak; Kim,
Joseph L.; Xi, Ning; Yang, Kevin; Yuan, Chester Chenguang
PA Amgen Inc., USA
SO U.S. Pat. Appl. Publ., 252 pp., Cont.-in-part of U.S. Ser. No. 46,681.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2003225106	A1	20031204	US 2002-197974		20020717
				US 2001-261339P	P	20010112
				US 2001-323764P	P	20010919
				US 2002-46681	A2	20020110
	US 2003125339	A1	20030703	US 2002-46681		20020110
				US 2001-261339P	P	20010112
				US 2001-323764P	P	20010919
	WO 2004007458	A1	20040122	WO 2003-US22417		20030715
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2002-197974	A	20020717

PATENT FAMILY INFORMATION:

FAN 2002:658116

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2002066470	A1	20020829	WO 2002-US743		20020111
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-261339P	P	20010112
				US 2001-323764P	P	20010919
				US 2002-46681	A	20020110
	US 2003125339	A1	20030703	US 2002-46681		20020110
				US 2001-261339P	P	20010112
				US 2001-323764P	P	20010919

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	BR 2002006435	A	20030923	BR 2002-6435		20020111
				US 2001-261339P	P	20010112
				US 2001-323764P	P	20010919
				US 2002-46681	A	20020110
				WO 2002-US743	W	20020111
	EP 1358184	A1	20031105	EP 2002-717325		20020111
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
				US 2001-261339P	P	20010112
				US 2001-323764P	P	20010919
				US 2002-46681	A	20020110
				WO 2002-US743	W	20020111
	EE 200300324	A	20031215	EE 2003-324		20020111
				US 2001-261339P	P	20010112
				US 2001-323764P	P	20010919
				US 2002-46681	A	20020110
				WO 2002 US743	W	20020111
	NO 2003003181	A	20030911	NO 2003-3181		20030711
				US 2001-261339P	P	20010112
				US 2001-323764P	P	20010919
				US 2002-46681	A	20020110
				WO 2002-US743	W	20020111

OS MARPAT 140:16647

IT **453561-07-4P 453561-08-5P 453561-23-4P**
453561-81-4P, 2-[(2,3-Dihydrobenzofuran-5-ylmethyl)amino]-N-[3,3-dimethyl-1-(piperidin-4-ylmethyl)-2,3 dihydro-1H-indol-6-yl]nicotinamide
453563-25-2P 453563-26-3P 453563-27-4P
453563-28-5P 453563-33-2P 453563-34-3P
453563-35-4P 453563-36-5P 453563-84-3P
453564-40-4P 453564-41-5P 453564-42-6P
629650-58-4P 629650-64-2P 629650-65-3P
629650-69-7P 629650-71-1P 629650-72-2P
629650-73-3P 629650-74-4P 629651-29-2P
629652-03-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-aminopyridine-3-carboxamides for treating angiogenesis
mediated diseases)

RN 453561-07-4 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[(6-quinolinylmethyl)amino] (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453561-08-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(3,4-dichlorophenyl)-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453561-23-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453561-81-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinylmethyl)-1H-indol-6-yl]- (9CI) (CA INDEX NAME)



RN 453563-25-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453563-26-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 453563-27-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 453563-28-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 453563-33-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 453563-34-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453563-35-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[6-[[[2 [[(2,3 dihydro-5-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3 dihydro-3,3-dimethyl-1H-indol-1-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 453563-36-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3 dihydro-5-benzofuranyl)methyl]amino]-N-[2,3-dihydro-3,3-dimethyl-1-[(1-methyl-4-piperidinyl)methyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453564-41-5 CAPLUS
CN 3-Pyridinecarboxamide, 2 [[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 453564-42-6 CAPLUS
CN 3-Pyridinecarboxamide,
2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-[(2S)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 629650-58-4 CAPLUS
CN 3-Pyridinecarboxamide,
2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-[1-methyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]phenyl]- (9CI) (CA INDEX

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453563-84-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[(2,3-dihydro-6-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 453564-40-4 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-[[[2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
NAME)



RN 629650-64-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-4-(trifluoromethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 629650-65-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-5-(trifluoromethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 629650-69-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl) (9CI) (CA INDEX NAME)



RN 629650-71-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-[3-[(tetrahydro-2-furanyl)methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 629650-72-2 CAPLUS

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 629651-29-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(5-benzoxazolylmethyl)amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 629652-03-5 CAPLUS
CN 1-Azetidinecarboxylic acid, 3-[[3-[[[2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



GI

L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, N-[3-[[(dimethylamino)acetyl]amino]-4-(1,1-dimethylethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 629650-73-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-[3-[[(3R)-tetrahydro-3-furanyl]oxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 629650-74-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-2-oxo-3,3-bis(trifluoromethyl)-1H-indol-6-yl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



L3 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title compds. [I; R = (un)substituted 4-pyridyl, 2-pyridyl, 4-pyrimidinyl, 4-quinolyl, etc.; R1 = (un)substituted aryl, cycloalkyl, 5-6 membered heteroaryl, 9-10 membered bicyclic and 11-14 membered tricyclic heterocyclyl], which are effective for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like, were prepared Thus, the title compound II was prepared from 2-aminonicotinic acid, 4-chloroaniline, and 4-pyridinecarboxaldehyde. The compds. I showed inhibition of KDR kinase at < 50 μM. Many compds. I inhibited VEGF-stimulated HUVEC proliferation at a level below 50 nM. Pharmaceutical composition comprising the compound I is claimed.

L3 ANSWER 5 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:913147 CAPLUS
DN 139:381477
TI Preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides as IKK2 inhibitors for the treatment of cancer and inflammation
IN Lennon, Patrick; Bonafoux, Dominique; Oburn, David S.; Wolfson, Serge G.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 312 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003095430	A1	20031120	WO 2003-US8917	20030319
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002 379090P	P 20020509
				WO 2002-US29774	A 20020919
	WO 2003024935	A2	20030327	WO 2002-US29774	20020919
	WO 2003024935	A3	20030821		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-323423P	P 20010919
				US 2002-379090P	P 20020509

PATENT FAMILY INFORMATION:
FAN 2003:242305

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003024935	A2	20030327	WO 2002-US29774	20020919
	WO 2003024935	A3	20030821		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

L3 ANSWER 5 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I



II

AB The present invention relates to substituted pyrazolyl derivs., compns. comprising such, intermediates, methods of making substituted pyrazolyl derivs., and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis. 4,5-Dihydro-1H-

L3 ANSWER 5 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509
US 2004110741	A1	20040610	US 2002-247096	20020919
			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509
EP 1444207	A2	20040811	EP 2002-775879	20020919

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509
			WO 2002-US29774	W 20020919
WO 2003095430	A1	20031120	WO 2003-US8917	20030319

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2002-379090P	P 20020509
			WO 2002-US29774	A 20020919

OS MARPAT 139:381477
IT **503555-09-7P**, 1-(1,3-Benzodioxol-5-yl)-8-[[[2-[(4-methoxybenzyl)amino]pyridin-3-yl]carbonyl]amino]-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides as IKK2 inhibitors for treatment of cancer and inflammation)
RN 503555-09-7 CAPLUS
CN 1H-Benz[g]indazole-3-carboxamide, 1-(1,3-benzodioxol-5-yl)-4,5-dihydro-8-[[[2-[[(4-methoxyphenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 5 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
benzo[g]indazole-3-carboxamides (shown as I; variables defined below; e.g.
II) were prepd. via conventional and solid phase synthetic methods as IκB protein kinase β (IKKβ or IKK2) inhibitors. Although the methods of prepn. are not claimed, 480 example prepns. and/or characterization data are included. For example, reaction of 7-nitro-1-tetralone with Et acetate in the presence of Li bis(trimethylsilyl)amide in ether gave the 1,3-diketone (87%), which was cyclized with 4-sulfonamidophenylhydrazine•HCl with HCl in MeOH to give the Et 1H-dihydrobenzo[g]indazolecarboxylate (69%). Amidation with NH4OH in MeOH provided II. In IKKβ resin enzyme assays, I exhibited IKKβ activity with IC50 values ranging from ≤ 1 μM to > 100 μM. Thus, I are useful for treating cancer, inflammation, and inflammation-assocd. disorders, such as arthritis (no data). For I: B is a 5 or 6 membered heteroaryl, aryl, (un)satd. heterocyclic (un)substituted with R1, R2, and R12; W is a 5 or 6 membered heteroaryl, aryl, (un)satd. heterocyclic. R1 = hydrido, halo, alkyl, aryl, heteroaryl, alkenyl, alkynyl, haloalkyl, CN, NO2, OR5, OCOOR5, CO2R7, CON(R6)R7, COR6, SR6, SOR6, SO2R6, NR6R7, NR6COR7, NR6CONHR7, NR6SO2R7, NR6SO2NHR7, and SO2N(R6)R7; R2 = halo, hydrido, hydroxyalkyl, alkyl, OR6, CN, NO2, SR6, NHR6, CON(R6)R7, NHCONHR6, CO2H, and haloalkyl; R1 and R2 may be taken together to form a 5 to 7 membered (un)satd. carbocyclic ring optionally contg. 0 to 3 heteroatoms N, O, or S, and wherein said ring is (un)substituted with R1. R12 = hydrido, halo, alkyl, and alkoxy; R15 = alkylsulfonamide, sulfamyl, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, halo, acyloxy, oxy, formyl, haloalkyl, cyano, haloalkoxy, acyl, carboxy, hydroxy, hydroxyalkyloxy, phenoxy, nitro, azido, benzyloxy, dialkylaminoacyl, thioalkyl, aminoacyloxy, thiocyanate, isothiocyanate, alkyldioxy, hydroxyalkyl, alkylamino, alkyloxycarbonyl, alkoxyalkyl, alkenylamino, alkynylamino, alkenyl, alkynyl, dialkylaminoalkyloxy, and heterocyclic; addnl. details are given in the claims.
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:665525 CAPLUS
DN 139:345320
TI Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching
AU Furet, Pascal; Bold, Guido; Hofmann, Francesco; Manley, Paul; Meyer, Thomas; Altmann, Karl-Heinz
CS Oncology Research, Novartis Pharma AG, Basel, CH-4002, Switz.
SO Bioorganic & Medicinal Chemistry Letters (2003), 13(18), 2967-2971
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 139:345320
IT **618359-41-4**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(identification, synthesis and structure-activity relationship studies on a new chemical class of potent angiogenesis inhibitors (anthranilamides)-based on conformational considerations and database searching)
RN 618359-41-4 CAPLUS
CN Benzamide, N-(2-fluorophenyl)-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



AB The vascular endothelial growth factor (VEGF) tyrosine kinase receptors KDR and Flt-1 are targets of current interest in anticancer drug research.
PTK787/ZK222584 is a potent inhibitor of these enzymes in clin. evaluation
as an antiangiogenic agent. The development of a hypothesis concerning the bioactive conformation of this compound has led to the discovery of a new class of potent inhibitors of KDR and Flt-1, the anthranilamides. This could be achieved with a limited exptl. effort, which only involved the testing of one archive compound and the synthesis and testing of one appropriate analog.
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:551370 CAPLUS
DN 139:111679
TI Combination of microsomal triglyceride transfer protein (MTP) inhibitors or apoB secretion inhibitors with fibrates for use as drugs
IN Thomas, Leo; Mark, Michael
PA Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
SO PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003057205	A2	20030717	WO 2003-EP57	20030107
WO 2003057205	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			DE 2002-10200633 A	20020110
			DE 2002-10256184 A	20021202
DE 10200633	A1	20030724	DE 2002-10200633	20020110
DE 10256184	A1	20040609	DE 2002-10256184	20021202
US 2003162788	A1	20030828	US 2003-339088	20030109
			DE 2002-10200633 A	20020110
			US 2002-353397P P	20020201
			DE 2002 10256184 A	20021202
			US 2002-435386P P	20021220

OS MARPAT 139:111679
IT **486436-62-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)
RN 486436-62-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]-4-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The invention discloses the use of fibrates for reducing the hepatic toxicity of MTP inhibitors, as well as pharmaceutical compns. that contain
an MTP inhibitor and a fibrate. Compound preparation is included.

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:551181 CAPLUS
DN 139:117339
TI Preparation of substituted arylamine derivatives as antitumor agents
IN Elbaum, Daniel; Askew, Benny; Booker, Shon; Germain, Julie; Habgood, Gregory; Handley, Michael; Kim, Tae-Seong; Li, Aiwen; Nishimura, Nobuko; Patel, Vinod F.; Yuan, Chester Chenguang; Kim, Joseph L.
PA Amgen Inc., USA
SO U.S. Pat. Appl. Publ., 106 pp., Cont.-in-part of U.S. Ser. No. 46,526.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003134836	A1	20030717	US 2002-197960	20020717
			US 2001-261360P P	20010112
			US 2001-323686P P	20010919
			US 2002-46526 A2	20020110
US 2002147198	A1	20021010	US 2002-46526	20020110
			US 2001-261360P P	20010112
			US 2001-323686P P	20010919
WO 2004007457	A2	20040122	WO 2003-US22276	20030715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-197960 A	20020717

PATENT FAMILY INFORMATION:
FAN 2002:539663

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002055501	A2	20020718	WO 2002-US742	20020111
WO 2002055501	A3	20021219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-261360P P	20010112
			US 2001-323686P P	20010919
			US 2002-46526 A	20020110
US 2002147198	A1	20021010	US 2002-46526	20020110
			US 2001-261360P P	20010112
			US 2001-323686P P	20010919
EP 1358161	A2	20031105	EP 2002-717324	20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2001-261360P P	20010112

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 2001-323686P	P	20010919
US 2002-46526	A	20020110
WO 2002-US742	W	20020111

OS MARPAT 139:117339

IT **561297-65-2P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted aminopyridines as antitumor agents)

RN 561297-65-2 CAPLUS

CN 1-Azetidinecarboxylic acid, 3-[[2-chloro-5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **561297-60-7P 561297-61-8P 561297-62-9P**
561297-63-0P 561297-64-1P 561297-66-3P
561297-70-9P 561297-71-0P 561297-72-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted aminopyridines as antitumor agents)

RN 561297-60-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl 1-(methylsulfonyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 561297-61-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[(dimethylamino)acetyl]amino]-4-(1,1-dimethylethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 561297-62-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino] N-[3-[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 561297-63-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[(methylsulfonyl)amino]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 561297-64-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 561297-66-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(3-azetidinylmethoxy)-4-chlorophenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 561297-70-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(3-azetidinylmethoxy)-5-(trifluoromethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 561297-71-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-hydroxy-3-nitrophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 561297-72-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-amino-4 hydroxyphenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT 442847-21-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted aminopyridines as antitumor agents)
RN 442847-21-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3 dihydro-3,3-dimethyl-1-(4-piperidinylmethyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



IT 442845-74-1P 442845-77-4P 442846-13-1P
442846-17-5P 442846-22-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation of substituted aminopyridines as antitumor

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
agents)
RN 442845-74-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-(3-fluoro-4 methylphenyl)-2-[[(4-methoxyphenyl)methyl]amino] (9CI) (CA INDEX NAME)



RN 442845-77-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442846-13-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[(4-fluorophenyl)methyl]amino] 3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-17-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[6-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-22-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-acetyl-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT 442845-71-8P 442845-72-9P 442845-73-0P
442845-75-2P 442845-76-3P 442845-78-5P
442845-79-6P 442845-80-9P 442845-81-0P
442845-82-1P 442845-83-2P 442845-84-3P
442845-85-4P 442845-86-5P 442845-87-6P
442845-88-7P 442845-89-8P 442845-90-1P
442845-91-2P 442845-92-3P 442845-93-4P
442845-94-5P 442845-95-6P 442845-96-7P
442845-97-8P 442845-99-0P 442846-00-6P
442846-01-7P 442846-02-8P 442846-03-9P
442846-04-0P 442846-05-1P 442846-06-2P
442846-07-3P 442846-08-4P 442846-09-5P
442846-10-8P 442846-11-9P 442846-12-0P
442846-14-2P 442846-15-3P 442846-16-4P
442846-18-6P 442846-19-7P 442846-20-0P
442846-21-1P 442846-23-3P 442846-24-4P
442846-25-5P 442846-26-6P 442846-27-7P
442846-28-8P 442846-29-9P 442846-30-2P
442846-31-3P 442846-32-4P 442846-33-5P
442846-34-6P 442846-35-7P 442846-36-8P
442846-38-0P 442846-39-1P 442846-40-4P
442846-42-6P 442846-44-8P 442847-23-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of substituted aminopyridines as antitumor agents)

RN 442845-71-8 CAPLUS
CN 2-Pyridinecarboxamide, N-(4 chlorophenyl)-3-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-72-9 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[[(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-73-0 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-fluoro-4-methylphenyl)-3-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 442845-75-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-(3-fluoro-4-methylphenyl)-2-[[(4-methoxyphenyl)methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 442845-76-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-(4-chlorophenyl)-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-78-5 CAPLUS
CN 3 Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[3-(trifluoromethyl)phenyl]methyl]amino] (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-79-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442845-80-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-81-0 CAPLUS

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, 2-[[(2-bromophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442845-82-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-(trifluoromethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-83-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-difluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-84-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[(4-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-85-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[(2-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-86-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(2-methylpropyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-87-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-88-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-methoxyphenyl)methyl]amino]-N-[4-(1-

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-89-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-aminophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-90-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 442845-91-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4 fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-92-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-93-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 442845-94-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-95-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-96-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-97-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-99-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl] (9CI) (CA INDEX NAME)



L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 442846-00-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-01-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-02-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,6-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-03-9 CAPLUS

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, 2-[[(3-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-04-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-05-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[3-(dimethylamino)propyl]-5-(trifluoromethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-06-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-07-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-08-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-bromo-2-fluorophenyl) 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846 09 5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-10-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-fluoro-3-[3-(4-morpholinyl)-1-propynyl]phenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-11-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(1,3-benzodioxol-5-ylmethyl)amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-12-0 CAPLUS
CN 3-Pyridinecarboxamide, 2 [[(4-fluorophenyl)methyl]amino]-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-14-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[2-(1,1-dimethylethyl)-5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-18-6 CAPLUS
CN Carbamic acid, [2-[6-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-19-7 CAPLUS
CN 2(1H) Isoquinolinecarboxylic acid, 7-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-3,4 dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-15-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(1-methyl-4-piperidinyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-16-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-[(dimethylamino)acetyl]-2,3-dihydro-3,3-dimethyl 1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-20 0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[3-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-21-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[2-(1,1-dimethylethyl)-5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-23-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-24-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-25-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[(2R)-2-pyrrolidinylmethoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-26-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-piperidinylmethoxy)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-27-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-28-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-29-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-(aminoacetyl)-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-30-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-31-3 CAPLUS
CN 3-Pyridinecarboxamide, 2 [[(4 fluorophenyl)methyl]amino]-N-[3-(4-piperidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-32-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-35-7 CAPLUS
CN 3 Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 442846-36-8 CAPLUS
CN 3 Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-2-oxo-7-quinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-33-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-34-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3 dihydro 3,3 dimethyl-1-[(1-methyl-4-piperidinyl)methyl]-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-38-0 CAPLUS
CN 3 Pyridinecarboxamide, N-5-benzofuranyl-2-[[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-39-1 CAPLUS
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-2-[[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-40-4 CAPLUS
CN 3 Pyridinecarboxamide, 2-[[(3,4-difluorophenyl)methyl]amino]-N-[4-(1,1-

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 442846-42-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 442846-44-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[(1-piperidinylmethyl]amino]phenyl]-2-[[(4-fluorophenyl)methyl]amino] (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

GI



AB The title compds. I (R2 = (un)substituted Ph, 9-10 membered bicyclic and 11-14 membered tricyclic (un)saturated heterocyclyl; R8 = halo, NH2, NO2, etc.], and their pharmaceutically acceptable derivs., are prepared and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. E.g., a multi-step synthesis of II, starting from 1-dimethylamino-2-propyne and 3-bromo-5-trifluoromethylaniline, was given. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

L3 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442847-23-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 442845-77-4
CMF C25 H20 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L3 ANSWER 9 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:454323 CAPLUS
DN 139:22501
TI Preparation of glycinamide heterocyclic derivatives as factor Xa inhibitors
IN Pinto, Donald J. P.; Han, Wei; Hu, Zilun
PA Bristol-Myers Squibb Company, USA; Qiao, Jennifer
SO PCT Int. Appl., 451 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048158	A1	20030612	WO 2002-US38239	20021127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-336994P	P 20011204
	US 2003232804	A1	20031218	US 2002-304070	20021125
				US 2001-336994P	P 20011204

PATENT FAMILY INFORMATION:
PAN 2003:454257

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048081	A2	20030612	WO 2002-US37212	20021118
	WO 2003048081	A3	20030912		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-336994P	P 20011204
	US 2003232804	A1	20031218	US 2002-304070	20021125
				US 2001-336994P	P 20011204

OS MARPAT 139:22501
IT **536759-09-8P 536759-10-1P 536759-11-2P 536759-12-3P 536759-13-4P 536759-14-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of glycinamide heterocyclic derivs. as factor Xa inhibitors)
RN 536759-09-8 CAPLUS
CN 1-Pyrrolidineacetamide, N-[4-[[[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]phenyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA

L3 ANSWER 9 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 536759-10-1 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 536759-11-2 CAPLUS
CN Benzamide, 2-[[[4-(acetylmethylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 536759-12-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 536759-13-4 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 536759-14-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 9 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB Compds. P4-P-M-M4 [M is a 3-10 membered carbocycle or a 4-10 membered heterocycle; P is null or a 5-7 membered carbocycle or heterocycle fused to ring M; one of P4 and M4 is -Z-A-B and the other is G1-G, where G is (un)substituted (fused) (hetero)aryl or (hetero)cyclyl; G1 is null or (un)substituted optionally-functionalized alk(en)(yn)yl; Z is a bond or (hetero)alkylene; A is (substituted) 3-10 membered carbocyclyl or 5-12 membered heterocyclyl; B is a functionalized amino group (with provisos)] or their pharmaceutically-acceptable salts were prepared for use as inhibitors of factor Xa. Thus, 1H-pyrazolo[3,4-c]pyridine derivative I.TFA was prepared by reactions of 3-aminobenzamide, 3 hydroxy-1-(4-iodophenyl)-4-(trifluoroacetyl)-5,6 dihydro-2(1H)-pyridinone, chloroacetyl chloride, and dimethylamine.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:454257 CAPLUS
DN 139:7167
TI Preparation of glycinamide heterocyclic derivatives as factor Xa inhibitors
IN Pinto, Donald J. P.; Han, Wei; Hu, Zilun
PA Bristol-Myers Squibb Company, USA; Qiao, Jennifer
SO PCT Int. Appl., 448 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048081	A2	20030612	WO 2002-US37212	20021118
	WO 2003048081	A3	20030912		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-336994P P	20011204
	US 2003232804	A1	20031218	US 2002-304070	20021125
				US 2001-336994P P	20011204

PATENT FAMILY INFORMATION:
FAN 2003:454323

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048158	A1	20030612	WO 2002-US38239	20021127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001 336994P P	20011204
	US 2003232804	A1	20031218	US 2002-304070	20021125
				US 2001-336994P P	20011204

OS MARPAT 139:7167
IT **536759-09-8P 536759-10-1P 536759-11-2P**
536759-12-3P 536759-13-4P 536759-14-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of glycinamide heterocyclic derivs. as factor Xa inhibitors)

L3 ANSWER 10 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 536759-11-2 CAPLUS
CN Benzamide, 2-[[[4-(acetylmethylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 536759-12-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 536759-13-4 CAPLUS
CN Benzamide,

L3 ANSWER 10 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 536759-09-8 CAPLUS
CN 1-Pyrrolidineacetamide, N-[4-[[[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]phenyl]amino]methyl]phenyl]-N-methyl (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 536759-10-1 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 10 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
mino]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 536759-14-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



GI



AB Compds. P4-P-M-M4 [M is a 3-10 membered carbocycle or a 4-10 membered heterocycle; P is null or a 5-7 membered carbocycle or heterocycle fused to ring M; one of P4 and M4 is -Z-A-B and the other is -G1-G, where G is (un)substituted (fused) (hetero)aryl or (hetero)cyclyl; G1 is null or (un)substituted optionally-functionalized alk(en)(yn)yl; Z is a bond or (hetero)alkylene; A is (substituted) 3-10 membered carbocyclyl or 5-12 membered heterocyclyl; B is a functionalized amino group (with provisos)] or their pharmaceutically-acceptable salts were prepared for use as inhibitors of factor Xa. Thus, 1H-pyrazolo[3,4-c]pyridine derivative

L3 ANSWER 10 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
was prepd. by reactions of 3-aminobenzamide, 3-hydroxy-1-(4-iodophenyl)-4-(trifluoroacetyl)-5,6-dihydro-2(1H)-pyridinone, chloroacetyl chloride, and dimethylamine.

L3 ANSWER 11 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:376824 CAPLUS
DN 138:368777
TI Preparation of pyridyl-substituted anthranilic acid amides for treating neoplastic disease
IN Bold, Guido; Furet, Pascal; Manley, Paul William
PA Novartis AG, Switz.; Novartis Pharma Gmbh
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003040101	A1	20030515	WO 2002-EP12445	20021107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
			GB 2001-26901	A 20011108
			GB 2002-12917	A 20020605

OS MARPAT 138:368777
IT **524729-00-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridyl-substituted anthranilic acid amides for treating neoplastic disease)
RN 524729-00-8 CAPLUS
CN Benzamide, 2-[[[3-[(methylamino)carbonyl]phenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 11 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I



II

AB The title compds. [I; Ar = II (wherein Ra = H, alkyl; and R1 = H, perfluoroalkyl; R2 = H, halo, alkyl, alkenyl, alkynyl); or Ar = 4-pyridyl and R1 = perfluoroalkyl; R2 = Br, I, alkyl, alkenyl, alkynyl; or R1 = H, and R2 = F, Br, I, Et, alkyl, alkenyl or alkynyl] and their N-oxides and salts, useful for the treatment especially of a neoplastic disease, such as a tumor disease, of retinopathy or age-related macular degeneration in the human or animal body, were prepared and formulated. Thus, reductive amination of 4 pyridinecarboxaldehyde with 2-amino-N-(4 bromo 3 trifluoromethylphenyl)benzamide (preparation given) in the presence of NaBH3CN afforded I [Ar = 4 pyridyl; R1 = CF3; R2 = Br]. The IC50 values that can be found for the compds. I are in range of 0.001 to 1 μM in test for activity against VEGF-receptor tyrosine kinase.
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:242305 CAPLUS
DN 138:271675
TI Preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides for the treatment of inflammation
IN Bergmanis, Arija A.; Bonafoux, Dominique; Clare, Michael; Crich, Joyce Z.; Fletcher, Theresa R.; Geng, Lifeng; Hagen, Timothy J.; Hamper, Bruce C.; Hanson, Gunnar J.; Houdek, Stephen C.; Huang, He; Iula, Donna M.; Koszyk, Francis J.; Lennon, Patrick J.; Liao, Shuyuan; Liao, Subo; Metz, Suzanne; Mohler, Scott B.; Nguyen, Maria; Oburn, David S.; Owen, Thomas J.; Partis, Richard A.; Scates, Angela M.; Stealey, Michael A.; Tollefson, Michael B.; Vazquez, Michael L.; Weier, Richard M.; Wolfson, Serge G.; Xu, Xiangdong
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 331 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003024935	A2	20030327	WO 2002-US29774	20020919
WO 2003024935	A3	20030821		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509
US 2004110741	A1	20040610	US 2002 247096	20020919
			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509
EP 1444207	A2	20040811	EP 2002-775879	20020919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509
			WO 2002-US29774	W 20020919
WO 2003095430	A1	20031120	WO 2003-US8917	20030319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-379090P	P 20020509

L3 ANSWER 12 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				WO 2002-US29774	A 20020919

PATENT FAMILY INFORMATION:

FAN 2003:913147

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003095430	A1	20031120	WO 2003-US8917	20030319
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-379090P	P 20020509
				WO 2002-US29774	A 20020919
	WO 2003024935	A2	20030327	WO 2002-US29774	20020919
	WO 2003024935	A3	20030821		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001 323423P	P 20010919
				US 2002-379090P	P 20020509

OS MARPAT 138:271675

IT **503555-09-7P**, 1-(1,3-Benzodioxol-5-yl)-8-[[[2-[(4-methoxybenzyl)amino]pyridin-3-yl]carbonyl]amino]-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(IKK2 inhibitor; preparation of benzo[g]carboxamides as IKK2 inhibitors for
treatment of cancer, inflammation, and inflammation-associated disorders)

RN 503555-09-7 CAPLUS

CN 1H-Benz[g]indazole-3-carboxamide, 1-(1,3-benzodioxol-5-yl)-4,5-dihydro-8-[[[2-[[(4-methoxyphenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 12 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I II

AB The present invention relates to substituted pyrazolyl derivs., compns. comprising such, intermediates, methods of making substituted pyrazolyl derivs., and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis. Title compds. I [wherein A = (un)substituted (CH2)m; m = 0-3; B = (un)substituted (hetero)aryl; X = N or C; Y and Z = independently N, C, CH, CR3, S, or O; R1 = H, halo, (halo)alkyl, (hetero)aryl, alkenyl, alkynyl, CN, NO2, alkoxy(carbonyl), carbamoyl, acyl, alkylthio, sulfamoyl, ureido, etc.; R2 = H, halo, (halo)alkyl, hydroxyalkyl, alkoxy, CN, NO2, alkylthio, amino, carbamoyl, ureido, CO2H, etc.; R3 = (un)substituted amidine, alkylamino, aminoalkyl, carbamoyl, NH2, or acylamino(methyl); R4 = H, halo, alkylsulfinyl, alkylsulfonyl, CN, alkoxycarbonyl, (halo)alkyl, hydroxyalkyl, haloalkoxy, heterocyclyl, NO2, acylamino, (hetero)aryl, alkenyl, alkoxy, alkylthio, sulfamoyl, acyl, ureido, carbamoyl, etc.; R5

L3 ANSWER 12 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

H, or (un)substituted (aryl)alkyl, (hetero)aryl, heterocyclylalkyl, or heteroarylalkyl; R11 = H, halo, (halo)alkyl, CN, alkoxycarbonyl, alkenyl, alkynyl, alkoxy, carbamoyl, etc.; R12 = H, halo, alkyl, or alkoxy; with provisos; and isomers, tautomers, carriers, esters, prodrugs, and pharmaceutically acceptable salts thereof] were prepd. via conventional and solid phase synthetic methods as IκB protein kinase β (IKKβ or IKK2) inhibitors. For example, reaction of 7-nitro-1-tetralone with Et acetate in the presence of Li bis(trimethylsilyl)amide in ether gave the 1,3-diketone (87%), which was cyclized with 4-sulfonamidophenylhydrazine•HCl with HCl in MeOH to give the Et 1H-dihydrobenzo[g]indazolecarboxylate (69%). Amidation with NH3OH in MeOH provided II. In IKKβ resin enzyme assays, I exhibited IKKβ activity with IC50 values ranging from ≤ 1 μM to > 100 μM. Thus, I are useful for treating cancer, inflammation, and inflammation-assocd. disorders, such as arthritis (no data).

L3 ANSWER 13 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:42101 CAPLUS

DN 138:106502

TI Preparation of biphenylcarboxylic acid amides as inhibitors of microsomal triglyceride transfer protein (MTP)

IN Priepke, Henning; Hauel, Norbert; Dahmann, Georg; Thomas, Leo; Mark, Michael

PA Boehringer Ingelheim Pharma K.-G., Germany

SO PCT Int. Appl., 193 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003004020	A1	20030116	WO 2002-EP7215	20020629
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DE 2001-10132686	A 20010705
	DE 10132686	A1	20030116	DE 2001-10132686	20010705
	US 2003073836	A1	20030417	US 2002-187860	20020702
				DE 2001-10132686	A 20010705
				US 2001-304584P	P 20010711

OS MARPAT 138:106502

IT **486436-62-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of biphenylcarboxylic acid amides as microsomal
triglyceride transfer protein (MTP) inhibitors)

RN 486436-62-8 CAPLUS

CN 1H Pyrrole-2-carboxamide, 1-methyl-N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]-4-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 13 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I

AB Title compds. I [X1 = CR1; X2 = CR2; X3 = CR3; X4 = CR4; with 1-2 of the groups being a N atom; R1, R2, R3, R4 = H, halo, alkyl, etc.; A = O, S, NH, etc.; R8 = (un)substituted Ph, 1-naphthyl, 2-naphthyl, etc.; R5 = H, (un)substituted alkyl; R6 = H, alkyl; R7 = (un)substituted alkyl; Y = 1-2 carbon atom(s) bound to (un)substituted 5-membered heteroaryl] and their pharmaceutically acceptable salts were prepared For example, coupling of acid II, e.g., prepared from 4-hydrazinobenzonitrile in 5-steps, and 4 phenylbenzylamine afforded biphenylcarboxylic acid amide III in 86% yield. In triglyceride transfer protein inhibition studies, compds. I exhibited IC50 values ≤ 100μM. Compds. I are claimed useful as inhibitors of microsomal triglyceride transfer protein (MTP) for the treatment of atherosclerosis.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:22869 CAPLUS
DN 138:89806
TI Preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for treatment of cardiovascular disease.
IN Ingraham, Richard H.; Proudfoot, John R.
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003002555	A1	20030109	WO 2002-US18752	20020614
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-302066P	P 20010629
US 2003022929	A1	20030130	US 2002 172457	20020614
			US 2001-302066P	P 20010629
EP 1406892	A1	20040414	EP 2002-739870	20020614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2001-302066P	P 20010629
			WO 2002-US18752	W 20020614
US 2004092567	A1	20040513	US 2003-670668	20030925
			US 2001-302066P	P 20010629
			US 2002-172457	A1 20020614

OS MARPAT 138:89806
IT **483342-21-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for
treatment of cardiovascular disease)
RN 483342-21-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I

AB A method of treating cardiovascular disease comprises administration of title compds. [I; R1, R3 = CF3, halo, cyano, alkyl, alkenyl, alkynyl, (substituted) cycloalkyl, heterocyclyl, etc.; R2 = H, halo, Me; L = NHCO, NHCS, NH, NHCH2, NHCOCO, etc.; R4 = (substituted) alkyl, alkoxy, alkylthio, alkylamino, alkoxyalkyl, alkylthioalkyl, carbocyclyl, heterocyclyl, etc.; R8 = H, NH2] (no data). Thus, 2-chloronicotinic acid in MeCN was treated with EDC and then with 1-(4-aminophenyl)-3-(3-pyridyl)-5-trifluoromethylpyrazole under ice cooling followed by stirring for 1 h to give I (R1 = 3-pyridyl; R2, R8 = H; R3 = CF3; L = NHCO; R4 = 2-chloropyridin-3-yl).

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:900736 CAPLUS
DN 138:4612
TI Preparation of 2-heterocyclyl-4-aminopyrimidine-5-carboxamide and 5-heterocyclyl-3-aminopyrazine-2-carboxamide derivatives as selective inhibitors of phosphodiesterase IV
IN Yamada, Koichiro; Matsumoto, Kenji; Omori, Kenji; Yoshikawa, Kohei
PA Tanabe Seiyaku Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 53 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2002338466	A2	20021127	JP 2002-61580	20020307
			JP 2001-73385	A 20010315

OS MARPAT 138:4612
IT **330785-09-6P 330785-10-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclylaminopyrimidinecarboxamide and heterocyclylaminopyrazinecarboxamide derivs. as selective inhibitors of
phosphodiesterase IV for prevention and/or treatment of diseases)
RN 330785-09-6 CAPLUS
CN Pyrazinecarboxamide, 3-[[[3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330785-10-9 CAPLUS
CN Pyrazinecarboxamide, 3-[[[3-chloro-4-methoxyphenyl)methyl]amino]-5-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-N-(trans-4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Relative stereochemistry.



GI



I

AB Disclosed is a pharmaceutical composition containing the title compound [I; the ring
A = (un)substituted N-containing heterocyclyl; R1 = (un)substituted lower alkyl, NH-Q-R3, NH-R4; wherein R3 = (un)substituted N-containing heterocyclyl;
Q = a single bond, lower alkylene; R4 = (un)substituted cycloalkyl; R2 = (un)substituted aryl; one of Y and Z is CH and the other is N] or pharmacol. acceptable salt thereof as the active ingredient for the prevention and/or treatment of impotence, pulmonary hypertension, or diabetic stomach failure or paralysis. Thus, a solution of 2.057 g 2-methylthio-4-(3-chloro-4-methoxybenzylamino)-5-formylpyrimidine was treated with 1.468 g m-chloroperbenzoic acid (80%) at 0° for 30 min, followed by successively adding 0.901 g L-prolinol and 1.33 mL Et3N, and the resulting mixture was allowed to react at 0° for 1 h to give 2.00 g [S]-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-formylpyrimidine (II). A solution of 91.0 mg II in 20

L3 ANSWER 15 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
mL THF was reacted with 1.1 mL 1.10 M MeLi/Et2O at -78° for 10 min to give, after treatment with aq. NaHCO3 and extn. with EtOAc, an EtOAc soln. of crude (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-(1-hydroxyethyl)pyrimidine which was stirred with 0.5 g MnO2 at room temp. overnight and then at refluxing temp. for 5 h to give (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-acetylpyrimidine (III). III and inhibitors N-(2-pyridylmethyl) 2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine-5-carboxamide showed IC50 of 5.18 and 0.0859
μM, resp., against PDE IV isolated from a dog lung. III in vitro exhibited the relaxant activity on rabbit corpus cavernosum with ED50 of 1
nM.

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:658116 CAPLUS
DN 137:201332
TI Preparation of heterocyclylalkylamine derivatives as remedies for angiogenesis mediated diseases
IN Chen, Guoqing; Adams, Jeffrey; Bemis, Jean; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Geuns-meyer, Stephanie; Handley, Michael; Huang, Qi; Kim, Joseph L.; Kim, Tae-seong; Kiselyov, Alexander; Ouyang, Xiaohu; Patel, Vinod F.; Smith, Leon M.; Stec, Markian; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang
PA Amgen Inc., USA
SO PCT Int. Appl., 502 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002066470	A1	20020829	WO 2002-US743	20020111
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-261339P	P 20010112
				US 2001-323764P	P 20010919
				US 2002-46681	A 20020110
	US 2003125339	A1	20030703	US 2002-46681	20020110
				US 2001-261339P	P 20010112
				US 2001-323764P	P 20010919
	BR 2002006435	A	20030923	BR 2002-6435	20020111
				US 2001-261339P	P 20010112
				US 2001-323764P	P 20010919
				US 2002-46681	A 20020110
				WO 2002-US743	W 20020111
	EP 1358184	A1	20031105	EP 2002-717325	20020111
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2001-261339P	P 20010112
				US 2001-323764P	P 20010919
				US 2002-46681	A 20020110
				WO 2002-US743	W 20020111
	EE 200300324	A	20031215	EE 2003-324	20020111
				US 2001-261339P	P 20010112
				US 2001-323764P	P 20010919
				US 2002-46681	A 20020110
				WO 2002-US743	W 20020111
	NO 2003003181	A	20030911	NO 2003-3181	20030711
				US 2001-261339P	P 20010112
				US 2001-323764P	P 20010919
				US 2002-46681	A 20020110
				WO 2002-US743	W 20020111

PATENT FAMILY INFORMATION:
FAN 2003:950057
PATENT NO. KIND DATE APPLICATION NO. DATE

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PI	US 2003225106	A1	20031204	US 2002-197974	20020717
				US 2001-261339P	P 20010112
				US 2001-323764P	P 20010919
				US 2002-46681	A2 20020110
	US 2003125339	A1	20030703	US 2002-46681	20020110
				US 2001-261339P	P 20010112
				US 2001-323764P	P 20010919
	WO 2004007458	A1	20040122	WO 2003-US22417	20030715
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-197974	A 20020717

OS MARPAT 137:201332
IT **453561-07-4P 453561-08-5P 453561-23-4P**
453561-81-4P, 2-[(2,3-Dihydrobenzofuran-5-ylmethyl)amino]-N-(3,3-dimethyl-1-(piperidin-4-ylmethyl)-2,3-dihydro-1H-indol-6-yl]nicotinamide
453563-25-2P 453563-26-3P 453563-27-4P
453563-28-5P 453563-33-2P 453563-34-3P
453563-35-4P 453563-36-5P 453563-84-3P
453564-40-4P 453564-41-5P 453564-42-6P
453564-46-0P 453564-69-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclylalkylamine derivs. as remedies for angiogenesis
mediated diseases)
RN 453561-07-4 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453561-08-5 CAPLUS

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, N-(3,4-dichlorophenyl)-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453561-23-4 CAPLUS
CN 3 Pyridinecarboxamide, N-(4-chlorophenyl)-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453561-81-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[2,3-dihydro-3,3-dimethyl 1-(4-piperidinylmethyl)-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453563-27-4 CAPLUS
CN 3 Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 453563-28-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453563-25-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1 dimethylethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453563-26-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 453563-33-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 453563-34-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 453563-35-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[6-[[[2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453563-36-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[2,3-dihydro-3,3-dimethyl-1-[(1-methyl-4-piperidinyl)methyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)



RN 453563-84-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[(2,3-dihydro-6-

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453564-42-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5 benzofuranyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-[(2S)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 453564-46-0 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[(5-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453564-69-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(7-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl] , 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 453564-40-4 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-[[[2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino) 3-pyridinyl]carbonyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 453564-41-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3 dihydro-5-benzofuranyl)methyl]amino]-N-(1,2,3,4-tetrahydro 4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I



II

AB Title compds. [I; A1, A2 independently = C, N; A = 5-, or 6 membered partially saturated heterocyclyl, 5-, or 6-membered heterocyclyl, 9-, or 10 membered fused partially saturated heterocyclyl, 9-, 10-, or 11-membered fused heteroaryl, naphthyl, 4-, 5-, or 6-membered cycloalkenyl; X = C:ZNR3, C:ZN(R3)R4; Z = O, S; Y = N:CH, NR5(CR6R7), R8N(R5)(CR6R7), NR5(CR6R7)R8; R = 5-, or 6-membered (un)substituted heterocyclyl, 9-, 10-, 11-membered heterocyclyl; R1 = 6-10-membered (un)substituted aryl, 5-, or 6-membered (un)substituted heterocyclyl, 9-11 membered (un)substituted fused heterocyclyl, cycloalkyl, cycloalkenyl; R2 = H, halo, oxo, SH, COOH, CHO; R3 = H, alkyl, 5-, or 6-membered heterocyclyl; R4 = alkylenyl, alkenylenyl, alkynylenyl; R5 = H, alkyl, aralkyl, C6H5; R6, R7 independently = H, halo, CN, alkyl; R6R7 = cycloalkyl; R8 = alkylenyl; etc.] are prepared and are effective for prophylaxis and treatment of

L3 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
diseases, such as angiogenesis mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compds. as well as to intermediates useful in such processes. Thus, the title compd. II was prepd. from Me 3-amino-2-thiophenecarboxylate, 4-chloroaniline, and 4-pyridine carboxaldehyde via coupling reaction.
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:637637 CAPLUS
DN 137:185325
TI Preparation of acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenylamines as stimulators of endothelial NO-synthase transcription
IN Strobel, Hartmut; Wohlfart, Paulus
PA Aventis Pharma Deutschland GmbH, Germany
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064546	A2	20020822	WO 2002-EP1449	20020212
	WO 2002064546	A3	20021107		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				EP 2001-102853 A	20010213
	EE 200300370	A	20031015	EE 2003-370	20020212
				EP 2001 102853 A	20010213
				WO 2002-EP1449 W	20020212
	EP 1362027	A2	20031119	EP 2002-722069	20020212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				EP 2001-102853 A	20010213
				WO 2002-EP1449 W	20020212
	JP 2004518720	T2	20040624	JP 2002-564479	20020212
				EP 2001-102853 A	20010213
				WO 2002-EP1449 W	20020212
	BR 2002007197	A	20040706	BR 2002-7197	20020212
				EP 2001-102853 A	20010213
				WO 2002-EP1449 W	20020212
	US 2003008915	A1	20030109	US 2002-73203	20020213
	US 6759412	B2	20040706		
				EP 2001-102853 A	20010213
	NO 2003003566	A	20031013	NO 2003-3566	20030812
				EP 2001 102853 A	20010213
				WO 2002-EP1449 W	20020212

OS MARPAT 137:185325
IT **450368-07-7P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(eNOS transcription stimulator; preparation of acylated tetrahydrobenzocycloheptenylamines as stimulators of endothelial NO-synthase transcription)
RN 450368-07-7 CAPLUS

L3 ANSWER 17 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 2-Pyridinecarboxamide, 6-chloro-3-[(phenylmethyl)amino]-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)- (9CI) (CA INDEX NAME)



GI



AB Title compds. I [wherein R1 and R4 = independently H, (pseudo)halo, CF3, NO2, or (un)substituted alkyl, alkenyl, alkynyl, Ph, heteroaryl, amino, alkoxy, sulfamoyl, etc.; R2 and R3 = independently H, (pseudo)halo, OH, PhO, alkoxy, CF3, CN, NO2, or (un)substituted alkyl, amino, acylamino, etc.; A = CH2, CHOH, or CH(alkyl); B, C, and D = independently CH2 or CH(alkyl); R5 = (un)substituted (hetero)aryl; and stereoisomers, mixts., or pharmaceutically acceptable salts thereof] were prepared as stimulators of endothelial NO-synthase (eNOS) transcription, which has a vasodilating effect and inhibits the aggregation of platelets, the adhesion of leukocytes to the endothelium, and the proliferation of intimal smooth muscle cells. For example, amidation of 4-fluorobenzoic acid chloride with 6,7,8,9-tetrahydro-5H-benzocyclohepten-6-ylamine in the presence of TEA in dioxane afforded II. The latter activated eNOS transcription in primary human umbilical vein cord endothelial cells (HUVEC) with EC50 of 0.02 μM. I are useful for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchial, chronic renal failure, cirrhosis of the liver, osteoporosis, or restricted memory performance or for a restricted ability to learn, or the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives (no data).

L3 ANSWER 18 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:603273 CAPLUS
DN 138:122629
TI Synthesis of 1,4-benzodiazepine-2,5-dione derivatives
AU Ho, Tong-Ing; Chen, Wen-Shiong; Hsu, Chi-Wei; Tsai, Yeun-Min; Fang, Jim-Min
CS Dep. of Chem., National Taiwan Univ., Taipei, Taiwan
SO Heterocycles (2002), 57(8), 1501-1506
CODEN: HTCYAM; ISSN: 0385-5414
PB Japan Institute of Heterocyclic Chemistry
DT Journal
LA English
OS CASREACT 138:122629
IT **489446-50-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2,5-dioxo-1H-1,4-benzodiazepine-3-carboxylate derivs.)
RN 489446-50-6 CAPLUS
CN Benzamide, N-(4-methoxyphenyl)-2-[[(3-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



AB A synthesis of a series of 1,4-benzodiazepine-2,5-dione derivs. with a carboxy group at the 3-position is realized in good yields by using Me malonylchloride as a key reagent and intramol. nucleophilic substitution as ring closure reaction. The synthesis of 4-(4-Methoxyphenyl)-1-[(3-methoxyphenyl)methyl]-2,5-dioxo-1H-1,4-benzodiazepine-3-carboxylic acid Me ester was described.
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:539663 CAPLUS
DN 137:109210
TI Preparation of substituted arylamine derivatives and methods of use as antitumor agents
IN Chen, Guoqing; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Huang, Qi; Kim, Joseph L.; Kim, Tae-Seong; Patel, Vinod F.; Smith, Leon M.; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang
PA Amgen Inc., USA
SO PCT Int. Appl., 253 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055501	A2	20020718	WO 2002-US742	20020111
	WO 2002055501	A3	20021219		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-261360P	P 20010112
				US 2001-323686P	P 20010919
				US 2002-46526	A 20020110
	US 2002147198	A1	20021010	US 2002-46526	20020110
				US 2001-261360P	P 20010112
				US 2001-323686P	P 20010919
	EP 1358161	A2	20031105	EP 2002-717324	20020111
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2001-261360P	P 20010112
				US 2001-323686P	P 20010919
				US 2002-46526	A 20020110
				WO 2002-US742	W 20020111

PATENT FAMILY INFORMATION:
FAN 2003:551181

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003134836	A1	20030717	US 2002-197960	20020717
				US 2001-261360P	P 20010112
				US 2001-323686P	P 20010919
				US 2002-46526	A2 20020110
	US 2002147198	A1	20021010	US 2002-46526	20020110
				US 2001-261360P	P 20010112
				US 2001-323686P	P 20010919
	WO 2004007457	A2	20040122	WO 2003-US22276	20030715
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2002-197960 A 20020717

OS MARPAT 137:109210
IT **442847-21-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted aminopyridines as antitumor agents)
RN 442847-21-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinylmethyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



IT **442845-74-1P 442845-77-4P 442846-13-1P**
442846-17-5P 442846-22-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation of substituted aminopyridines as antitumor agents)
RN 442845-74-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-(3-fluoro-4-methylphenyl)-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-77-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442846-13-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-17-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[6-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-22-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-acetyl-3,4 dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT 442845-71-8P 442845-72-9P 442845-73-0P
442845-75-2P 442845-76-3P 442845-78-5P
442845-79-6P 442845-80-9P 442845-81-0P
442845-82-1P 442845-83-2P 442845-84-3P
442845-85-4P 442845-86-5P 442845-87-6P
442845-88-7P 442845-89-8P 442845-90-1P
442845-91-2P 442845-92-3P 442845-93-4P
442845-94-5P 442845-95-6P 442845-96-7P
442845-97-8P 442845-99-0P 442846-00-6P
442846-01-7P 442846-02-8P 442846-03-9P
442846-04-0P 442846-05-1P 442846-06-2P
442846-07-3P 442846-08-4P 442846-09-5P
442846-10-8P 442846-11-9P 442846-12-0P
442846-14-2P 442846-15-3P 442846-16-4P
442846-18-6P 442846-19-7P 442846-20-0P
442846-21-1P 442846-23-3P 442846-24-4P
442846-25-5P 442846-26-6P 442846-27-7P
442846-28-8P 442846-29-9P 442846-30-2P
442846-31-3P 442846-32-4P 442846-33-5P
442846-34-6P 442846-35-7P 442846-36-8P
442846-38-0P 442846-39-1P 442846-40-4P
442846-42-6P 442846-44-8P 442846-46-0P
442846-48-2P 442846-50-6P 442846-52-8P
442846-53-9P 442847-23-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of substituted aminopyridines as antitumor agents)

RN 442845-71-8 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-72-9 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[[(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-73-0 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-fluoro 4-methylphenyl)-3-[[(4 methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 442845-75-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-(3-fluoro-4-methylphenyl)-2-[[(4-methoxyphenyl)methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 442845-76-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-(4-chlorophenyl)-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-78-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-79-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442845-80-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-81-0 CAPLUS

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, 2-[[(2-bromophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442845-82-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-(trifluoromethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-83-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-difluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-84-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[(4-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-85-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[(2-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-86-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(2-methylpropyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-87-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-88-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-methoxyphenyl)methyl]amino]-N-[4 (1-

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-89-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-aminophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-90-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 442845 91-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-92-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-93-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-97-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-99-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 442845-94-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-95-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-96-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 442846-00-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-01-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-02-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,6-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-03-9 CAPLUS

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, 2-[[(3-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-04-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-05-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[3-(dimethylamino)propyl]-5-(trifluoromethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-06-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-07-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-08-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-bromo-2-fluorophenyl)-2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-09-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-10-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-fluoro-3-[3-(4-morpholinyl)-1-propynyl]phenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-11-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(1,3-benzodioxol-5-ylmethyl)amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-12-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-14-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[2-(1,1-dimethylethyl)-5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-15-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(1-methyl-4-piperidinyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-16-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-[(dimethylamino)acetyl]-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-18-6 CAPLUS
CN Carbamic acid, [2-[6-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-19-7 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-20-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[3-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-21-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[2-(1,1-dimethylethyl)-5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-23-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[[[2-[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-24-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-25-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[(2R)-2-pyrrolidinylmethoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-26-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-piperidinylmethoxy)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-27-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-28-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-29-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-(aminoacetyl)-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-30-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-31-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-(4 piperidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-32-4 CAPLUS
CN 3-Pyridinecarboxamide,
N-(3,4-dihydro-2,2-dimethyl-2H 1,4-benzoxazin-6-yl)-
2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-35-7 CAPLUS
CN 3-Pyridinecarboxamide,
2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-
(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 442846-36-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-
tetrahydro-4,4-dimethyl 2-oxo-7-quinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-33-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[[(2S)-1-
methyl-2-pyrrolidinyl]methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RN 442846-34-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-[(1-methyl-4-
piperidinyl)methyl]-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]-
(9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-38-0 CAPLUS
CN 3-Pyridinecarboxamide, N-5-benzofuranyl-2-[[[3-
(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-39-1 CAPLUS
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-2-[[[3-
(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-40-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3,4-difluorophenyl)methyl]amino]-N-[4-(1,1-

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 442846-42-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 442846-44-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4 (1,1-dimethylethyl)-3-[(1-piperidinylmethyl)amino]phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-46-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-48-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-(2-pyrrolidinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846 50-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-(2-pyrrolidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-52-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(2-pyrrolidinylmethoxy)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846 53-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[(1-methyl-2-pyrrolidinyl)methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442847-23-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 442845-77-4
CMF C25 H20 F N3 O2

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [B1 and B2 independently equal C or N, wherein B1B2 form part of 5-6 membered heteroaryl ring A; R1 = one or more substituents selected from H, halo, oxo, (un)substituted cycloalkyl, phenylalkyl, etc.;
R2 = (un)substituted cycloalkyl, cycloalkenyl, 6 10 membered aryl or 5-6 membered heterocyclyl, etc.; R3 = (un)substituted aryl; R4 = H, alkyl, (un)substituted Ph or aralkyl; X1 = bond, alkylenyl, alkenylenyl and alkynylenyl, where one of the CH2 groups may be substituted with O or NH, wherein X1 is optionally substituted with OH; X2 = (un)substituted N containing linker, e.g., -NHCH2-], and there pharmaceutically acceptable derivs., are prepared and disclosed as agents effective for prophylaxis and
treatment of diseases, such as angiogenesis mediated diseases. Thus, II was prepared via arylation of 1-dimethylamino-2-propyne with 3-bromo-5-trifluoromethylaniline, hydrogenation, amidation with 2 chloropyridine-3-carbonyl chloride and chloro-substitution with 4-fluorobenzylamine. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The

L3 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

L3 ANSWER 20 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:171853 CAPLUS
DN 136:232201
TI Preparation of cyclic amine derivatives as CCR3 antagonists
IN Morihira, Koichiro; Inami, Hiroshi; Kubota, Hirokazu; Yokoyama, Kazuhiro; Morokata, Tatsuaki; Takeuchi, Makoto; Takahashi, Toshiya; Kaneko, Masayuki; Imaoka, Takayuki; Torii, Yuichi; Tura, Yosuke
PA Yamanouchi Pharmaceutical Co., Ltd., Japan; Toray Industries, Inc.
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002018335	A1	20020307	WO 2001-JP7321	20010827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			JP 2000-257451	A 20000828
AU 2001080187	A5	20020313	AU 2001-80187	20010827
			JP 2000-257451	A 20000828
			WO 2001-JP7321	W 20010827

OS MARPAT 136:232201
IT 403477-79-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic amine derivs. as CCR3 antagonists)
RN 403477-79-2 CAPLUS
CN Benzamide, 2-[[(2-chlorophenyl)methyl]amino]-N-[8-[(6-fluoro-2-naphthalenyl)methyl]-8-azabicyclo[3.2.1]oct-3-yl]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 20 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB The title compds. I [ring A = (un)substituted heterocyclic ring, etc.; X = bond, O, CO, etc.; ring B = Q1, etc.; ring V3 = hydrocarbon ring, etc.; W = CH, N; Y = CO, etc.; R21, R22 = H, halo, etc.; T1 = (CH2)n; n = 0 - 2; ring D = (un)substituted aryl, etc.] are prepared In an in vitro test (for
CCR3 antagonism) using cells, compds. of this invention showed IC50 values
of 0.001 μM to 0.45 μM.
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:11104 CAPLUS
DN 136:69743
TI Preparation of pyridyl benzamides and related compounds as Factor Xa inhibitors.
IN Zhu, Bing-Yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick A.; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
PA USA
SO U.S. Pat. Appl. Publ., 259 pp., Cont.-in-part of U.S. Ser. No. 663,420. CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002002183	A1	20020103	US 2001-794225	20010228
	US 6376515	B2	20020423		
				US 2000-185746P P	20000229
				US 2000-663420 A2	20000915
	US 2003162690	A1	20030828	US 2002-126976	20020422
				US 2000-185746P P	20000229
				US 2000-663420 A2	20000915
				US 2001-794225 A1	20010228
	US 2004097561	A1	20040520	US 2003-687334	20031015
				US 2000-185746P P	20000229
				US 2000-663420 A2	20000915
				US 2001-794225 A1	20010228
				US 2002-126976 A1	20020422

PATENT FAMILY INFORMATION:
FAN 2001:208239

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019788	A2	20010322	WO 2000-US25196	20000915
	WO 2001019788	A3	20010809		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-154332P P	19990917
				US 2000-185746P P	20000229
	AU 2000074867	A5	20010417	AU 2000-74867	20000915
				US 1999-154332P P	19990917
				US 2000-185746P P	20000229
				WO 2000-US25196 W	20000915
	EP 1216228	A2	20020626	EP 2000-963452	20000915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
				US 1999-154332P P	19990917
				US 2000-185746P P	20000229
				WO 2000-US25196 W	20000915

L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	BR 2000014076	A	20021015	BR 2000-14076 20000915
				US 1999-154332P P 19990917
				US 2000-185746P P 20000229
				WO 2000-US25196 W 20000915
	JP 2003509406	T2	20030311	JP 2001-523368 20000915
				US 1999-154332P P 19990917
				US 2000-185746P P 20000229
				WO 2000-US25196 W 20000915
	NO 2002001229	A	20020521	NO 2002-1229 20020312
				US 1999-154332P P 19990917
				US 2000-185746P P 20000229
				WO 2000-US25196 W 20000915

FAN 2001:208248

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019798	A2	20010322	WO 2000-US25195	20000915
	WO 2001019798	A3	20011025		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-154332P P	19990917
	AU 2000074866	A5	20010417	AU 2000-74866	20000915
				US 1999-154332P P	19990917
				WO 2000-US25195 W	20000915
	EP 1216231	A2	20020626	EP 2000-963451	20000915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
				US 1999-154332P P	19990917
				WO 2000-US25195 W	20000915
	BR 2000014078	A	20021231	BR 2000-14078 20000915
				US 1999-154332P P 19990917
				WO 2000-US25195 W 20000915
	TR 200201413	T2	20030221	TR 2002-200201413 20000915
				US 1999-154332P P 19990917
	JP 2003509412	T2	20030311	JP 2001-523378 20000915
				US 1999-154332P P 19990917
				WO 2000-US25195 W 20000915
	NZ 517828	A	20031031	NZ 2000-517828 20000915
				US 1999-154332P P 19990917
				WO 2000-US25195 W 20000915
	NO 2002001230	A	20020521	NO 2002-1230 20020312
				US 1999-154332P P 19990917
				WO 2000-US25195 W 20000915

FAN 2001:661391

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064642	A2	20010907	WO 2001-US6247	20010228
	WO 2001064642	A3	20020502		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

				US 2000-185746P P 20000229
				US 2000-663420 A 20000915
FAN	2001:661392			
	PATENT NO.	KIND	DATE	APPLICATION NO. DATE
PI	WO 2001064643	A2	20010907	WO 2001-US6255 20010228
	WO 2001064643	A3	20020404	
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				US 2000 185746P P 20000229
				US 2000-663420 A 20000915
	EP 1259485	A2	20021127	EP 2001-918257 20010228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
				US 2000-185746P P 20000229
				US 2000-663420 A 20000915
				WO 2001-US6255 W 20010228
FAN	2002:522631			
	PATENT NO.	KIND	DATE	APPLICATION NO. DATE
PI	US 2002091116	A1	20020711	US 2001-794214 20010228
	US 6632815	B2	20031014	
				US 1999-154332P P 19990917
				US 2000-662807 A2 20000915
	US 6720317	B1	20040413	US 2000-662807 20000915
				US 1999-154332P P 19990917
	US 6686368	B1	20040203	US 2003-387927 20030312
				US 1999-154332P P 19990917
				US 2000-662807 A3 20000915
	US 2004116399	A1	20040617	US 2003-600695 20030620
				US 1999-154332P P 19990917
				US 2000-662807 A2 20000915
				US 2001-794214 A1 20010228

OS MARPAT 136:69743
IT **358659-61-7P 358659-62-8P 358659-63-9P 358659-64-0P 358659-65-1P 358659-66-2P 358659-67-3P 358659-68-4P 358659-69-5P 358659-74-2P 358659-75-3P 358659-76-4P 358659-77-5P 358659-78-6P 358659-79-7P 358659-80-0P 358659-81-1P 358659-82-2P 358659-83-3P 358659-84-4P 358659-85-5P 358659-87-7P 358659-88-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(Uses)
(prepn. of pyridyl benzamides and related compds. as Factor Xa inhibitors)
RN 358659-61-7 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-62-8 CAPLUS
CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 358659-63-9 CAPLUS
CN Benzamide,
N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(methylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-64-0 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-65-1 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-66-2 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-67-3 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-68-4 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-69-5 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-74-2 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-75-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-76-4 CAPLUS

L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(4-methyl-1-piperazinyl)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-77-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(hexahydro-1H-azepin-1-yl)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-78-6 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)



RN 358659-79-7 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-80-0 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-fluoro- (9CI) (CA INDEX NAME)



RN 358659-81-1 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-82-2 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-87-7 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-88-8 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-83-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-84-4 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-85-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R2C(:NR3), (substituted) Ph, naphthyl, heterocyclyl, etc.; R1-R3 = H, OR5, NR5R6, alkyl, alkenyl, etc.;
R1R2 or R2R3 = atoms to form (substituted) cycloalkyl, heterocyclyl; R5, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) alkylphenyl, alkylnaphthyl; R5R6 = atoms to form a 3-8 membered (substituted) ring; Q = bond, CH2, CO, O, S, SO, SO2, NR7, SO2NR7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, (substituted) alkylphenyl, alkylnaphthyl; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, O, S, SO, SO2, alkylcarbonyl, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, 3-8 membered (fused) (aromatic) heterocyclyl; J = bond, NR9CO, O, S, SO, SO2, CH2, NR9SO2, etc.; X = (substituted) Ph, naphthyl, (fused) heteroaryl], were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-aminophenylcarboxamide (preparation given), 4-cyanobenzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-cyanophenylcarbonyl)amino]phenylcarboxamide. The latter in MeOH at 0° was saturated with HCl and stirred overnight followed by solvent evaporation The residue was refluxed 2 h with NH4OAc in MeOH to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-amidinophenylcarbonyl)amino]phenylcarboxamide.

L3 ANSWER 22 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:816647 CAPLUS
DN 135:357948
TI Preparation of heterocyclic compounds as phosphodiesterase V (PDE V) inhibitors
IN Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohei
PA Tanabe Seiyaku Co., Ltd., Japan
SO PCT Int. Appl., 207 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				JP 2000-130371	A 20000428
	AU 2001041142	A5	20011112	AU 2001-41142	20010315
				JP 2000-130371	A 20000428
				WO 2001-JP2034	W 20010315
	EP 1277741	A1	20030122	EP 2001-912373	20010315
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				JP 2000-130371	A 20000428
				WO 2001-JP2034	W 20010315
	NZ 522217	A	20040430	NZ 2001-522217	20010315
				JP 2000-130371	A 20000428
				WO 2001 JP2034	W 20010315
	US 2003229089	A1	20031211	US 2002-258545	20021025
				JP 2000-130371	A 20000428
				WO 2001-JP2034	W 20010315
	US 2004142930	A1	20040722	US 2003-699804	20031104
				JP 2000-130371	A 20000428
				JP 2000-277652	A 20000913
				WO 2001-JP2034	W 20010315
				US 2002-258545	A2 20021025

PATENT FAMILY INFORMATION:
FAN 2001:208252

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019802	A1	20010322	WO 2000-JP6258	20000913
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
	AU 2000073118	A5	20010417	AU 2000-73118	20000913
	AU 767558	B2	20031113		
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	W 20000913
	BR 2000014526	A	20020618	BR 2000-14526	20000913
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	W 20000913
	TR 200200701	T2	20020621	TR 2002-200200701	20000913
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
	EP 1219609	A1	20020703	EP 2000-960979	20000913
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
				JP 1999-261852	A 19990916
				JP 2000 130371	A 20000428
				WO 2000-JP6258	W 20000913
	RU 2233273	C2	20040727	RU 2002-109792	20000913
				JP 1999 261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	W 20000913
	US 2003032647	A1	20030213	US 2001-925892	20010810
	US 6656935	B2	20031202		
				JP 1999-261852	A 19990916
				JP 2000 130371	A 20000428
				WO 2000-JP6258	A1 20000913
	ZA 2002001499	A	20020902	ZA 2002-1499	20020222
				JP 1999-261852	A 19990916
	NO 2002001308	A	20020424	NO 2002-1308	20020315
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	W 20000913
	BG 106566	A	20030228	BG 2002-106566	20020402
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000 JP6258	W 20000913
	US 2003229095	A1	20031211	US 2003-426884	20030501
				JP 1999-261852	A 19990916
				JP 2000 130371	A 20000428
				WO 2000-JP6258	A1 20000913
				US 2001-925892	A3 20010810

FAN 2004:589247

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004142930	A1	20040722	US 2003-699804	20031104
				JP 2000-130371	A 20000428
				JP 2000-277652	A 20000913
				WO 2001 JP2034	W 20010315
				US 2002-258545	A2 20021025
	JP 2002012587	A2	20020115	JP 2000-277652	20000913

L3 ANSWER 22 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
	WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				JP 2000-130371	A 20000428
	US 2003229089	A1	20031211	US 2002-258545	20021025
				JP 2000-130371	A 20000428
				WO 2001-JP2034	W 20010315

OS MARPAT 135:357948
IT **372115-86-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as phosphodiesterase V inhibitors preventive or therapeutic agents for various diseases due to dysfunction of signal transduction through cGMP)
RN 372115-86-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-chloro 4 methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-6-[(2S)-2-(hydroxymethyl)-1 pyrrolidinyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI

L3 ANSWER 22 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB Compds. of the general formula (I) or pharmacol. acceptable salts thereof [wherein X is :CH or N; Y is NH, NR4, S, O, CH:N, N:CH, N:N, CH:CH, or the like; R1 is lower alkoxy, amino, a nitrogenous heterocyclic group, or a hydroxyl group substituted with a heterocyclic group (wherein each group may be substituted); R2 is either a lower alkylamino or lower alkoxy group which may be substituted with aryl, or a lower alkoxy group substituted with a nitrogenous aromatic heterocyclic group; and R3 is aryl, a nitrogenous heterocyclic group, lower alkyl, lower alkoxy, lower cycloalkoxy, a hydroxyl group substituted with a nitrogenous heterocyclic group, or amino (wherein each group may be substituted), or alternatively, R3 and the substituent of Y may be united to form a lactone ring] or pharmacol. acceptable salts thereof are prepared These compds. exhibit excellent PDE V inhibitory activity and are useful as preventive or therapeutic agents for various diseases due to dysfunction of the signal transduction through cGMP, in particular impotence, pulmonary hypertension, and diabetic renal failure paralysis (no data). Thus, 2-(hydroxymethyl)pyridine was treated wit NaH in THF at room temperature for 30 min and then condensed with 2-chloro-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine (preparation given) in THF at room temperature for 1 h to give 2-(2-pyridylmethoxy)-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine.
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:661392 CAPLUS
DN 135:226888
TI Preparation of pyridyl benzamides and related compounds as Factor Xa inhibitors.
IN Zhu, Bing-yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
PA Cor Therapeutics, Inc., USA
SO PCT Int. Appl., 322 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064643	A2	20010907	WO 2001-US6255	20010228
	WO 2001064643	A3	20020404		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915
	EP 1259485	A2	20021127	EP 2001 918257	20010228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915
				WO 2001-US6255	W 20010228

PATENT FAMILY INFORMATION:
FAN 2001:208239

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019788	A2	20010322	WO 2000-US25196	20000915
	WO 2001019788	A3	20010809		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
	AU 2000074867	A5	20010417	AU 2000-74867	20000915
				US 1999 154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	EP 1216228	A2	20020626	EP 2000-963452	20000915

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	BR 2000014076	A	20021015	BR 2000-14076	20000915
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	JP 2003509406	T2	20030311	JP 2001-523368	20000915
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	NO 2002001229	A	20020521	NO 2002-1229	20020312
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915

FAN 2001:208248

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019798	A2	20010322	WO 2000-US25195	20000915
	WO 2001019798	A3	20011025		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-154332P	P 19990917
	AU 2000074866	A5	20010417	AU 2000-74866	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	EP 1216231	A2	20020626	EP 2000-963451	20000915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
				US 1999 154332P	P 19990917
				WO 2000-US25195	W 20000915
	BR 2000014078	A	20021231	BR 2000-14078	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	TR 200201413	T2	20030221	TR 2002-200201413	20000915
				US 1999-154332P	P 19990917
	JP 2003509412	T2	20030311	JP 2001-523378	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	NZ 517828	A	20031031	NZ 2000-517828	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	NO 2002001230	A	20020521	NO 2002-1230	20020312
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915

FAN 2001:661391

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
PI WO 2001064642 A2 20010907 WO 2001-US6247 20010228
WO 2001064642 A3 20020502
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 2000 185746P P 20000229
US 2000-663420 A 20000915

FAN 2002:11104

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002002183	A1	20020103	US 2001-794225	20010228
	US 6376515	B2	20020423		
				US 2000-185746P	P 20000229
				US 2000-663420	A2 20000915
	US 2003162690	A1	20030828	US 2002-126976	20020422
				US 2000-185746P	P 20000229
				US 2000-663420	A2 20000915
				US 2001-794225	A1 20010228
	US 2004097561	A1	20040520	US 2003-687334	20031015
				US 2000-185746P	P 20000229
				US 2000-663420	A2 20000915
				US 2001-794225	A1 20010228
				US 2002-126976	A1 20020422

FAN 2002:522631

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002091116	A1	20020711	US 2001 794214	20010228
	US 6632815	B2	20031014		
				US 1999-154332P	P 19990917
				US 2000-662807	A2 20000915
	US 6720317	B1	20040413	US 2000-662807	20000915
				US 1999-154332P	P 19990917
	US 6686368	B1	20040203	US 2003-387927	20030312
				US 1999-154332P	P 19990917
				US 2000-662807	A3 20000915
	US 2004116399	A1	20040617	US 2003-600695	20030620
				US 1999-154332P	P 19990917
				US 2000-662807	A2 20000915
				US 2001-794214	A1 20010228

OS MARPAT 135:226888
IT **358659-61-7P 358659-62-8P 358659-63-9P 358659-64-0P 358659-65-1P 358659-66-2P 358659-67-3P 358659-68-4P 358659-69-5P 358659-74-2P 358659-75-3P 358659-76-4P 358659-77-5P 358659-78-6P 358659-79-7P 358659-80-0P 358659-81-1P 358659-82-2P 358659-83-3P 358659-84-4P 358659-85-5P 358659-87-7P 358659-88-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of pyridyl benzamides and related compds. as Factor Xa inhibitors)

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 358659-61-7 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-62-8 CAPLUS
CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 358659-63-9 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(methylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-64-0 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-65-1 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-69-5 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-74-2 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-75-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-76-4 CAPLUS

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-66-2 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-67-3 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-68-4 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(imino(4-methyl-1-piperazinyl)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-77-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(hexahydro-1H-azepin-1-yl)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-78-6 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)



RN 358659-79-7 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-80-0 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-fluoro- (9CI) (CA INDEX NAME)



RN 358659-81-1 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-82-2 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-87-7 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-88-8 CAPLUS
CN Benzamide, N (5-chloro-2-pyridinyl)-5 fluoro-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-83-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-84-4 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-85-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R2C(:NR3), (substituted) Ph, naphthyl, heterocyclyl, etc.; R1-R3 = H, OR5, NR5R6, alkyl, alkenyl, etc.; R1R2 or R2R3 = atoms to form (substituted) cycloalkyl, heterocyclyl; R5, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) alkylphenyl, alkylnaphthyl; R5R6 = atoms to form a 3-8 membered (substituted) ring; Q = bond, CH2, CO, O, S, SO, SO2, NR7, SO2NR7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, (substituted) alkylphenyl, alkylnaphthyl; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, O, S, SO, SO2, alkylcarbonyl, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, 3-8 membered (fused) (aromatic) heterocyclyl; J = bond, NR9CO, O, S, SO, SO2, CH2, NR9SO2, etc.; X = (substituted) Ph, naphthyl, (fused) heteroaryl], were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-aminophenylcarboxamide (preparation given), 4-cyanobenzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-cyanophenylcarbonyl)amino]phenylcarboxamide. The latter in MeOH at 0° was saturated with HCl and stirred overnight followed by solvent evaporation The residue was refluxed 2 h with NH4OAc in MeOH to give 70% N-(5-bromo-2 pyridinyl)-[2-(4-amidinophenylcarbonyl)amino]phenylcarboxamide.

L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:661391 CAPLUS
DN 135:210946
TI Preparation of pyridylamides as Factor Xa inhibitors.
IN Zhu, Bing-yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
PA Cor Therapeutics, Inc., USA
SO PCT Int. Appl., 306 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064642	A2	20010907	WO 2001-US6247	20010228
	WO 2001064642	A3	20020502		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000 185746P	P 20000229
				US 2000-663420	A 20000915

PATENT FAMILY INFORMATION:

FAN 2001:208239

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019788	A2	20010322	WO 2000-US25196	20000915
	WO 2001019788	A3	20010809		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
	AU 2000074867	A5	20010417	AU 2000-74867	20000915
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	EP 1216228	A2	20020626	EP 2000-963452	20000915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	BR 2000014076	A	20021015	BR 2000-14076	20000915
				US 1999-154332P	P 19990917

L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	JP 2003509406	T2	20030311	JP 2001-523368	20000915
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	NO 2002001229	A	20020521	NO 2002-1229	20020312
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915

FAN 2001:208248

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019798	A2	20010322	WO 2000-US25195	20000915
	WO 2001019798	A3	20011025		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-154332P	P 19990917
	AU 2000074866	A5	20010417	AU 2000 74866	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	EP 1216231	A2	20020626	EP 2000-963451	20000915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	BR 2000014078	A	20021231	BR 2000-14078	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	TR 200201413	T2	20030221	TR 2002-200201413	20000915
				US 1999-154332P	P 19990917
	JP 2003509412	T2	20030311	JP 2001-523378	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	NZ 517828	A	20031031	NZ 2000-517828	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	NO 2002001230	A	20020521	NO 2002-1230	20020312
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915

FAN 2001:661392

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064643	A2	20010907	WO 2001-US6255	20010228
	WO 2001064643	A3	20020404		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				

L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
				RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915
	EP 1259485	A2	20021127	EP 2001 918257	20010228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915
				WO 2001-US6255	W 20010228

FAN 2002:11104

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002002183	A1	20020103	US 2001-794225	20010228
	US 6376515	B2	20020423		
				US 2000 185746P	P 20000229
				US 2000-663420	A2 20000915
	US 2003162690	A1	20030828	US 2002-126976	20020422
				US 2000 185746P	P 20000229
				US 2000-663420	A2 20000915
				US 2001-794225	A1 20010228
	US 2004097561	A1	20040520	US 2003-687334	20031015
				US 2000-185746P	P 20000229
				US 2000-663420	A2 20000915
				US 2001-794225	A1 20010228
				US 2002-126976	A1 20020422

FAN 2002:522631

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002091116	A1	20020711	US 2001-794214	20010228
	US 6632815	B2	20031014		
				US 1999-154332P	P 19990917
				US 2000-662807	A2 20000915
	US 6720317	B1	20040413	US 2000 662807	20000915
				US 1999-154332P	P 19990917
	US 6686368	B1	20040203	US 2003-387927	20030312
				US 1999-154332P	P 19990917
				US 2000-662807	A3 20000915
	US 2004116399	A1	20040617	US 2003-600695	20030620
				US 1999-154332P	P 19990917
				US 2000-662807	A2 20000915
				US 2001-794214	A1 20010228

OS MARPAT 135:210946
IT **358659-61-7P 358659-62-8P 358659-63-9P 358659-64-0P 358659-65-1P 358659-66-2P 358659-67-3P 358659-68-4P 358659-69-5P 358659-74-2P 358659-75-3P 358659-76-4P 358659-77-5P 358659-78-6P 358659-79-7P 358659-80-0P 358659-81-1P 358659-82-2P 358659-83-3P 358659-84-4P 358659-85-5P 358659-87-7P 358659-88-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(prepn. of pyridylamides as Factor Xa inhibitors)
RN 358659-61-7 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-62-8 CAPLUS
CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)





RN 358659-63-9 CAPLUS
CN Benzamide,
N-(5-chloro-2-pyridinyl)-2-[[[4-(imino(methylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-64-0 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-65-1 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-69-5 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-74-2 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-75-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-76-4 CAPLUS

L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-66-2 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-67-3 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-68-4 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl) (9CI) (CA INDEX NAME)

L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(4-methyl-1-piperazinyl)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-77-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(hexahydro-1H-azepin-1-yl)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-78-6 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)



RN 358659-79-7 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)

L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-80-0 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-fluoro- (9CI) (CA INDEX NAME)



RN 358659-81-1 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-82-2 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-83-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-84-4 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-85-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-87-7 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-88-8 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino 1 pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R1C(:NR3), (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl, etc.; R1-R3 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (alkyl)aryl, (alkyl)heteroaryl, etc.; R1R2 or R2R3 = atoms to form a 3-8 membered (substituted) (heterocyclic) ring; Q = bond, CH2, CO, O, NR7, etc.; R7 = H, alkyl, (alkyl)aryl, (alkyl)heteroaryl, etc.; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, S, SO, SO2, alkoxy, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, heterocyclyl, fused cyclic system; J = bond, NR9CO, O, S, SO, SO2, SO2NR9, CH2, NR9, etc.; R9 = H, alkyl, (alkyl)aryl, etc.; X = (substituted) Ph, naphthyl, heteroaryl, fused bicyclyl], were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl) 2-aminophenylcarboxamide (preparation given), 4-[(2-tert-butylaminosulfonyl)phenyl]benzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 85% N-(5-bromo-2-pyridinyl)-[2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino]phenylcarboxamide.

L3 ANSWER 25 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:565010 CAPLUS
DN 135:137407
TI Preparation of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors
IN Manley, Paul William; Bold, Guido
PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001055114	A1	20010802	WO 2001-EP835	20010125
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				GB 2000-1930 A	20000127
	AU 2001028499	A5	20010807	AU 2001-28499	20010125
	AU 771626	B2	20040401		
				GB 2000-1930 A	20000127
				WO 2001 EP835 W	20010125
	BR 2001007805	A	20021022	BR 2001-7805	20010125
				GB 2000-1930 A	20000127
				WO 2001-EP835 W	20010125
	EP 1259487	A1	20021127	EP 2001-946854	20010125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				GB 2000-1930 A	20000127
				WO 2001-EP835 W	20010125
	JP 2003520853	T2	20030708	JP 2001-555056	20010125
				GB 2000-1930 A	20000127
				WO 2001-EP835 W	20010125
	NZ 520005	A	20040227	NZ 2001-520005	20010125
				GB 2000-1930 A	20000127
				WO 2001-EP835 W	20010125
	NO 2002003218	A	20020916	NO 2002-3218	20020702
				GB 2000-1930 A	20000127
				WO 2001-EP835 W	20010125
	US 2003032656	A1	20030213	US 2002-181005	20020711
	US 6624174	B2	20030923		
				GB 2000-1930 A	20000127
				WO 2001 EP835 W	20010125
	ZA 2002005988	A	20030728	ZA 2002-5988	20020726
				GB 2000-1930 A	20000127

OS MARPAT 135:137407
IT **62636-33-3P 352227-86-2P 352227-92-0P 352228-00-3P**

L3 ANSWER 25 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 352228-00-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-hydroxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; n = 1-6; W = O, S; R1, R3 = H, alkyl, acyl; R2 = (un)substituted cycloalkyl, aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S; R, R' = H, alkyl; X = (un)substituted aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S] and their pharmaceutically acceptable salts, useful for therapy of

L3 ANSWER 25 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors)
RN 62636-33-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 352227-86-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-[(methylamino)carbonyl]phenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 352227-92-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-hydroxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 25 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
a disease which responds to an inhibition of the VEGF-receptor tyrosine kinase activity (such as neoplastic disease), were prepd. and formulated. Thus, amidation of 3-aminobenzotrifluoride with 2-chloronicotinoyl chloride followed by reacting 4-pyridineethanamine with the resulting carboxamide afforded I [n = 2; R, R' = H; X = 4-pyridyl; W = O; R1, R3 = H; R2 = 3-(F3C)C6H4].
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 26 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:208252 CAPLUS
DN 134:252363
TI Preparation and effect of nitrogen-containing-six-membered aromatic compounds as PDE V activity inhibitors
IN Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohei
PA Tanabe Seiyaku Co., Ltd., Japan
SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019802	A1	20010322	WO 2000-JP6258	20000913
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
	AU 2000073118	A5	20010417	AU 2000-73118	20000913
	AU 767558	B2	20031113		
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	W 20000913
	BR 2000014526	A	20020618	BR 2000-14526	20000913
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	W 20000918
	TR 200200701	T2	20020621	TR 2002-200200701	20000913
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
	EP 1219609	A1	20020703	EP 2000-960979	20000913
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	W 20000913
	RU 2233273	C2	20040727	RU 2002-109792	20000913
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	W 20000913
	US 2003032647	A1	20030213	US 2001-925892	20010810
	US 6656935	B2	20031202		
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	A1 20000913
	ZA 2002001499	A	20020902	ZA 2002-1499	20020222
				JP 1999-261852	A 19990916
	NO 2002001308	A	20020424	NO 2002-1308	20020315

L3 ANSWER 26 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	W 20000913
	BG 106566	A	20030228	BG 2002-106566	20020402
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	W 20000913
	US 2003229095	A1	20031211	US 2003-426884	20030501
				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
				WO 2000-JP6258	A1 20000913
				US 2001-925892	A3 20010810

PATENT FAMILY INFORMATION:

FAN	2001:816647				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				JP 2000-130371	A 20000428
	AU 2001041142	A5	20011112	AU 2001-41142	20010315
				JP 2000-130371	A 20000428
				WO 2001-JP2034	W 20010315
	EP 1277741	A1	20030122	EP 2001-912373	20010315
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				JP 2000-130371	A 20000428
				WO 2001-JP2034	W 20010315
	NZ 522217	A	20040430	NZ 2001-522217	20010315
				JP 2000-130371	A 20000428
				WO 2001-JP2034	W 20010315
	US 2003229089	A1	20031211	US 2002-258545	20021025
				JP 2000-130371	A 20000428
				WO 2001-JP2034	W 20010315
	US 2004142930	A1	20040722	US 2003-699804	20031104
				JP 2000-130371	A 20000428
				JP 2000-277652	A 20000913
				WO 2001-JP2034	W 20010315
				US 2002-258545	A2 20021025

FAN	2004:589247				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004142930	A1	20040722	US 2003-699804	20031104
				JP 2000-130371	A 20000428
				JP 2000-277652	A 20000913
				WO 2001-JP2034	W 20010315
				US 2002-258545	A2 20021025
	JP 2002012587	A2	20020115	JP 2000-277652	20000913

L3 ANSWER 26 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				JP 1999-261852	A 19990916
				JP 2000-130371	A 20000428
	WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				JP 2000-130371	A 20000428
	US 2003229089	A1	20031211	US 2002-258545	20021025
				JP 2000-130371	A 20000428
				WO 2001-JP2034	W 20010315

OS MARPAT 134:252363
IT **330785-09-6P 330785-10-9P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and effect of heteroarom. compds. as PDE V activity inhibitors)
RN 330785-09-6 CAPLUS
CN Pyrazinecarboxamide, 3-[[[3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330785-10-9 CAPLUS
CN Pyrazinecarboxamide, 3-[[[3-chloro-4-methoxyphenyl)methyl]amino]-5-(5,6-dihydroimidazo(1,2-a)pyrazin-7(8H) yl)-N-(trans-4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L3 ANSWER 26 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I



II

AB Title compds. [I; A is an optionally substituted nitrogenous heterocyclic group; R1 is optionally substituted lower alkyl, NHQR3 (wherein R3 is an optionally substituted nitrogenous heterocyclic group; and Q is lower alkylene or a single bond), or NHR4 (wherein R4 is optionally substituted cycloalkyl); R2 is optionally substituted aryl; and either of Y and Z is CH and the other is N], pharmacol. acceptable salts are prepared and are exhibiting an excellent selective inhibitory activity against PDE V and being useful as preventive or therapeutic drugs for erectile dysfunction (no data). Thus, the title compound II was prepared

L3 ANSWER 26 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:457059 CAPLUS
DN 133:89437
TI Preparation of heteroaryl-substituted aromatic amides as factor Xa inhibitors
IN Beight, Douglas Wade; Craft, Trelia Joyce; Denny, Carl Penman; Franciskovich, Jeffry Bernard; Goodson, Theodore, Jr.; Hall, Steven Edward; Herron, David Kent; Joseph, Sajan Pariyadan; Klimkowski, Valentine Joseph; Masters, John Joseph; Mendel, David; Milot, Guy; Pineiro-Nunez, Marta Maria; Sawyer, Jason Scott; Shuman, Robert Theodore; Smith, Gerald Floyd; Tebbe, Anne Louise; Tinsley, Jennifer Marie; Weir, Leonard Crayton; Wikel, James Howard; Wiley, Michael Robert; Yee, Ying Kwong
PA Eli Lilly and Co., USA; Kyle, Jeffrey, Alan; et al.
SO PCT Int. Appl., 403 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039118	A1	20000706	WO 1999-US29946	19991215
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1998-113556P	P 19981223
	CA 2361149	AA	20000706	CA 1999-2361149	19991215
				US 1998-113556P	P 19981223
				WO 1999-US29946	W 19991215
	EP 1140903	A1	20011010	EP 1999-964279	19991215
	EP 1140903	B1	20040804		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				US 1998 113556P	P 19981223
				WO 1999-US29946	W 19991215
	JP 2002533454	T2	20021008	JP 2000-591029	19991215
				US 1998-113556P	P 19981223
				WO 1999-US29946	W 19991215
	US 6635657	B1	20031021	US 2001-857751	20010608
				US 1998-113556P	P 19981223
				WO 1999-US29946	W 19991215
	US 2004029874	A1	20040212	US 2003-629760	20030729
	US 6759414	B2	20040706		
				US 1998-113556P	P 19981223
				WO 1999-US29946	W 19991215
				US 2001-857751	A3 20010608

OS MARPAT 133:89437
IT **280769-65-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L3 ANSWER 27 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroaryl-substituted arom. amides as factor Xa inhibitors)
RN 280769 65 5 CAPLUS
CN Benzamide, 2-[[[4-(acetylamino)phenyl]methyl]amino] 5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)





GI



AB The title compds. [I; A3-A6, together with the two carbons to which they are attached, complete a substituted benzene in which A3 = CR3, A4 = CR4, A5 = CR5, and A6 = CR6 (wherein R3 = H, Me, MeO, etc.; one of R4 and R5 = H, alkyl, halo, etc.; the other of R4 and R5 = H; R6 = H, Me, F, etc.); L1 = CONH; Q1 = 2-pyridinyl (un)substituted at the 5-position, 3-pyridinyl (un)substituted at the 6-position, 2-pyrimidinyl (un)substituted at the 5-position, etc.; R2 = L2Q2 (L2 = NHCO, NHCH2, OCH2, etc.; Q2 = (un)substituted piperidinyl, piperazinyl, Ph, etc.)] and their pharmaceutically acceptable salts, useful as inhibitors of factor Xa (no data), were prepared and formulated. E.g., a multi-step synthesis of II.HCl was given. In general, compds. I are effective at 0.01-1000 mg/kg/day.
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 28 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:335388 CAPLUS
DN 132:347491
TI Preparation of N aryl(thio)anthranilic acid amides as VEGF receptor tyrosine kinase inhibitors
IN Altmann, Karl-Heinz; Bold, Guido; Furet, Pascal; Manley, Paul William; Wood, Jeanette Marjorie; Ferrari, Stefano; Hofmann, Francesco; Mestan, Jurgen; Huth, Andreas; Kruger, Martin; Seidelmann, Dieter; Menrad, Andreas; Haberey, Martin; Thierauch, Karl-Heinz
PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Schering Aktiengesellschaft
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000027820	A1	20000518	WO 1999-EP8545	19991108
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				GB 1998-24579	A 19981110
	CA 2346898	AA	20000518	CA 1999-2346898	19991108
				GB 1998-24579	A 19981110
				WO 1999-EP8545	W 19991108
	BR 9915210	A	20010724	BR 1999-15210	19991108
				GB 1998-24579	A 19981110
				WO 1999-EP8545	W 19991108
	TR 200101237	T2	20010821	TR 2001-200101237	19991108
				GB 1998-24579	A 19981110
	EP 1129075	A1	20010905	EP 1999-971802	19991108
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				GB 1998-24579	A 19981110
				WO 1999-EP8545	W 19991108
	JP 2002529453	T2	20020910	JP 2000-581000	19991108
				GB 1998 24579	A 19981110
				WO 1999-EP8545	W 19991108
	AU 758230	B2	20030320	AU 2000-13811	19991108
				GB 1998-24579	A 19981110
				WO 1999-EP8545	W 19991108
	NZ 511339	A	20030725	NZ 1999 511339	19991108
				GB 1998-24579	A 19981110
				WO 1999-EP8545	W 19991108
	NO 2001001894	A	20010704	NO 2001-1894	20010417
				GB 1998-24579	A 19981110
				WO 1999 EP8545	W 19991108
	ZA 2001003290	A	20030123	ZA 2001-3290	20010423
				GB 1998-24579	A 19981110
	US 2002019414	A1	20020214	US 2001 850434	20010507
	US 6448277	B2	20020910		
				GB 1998-24579	A 19981110
				WO 1999-EP8545	W 19991108

L3 ANSWER 28 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	ZA 2001004673	A	20020909	ZA 2001-4673	20010607
				GB 1998-24579 A	19981110
	US 2003064992	A1	20030403	US 2002-180289	20020626
				GB 1998-24579 A	19981110
				WO 1999-EP8545 W	19991108
				US 2001-850434 A3	20010507

PATENT FAMILY INFORMATION:

FAN 2000:335387

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000027819	A2	20000518	WO 1999-EP8478	19991109
	WO 2000027819	A3	20000817		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				GB 1998-24579 A	19981110
				DE 1999-19910396 A	19990303
	DE 19910396	A1	20000907	DE 1999-19910396	19990303
	DE 19910396	C2	20011213		
	BR 9915553	A	20010814	BR 1999-15553	19991109
				GB 1998-24579 A	19981110
				DE 1999-19910396 A	19990303
				WO 1999 EP8478 W	19991109
	EP 1129074	A2	20010905	EP 1999-953967	19991109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				GB 1998-24579 A	19981110
				DE 1999-19910396 A	19990303
				WO 1999-EP8478 W	19991109
	TR 200101307	T2	20020521	TR 2001 200101307	19991109
				GB 1998-24579 A	19981110
				DE 1999-19910396 A	19990303
	JP 2002529452	T2	20020910	JP 2000-580999	19991109
				GB 1998-24579 A	19981110
				DE 1999-19910396 A	19990303
				WO 1999-EP8478 W	19991109
	EE 200100258	A	20021216	EE 2001-258	19991109
				GB 1998 24579 A	19981110
				DE 1999-19910396 A	19990303
				WO 1999-EP8478 W	19991109
	NZ 511413	A	20040130	NZ 1999-511413	19991109
				GB 1998-24579 A	19981110
				DE 1999-19910396 A	19990303
				WO 1999-EP8478 W	19991109
	AU 771180	B2	20040318	AU 2000-10454	19991109
				GB 1998-24579 A	19981110
				DE 1999-19910396 A	19990303
				WO 1999-EP8478 W	19991109
	NO 2001002245	A	20010710	NO 2001-2245	20010507

L3 ANSWER 28 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				GB 1998-24579 A	19981110
				DE 1999-19910396 A	19990303
				WO 1999-EP8478 W	19991109
	BG 105588	A	20020430	BG 2001-105588	20010611
				GB 1998-24579 A	19981110
				DE 1999-19910396 A	19990303
				WO 1999-EP8478 W	19991109

OS MARPAT 132:347491

IT **269390-99-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-aryl(thio)anthranilic acid amides as VEGF receptor tyrosine kinase inhibitors)

RN 269390-99-0 CAPLUS

CN Benzamide, 2-[(5-quinolinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI



I

AB Use of title compds. I; W = O, S; X = NR8; Y = CR9R10(CH2)n, SO2; R9, R10 = H, alkyl; n = 0-3; R1 = aryl; R2 = mono- or bicyclic heteroaryl with the exception that R2 cannot = 2-phthalimidyl, and when Y = SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; R3-R6 = H, substituent; R7, R8 = H, alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof, for the

L3 ANSWER 28 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

prepn. of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity is claimed. Thus, a mixt. of 4-pyridinecarboxaldehyde and 2-amino-N-(4-trifluoromethylphenyl)benzamide (prepn. given) in MeOH contg. HOAc was treated with NaBH3CN followed by 16 h stirring to give 2-[(4-pyridyl)methyl]amino-N-[4-(trifluoromethyl)phenyl]benzamide. Tested I inhibited Flt-1 VEGF receptor tyrosine kinase with IC50 = 0.18-0.56 μM.

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 29 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:409260 CAPLUS

DN 131:73440

TI Preparation of aromatic amide derivatives as ACC inhibitor

IN Igawa, Hiroshi; Nishimura, Masato; Okada, Keiji; Nakamura, Takashi

PA Fujirebio, Inc., Japan

SO Jpn. Kokai Tokkyo Koho, 72 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11171848	A2	19990629	JP 1998-270721	19980925
				JP 1997-277942	19970926

OS MARPAT 131:73440

IT **228580-72-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of aromatic amide derivs. as ACC inhibitor)

RN 228580-72-1 CAPLUS

CN Benzoic acid, 2-[[4-(phenylethynyl)-2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



IT **228580-60-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aromatic amide derivs. as ACC inhibitor)

RN 228580-60-7 CAPLUS

CN Benzoic acid, 2-[[2-[(phenylmethyl)amino]benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



IT **228580-61-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of aromatic amide derivs. as ACC inhibitor)

L3 ANSWER 29 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 228580-61-8 CAPLUS
CN Benzoic acid, 2-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; R = 3-CF3C6H4, C6H5(CH2)2, C6H5, CH3(CH2)5, CH3(CH2)3, CH3(CH2)2, CH3CH2, CH3, C6H5(CH2)3, etc.; R1 = H, CH3(CH2)4, 5-CH3(CH2)5CC, 5-CH3CH2CC, 5-(CH3)3CCC, 4-C6H5CH2O, 4-C6H5CC, 3-C6H5CC, 3-C6H5CC, 3 (4-NO2C6H4)CC, 3-(4-NCC6H4)CC, 3-(4-HOC6H4)CC, etc.; R2 = 5 OH, 5-Cl, 5-OMe, 5-Me, 5-Br, etc.; R3 = H, CH3, etc.; R4 = CO2H, AcNHSO2, CH3(CH2)4CONHSO2, 4-CF3C6H4CONHSO2, PHCONHSO2, (CH3)3CONHSO2, CH3(CH2)2NHCONHSO2, etc.; X = CH, N; dotted bond = single, double] are prepared and tested as ACC (acetyl-CoA carboxylase) inhibitors in treatment of lipids oxidation related diseases, such as myocardial infarction, cerebral infarction, and diabetes. The title compound I (R = 3-CF3C6H4; R1 = H; R2 = H; R3 = H; X = CH; dotted bonds were double bonds) was prepared with 72% yield from 3-EtO2CC6H4NH2 and 3-(2-HO2CC6H4NH)C6H4CF3.

L3 ANSWER 30 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:236274 CAPLUS
DN 128:282780
TI Preparation of heterocyclic inhibitors of microsomal triglyceride transfer protein
IN Biller, Scott A.; Dickson, John K.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Sulsky, Richard B.; Tino, Joseph A.
PA Bristol-Myers Squibb Co., USA
SO U.S., 185 pp., Cont.-in-part of U.S. Ser. No. 391,901, abandoned. CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5739135	A	19980414	US 1995-472067	19950606
				US 1993-117362 A2	19930903
				US 1994-284808 B2	19940805
				US 1995-391901 B2	19950221
	CA 2091102	AA	19930907	CA 1993-2091102	19930305
				US 1992-847503 A	19920306
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503 A	19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503 A	19920306
	EP 584446	A2	19940302	EP 1993 103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1992-847503 A	19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503 A	19920306
	PT 584446	T	20020930	PT 1993-103697	19930308
				US 1992-847503 A	19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308
				US 1992-847503 A	19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992-847503 A	19920306
	US 5595872	A	19970121	US 1993-117362	19930903
				US 1992-847503 B2	19920306
				US 1993-15449 B2	19930222
	US 5789197	A	19980804	US 1995-486924	19950607
				US 1992-847503 B2	19920306
				US 1993-15449 B2	19930222
				US 1993-117362 A3	19930903
	US 6492365	B1	20021210	US 1995-486929	19950607
				US 1992 847503 B2	19920306
				US 1993-15449 B2	19930222
				US 1993-117362 A3	19930903
	US 5712279	A	19980127	US 1996 548811	19960111
				US 1995-391901 B2	19950221
				US 1995-472067 A2	19950606

L3 ANSWER 30 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	IL 116917	A1	20000831	IL 1996-116917	19960126
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
	TW 486469	B	20020511	TW 1996-85100978	19960126
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
	CA 2213466	AA	19960829	CA 1996-2213466	19960201
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
	WO 9626205	A1	19960829	WO 1996-US824	19960201
	W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
	AU 9647631	A1	19960911	AU 1996-47631	19960201
	AU 699865	B2	19981217		
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
				WO 1996-US824 W	19960201
	CN 1176640	A	19980318	CN 1996-192015	19960201
	CN 1108301	B	20030514		
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
	EP 886637	A1	19981230	EP 1996-903604	19960201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
				WO 1996-US824 W	19960201
	JP 11500442	T2	19990112	JP 1996-525679	19960201
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
				WO 1996-US824 W	19960201
	NZ 302055	A	20000228	NZ 1996-302055	19960201
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
				WO 1996-US824 W	19960201
	PL 185443	B1	20030530	PL 1996-322003	19960201
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
				WO 1996-US824 W	19960201
	ZA 9601340	A	19970911	ZA 1996-1340	19960220
				US 1995-391901 A	19950221
	US 5883099	A	19990316	US 1997-896872	19970721
				US 1993-117362 A2	19930903
				US 1994-284808 B2	19940805
				US 1995-391901 B2	19950221
				US 1995-472067 A3	19950606
	US 6034098	A	20000307	US 1997-898304	19970721
				US 1993-117362 A2	19930903
				US 1994-284808 B2	19940805
				US 1995-391901 B2	19950221
				US 1995-472067 A3	19950606
	US 6066650	A	20000523	US 1997-898303	19970721
				US 1993-117362 A2	19930903
				US 1994-284808 B2	19940805
				US 1995-391901 B2	19950221
				US 1995-472067 A1	19950606

L3 ANSWER 30 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	FI 9703416	A	19970820	FI 1997-3416	19970820
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
				WO 1996-US824 W	19960201
	NO 9703821	A	19970820	NO 1997-3821	19970820
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
				WO 1996-US824 W	19960201
	LT 4367	B	19980825	LT 1997-152	19970919
				US 1995-391901 A	19950221
	LV 11951	B	19981120	LV 1997-171	19970919
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
	US 2003166590	A1	20030904	US 2001-933593	20010821
				US 1992-847503 B2	19920306
				US 1993-15449 B2	19930222
				US 1993-117362 A3	19930903
				US 1995-486929 A3	19950607

PATENT FAMILY INFORMATION:
FAN 1995:568500

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 643057	A1	19950315	EP 1994-113800	19940902
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1993-117362 A	19930903
	CA 2091102	AA	19930907	CA 1993-2091102	19930305
				US 1992-847503 A	19920306
	ZA 9301601	A	19931005	ZA 1993-1601	19930305
				US 1993-117362 A	19930903
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503 A	19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503 A	19920306
	EP 584446	A2	19940302	EP 1993-103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1992-847503 A	19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503 A	19920306
	PT 584446	T	20020930	PT 1993-103697	19930308
				US 1992-847503 A	19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308
				US 1992-847503 A	19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992-847503 A	19920306
	US 5595872	A	19970121	US 1993-117362	19930903
				US 1992-847503 B2	19920306
				US 1993-15449 B2	19930222
	CA 2131430	AA	19950304	CA 1994-2131430	19940902
				US 1993-117362 A	19930903
	FI 9404048	A	19950304	FI 1994-4048	19940902
				US 1993-117362 A	19930903
	NO 9403260	A	19950306	NO 1994-3260	19940902
				US 1993-117362 A	19930903

L3 ANSWER 30 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	AU 9471642	A1	19950316	AU 1994-71642	19940902
	AU 690125	B2	19980423		
				US 1993-117362	A 19930903
	ZA 9406772	A	19950403	ZA 1994-6772	19940902
				US 1993-117362	A 19930903
	JP 07165712	A2	19950627	JP 1994-210057	19940902
				US 1993-117362	A 19930903
	CN 1106003	A	19950802	CN 1994-115640	19940902
				US 1993-117362	A 19930903
	HU 70613	A2	19951030	HU 1994-2542	19940902
				US 1993-117362	A 19930903
	US 5789197	A	19980804	US 1995-486924	19950607
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
	US 6492365	B1	20021210	US 1995-486929	19950607
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
	US 2003166590	A1	20030904	US 2001-933593	20010821
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
				US 1995-486929	A3 19950607

FAN 1996:641305

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9626205	A1	19960829	WO 1996-US824	19960201

W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
	CA 2091102	AA	19930907	CA 1993-2091102	19930305
				US 1992-847503	A 19920306
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503	A 19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503	A 19920306
	EP 584446	A2	19940302	EP 1993-103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

				US 1992-847503	A 19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503	A 19920306
	PT 584446	T	20020930	PT 1993-103697	19930308
				US 1992-847503	A 19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308
				US 1992-847503	A 19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992-847503	A 19920306

L3 ANSWER 30 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	US 5739135	A	19980414	US 1995-472067	19950606
				US 1993-117362	A2 19930903
				US 1994-284808	B2 19940805
				US 1995-391901	B2 19950221
	AU 9647631	A1	19960911	AU 1996-47631	19960201
	AU 699865	B2	19981217		
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	EP 886637	A1	19981230	EP 1996-903604	19960201

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE

				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	JP 11500442	T2	19990112	JP 1996-525679	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	NZ 302055	A	20000228	NZ 1996-302055	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	PL 185443	B1	20030530	PL 1996-322003	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	ZA 9601340	A	19970911	ZA 1996-1340	19960220
				US 1995-391901	A 19950221
	FI 9703416	A	19970820	FI 1997-3416	19970820
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	NO 9703821	A	19970820	NO 1997-3821	19970820
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	LT 4367	B	19980825	LT 1997-152	19970919
				US 1995-391901	A 19950221

FAN 1998:115356

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5712279	A	19980127	US 1996-548811	19960111
			US 1995-391901	B2 19950221
			US 1995-472067	A2 19950606
CA 2091102	AA	19930907	CA 1993-2091102	19930305
			US 1992-847503	A 19920306
HU 67962	A2	19950529	HU 1993-627	19930305
HU 218419	B	20000828		
			US 1992-847503	A 19920306
JP 06038761	A2	19940215	JP 1993-46499	19930308
			US 1992-847503	A 19920306
EP 584446	A2	19940302	EP 1993-103697	19930308
EP 584446	A3	19950426		
EP 584446	B1	20020619		

L3 ANSWER 30 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1992-847503	A 19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503	A 19920306
	PT 584446	T	20020930	PT 1993-103697	19930308
				US 1992-847503	A 19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308
				US 1992 847503	A 19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992 847503	A 19920306
	US 5739135	A	19980414	US 1995-472067	19950606
				US 1993-117362	A2 19930903
				US 1994-284808	B2 19940805
				US 1995-391901	B2 19950221
	ZA 9601340	A	19970911	ZA 1996 1340	19960220
				US 1995-391901	A 19950221
	LT 4367	B	19980825	LT 1997-152	19970919
				US 1995-391901	A 19950221

OS MARPAT 128:282780

IT **182429-79-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic inhibitors of microsomal triglyceride transfer protein)

RN 182429-79-4 CAPLUS

CN 9H Fluorene-9-carboxamide, 9-[4-[4-[[2-[(phenylmethyl)amino]benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L3 ANSWER 30 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I-V; Q = C(O), S(O)2; X = CHR8, C(O), CHR9CHR10, CR9:CR10 (wherein R8-R10 = H, alkyl, alkenyl, etc.); Y = (CH2)m, C(O) (m = 2-3); R1 = alkyl, alkenyl, alkynyl, etc.; R2-R4 = H, halo, alkyl, etc.; R5 = alkyl, alkenyl, alkynyl, etc.; R6 = H, C1-4 alkyl, C1-4 alkenyl] which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases such as hyperglycemia and obesity, were prepared. Thus, reaction of 1-(3,3-diphenylpropyl)-4-piperidinamine.HCl (preparation described) with benzoyl chloride in the presence of Et3N in CH2Cl2 afforded 84% the title compound III.HCl [Q = C(O); R1 = 3,3-diphenylpropyl; R5 = Ph; R6 = H]. Compds. I-V are effective at 5-500 mg/day.

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:641305 CAPLUS
DN 125:275663
TI Preparation of 9-(piperidinoalkyl)fluorene-9-carboxamides and analogs as microsomal triglyceride transfer protein inhibitors
IN Wetterau, John R. II; Sharp, Daru Young; Gregg, Richard E.; Biller, Scott A.; Dickson, John A.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Robl, Jeffrey A.; et al.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 427 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9626205	A1	19960829	WO 1996-US824	19960201
	W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
	CA 2091102	AA	19930907	CA 1993-2091102	19930305
				US 1992-847503	A 19920306
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503	A 19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503	A 19920306
	EP 584446	A2	19940302	EP 1993-103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1992-847503	A 19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503	A 19920306
	PT 584446	T	20020930	PT 1993-103697	19930308
				US 1992-847503	A 19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308
				US 1992-847503	A 19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992-847503	A 19920306
	US 5739135	A	19980414	US 1995-472067	19950606
				US 1993-117362	A2 19930903
				US 1994-284808	B2 19940805
				US 1995-391901	B2 19950221
	AU 9647631	A1	19960911	AU 1996-47631	19960201
	AU 699865	B2	19981217		
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	EP 886637	A1	19981230	EP 1996-903604	19960201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				

L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	JP 11500442	T2	19990112	JP 1996-525679	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	NZ 302055	A	20000228	NZ 1996-302055	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996 US824	W 19960201
	PL 185443	B1	20030530	PL 1996-322003	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	ZA 9601340	A	19970911	ZA 1996-1340	19960220
				US 1995-391901	A 19950221
	FI 9703416	A	19970820	FI 1997-3416	19970820
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	NO 9703821	A	19970820	NO 1997-3821	19970820
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	LT 4367	B	19980825	LT 1997-152	19970919
				US 1995 391901	A 19950221

PATENT FAMILY INFORMATION:
FAN 1995:568500

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 643057	A1	19950315	EP 1994-113800	19940902
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1993-117362	A 19930903
	CA 2091102	AA	19930907	CA 1993-2091102	19930305
				US 1992-847503	A 19920306
	ZA 9301601	A	19931005	ZA 1993-1601	19930305
				US 1993-117362	A 19930903
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503	A 19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503	A 19920306
	EP 584446	A2	19940302	EP 1993-103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1992-847503	A 19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503	A 19920306
	PT 584446	T	20020930	PT 1993-103697	19930308
				US 1992-847503	A 19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308

L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1992-847503	A 19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992-847503	A 19920306
	US 5595872	A	19970121	US 1993-117362	19930903
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
	CA 2131430	AA	19950304	CA 1994-2131430	19940902
				US 1993 117362	A 19930903
	FI 9404048	A	19950304	FI 1994-4048	19940902
				US 1993-117362	A 19930903
	NO 9403260	A	19950306	NO 1994-3260	19940902
				US 1993-117362	A 19930903
	AU 9471642	A1	19950316	AU 1994-71642	19940902
	AU 690125	B2	19980423		
				US 1993-117362	A 19930903
	ZA 9406772	A	19950403	ZA 1994-6772	19940902
				US 1993-117362	A 19930903
	JP 07165712	A2	19950627	JP 1994-210057	19940902
				US 1993-117362	A 19930903
	CN 1106003	A	19950802	CN 1994-115640	19940902
				US 1993-117362	A 19930903
	HU 70613	A2	19951030	HU 1994-2542	19940902
				US 1993-117362	A 19930903
	US 5789197	A	19980804	US 1995-486924	19950607
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
	US 6492365	B1	20021210	US 1995-486929	19950607
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
	US 2003166590	A1	20030904	US 2001-933593	20010821
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
				US 1995-486929	A3 19950607

FAN 1998:115356

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5712279	A	19980127	US 1996-548811	19960111
				US 1995-391901	B2 19950221
				US 1995-472067	A2 19950606
	CA 2091102	AA	19930907	CA 1993-2091102	19930305
				US 1992-847503	A 19920306
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503	A 19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503	A 19920306
	EP 584446	A2	19940302	EP 1993-103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1992-847503	A 19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503	A 19920306
	PT 584446	T	20020930	PT 1993-103697	19930308

L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1992-847503	A 19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308
				US 1992-847503	A 19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992-847503	A 19920306
	US 5739135	A	19980414	US 1995-472067	19950606
				US 1993-117362	A2 19930903
				US 1994-284808	B2 19940805
				US 1995-391901	B2 19950221
	ZA 9601340	A	19970911	ZA 1996-1340	19960220
				US 1995-391901	A 19950221
	LT 4367	B	19980825	LT 1997-152	19970919
				US 1995-391901	A 19950221

FAN 1998:236274

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5739135	A	19980414	US 1995-472067	19950606
				US 1993-117362	A2 19930903
				US 1994-284808	B2 19940805
				US 1995-391901	B2 19950221
	CA 2091102	AA	19930907	CA 1993-2091102	19930305
				US 1992-847503	A 19920306
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503	A 19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503	A 19920306
	EP 584446	A2	19940302	EP 1993-103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1992-847503	A 19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503	A 19920306
	PT 584446	T	20020930	PT 1993-103697	19930308
				US 1992-847503	A 19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308
				US 1992-847503	A 19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992-847503	A 19920306
	US 5595872	A	19970121	US 1993 117362	19930903
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
	US 5789197	A	19980804	US 1995-486924	19950607
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
	US 6492365	B1	20021210	US 1995-486929	19950607
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
	US 5712279	A	19980127	US 1996-548811	19960111
				US 1995-391901	B2 19950221
				US 1995-472067	A2 19950606
	IL 116917	A1	20000831	IL 1996-116917	19960126
				US 1995-391901	A 19950221

L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1995-472067	A 19950606
	TW 486469	B	20020511	TW 1996-85100978	19960126
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
	CA 2213466	AA	19960829	CA 1996-2213466	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
	WO 9626205	A1	19960829	WO 1996-US824	19960201
	W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
	AU 9647631	A1	19960911	AU 1996-47631	19960201
	AU 699865	B2	19981217		
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	CN 1176640	A	19980318	CN 1996-192015	19960201
	CN 1108301	B	20030514		
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
	EP 886637	A1	19981230	EP 1996-903604	19960201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	JP 11500442	T2	19990112	JP 1996-525679	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	NZ 302055	A	20000228	NZ 1996-302055	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	PL 185443	B1	20030530	PL 1996-322003	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	ZA 9601340	A	19970911	ZA 1996-1340	19960220
				US 1995-391901	A 19950221
	US 5883099	A	19990316	US 1997-896872	19970721
				US 1993-117362	A2 19930903
				US 1994-284808	B2 19940805
				US 1995-391901	B2 19950221
				US 1995-472067	A3 19950606
	US 6034098	A	20000307	US 1997-898304	19970721
				US 1993-117362	A2 19930903
				US 1994-284808	B2 19940805
				US 1995-391901	B2 19950221
				US 1995-472067	A3 19950606
	US 6066650	A	20000523	US 1997-898303	19970721
				US 1993-117362	A2 19930903
				US 1994-284808	B2 19940805

L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1995-391901	B2 19950221
				US 1995-472067	A1 19950606
	FI 9703416	A	19970820	FI 1997-3416	19970820
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	NO 9703821	A	19970820	NO 1997-3821	19970820
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	LT 4367	B	19980825	LT 1997-152	19970919
				US 1995-391901	A 19950221
	LV 11951	B	19981120	LV 1997-171	19970919
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
	US 2003166590	A1	20030904	US 2001-933593	20010821
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
				US 1995-486929	A3 19950607

OS MARPAT 125:275663

IT **182429-79-4P 182433-96-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 9-(piperidinoalkyl)fluorene-9-carboxamides and analogs as microsomal triglyceride transfer protein inhibitors)

RN 182429-79-4 CAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[[2-[(phenylmethyl)amino]benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 182433-96-1 CAPLUS
CN 9H-Fluorene-9-carboxamide, 9-[4-[1-oxido-4-[[2-[(phenylmethyl)amino]benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



GI

L3 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





I

AB R5Z3NRR6 [R = piperidyl group Q1; R5 = alkyl, alkoxy, (hetero)aryl, etc.; R6 = H, alk(en)yl; R5R6 = atoms to form a benzanellated ring; Z3 = CO or SO2; 1 of Z4,Z5 = NR1 and the other = CH2; R1 = e.g., (un)substituted aryl group Q2; R12 = H, (halo)alkyl, heteroaryl, etc.; Z = bond, O, S, alkylimino, etc.; Z1,Z2 = bond, O, SO0-2, CO, etc.; Z11 = bond, alkylene, arylene, etc.] were prepared as microsomal triglyceride transfer protein inhibitors (no data). Thus, N-propyl-9-fluorenecarboxamide (preparation given) was alkylated by I(CH2)4OSiMe2CMe3 (preparation given) and the deprotected and iodinated product aminated by 2-(4-piperidinyl)-2,3-dihydro-1H-isoindol-1-one (preparation given) to give title compound I.

L3 ANSWER 32 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1992:571361 CAPLUS

DN 117:171361

TI Synthesis of biologically active 4(3H)-quinazolinonium perchlorates

AU Chernobrovin, N. I.; Kozhevnikov, Yu. V.; Morozova, G. E.; Chernobrovina, T. A.

CS Perm. Farm. Inst., Perm, Russia

SO Khimiko-Farmatsevticheskii Zhurnal (1992), 26(3), 48-51
CODEN: KHFZAN; ISSN: 0023-1134

DT Journal

LA Russian

IT **139602-64-5P 139602-66-7P 139602-67-8P**
139602-68-9P 139602-69-0P 139602-71-4P
139602-72-5P 139602-73-6P 143424-22-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acetylation of)

RN 139602-64-5 CAPLUS

CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 139602-66-7 CAPLUS

CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)





RN 139602-67-8 CAPLUS

CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 32 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139602-68-9 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-2-[[(2,4-dimethoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 139602-69-0 CAPLUS

CN Benzamide, 2-[[(3,4 dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 139602-71-4 CAPLUS

CN Benzamide, 2 [[(3,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 32 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 139602-72-5 CAPLUS

CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 139602-73-6 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-2-[[(3,4-dimethoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 143424-22-0 CAPLUS

CN Benzamide, 2-[[(2,4 dimethoxyphenyl)methyl]amino]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 32 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB Title salts I (R = H, 3-Me, 4-Me, 4-MeO, 4-Cl; R1 = OMe, R2 = H; R1 = H, R2 = OMe) were prepared by condensation of anthranilanilides with dimethoxybenzaldehydes, followed by borohydride reduction of the imine group, N-acetylation, and acid cyclization. The acute toxicity and anticonvulsant, analgesic, and antimicrobial activities of some I were tested.

L3 ANSWER 33 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1992:128388 CAPLUS

DN 116:128388

TI Arylamides of N-(p-2',4'- or -3',4'-dimethoxybenzyl)anthranilic acid

IN Chernobrovin, N. I.; Kozhevnikov, Yu. V.; Zalesov, V. S.; Semenova, Z. N.

PA Perm Pharmaceutical Institute, USSR

SO U.S.S.R.
From: Otkrytiya, Izobret. 1991, (28), 258.
CODEN: URXXAF

DT Patent

LA Russian

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI SU 1156362	A1	19910730	SU 1983-3573020	19830217
			SU 1983-3573020	19830217

IT **139602-64-5 139602-65-6 139602-66-7 139602-67-8 139602-68-9 139602-69-0 139602-70-3 139602-71-4 139602-72-5 139602-73-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(intermediate for quinazolinonium perchlorate derivs.)

RN 139602-64-5 CAPLUS

CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 139602-65-6 CAPLUS

CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 139602-66-7 CAPLUS

CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 33 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





RN 139602-67-8 CAPLUS

CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino] N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 139602-68-9 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-2-[[(2,4-dimethoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 139602-69-0 CAPLUS

CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)

L3 ANSWER 33 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139602-70-3 CAPLUS

CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino] N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 139602-71-4 CAPLUS

CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 139602-72-5 CAPLUS

CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino] N-(4-methylphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 33 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139602-73-6 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-2-[[[3,4-dimethoxyphenyl)methyl]amino]-(9CI) (CA INDEX NAME)



GI



AB The title compds. (I; R = H, Me, p-Cl; R1 o-OMe, m-OMe) are intermediates for biol. active 1-(2',4'- or -3',4'-dimethoxybenzyl)-2-methyl-3-aryl-4-(3H)-quinazolinonium perchlorates.

L3 ANSWER 34 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:514559 CAPLUS
DN 115:114559
TI Preparation of 5,11-dihydro-6H-dipyrido [3,2-b:2',3'-e](1,4) diazepines and their use in the prevention or treatment of HIV infection
IN Hargrave, Karl D.; Schmidt, Guenther; Engel, Wolfhard; Trummlitz, Guenther; Eberlein, Wolfgang
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl, G.m.b.H.
SO Eur. Pat. Appl., 42 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 429987	A2	19910605	EP 1990-121954	19901116
	EP 429987	A3	19920122		
	EP 429987	B1	19990317		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	CA 2030056	AA	19910518	CA 1990-2030056	19901115
	CA 2030056	C	19951017		
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
	FI 9005674	A	19910518	FI 1990-5674	19901116
	FI 94529	B	19950615		
	FI 94529	C	19950925		
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	NO 9004986	A	19910521	NO 1990-4986	19901116
	NO 175478	B	19940711		
	NO 175478	C	19941019		
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	HU 56103	A2	19910729	HU 1990-7186	19901116
	HU 208139	B	19930830		
				US 1989-438923 A	19891117
	JP 04178386	A2	19920625	JP 1990-311230	19901116
	JP 2912007	B2	19990628		
				US 1989-438923 A	19891117
	IL 96367	A1	19970218	IL 1990-96367	19901116
				US 1989-438923 A	19891117
				IL 1990-94883 A0	19900627
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	AT 177744	E	19990415	AT 1990-121954	19901116
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	ES 2130114	T3	19990701	ES 1990-121954	19901116
				US 1989-438923 A	19891117

L3 ANSWER 34 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	AU 9066732	A1	19910523	AU 1990-66732	19901119
	AU 630251	B2	19921022		
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	ZA 9009246	A	19920729	ZA 1990-9246	19901119
				US 1989-438923 A	19891117
	JP 04257584	A2	19920911	JP 1991-211068	19910822
	JP 2539116	B2	19961002		
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	HU 59407	A2	19920528	HU 1991-2865	19910904
	HU 214595	B	19980428		
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	RU 2040527	C1	19950725	RU 1992-5011559	19920506
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
	US 5620974	A	19970415	US 1994-279464	19940722
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
				US 1993-91418 A3	19930713
	HK 1011025	A1	20000420	HK 1998-112090	19981117
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019

PATENT FAMILY INFORMATION:

FAN 1991:102069

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 393529	A1	19901024	EP 1990-107098	19900412
	EP 393529	B1	19930630		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1989-340970 A	19890420
	AT 91128	E	19930715	AT 1990 107098	19900412
				US 1989-340970 A	19890420
				EP 1990-107098 A	19900412
	ES 2058656	T3	19941101	ES 1990-107098	19900412
				US 1989-340970 A	19890420
	CA 2014771	AA	19901020	CA 1990-2014771	19900418
	CA 2014771	C	20000801		
				US 1989-340970 A	19890420
	JP 03063276	A2	19910319	JP 1990-104379	19900419
	JP 2851913	B2	19990127		
				US 1989 340970 A	19890420

L3 ANSWER 34 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
	US 5620974	A	19970415	US 1994-279464	19940722
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
				US 1993-91418 A3	19930713

FAN 1991:449732

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 410148	A1	19910130	EP 1990-112072	19900626
	EP 410148	B1	19940406		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1989-372974 A	19890628
	CA 2019812	AA	19901228	CA 1990-2019812	19900626
	CA 2019812	C	20001121		
				US 1989-372974 A	19890628
	DD 295849	A5	19911114	DD 1990-342100	19900626
				US 1989-372974 A	19890628
	AT 103918	E	19940415	AT 1990-112072	19900626
				US 1989-372974 A	19890628
				EP 1990-112072 A	19900626
	ES 2063203	T3	19950101	ES 1990-112072	19900626
				US 1989-372974 A	19890628
	NO 9002851	A	19910102	NO 1990-2851	19900627
	NO 174468	B	19940131		
	NO 174468	C	19940518		
				US 1989-372974 A	19890628
	HU 55017	A2	19910429	HU 1990-4021	19900627
	HU 206504	B	19921130		
				US 1989-372974 A	19890628
	JP 03115283	A2	19910516	JP 1990-169663	19900627
	JP 2911967	B2	19990628		
				US 1989-372974 A	19890628
	ZA 9004991	A	19920325	ZA 1990-4991	19900627
				US 1989-372974 A	19890628
	FI 92828	B	19940930	FI 1990-3225	19900627
	FI 92828	C	19950110		
				US 1989-372974 A	19890628
	IL 94883	A1	19941007	IL 1990-94883	19900627
				US 1989-372974 A	19890628
	AU 9057921	A1	19910103	AU 1990-57921	19900628
	AU 620724	B2	19920220		
				US 1989-372974 A	19890628
	RU 2024522	C1	19941215	RU 1992-5011432	19920427
				US 1989-372974 A	19890628
	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906

L3 ANSWER 34 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1990-600390	B2 19901019
				US 1991-740828	B1 19910805
US 5620974	A	19970415	US 1994-279464		19940722
			US 1989-340970	B2	19890420
			US 1989-372974	B2	19890628
			US 1989-438923	B2	19891117
			US 1990-579001	B2	19900906
			US 1990-600390	B2	19901019
			US 1991-740828	B1	19910805
			US 1993-91418	A3	19930713

OS MARPAT 115:114559
IT **132312-45-9P 132362-76-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antiviral dihydrodipyridodiazepines)
RN 132312-45-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)





RN 132362-76-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



GI



I II

AB Title compds. I (Z = O, S, :NCN, :NOR9; R1-R8 = various subsets of groups selected from H, alkyl, cycloalkyl, fluoroalkyl, aryl, tetrahydrofuryl, alkanoyl, trihalomethyl, alkoxycarbonyl, halo, amino, and many more; R9 = C1-3 alkyl; numerous provisions and exceptions) were prepared for prevention and treatment of HIV-1 infection. For example, 2-hydroxy-4-methyl-3-nitropyridine was converted by chlorination with POCl3 and reduction to 3-amino-2-chloro-4-methylpyridine, which underwent amidation with 2-chloronicotinoyl chloride and condensation with EtNH2 to give (chloromethylpyridinyl)(ethylamino)pyridinecarboxamide II. Cyclization of II by NaH in DMF at reflux temperature gave I (Z = O, R1 = R3 =R4 = R6-R8 = H, R2 = Et, R5 = Me) (III). At 3 μg/mL, III gave 100% inhibition of HIV-1 replication in a human T-cell culture assay. III also gave 100% inhibition of HIV-1 reverse transcriptase at 10 μg/mL in vitro; no activity was seen for I against 2 related enzymes, indicating high specificity. Three formulations, 77 synthetic examples, and addnl. test results including cytotoxicity are given.

L3 ANSWER 35 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:449732 CAPLUS
DN 115:49732
TI Preparation of 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-ones and thiones and their use in the prevention or treatment of AIDS
IN Schmidt, Guenther; Engel, Wolfhard; Trummlitz, Guenter; Eberlein, Wolfgang; Hargrave, Karl D.
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl, G.m.b.H.
SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 410148	A1	19910130	EP 1990-112072	19900626
EP 410148	B1	19940406		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
			US 1989-372974	A 19890628
CA 2019812	AA	19901228	CA 1990-2019812	19900626
CA 2019812	C	20001121		
			US 1989-372974	A 19890628
DD 295849	A5	19911114	DD 1990-342100	19900626
			US 1989-372974	A 19890628
AT 103918	E	19940415	AT 1990-112072	19900626
			US 1989-372974	A 19890628
			EP 1990-112072	A 19900626
ES 2063202	T3	19950101	ES 1990-112072	19900626
			US 1989 372974	A 19890628
NO 9002851	A	19910102	NO 1990-2851	19900627
NO 174468	B	19940131		
NO 174468	C	19940518		
			US 1989-372974	A 19890628
HU 55017	A2	19910429	HU 1990-4021	19900627
HU 206504	B	19921130		
			US 1989-372974	A 19890628
JP 03115283	A2	19910516	JP 1990-169663	19900627
JP 2911967	B2	19990628		
			US 1989-372974	A 19890628
ZA 9004991	A	19920325	ZA 1990-4991	19900627
			US 1989 372974	A 19890628
FI 92828	B	19940930	FI 1990-3225	19900627
FI 92828	C	19950110		
			US 1989 372974	A 19890628
IL 94883	A1	19941007	IL 1990-94883	19900627
			US 1989-372974	A 19890628
AU 9057921	A1	19910103	AU 1990-57921	19900628
AU 620724	B2	19920220		
			US 1989-372974	A 19890628
RU 2024522	C1	19941215	RU 1992-5011432	19920427
			US 1989-372974	A 19890628
US 5366972	A	19941122	US 1993-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991 740828	B1 19910805

L3 ANSWER 35 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 5620974	A	19970415	US 1994-279464	19940722
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713

PATENT FAMILY INFORMATION:
FAN 1991:102069

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 393529	A1	19901024	EP 1990-107098	19900412
EP 393529	B1	19930630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
			US 1989-340970	A 19890420
AT 91128	E	19930715	AT 1990-107098	19900412
			US 1989 340970	A 19890420
			EP 1990-107098	A 19900412
ES 2058656	T3	19941101	ES 1990-107098	19900412
			US 1989 340970	A 19890420
CA 2014771	AA	19901020	CA 1990-2014771	19900418
CA 2014771	C	20000801		
			US 1989-340970	A 19890420
JP 03063276	A2	19910319	JP 1990-104379	19900419
JP 2851913	B2	19990127		
			US 1989-340970	A 19890420
US 5366972	A	19941122	US 1993-91418	19930713
			US 1989 340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
US 5620974	A	19970415	US 1994-279464	19940722
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713

FAN 1991:514559

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 429987	A2	19910605	EP 1990-121954	19901116
EP 429987	A3	19920122		
EP 429987	B1	19990317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
CA 2030056	AA	19910518	CA 1990-2030056	19901115
CA 2030056	C	19951017		
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
FI 9005674	A	19910518	FI 1990-5674	19901116
FI 94529	B	19950615		
FI 94529	C	19950925		

L3 ANSWER 35 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	NO 9004986	A	19910521	NO 1990-4986	19901116
	NO 175478	B	19940711		
	NO 175478	C	19941019		
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	HU 56103	A2	19910729	HU 1990-7186	19901116
	HU 208139	B	19930830		
				US 1989-438923	A 19891117
	JP 04178386	A2	19920625	JP 1990-311230	19901116
	JP 2912007	B2	19990628		
				US 1989-438923	A 19891117
	IL 96367	A1	19970218	IL 1990-96367	19901116
				US 1989-438923	A 19891117
				IL 1990 94883	A0 19900627
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	AT 177744	E	19990415	AT 1990-121954	19901116
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	ES 2130114	T3	19990701	ES 1990-121954	19901116
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	AU 9066732	A1	19910523	AU 1990-66732	19901119
	AU 630251	B2	19921022		
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	ZA 9009246	A	19920729	ZA 1990-9246	19901119
				US 1989-438923	A 19891117
	JP 04257584	A2	19920911	JP 1991-211068	19910822
	JP 2539116	B2	19961002		
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	HU 59407	A2	19920528	HU 1991 2865	19910904
	HU 214595	B	19980428		
				US 1990-579001	A 19900906
				US 1990 600390	A 19901019
	RU 2040527	C1	19950725	RU 1992-5011559	19920506
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970	B2 19890420
				US 1989-372974	B2 19890628
				US 1989 438923	B2 19891117
				US 1990-579001	B2 19900906
				US 1990-600390	B2 19901019
				US 1991-740828	B1 19910805
	US 5620974	A	19970415	US 1994-279464	19940722

L3 ANSWER 35 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1989-340970	B2 19890420
				US 1989-372974	B2 19890628
				US 1989-438923	B2 19891117
				US 1990-579001	B2 19900906
				US 1990-600390	B2 19901019
				US 1991-740828	B1 19910805
				US 1993 91418	A3 19930713
	HK 1011025	A1	20000420	HK 1998-112090	19981117
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019

OS MARPAT 115:49732

IT **132312-45-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of drug for treatment of AIDS)

RN 132312-45-9 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)





GI



I

AB The title compds. I [Z = O, S; R1 = H, (substituted) alkyl, arylmethyl,

L3 ANSWER 35 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

etc.; R2 = H, (substituted) alkyl, alkenyl, etc.; R3-R8 = H, or 1 of R3-R8 is alkyl, alkoxy, alkylthio, etc., and the remaining 5 of R3-R8 are each H, or R3-R5 are H, alkyl with the proviso that at least one is H or 1 of R3-R5 is Bu with the remaining 2 being H; and R6-R8 are H, alkyl with the proviso that at least 1 is H, or 1 of R6-R8 is Bu with the remaining 2 being H; with the proviso that when R1 and R2 are H, alkyl and R3-R8 are all H then Z is S] were prepd. A mixt. of 5,11-dihydro-11-ethyl 5-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one and Lawesson's reagent in toluene was refluxed for 2.5 h to give I (R1 = Me; Z = S; R2 = Et; R3 = R4 = R5 = R6 = R7 = R8 = H), which at 10 μg/mL gave 100% in vitro inhibition of reverse transcriptase.

L3 ANSWER 36 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:449642 CAPLUS

DN 115:49642

TI Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones

AU Hargrave, Karl D.; Proudfoot, John R.; Grozinger, Karl G.; Cullen, Ernest; Kapadia, Suresh R.; Patel, Usha R.; Fuchs, Victor U.; Mauldin, Scott C.; Vitous, Jana; et al.

CS Boehringer Ingelheim Pharm., Inc., Ridgefield, CT, 06877, USA

SO Journal of Medicinal Chemistry (1991), 34(7), 2231-41

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

OS CASREACT 115:49642

IT **132312-45-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and reductive intramol. cyclocondensation of, dipyridodiazepinone from)

RN 132312-45-9 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)





GI



I II

AB Novel pyrido[2,3-b][1,4]benzodiazepinones, pyrido[2,3-b][1,5]benzodiazepinones, and dipyrido[3,2-b:2',3'-e][1,4]diazepinones e.g., I (X = N, X1 = CH; X = CH; X1 = N) and II inhibited human immunodeficiency virus type 1 reverse transcriptase in vitro at concns.

L3 ANSWER 36 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
low as 35 nM. In all three series, small substituents (e.g., Me, Et, Ac) are preferred at the lactam nitrogen, whereas slightly larger alkyl moieties (e.g., Et, cyclopropyl) are favored at the other (N-11) diazepinone nitrogen. In general, lipophilic substituents are preferred on the A ring, whereas substitution on the C ring generally reduces potency relative to the corresponding compds. with no substituents on the arom. ring. Max. potency is achieved with Me substitution at the position
ortho to the lactam nitrogen atom; however, in this case an unsubstituted lactam nitrogen is preferred. Addnl. substituents on the A ring can be readily tolerated. II (BI-RG-587) is a potent (IC50 = 84 nM) and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, and has
been chosen for preclin. development. II is noncytotoxic except at high doses and effective against all clin. isolates of HIV-1, including those which are AZT resistant. It is specific for HIV-1, ineffective against HIV-2, inactive against simian and feline reverse transcriptase, and does not inhibit DNA polymerases.

L3 ANSWER 37 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:102069 CAPLUS
DN 114:102069
TI Preparation of 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-ones as drugs for prevention or treatment of AIDS
IN Schmidt, Guenther; Engel, Wolfhard; Trummlitz, Guenter; Eberlein, Wolfgang; Hargrave, Karl D.
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl, G.m.b.H.
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 393529	A1	19901024	EP 1990 107098	19900412
	EP 393529	B1	19930630		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1989-340970 A	19890420
	AT 91128	E	19930715	AT 1990-107098	19900412
				US 1989-340970 A	19890420
				EP 1990-107098 A	19900412
	ES 2058656	T3	19941101	ES 1990-107098	19900412
				US 1989-340970 A	19890420
	CA 2014771	AA	19901020	CA 1990-2014771	19900418
	CA 2014771	C	20000801		
				US 1989-340970 A	19890420
	JP 03063276	A2	19910319	JP 1990-104379	19900419
	JP 2851913	B2	19990127		
				US 1989-340970 A	19890420
	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
	US 5620974	A	19970415	US 1994-279464	19940722
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
				US 1993-91418 A3	19930713

PATENT FAMILY INFORMATION:
FAN 1991:449732

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 410148	A1	19910130	EP 1990-112072	19900626
	EP 410148	B1	19940406		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1989-372974 A	19890628
	CA 2019812	AA	19901228	CA 1990-2019812	19900626

L3 ANSWER 37 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	CA 2019812	C	20001121		
				US 1989-372974 A	19890628
	DD 295849	A5	19911114	DD 1990-342100	19900626
				US 1989-372974 A	19890628
	AT 103918	E	19940415	AT 1990-112072	19900626
				US 1989-372974 A	19890628
				EP 1990-112072 A	19900626
	ES 2063202	T3	19950101	ES 1990-112072	19900626
				US 1989-372974 A	19890628
	NO 9002851	A	19910102	NO 1990-2851	19900627
	NO 174468	B	19940131		
	NO 174468	C	19940518		
				US 1989-372974 A	19890628
	HU 55017	A2	19910429	HU 1990-4021	19900627
	HU 206504	B	19921130		
				US 1989-372974 A	19890628
	JP 03115283	A2	19910516	JP 1990-169663	19900627
	JP 2911967	B2	19990628		
				US 1989-372974 A	19890628
	ZA 9004991	A	19920325	ZA 1990-4991	19900627
				US 1989-372974 A	19890628
	FI 92828	B	19940930	FI 1990-3225	19900627
	FI 92828	C	19950110		
				US 1989-372974 A	19890628
	IL 94883	A1	19941007	IL 1990-94883	19900627
				US 1989-372974 A	19890628
	AU 9057921	A1	19910103	AU 1990-57921	19900628
	AU 620724	B2	19920220		
				US 1989-372974 A	19890628
	RU 2024522	C1	19941215	RU 1992-5011432	19920427
				US 1989-372974 A	19890628
	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
	US 5620974	A	19970415	US 1994-279464	19940722
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
				US 1993-91418 A3	19930713

FAN 1991:514559

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 429987	A2	19910605	EP 1990-121954	19901116
	EP 429987	A3	19920122		
	EP 429987	B1	19990317		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	CA 2030056	AA	19910518	CA 1990-2030056	19901115
	CA 2030056	C	19951017		
				US 1989-438923 A	19891117

L3 ANSWER 37 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1990-579001 A	19900906
	FI 9005674	A	19910518	FI 1990-5674	19901116
	FI 94529	B	19950615		
	FI 94529	C	19950925		
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	NO 9004986	A	19910521	NO 1990-4986	19901116
	NO 175478	B	19940711		
	NO 175478	C	19941019		
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	HU 56103	A2	19910729	HU 1990-7186	19901116
	HU 208139	B	19930830		
				US 1989-438923 A	19891117
	JP 04178386	A2	19920625	JP 1990-311230	19901116
	JP 2912007	B2	19990628		
				US 1989-438923 A	19891117
	IL 96367	A1	19970218	IL 1990-96367	19901116
				US 1989-438923 A	19891117
				IL 1990-94883 A0	19900627
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	AT 177744	E	19990415	AT 1990-121954	19901116
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	ES 2130114	T3	19990701	ES 1990-121954	19901116
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	AU 9066732	A1	19910523	AU 1990-66732	19901119
	AU 630251	B2	19921022		
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	ZA 9009246	A	19920729	ZA 1990-9246	19901119
				US 1989-438923 A	19891117
	JP 04257584	A2	19920911	JP 1991 211068	19910822
	JP 2539116	B2	19961002		
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	HU 59407	A2	19920528	HU 1991-2865	19910904
	HU 214595	B	19980428		
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	RU 2040527	C1	19950725	RU 1992-5011559	19920506
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
	US 5620974	A	19970415	US 1994-279464	19940722

L3 ANSWER 37 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

			US 1989-340970	B2	19890420
			US 1989-372974	B2	19890628
			US 1989-438923	B2	19891117
			US 1990-579001	B2	19900906
			US 1990-600390	B2	19901019
			US 1991-740828	B1	19910805
			US 1993-91418	A3	19930713
	HK 1011025	A1	20000420	HK 1998-112090	19981117
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019

OS MARPAT 114:102069
IT **132312-45-9P 132362-76-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for dipyridodiazepinone reverse transcriptase inhibitor)
RN 132312-45-9 CAPLUS
CN 3 Pyridinecarboxamide, N-(2 chloro-3-pyridinyl)-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)





RN 132362-76-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 37 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title compds. (I; R1, R2 = H, C1-5 alkyl), were prepared Thus, N-(2-chloro-3-pyridinyl)-2-[[(4-methoxyphenyl)methyl]amino]-3-pyridinecarboxamide (preparation given) was refluxed 8 h with NaH in DMF to give 50% 5,11-dihydro-11-[(4-methoxyphenyl)methyl]-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, which was converted to title compound II in 3 steps.
II at 10 μg/mL gave 100% inhibition of HIV-I reverse transcriptase. Dosage formulations were prepared containing I (R1 = H, R2 = Pr).

L3 ANSWER 38 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1984:611088 CAPLUS
DN 101:211088
TI Studies of 4[3H]-quinazolone. XII. Synthesis and biological activity of 1-benzyl(4'-nitrobenzyl)-2 methyl-3-alkyl(aryl)-4(3H)-quinazolinone perchlorates
AU Chernobrovin, N. I.; Kozhevnikov, Yu. V.; Zalesov, V. S.; Gradel, I. I.
CS Perm. Farm. Inst., Perm, USSR
SO Khimiko-Farmatsevticheskii Zhurnal (1984), 18(7), 830-3
CODEN: KHFZAN; ISSN: 0023-1134
DT Journal
LA Russian
IT **92944-76-8P 92944-77-9P 92944-78-0P**
92944-79-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acetylation of)
RN 92944-76-8 CAPLUS
CN Benzamide, N-(2,4-dimethylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 92944-77-9 CAPLUS
CN Benzamide, N-(4-methoxyphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 92944-78-0 CAPLUS
CN Benzamide, N-(4-methoxyphenyl)-2-[[(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 38 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 92944-79-1 CAPLUS
CN Benzamide, N-(4-ethoxyphenyl)-2-[[(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



GI



I

L3 ANSWER 38 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
AB The title compds. I (R = 2,4-xylyl, 4-MeOC6H4, Bu, hexyl, R1 = H; R = 4-MeOC6H4, 4-EtOC6H4, R1 = NO2) were prepared in 58.6-83.4% yields by acetylation of o-RNHCOC6H4NR2CH2C6H4R1 p (II, R2 = H) to give 61.3-98.1% II (R2 = Ac) which were cyclized by refluxing in MeOH containing 57% HClO4. I (R = 4-MeOC6H4, R1 = NO2) was an effective antispasmodic for white mice at 150 mg/kg dosage.

L3 ANSWER 39 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1984:34516 CAPLUS
DN 100:34516
TI New synthesis of 11-acyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones and related studies
AU Kovac, T.; Oklobdzija, M.; Comisso, G.; Decorte, E.; Pajdiga, T.; Moimas, F.; Angeli, C.; Zonno, F.; Toso, R.; Sunjic, V.
CS Chem. Res. Co., San Giovanni, Italy
SO Journal of Heterocyclic Chemistry (1983), 20(5), 1339-49
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 100:34516
IT **88369-73-7P 88369-74-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 88369-73-7 CAPLUS
CN Benzamide, N-(2-chloro-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 88369-74-8 CAPLUS
CN Benzamide, N-(2-chloro-1-oxido-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI)
(CA INDEX NAME)



GI

L3 ANSWER 39 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB 11-Acyl-5,11 dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones I (R = 4-methylpiperazino, imidazolo, 2-methylimidazolo) were prepared via N-α-chloroacetylation and aminolysis. Other attempts at cyclization to form I are also reported.

L3 ANSWER 40 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1983:558250 CAPLUS
DN 99:158250
TI Antihypertensive sulfamoylbenzamides
PA Mitsui Toatsu Chemicals, Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 58124766	A2	19830725	JP 1982-4979	19820118
	JP 02033030	B4	19900725		
				JP 1982-4979	19820118

OS CASREACT 99:158250
IT **87445-66-7P 87445-71-4P 87445-72-5P**
87445-73-6P 87445-74-7P 87445-75-8P
87445-76-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antihypertensive activity of)
RN 87445-66-7 CAPLUS
CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 87445-71-4 CAPLUS
CN Benzamide,
5-(aminosulfonyl)-4-chloro-2-[[(4-chlorophenyl)methyl]amino]-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 40 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 87445-72-5 CAPLUS
CN Benzamide, 5-(aminosulfonyl)-4-chloro-2-[[(2-chlorophenyl)methyl]amino]-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 87445-73-6 CAPLUS
CN Benzamide, 5-(aminosulfonyl)-4-chloro-2-[[(2,4-dichlorophenyl)methyl]amino]-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)- (9CI)
(CA INDEX NAME)

L3 ANSWER 40 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 87445-74-7 CAPLUS
CN Benzamide, 5-(aminosulfonyl)-4-chloro-2-[[(3,4-dichlorophenyl)methyl]amino]-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)- (9CI)
(CA INDEX NAME)



RN 87445-75-8 CAPLUS
CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-2-[[(3-methylphenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 40 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 87445-76-9 CAPLUS
CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-2-[[(2-methylphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



GI



I, R=NR1CH2R2
II, R=halo

AB I [R1 = H, (substituted) alkyl; R2 = substituted Ph, (substituted) benzyl] were prepared via condensation of II with HNR1CH2R2. Thus, heating a

L3 ANSWER 40 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

of 6 g II (R = Cl) with 25 mL H2NCH2Ph at 90° for 45 h gave 5 g I (R1 = H, R2 = Ph). At 30 mg/kg/day p.o. I decreased deoxycorticosterone acetate/saline-induced hypertension (182-195 mmHg) in rats by 9-24% in 5 days.

L3 ANSWER 41 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1977:534708 CAPLUS
DN 87:134708
TI Substituted anthranilamides and preparation thereof
IN Shetty, Bolva V.
PA Pennwalt Corp., USA
SO Can., 26 pp.
CODEN: CAXXA4
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 1000736	A1	19761130	CA 1971-103215	19710120
				CA 1971-103215	19710120

IT **23375-97-5P 28524-75-6P 28524-80-3P**
31933-24-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 23375-97-5 CAPLUS
CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 28524-75-6 CAPLUS
CN Benzamide, 4-chloro-5-[(methylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 28524-80-3 CAPLUS
CN Benzamide, 4-chloro-5-[(dimethylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 41 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 31933-24-1 CAPLUS
CN Benzamide, 5-[[bis(phenylmethyl)amino]sulfonyl]-4 chloro N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



AB Substituted anthranilamides 5,2,4-(RR1NO2S)(R2HN)C1C6H2CONHC6H2R3R4R5 (I; R, R1 = H, alkyl, Ph, PhCH2; R2 = H, alkyl, PhCH2, Ac; R3, R4, R5 = H, alkyl, alkoxy, NH2, etc.), useful in the synthesis of diuretic 1,2,3,4-tetrahydro-7-chloro-3-phenyl-6-sulfamoyl-4-quinazolinone derivs., were prepared by one of several routes. Thus, 2,5-MeC1C6H3NH2 was converted by sequential acetylation, sulfamoylation, oxidation, and hydrolysis, then treatment with COC12-AcOH, followed by 2-MeC6H4NH2, into I (R = R1 = R2 = R3 = R4 = H, R5 = 2-Me).

L3 ANSWER 42 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1977:467996 CAPLUS
DN 87:67996
TI Substituted anthranilamides
IN Shetty, Bolva V.
PA Pennwalt Corp., USA
SO Can., 26 pp.
CODEN: CAXXA4
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 1000736		19761130	CA 1971-103215	19710120

IT **23375-97-5P 28524-75-6P 28524-80-3P**
31933-24-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 23375-97-5 CAPLUS
CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 28524-75-6 CAPLUS
CN Benzamide, 4-chloro-5-[(methylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 28524-80-3 CAPLUS
CN Benzamide, 4-chloro-5-[(dimethylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L3 ANSWER 42 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 31933-24-1 CAPLUS
CN Benzamide, 5-[[bis(phenylmethyl)amino]sulfonyl]-4-chloro-N (2-methylphenyl) 2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



GI



AB Sixteen anthranilamides I (R = H, PhCH2, CH2CH2NEt, CH2CH2OH; R1 = R2 = H, Me, PhCH2, or R1 = H, R2 = Me; R3, R4, R5 independently = H, Me, Cl, MeO, SO2NH2, Et, OH), which are useful in the preparation of quinazolinone derivs., were prepared by different routes. Thus, sequential treatment of 5,2,4-(ClO2S)C12C6H2CO2H with (PhCH2)2NH, SOCl2, 2-MeC6H4NH2, and PhCH2NH2 gave I (R = R1 = R2 = PhCH2, R3 = 2-Me, R4 = R5 = H).

L3 ANSWER 43 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1977:171214 CAPLUS
DN 86:171214
TI Synthesis and pharmacological properties of 2-aminonicotinamide derivatives
AU Zhmurenko, L. A.; Borisenko, S. A.; Salimov, R. M.; Glozman, O. M.; Zagorevskii, V. A.
CS Nauchno-Issled. Inst. Farmakol., Moscow, USSR
SO Fiziologicheski Aktivnye Veshchestva (1976), 8, 89-92
CODEN: FAVUAI; ISSN: 0533-1153
DT Journal
LA Russian
IT **62636-33-3P 62636-39-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and pharmacol. properties of)
RN 62636-33-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 62636-39-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-methoxyphenyl)-2-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

GI

L3 ANSWER 43 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB The title compds. I [R = H, m-F3CC6H4, o-MeOC6H4, NR21 = HOCH2CH2NH, PhCH2NH, 4-methyl-1-piperazinyl, 4-(2-hydroxyethyl)-1-piperazinyl, piperidino], useful as sedatives and muscle relaxants, were obtained in 56-98% yields by amination of chloronicotinamides with R21NH.

L3 ANSWER 44 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1973:537186 CAPLUS
DN 79:137186
TI 3-Aryl 6-sulfamoyl-7-halo-1,2,3,4-tetrahydro-4-quinazolinones
IN Shetty, Bola V.
PA Pennwalt Corp.
SO U.S., 15 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3761480	A	19730925	US 1972-235087	19720315
				US 1968-743615	19680710
				US 1970-874960	19701107
	US 3567746	A	19710302	US 1968-743615	19680710

PATENT FAMILY INFORMATION:

FAN 1971:405517

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3567746	A	19710302	US 1968-743615	19680710
	US 3761480	A	19730925	US 1972-235087	19720315
				US 1968-743615	19680710
				US 1970-874960	19701107
	US 3862949	A	19750128	US 1972-315702	19721215
				US 1968-743615	19680710
				US 1969-874960	19691107
				US 1970-50895	19700629

FAN 1972:85835

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2131622	A	19720105	DE 1971-2131622	19710625
				US 1970-50895	19700629
	CH 546244	A	19740228	CH 1971-8509	19710611
				US 1970-50895	19700629
	NL 7108861	A	19711231	NL 1971-8861	19710625
				US 1970-50895	19700629
	FR 2104765	A5	19720421	FR 1971-23420	19710628
	FR 2104765	B1	19751010		
				US 1970-50895	19700629

IT **23375-97-5 28524-80-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation of, with aldehydes)
RN 23375-97-5 CAPLUS
CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 28524-80-3 CAPLUS
CN Benzamide, 4-chloro-5-[(dimethylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 44 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **28524-75-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation with aldehydes)
RN 28524-75-6 CAPLUS
CN Benzamide, 4-chloro-5-[(methylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.
AB Cyclization of I by condensation with R1CHO or the acetal gave II with diuretic activity. Thus, PhCH2CH(OMe)2 was reacted with I (R = 2-Me) in HOAc containing H2SO4 and stirred overnight to give II (R = 2-Me, R1 = PhCH2).
An addnl. 53 examples are given.

L3 ANSWER 45 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1971:405517 CAPLUS
DN 75:5517
TI Diuretic sulfamoyl o-benzotoluidides
IN Shetty, Bola V.
PA Pennwalt Corp.
SO U.S., 7 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3567746	A	19710302	US 1968-743615	19680710
	US 3761480	A	19730925	US 1972-235087	19720315
				US 1968-743615	19680710
				US 1970-874960	19701107
	US 3862949	A	19750128	US 1972-315702	19721215
				US 1968-743615	19680710
				US 1969-874960	19691107
				US 1970-50895	19700629

PATENT FAMILY INFORMATION:
FAN 1972:85835

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2131622	A	19720105	DE 1971-2131622	19710625
				US 1970-50895	19700629
	CH 546244	A	19740228	CH 1971-8509	19710611
				US 1970-50895	19700629
	NL 7108861	A	19711231	NL 1971-8861	19710625
				US 1970-50895	19700629
	FR 2104765	A5	19720421	FR 1971-23420	19710628
	FR 2104765	B1	19751010		
				US 1970-50895	19700629

FAN 1973:537186

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3761480	A	19730925	US 1972-235087	19720315
				US 1968-743615	19680710
				US 1970-874960	19701107
	US 3567746	A	19710302	US 1968-743615	19680710

IT **23375-97-5P 28524-75-6P 28524-80-3P 31933-24-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 23375-97-5 CAPLUS
CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 45 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 28524-75-6 CAPLUS
CN Benzamide, 4-chloro-5-[(methylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 28524-80-3 CAPLUS
CN Benzamide, 4-chloro-5-[(dimethylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 31933-24-1 CAPLUS
CN Benzamide, 5-[(bis(phenylmethyl)amino]sulfonyl]-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 45 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB 5-Chloro-o-toluidine with Ac2O gave 5'-chloro-2'-methylacetanilide, which was heated with ClSO3H and NH4OH to give 5'-chloro 2'-methyl-4'-sulfamoylacetanilide (I). I was oxidized with KMnO4 to give N-acetyl-4-chloro-5-sulfamoylanthranilic acid, which was refluxed in aqueous NaOH to give 4-chloro-5-sulfamoylanthranilic acid (II). II in Ac2O was treated with COCl2 to give 7-chloro-6-sulfamoylisatoic anhydride, which was heated with o-toluidine to give 2-amino-4-chloro-5-sulfamoyl-N-o-tolylbenzamide (III). Nine other benzamides were similarly prepared III heated with MeCHO and MeO(CH2)2OMe in DMF gave 2-methyl-3-o-tolyl-6-sulfamoyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone (IV). The 2-Ph, 2-Me, and 2-(CH2Cl) analogs of IV were similarly prepared

L3 ANSWER 46 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1971:141846 CAPLUS
DN 74:141846
TI N- and N,N-Alkyl, -acyl, and -arylsulfamyltetrahydroquinazolinones as diuretics
IN Shetty, Bola V.
SO U.S., 6 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3557111	A	19710119	US 1968-717437	19680329
	GB 1256969	A	19711215	GB 1969-1256969	19690320
				US 1968-717437	19680329

IT **28524-75-6P 28524-80-3P 31933-24-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 28524-75-6 CAPLUS
CN Benzamide, 4-chloro-5-[(methylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 28524-80-3 CAPLUS
CN Benzamide, 4-chloro-5-[(dimethylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 31933-24-1 CAPLUS
CN Benzamide, 5-[(bis(phenylmethyl)amino]sulfonyl]-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 46 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title tetrahydroquinazolinones which have diuretic and saluretic properties, are prepared 5-Chloro-o-toluidine in H2O was stirred 4 hr with
Ac2O to give 5-chloro 2 methylacetanilide (I), m. 138-9°. I was cautiously added to ClSO3H under N, then NaCl added, the mixture heated 3 hr, and treated with NH4OH to give 5 chloro-2-methyl-4-sulfamoylacetamide (II) m. 248-50°. II was oxidized with KMnO4 to N-acetyl-4-chloro-5-sulfamoylanthranilic acid (III), m. 264-66°. III refluxed 3 hr with 3N NaOH, then brought to pH 4 with HCl gave 4-chloro-5-sulfamoylanthranilic acid (IV) m. 275-6°. IV in HOAc with COCl2 gave 7-chloro-6-sulfamoylisatoic acid (V), m. 290-2°. V, under N, heated with 1,2-MeC6H4NH2 gave 2-amino-4-chloro-5-sulfamoyl N
(o-tolyl)benzamide (VI) m. 289-92°. To VI in HOAc was added MeCH(OMe)2 in H2SO4 and the mixture stirred 3.5 hr to give 2-methyl-3-(o-tolyl)-6-sulfamoyl 7 chloro-1,2,3,4-tetrahydro-4-quinazolinone (VII) m. 246-50°. VII in C5H5N, stirred 6 hr with Ac2O gave 7-chloro-6-acetylsulfamoyl-2-methyl-3-(o-tolyl)-1,2,3,4-quinazolinone m. 243-6°. An addnl. 3 examples are described.

L3 ANSWER 47 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Et3N; after 30 min, ice-cold 6-aminopenicillanic acid and Et3N in CHCl3 was added and the soln. kept 12 hr to give, after alk. addn., Na 6-(3-benzyloxy-2-picolinamido)penicillanate. Prepd. similarly were: Na 7-(3-benzyloxy-2-picolinamido)cephalosporanate, Na 6-(3-hydroxy-2-picolinamido)penicillanate, and Na 7-(3-hydroxy-2-picolinamido)-cephalosporanate.

L3 ANSWER 47 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1971:76431 CAPLUS
DN 74:76431
TI 3-Substituted picolinyl penicillins and cephalosporins, useful as animal feed supplements and in germicidal preparations employed as surface disinfectants
IN Schwarz, J. S. Paul; Sheehan, John T.
PA E. R. Squibb and Sons, Inc.
SO U.S., 11 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3553203	A	19710105	US 1969-834157	19690617
	BR 6915314	A0	19730419	BR 1969-215314	19691219
				US 1969-834157	19690617
	CA 963003	A1	19750218	CA 1970-85025	19700609
				US 1969-834157	19690617
	DE 2028830	A	19710107	DE 1970-2028830	19700611
				US 1969-834157	19690617
	CH 517116	A	19711231	CH 1970-517116	19700616
				US 1969-834157	19690617
	FR 2052982	A1	19710416	FR 1970-22345	19700617
	FR 2052982	A5	19710416		
				US 1969-834157	19690617

IT **30861-03-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 30861-03-1 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[3-(benzylamino)picolinamido]-3,3-dimethyl-7-oxo-, monosodium salt (8CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

AB The title compds. were prepared Thus, ClCO2Et was added to an ice-cold solution of 3-benzyloxy 2 picolinic acid-HCl sesquihydrate in CHCl3 containing

L3 ANSWER 48 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1970:477191 CAPLUS
DN 73:77191
TI Synthesis and activity of some 3-aryl- and 3-aralkyl-1,2,3,4-tetrahydro-4-oxo-6-quinazolinesulfonamides
AU Shetty, Bola V.; Campanella, Liborio A.; Thomas, Telfer L.; Fedorchuk, M.; Davidson, T. A.; Michelson, L.; Volz, H.; Zimmerman, S. E.; Belair, E. J.; Truant, A. P.
CS Dep. Chem., Pennwalt Corp., Rochester, NY, USA
SO Journal of Medicinal Chemistry (1970), 13(5), 886-95
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 73:77191
IT **23375-97-5P 28524-75-6P 28524-80-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 23375-97-5 CAPLUS
CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 28524-75-6 CAPLUS
CN Benzamide, 4-chloro-5-[(methylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 28524-80-3 CAPLUS
CN Benzamide, 4-chloro-5-[(dimethylamino)sulfonyl]-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 48 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI For diagram(s), see printed CA Issue.

AB A series of 3-aryl- and 3-aralkyl di- and -tetrahydro-4-oxo-6-quinazolinesulfonamides were synthesized and tested for pharmacol. activity. Several of the compds. were potent diuretics, especially I (metolazone), a potent, virtually nontoxic diuretic and natriuretic.

L3 ANSWER 49 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

warmed to 190°, kept 5 min., left to cool (50°), poured into 3 l. of Et2O, and the ppt. washed and dried to give 2-benzylamino-4 chloro-5-sulfamyl-N-(O-tolyl)benzamide (II). Acetal (3.0 g.) was added to a suspension of 5.3 g. II in AcOH followed by 4 drops of H2SO4 dropwise during 5 min., the soln. stirred overnight, the ppt. filtered, washed with Et2O and dried to give 3.2 g. of I, m. 193-5° (AcOH). Some pharmacol. data are given.

L3 ANSWER 49 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1969:470632 CAPLUS

DN 71:70632

TI 1-Benzyl-2-methyl-3-(o-tolyl)-6-sulfamoyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone

IN Shetty, Bola V.

PA Wallace and Tiernan Inc.

SO U.S., 5 pp. Continuation-in-part of U.S. 3360518
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3452019	A	19690624	US 1967-683450	19671116
			US 1967-683450	19671116

IT **23375-97-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 23375-97-5 CAPLUS

CN Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2-methylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



AB The title compound I, useful as a diuretic, saluretic, and antihypertensive, was prepared Thus, 800 g. of 2,4-dichlorobenzoic acid was added to 4 kg. of ClSO3H at room temperature, the mixture refluxed 90 min., left to cool to 30°, 8 kg. of ice and 5 l. of H2O added slowly, the mixture cooled to 0°, 8 l. of 28% NH4OH added, acidified with HCl after 2 hrs., and the precipitate filtered, washed, dried, and clarified with C to give 790 g. 2,4-dichloro-5-sulfamylbenzoic acid, m. 225-8° (H2O). This compound (270 g.) was added to 500 cc. of PhCH2NH2, the temperature quickly raised to 130°, kept 1 hr., cooled to 100°, the mixture poured into 5 l. of ice water, acidified with 400 cc. of HCl, and stirred 4 hrs. and the precipitate filtered to give 192 g. of 4 chloro-5-sulfamyl-N-benzylanthranilic acid, m. 242-6° (decomposition) (95% EtOH). This compound (35.0 g.) and 15 cc. of liquid COCl2 was added to 400 cc. glacial AcOH, the mixture stirred 24 hrs., and the precipitate filtered, washed with Et2O and air dried to give 25.2 g. 4-benzyl-6 chloro-7- sulfamylisatoic anhydride. This compound (25 g.) was added to 300 cc. of o-toluidine at room temperature, the mixture quickly

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	391.35	546.98

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-36.02	-36.02

STN INTERNATIONAL LOGOFF AT 10:02:54 ON 14 AUG 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	May 12	EXTEND option available in structure searching
NEWS 4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS 8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS 9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS 10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS 11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS 12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS 13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS 14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS 15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:05:29 ON 14 AUG 2004

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:05:38 ON 14 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2004 HIGHEST RN 726125-61-7
DICTIONARY FILE UPDATES: 12 AUG 2004 HIGHEST RN 726125-61-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10823809.3

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Cb,Hy
G2 N,CH

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 10:06:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 123026 TO ITERATE

100.0% PROCESSED 123026 ITERATIONS 240 ANSWERS
SEARCH TIME: 00.00.02

L2 240 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'CAPLUS' ENTERED AT 10:06:13 ON 14 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Aug 2004 VOL 141 ISS 8
FILE LAST UPDATED: 13 Aug 2004 (20040813/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 37 L2

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:41461 CAPLUS
DN 140:93789
TI Preparation of substituted anthranilic amide derivatives as VEGF modulators and methods of use against cancer and other disorders
IN Huang, Qi; Chen, Guoqing; Li, Aiwen; Riahi, Babak; Tasker, Andrew; Yang, Kevin; Yuan, Chester Chenguang
PA Amgen Inc., USA
SO PCT Int. Appl., 204 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004005279	A2	20040115	WO 2003-US21601	20030709
	WO 2004005279	A3	20040311		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-395144P	P 20020709
				US 2003-615809	A 20030708
	US 2004087568	A1	20040506	US 2003-615809	20030708
				US 2002-395144P	P 20020709

OS MARPAT 140:93789
IT **645418-48-0P**, N-(1-Acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(4-fluorobenzylamino)benzamide **645418-50-4P**, 2-(4-Fluorobenzylamino)-N-[4-[1-methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide **645418-56-0P**, N [3,3-Dimethyl 1-[(4-methylpiperazin-1-yl)carbonyl]-2,3-dihydro-1H-indol-6-yl]-2-(4-fluorobenzylamino)benzamide **645418-64-0P**, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-(4 fluorobenzylamino)benzamide **645418-68-4P**, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-fluoro-6-(4-fluorobenzylamino)benzamide **645418-98-0P**, 4,4-Dimethyl-7-[[2-[[(quinoxalin-5-yl)methyl]amino)benzoyl]amino]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester **645418-99-1P**, N-(4,4-Dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-[[(quinoxalin-5-yl)methyl]amino]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted anthranilic amide derivs. as VEGF modulators and methods of use against cancer and other disorders)
RN 645418-48-0 CAPLUS
CN Benzamide, N-(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 645418-50-4 CAPLUS
CN Benzamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 645418-56-0 CAPLUS
CN Benzamide, N-[2,3-dihydro-3,3-dimethyl-1-[(4-methyl-1-piperazinyl)carbonyl]-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 645418-64-0 CAPLUS
CN Benzamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 645418-68-4 CAPLUS
CN Benzamide, 5-fluoro-2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 645418-98-0 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-4,4-dimethyl-7-[[2-[(5-quinoxalinylmethyl)amino]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 645418-99-1 CAPLUS
CN Benzamide, 2-((5-quinoxalinylmethyl)amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)



IT **645418-65-1P**, 7-[[2-(4-Fluorobenzylamino)benzoyl]amino]-4,4-dimethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted anthranilic amide derivs. as VEGF modulators and
methods of use against cancer and other disorders)
RN 645418-65-1 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-[[2-[[(4-fluorophenyl)methyl]amino]benzoyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I



II

AB Selected substituted anthranilic amide derivs. (shown as I; variables defined below; e.g. II) are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving cancer and the like. Although the methods of preparation are not claimed, .apprx.139 example prepns. of I and .apprx.80 of intermediates are included. For example, II was prepared in 3 steps starting from 2-nitrobenzoic acid and [4-[1-Methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]amine and involving intermediates 2-nitro-N-[4-[1-methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide and 2-amino-N-[4-[1-methyl-1-(1-methylpiperidin-4-yl)ethyl]phenyl]benzamide. Compds. I showed inhibition of KDR at doses <50 μM. Some of the exemplified I inhibit VEGF-stimulated HUVEC proliferation <1 μM. Compds. I are active at doses <150 mpk in a tumor model. For I: R = (un)substituted 9- or 10-membered fused heterocyclyl, -(CH2)1-2-R3; R1 = (un)substituted 5-6 membered satd. or partially satd. heterocyclyl, 9-10 membered bicyclic and 13-14 membered tricyclic satd. or partially satd. heterocyclyl, and phenyl; R2 is ≥1 substituents = H, halo, hydroxy, amino, C1-6-alkyl, C1-6-haloalkyl, C1-6-alkoxy, C1-2-alkylamino, aminosulfonyl, C3-6-cycloalkyl, cyano, C1-2-hydroxyalkyl, nitro, C2-3-alkenyl, C2-3-alkynyl, C1-6-haloalkoxy, C1-6-carboxyalkyl, 4-6-membered heterocyclyl-C1-6-alkylamino, (un)substituted Ph and (un)substituted 4-6 membered heterocyclyl; Ra = H, C1-2-alkyl; addnl. details are given in the claims.

L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:950836 CAPLUS

DN 140:16722

TI Preparation of 1,1-disubstituted cycloalkyl derivatives as factor Xa inhibitors for treating a thromboembolic disorder

IN Qiao, Jennifer X.; Pinto, Donald J.; Orwat, Michael J.; Han, Wei; Friedrich, Sarah R.

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 686 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003099276	A1	20031204	WO 2003-US13893	20030505

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002-379357P P 20020510
US 2002-415367P P 20021002

OS MARPAT 140:16722

IT **630385-55-6P 630385-58-9P 630385-59-0P**
630388-70-4P 630388-71-5P 630388-72-6P
630388-73-7P 630388-74-8P 630388-75-9P
630388-76-0P 630388-77-1P 630388-84-0P
630388-85-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 1,1-disubstituted cycloalkyl derivs. as factor Xa inhibitors for treating thromboembolic disorder)

RN 630385-55-6 CAPLUS

CN Benzeneacetic acid, 4-[[[2-[[(5-chloro-2-pyridinyl)amino]carbonyl]phenyl]amino]methyl]-α,α-dimethyl-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





RN 630385-58-9 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(2-hydroxy-1,1-dimethylethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 630385-59-0 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[2-(dimethylamino)-1,1-dimethylethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 630388-70-4 CAPLUS

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[(2-oxo-1-

L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
pyrrolidinyl)methyl]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 630388-71-5 CAPLUS
CN Benzamide,
2-[[[4-[1-[(acetylmethylamino)methyl]cyclopropyl]phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 630388-72-6 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[[methyl[(methylamino)carbonyl]amino]methyl]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 630388-73-7 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[[methyl(methylsulfonyl)amino]methyl]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 630388-74-8 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[(methylsulfonyl)amino]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 630388-75-9 CAPLUS
CN Benzamide, 2-[[[4-[1-(acetylamino)cyclopropyl]phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 630388-76-0 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[[(2-hydroxyethyl)amino]methyl]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 630388-77-1 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[[(2-hydroxyethyl)methylamino]methyl]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 630388-84-0 CAPLUS
CN Benzamide,
5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[1-[2-(dimethylamino)-2-oxoethyl]cyclopropyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 630388-85-1 CAPLUS
CN Benzamide,
2-[[[4-[1-(2-amino-2-oxoethyl)cyclopropyl]phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB The present application describes 1,1-disubstituted cycloalkyl compds. and
derivs. thereof (P4-P-M-M4; variables defined below; most of the examples contain 1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one, e.g. the trifluoroacetate of I), or pharmaceutically acceptable salt forms thereof,
which are useful as inhibitors of factor Xa for treatment of a thromboembolic disorder. Although the methods of preparation are not claimed,
apprx.240 example prepns. are included. A number of I exhibit Ki's of <10
μM towards factor Xa; also some I are direct acting inhibitors (Ki < 10 μM) of the serine protease thrombin as indicated by their ability to inhibit the cleavage of small mol. substrates by thrombin in a purified system; the specific compds. are not stated. For I: M is a 3-10 membered carbocycle or a 4-10 membered heterocycle, consisting of: C atoms and 1-3 heteroatoms = O, S(O)p, N, and NZ2; ring M is substituted with 0-3 R1a and
0-2 carbonyl groups, and there are 0-3 ring double bonds; P is fused onto ring M and is a 5, 6, or 7 membered carbocycle or a 5, 6, or 7 membered heterocycle, consisting of: C atoms and 1-3 heteroatoms = O, S(O)p, and N;
ring P is substituted with 0-3 R1a and 0-2 carbonyl groups, and there are 0-3 ring double bonds; alternatively, ring P is absent and P4 is directly attached to ring M, provided that when ring P is absent, P4 and M4 are attached to the 1,2, 1,3, or 1,4 positions of ring M. One of P4 and M4 is
Z-A-B and the other -G1-G, provided that P4 and M4 are attached to different rings when ring P is present; G is consists of 2 fused rings D and E (ring D, including the two atoms of Ring E to which it is attached, is a 5-6 membered ring consisting of carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O)p; E is selected from (un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl; alternatively, ring D is absent and ring E is selected from (un)substituted Ph, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl,

L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, thienyl, and thiazolyl); G1 is absent or = (CR3R3a)1-5, etc. A = (un)substituted C3-10
carbocycle and 5-12 membered heterocycle consisting of: C atoms and 1-4 heteroatoms N, O, and S(O)p; B is Y-R4a or X-Y-R4a, provided that Z and B are attached to different atoms on A and A and R4a or X and R4a are attached to the same atom on Y; Z = a bond, -(CR3R3e)1-4-, etc. Addnl. details including provisos are given in the claims.
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:950057 CAPLUS
DN 140:16647
TI Preparation of 2-aminopyridine-3-carboxamides as remedies for angiogenesis
mediated diseases
IN Askew, Benny; Adams, Jeffrey; Booker, Shon; Chen, Guoqing; Dipietro, Lucian V.; Elbaum, Daniel; Germain, Julie; Geuns-Meyer, Stephanie D.; Habgood, Gregory J.; Handley, Michael; Huang, Qi; Kim, Tae-seong; Li, Aiwen; Nishimura, Nobuko; Nomak, Rana; Patel, Vinod F.; Riahi, Babak; Kim,
Joseph L.; Xi, Ning; Yang, Kevin; Yuan, Chester Chenguang
PA Amgen Inc., USA
SO U.S. Pat. Appl. Publ., 252 pp., Cont.-in-part of U.S. Ser. No. 46,681.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003225106	A1	20031204	US 2002-197974	20020717
				US 2001-261339P P	20010112
				US 2001-323764P P	20010919
				US 2002-46681 A2	20020110
	US 2003125339	A1	20030703	US 2002-46681	20020110
				US 2001-261339P P	20010112
				US 2001-323764P P	20010919
	WO 2004007458	A1	20040122	WO 2003-US22417	20030715

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PATENT FAMILY INFORMATION:
FAN 2002:658116

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002066470	A1	20020829	WO 2002-US743	20020111

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2001-261339P	P 20010112
				US 2001-323764P	P 20010919
	US 2003125339	A1	20030703	US 2002-46681	A 20020110
				US 2002-46681	20020110
				US 2001-261339P	P 20010112
				US 2001-323764P	P 20010919

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	BR 2002006435	A	20030923	BR 2002-6435	20020111
				US 2001-261339P	P 20010112
				US 2001-323764P	P 20010919
				US 2002-46681	A 20020110
				WO 2002-US743	W 20020111
	EP 1358184	A1	20031105	EP 2002-717325	20020111

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

				US 2001-261339P	P 20010112
				US 2001 323764P	P 20010919
				US 2002-46681	A 20020110
				WO 2002-US743	W 20020111
	EE 200300324	A	20031215	EE 2003-324	20020111
				US 2001-261339P	P 20010112
				US 2001-323764P	P 20010919
				US 2002-46681	A 20020110
				WO 2002-US743	W 20020111
	NO 2003003181	A	20030911	NO 2003-3181	20030711
				US 2001-261339P	P 20010112
				US 2001-323764P	P 20010919
				US 2002-46681	A 20020110
				WO 2002-US743	W 20020111

OS MARPAT 140:16647
IT **453561-07-4P 453561-08-5P 453561-23-4P**
453561-81-4P, 2-[(2,3-Dihydrobenzofuran-5-ylmethyl)amino]-N-[3,3-dimethyl-1-(piperidin-4-ylmethyl)-2,3-dihydro-1H-indol-6-yl]nicotinamide
453563-25-2P 453563-26-3P 453563-27-4P
453563-28-5P 453563-33-2P 453563-34-3P
453563-35-4P 453563-36-5P 453563-86-3P
453564-40-4P 453564-41-5P 453564-42-6P
629650-58-4P 629650-64-2P 629650-65-3P
629650-69-7P 629650-71-1P 629650-72-2P
629650-73-3P 629650-74-4P 629651-29-2P
629652-03-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-aminopyridine-3-carboxamides for treating angiogenesis
mediated diseases)
RN 453561-07-4 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[(6-quinolinylmethyl)amino]-(9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453561-08-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(3,4 dichlorophenyl)-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453561-23-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453561 81-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinylmethyl)-1H-indol-6-yl]- (9CI) (CA INDEX NAME)



RN 453563-25-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453563-26-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 453563-27-4 CAPLUS
CN 3-Pyridinecarboxamide,
2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 453563-28-5 CAPLUS
CN 3-Pyridinecarboxamide,
2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 453563-33-2 CAPLUS
CN 3-Pyridinecarboxamide,
2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 453563-34-3 CAPLUS
CN 3-Pyridinecarboxamide,
N-(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453563-35-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[6-[[[2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 453563-36-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[2,3-dihydro 3,3-dimethyl-1-[(1-methyl-4-piperidinyl)methyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453564-41-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3 dihydro-5-benzofuranyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 453564-42-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-[(2S)-2 pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 629650-58-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-[1-methyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]phenyl]- (9CI) (CA INDEX

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453563-84-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[(2,3-dihydro-6-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 453564-40-4 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-[[[2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
NAME)



RN 629650-64-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-4-(trifluoromethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 629650-65-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-5-(trifluoromethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 629650-69-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 629650-71-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-[3-[(tetrahydro-2-furanyl)methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 629650-72-2 CAPLUS

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 629651-29-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(5-benzoxazolylmethyl)amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 629652-03-5 CAPLUS
CN 1-Azetidinecarboxylic acid, 3-[[3-[[[2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



GI

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, N-[3-[[(dimethylamino)acetyl]amino]-4-(1,1-dimethylethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 629650-73-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-[3-[[(3R)-tetrahydro-3-furanyl]oxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 629650-74-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-2-oxo-3,3-bis(trifluoromethyl)-1H-indol-6-yl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The title compds. [I; R = (un)substituted 4-pyridyl, 2-pyridyl, 4-pyrimidinyl, 4-quinolyl, etc.; R1 = (un)substituted aryl, cycloalkyl, 5-6 membered heteroaryl, 9-10 membered bicyclic and 11-14 membered tricyclic heterocyclyl], which are effective for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like, were prepared Thus, the title compound II was prepared from 2-aminonicotinic acid, 4-chloroaniline, and 4-pyridinecarboxaldehyde. The compds. I showed inhibition of KDR kinase at < 50 μM. Many compds. I inhibited VEGF-stimulated HUVEC proliferation at a level below 50 nM. Pharmaceutical composition comprising the compound I is claimed.

L3 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:913147 CAPLUS

DN 139:381477

TI Preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides as IKK2 inhibitors for the treatment of cancer and inflammation

IN Lennon, Patrick; Bonafoux, Dominique; Oburn, David S.; Wolfeon, Serge G.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 312 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003095430	A1	20031120	WO 2003-US8917	20030319
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-379090P	P 20020509
				WO 2002-US29774	A 20020919
	WO 2003024935	A2	20030327	WO 2002-US29774	20020919
	WO 2003024935	A3	20030821		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-323423P	P 20010919
				US 2002-379090P	P 20020509

PATENT FAMILY INFORMATION:

FAN	2003:242305				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003024935	A2	20030327	WO 2002-US29774	20020919
	WO 2003024935	A3	20030821		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

L3 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I



II

AB The present invention relates to substituted pyrazolyl derivs., compns. comprising such, intermediates, methods of making substituted pyrazolyl derivs., and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis. 4,5-Dihydro-1H-

L3 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509
US 2004110741	A1	20040610	US 2002-247096	20020919
			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509
EP 1444207	A2	20040811	EP 2002-775879	20020919

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509
			WO 2002-US29774	W 20020919
WO 2003095430	A1	20031120	WO 2003-US8917	20030319

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2002-379090P	P 20020509
	WO 2002-US29774	A 20020919

OS MARPAT 139:381477

IT **503555-09-7P**, 1-(1,3-Benzodioxol-5-yl)-8-[[[2-[(4-methoxybenzyl)amino]pyridin-3-yl]carbonyl]amino]-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides as IKK2 inhibitors for treatment of cancer and inflammation)

RN 503555-09-7 CAPLUS

CN 1H-Benz[g]indazole-3-carboxamide, 1-(1,3-benzodioxol-5-yl)-4,5-dihydro-8-[[[2-[[(4-methoxyphenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

benzo[g]indazole-3-carboxamides (shown as I; variables defined below; e.g.
II) were prepd. via conventional and solid phase synthetic methods as IκB protein kinase β (IKKβ or IKK2) inhibitors. Although the methods of prepn. are not claimed, 480 example prepns. and/or characterization data are included. For example, reaction of 7-nitro 1-tetralone with Et acetate in the presence of Li bis(trimethylsilyl)amide in ether gave the 1,3-diketone (87%), which was cyclized with 4-sulfonamidophenylhydrazine•HCl with HCl in MeOH to give the Et 1H-dihydrobenzo[g]indazolecarboxylate (69%). Amidation with NH4OH in MeOH provided II. In IKKβ resin enzyme assays, I exhibited IKKβ activity with IC50 values ranging from ≤ 1 μM to > 100 μM. Thus, I are useful for treating cancer, inflammation, and inflammation-assocd. disorders, such as arthritis (no data). For I: B is a 5 or 6 membered heteroaryl, aryl, (un)satd. heterocyclic (un)substituted with R1, R2, and R12; W is a 5 or 6 membered heteroaryl, aryl, (un)satd. heterocyclic. R1 = hydrido, halo, alkyl, aryl, heteroaryl, alkenyl, alkynyl, haloalkyl, CN, NO2, OR5, OCOOR5, CO2R7, CON(R6)R7, COR6, SR6, SOR6, SO2R6, NR6R7, NR6COR7, NR6CONHR7, NR6SO2R7, NR6SO2NHR7, and SO2N(R6)R7; R2 = halo, hydrido, hydroxyalkyl, alkyl, OR6, CN, NO2, SR6, NHR6, CON(R6)R7, NHCONHR6, CO2H, and haloalkyl; R1 and R2 may be taken together to form a 5 to 7 membered (un)satd. carbocyclic ring optionally contg. 0 to 3 heteroatoms N, O, or S, and wherein said ring is (un)substituted with R1. R12 = hydrido, halo, alkyl, and alkoxy; R15 = alkylsulfonamide, sulfamyl, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, halo, acyloxy, oxy, formyl, haloalkyl, cyano, haloalkoxy, acyl, carboxy, hydroxy, hydroxyalkyloxy, phenoxy, nitro, azido, benzyloxy, dialkylaminoacyl, thioalkyl, aminoacyloxy, thiocyanate, isothiocyanate, alkyldioxy, hydroxyalkyl, alkylamino, alkyloxycarbonyl, alkoxyalkyl, alkenylamino, alkynylamino, alkenyl, alkynyl, dialkylaminoalkyloxy, and heterocyclic; addnl. details are given in the claims.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:665525 CAPLUS
DN 139:345320
TI Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching
AU Furet, Pascal; Bold, Guido; Hofmann, Francesco; Manley, Paul; Meyer, Thomas; Altmann, Karl-Heinz
CS Oncology Research, Novartis Pharma AG, Basel, CH-4002, Switz.
SO Bioorganic & Medicinal Chemistry Letters (2003), 13(18), 2967-2971
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 139:345320
IT **618359-41-4**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(identification, synthesis and structure-activity relationship studies on a new chemical class of potent angiogenesis inhibitors (anthranilamides)-based on conformational considerations and database searching)
RN 618359-41-4 CAPLUS
CN Benzamide, N-(2-fluorophenyl)-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



AB The vascular endothelial growth factor (VEGF) tyrosine kinase receptors KDR and Flt-1 are targets of current interest in anticancer drug research.
PTK787/ZK222584 is a potent inhibitor of these enzymes in clin. evaluation
as an antiangiogenic agent. The development of a hypothesis concerning the bioactive conformation of this compound has led to the discovery of a new class of potent inhibitors of KDR and Flt-1, the anthranilamides. This could be achieved with a limited exptl. effort, which only involved the testing of one archive compound and the synthesis and testing of one appropriate analog.
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:551370 CAPLUS
DN 139:111679
TI Combination of microsomal triglyceride transfer protein (MTP) inhibitors or apoB secretion inhibitors with fibrates for use as drugs
IN Thomas, Leo; Mark, Michael
PA Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
SO PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003057205	A2	20030717	WO 2003-EP57	20030107
WO 2003057205	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			DE 2002-10200633 A	20020110
			DE 2002 10256184 A	20021202
DE 10200633	A1	20030724	DE 2002-10200633	20020110
DE 10256184	A1	20040609	DE 2002-10256184	20021202
US 2003162788	A1	20030828	US 2003-339088	20030109
			DE 2002-10200633 A	20020110
			US 2002-353397P P	20020201
			DE 2002-10256184 A	20021202
			US 2002-435386P P	20021220

OS MARPAT 139:111679
IT **486436-62-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)
RN 486436-62-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]-4-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB The invention discloses the use of fibrates for reducing the hepatic toxicity of MTP inhibitors, as well as pharmaceutical compns. that contain
an MTP inhibitor and a fibrate. Compound preparation is included.

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:551181 CAPLUS
DN 139:117339
TI Preparation of substituted arylamine derivatives as antitumor agents
IN Elbaum, Daniel; Askew, Benny; Booker, Shon; Germain, Julie; Habgood, Gregory; Handley, Michael; Kim, Tae-Seong; Li, Aiwen; Nishimura, Nobuko; Patel, Vinod F.; Yuan, Chester Chenguang; Kim, Joseph L.
PA Amgen Inc., USA
SO U.S. Pat. Appl. Publ., 106 pp., Cont.-in-part of U.S. Ser. No. 46,526.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003134836	A1	20030717	US 2002-197960	20020717
			US 2001-261360P P	20010112
			US 2001-323686P P	20010919
			US 2002-46526 A2	20020110
US 2002147198	A1	20021010	US 2002-46526	20020110
			US 2001-261360P P	20010112
			US 2001-323686P P	20010919
WO 2004007457	A2	20040122	WO 2003-US22276	20030715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-197960 A	20020717

PATENT FAMILY INFORMATION:
FAN 2002:539663

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002055501	A2	20020718	WO 2002-US742	20020111
WO 2002055501	A3	20021219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-261360P P	20010112
			US 2001 323686P P	20010919
			US 2002-46526 A	20020110
US 2002147198	A1	20021010	US 2002-46526	20020110
			US 2001-261360P P	20010112
			US 2001-323686P P	20010919
EP 1358161	A2	20031105	EP 2002-717324	20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2001-261360P P	20010112

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 2001-323686P P 20010919
US 2002-46526 A 20020110
WO 2002-US742 W 20020111

OS MARPAT 139:117339

IT **561297-65-2P 561297-67-4P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted aminopyridines as antitumor agents)

RN 561297-65-2 CAPLUS

CN 1-Azetidinecarboxylic acid, 3-[[2-chloro-5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 561297-67-4 CAPLUS

CN 4-Pyridazinecarboxamide, 6-chloro N-[4-(1,1-dimethylethyl)phenyl]-3-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **561297-60-7P 561297-61-8P 561297-62-9P**
561297-63-0P 561297-64-1P 561297-66-3P
561297-68-5P 561297-70-9P 561297-71-0P
561297-72-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted aminopyridines as antitumor agents)

RN 561297-60-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(methylsulfonyl) 1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 561297-61-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[(dimethylamino)acetyl]amino]-4-(1,1-dimethylethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
NAME)



RN 561297-62-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 561297-63-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[(methylsulfonyl)amino]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 561297-64-1 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 561297-66-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(3-azetidinylmethoxy)-4-chlorophenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 561297-68-5 CAPLUS
CN 4-Pyridazinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-3-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 561297-70-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-(3-azetidinylmethoxy)-5-(trifluoromethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 561297-71-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-hydroxy-3-nitrophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 561297-72-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-amino-4-hydroxyphenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **442847-21-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted aminopyridines as antitumor agents)
RN 442847-21-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinylmethyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



IT **442845-77-4P 442846-13-1P 442846-17-5P**
442846-22-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation of substituted aminopyridines as antitumor agents)
RN 442845-77-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-fluorophenyl)methyl]amino]-N-(4-

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442846-13-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-17-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[6-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-22-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-acetyl-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



IT 442845-71-8P 442845-72-9P 442845-73-0P
442845-78-5P 442845-79-6P 442845-80-9P
442845-81-0P 442845-82-1P 442845-83-2P
442845-84-3P 442845-85-4P 442845-86-5P
442845-87-6P 442845-88-7P 442845-89-8P
442845-90-1P 442845-91-2P 442845-92-3P
442845-93-4P 442845-94-5P 442845-95-6P

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 442845-73-0 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-fluoro-4-methylphenyl)-3-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-78-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-79-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl) (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

442845-96-7P 442845-97-8P 442845-99-0P
442846-00-6P 442846-01-7P 442846-02-8P
442846-03-9P 442846-04-0P 442846-05-1P
442846-06-2P 442846-07-3P 442846-08-4P
442846-09-5P 442846-10-8P 442846-11-9P
442846-12-0P 442846-14-2P 442846-15-3P
442846-16-4P 442846-18-6P 442846-19-7P
442846-20-0P 442846-21-1P 442846-23-3P
442846-24-4P 442846-25-5P 442846-26-6P
442846-27-7P 442846-28-8P 442846-29-9P
442846-30-2P 442846-31-3P 442846-32-4P
442846-33-5P 442846-34-6P 442846-35-7P
442846-36-8P 442846-38-0P 442846-39-1P
442846-40-4P 442846-42-6P 442846-44-8P
442847-23-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of substituted aminopyridines as antitumor agents)

RN 442845-71-8 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 442845-72-9 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[[(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-80-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-81-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2-bromophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442845-82-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(trifluoromethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-83-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-difluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442845-84-3 CAPLUS
CN 3-Pyridinecarboxamide,
N-(4-chlorophenyl)-2-[[(4-cyanophenyl)methyl]amino]-
(9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-85-4 CAPLUS
CN 3-Pyridinecarboxamide,
N-(4-chlorophenyl)-2-[[(2-cyanophenyl)methyl]amino]-
(9CI) (CA INDEX NAME)



RN 442845-86-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(2-methylpropyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-87-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-88-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-methoxyphenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-89-8 CAPLUS

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, 2-[[(3-aminophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-90-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-91-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-92-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-93-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-94-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-97-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-99-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-95-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-96-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 442846-00-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-01-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-02-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,6-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-03-9 CAPLUS

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, 2-[[(3-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-04-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-05-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[3-(dimethylamino)propyl] 5-(trifluoromethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-06-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-07-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-08-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-bromo-2-fluorophenyl)-2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-09-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-10-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-fluoro-3-[3-(4-morpholinyl)-1-propynyl]phenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-11-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(1,3-benzodioxol-5-ylmethyl)amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-12-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-14-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[2-(1,1-dimethylethyl)-5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-18-6 CAPLUS
CN Carbamic acid, [2-[6-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-19-7 CAPLUS
CN 2(1H) Isoquinolinecarboxylic acid, 7-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-15-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(1-methyl-4-piperidinyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-16-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-[(dimethylamino)acetyl]-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-20-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[3-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-21-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[2-(1,1-dimethylethyl)-5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-23-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-24-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-25-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[(2R)-2-pyrrolidinylmethoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-26-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-piperidinylmethoxy)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-27-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-28-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-29-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-(aminoacetyl)-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-30-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-31-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-(4-piperidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-32-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[(4-fluorophenyl)methyl]amino] (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-35-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 442846-36-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino] N-(1,2,3,4-tetrahydro-4,4-dimethyl-2-oxo-7-quinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-33-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy] 5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-34-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-[(1 methyl-4-piperidinyl)methyl]-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-38-0 CAPLUS
CN 3-Pyridinecarboxamide, N-5-benzofuranyl-2-[[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-39-1 CAPLUS
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-2-[[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-40-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3,4-difluorophenyl)methyl]amino]-N-[4-(1,1-

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 442846-42-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 442846-44-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(1-piperidinylmethyl)amino]phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442847-23-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 442845-77-4
CMF C25 H20 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

GI



I II

AB The title compds. I [R2 = (un)substituted Ph, 9-10 membered bicyclic and 11-14 membered tricyclic (un)saturated heterocyclyl; R8 = halo, NH2, NO2, etc.], and their pharmaceutically acceptable derivs., are prepared and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. E.g., a multi-step synthesis of II, starting from 1-dimethylamino-2-propyne and 3-bromo-5-trifluoromethylaniline, was given. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

L3 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:454323 CAPLUS
DN 139:22501
TI Preparation of glycinamide heterocyclic derivatives as factor Xa inhibitors
IN Pinto, Donald J. P.; Han, Wei; Hu, Zilun
PA Bristol-Myers Squibb Company, USA; Qiao, Jennifer
SO PCT Int. Appl., 451 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048158	A1	20030612	WO 2002-US38239	20021127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-336994P	P 20011204
	US 2003232804	A1	20031218	US 2002-304070	20021125
				US 2001-336994P	P 20011204

PATENT FAMILY INFORMATION:
FAN 2003:454257

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048081	A2	20030612	WO 2002-US37212	20021118
	WO 2003048081	A3	20030912		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-336994P	P 20011204
	US 2003232804	A1	20031218	US 2002-304070	20021125
				US 2001-336994P	P 20011204

OS MARPAT 139:22501
IT **536759-09-8P 536759-10-1P 536759-11-2P**
536759-12-3P 536759-13-4P 536759-14-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of glycinamide heterocyclic derivs. as factor Xa inhibitors)
RN 536759-09-8 CAPLUS
CN 1-Pyrrolidineacetamide, N-[4-[[[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]phenyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA

L3 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 536759-10-1 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 536759-11-2 CAPLUS
CN Benzamide, 2-[[[4-(acetylmethylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 536759-12-3 CAPLUS
CN Benzamide,
N-(5-chloro-2-pyridinyl)-2-[[[4-[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]-5-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 536759-13-4 CAPLUS
CN Benzamide,
N-(5-chloro-2-pyridinyl)-2-[[[4-[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 536759-14-5 CAPLUS
CN Benzamide,
N-(5-chloro-2-pyridinyl)-2-[[[4-[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB Compds. P4-P M-M4 [M is a 3-10 membered carbocycle or a 4-10 membered heterocycle; P is null or a 5-7 membered carbocycle or heterocycle fused to ring M; one of P4 and M4 is -Z-A-B and the other is -G1-G, where G is (un)substituted (fused) (hetero)aryl or (hetero)cyclyl; G1 is null or (un)substituted optionally-functionalized alk(en)(yn)yl; Z is a bond or (hetero)alkylene; A is (substituted) 3-10 membered carbocyclyl or 5-12 membered heterocyclyl; B is a functionalized amino group (with provisos)] or their pharmaceutically-acceptable salts were prepared for use as inhibitors of factor Xa. Thus, 1H-pyrazolo[3,4-c]pyridine derivative I.TFA was prepared by reactions of 3-aminobenzamide, 3-hydroxy-1-(4-iodophenyl)-4-(trifluoroacetyl)-5,6-dihydro-2(1H)-pyridinone, chloroacetyl chloride, and dimethylamine.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:454257 CAPLUS
DN 139:7167
TI Preparation of glycinamide heterocyclic derivatives as factor Xa inhibitors
IN Pinto, Donald J. P.; Han, Wei; Hu, Zilun
PA Bristol-Myers Squibb Company, USA; Qiao, Jennifer
SO PCT Int. Appl., 448 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048081	A2	20030612	WO 2002-US37212	20021118
	WO 2003048081	A3	20030912		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-336994P P	20011204
	US 2003232804	A1	20031218	US 2002-304070	20021125
				US 2001-336994P P	20011204

PATENT FAMILY INFORMATION:

FAN	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	2003:454323				
PI	WO 2003048158	A1	20030612	WO 2002-US38239	20021127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-336994P P	20011204
	US 2003232804	A1	20031218	US 2002-304070	20021125
				US 2001-336994P P	20011204

OS MARPAT 139:7167
IT **536759-09-8P 536759-10-1P 536759-11-2P 536759-12-3P 536759-13-4P 536759-14-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of glycinamide heterocyclic derivs. as factor Xa inhibitors)

L3 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





RN 536759-11-2 CAPLUS
CN Benzamide, 2-[[[4-(acetylmethylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)





RN 536759-12-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]-5-methyl- (9CI) (CA INDEX NAME)





RN 536759-13-4 CAPLUS
CN Benzamide,

L3 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 536759-09-8 CAPLUS
CN 1-Pyrrolidineacetamide, N-[4-[[[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]phenyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 536759-10-1 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
mino]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)





RN 536759-14-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[[(dimethylamino)acetyl]methylamino]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



GI



I

AB Compds. P4-P-M-M4 [M is a 3-10 membered carbocycle or a 4-10 membered heterocycle; P is null or a 5-7 membered carbocycle or heterocycle fused to ring M; one of P4 and M4 is -Z-A-B and the other is -G1-G, where G is (un)substituted (fused) (hetero)aryl or (hetero)cyclyl; G1 is null or (un)substituted optionally-functionalized alk(en)(yn)yl; Z is a bond or (hetero)alkylene; A is (substituted) 3-10 membered carbocyclyl or 5-12 membered heterocyclyl; B is a functionalized amino group (with provisos)] or their pharmaceutically-acceptable salts were prepared for use as inhibitors of factor Xa. Thus, 1H-pyrazolo[3,4-c]pyridine derivative

L3 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
was prepd. by reactions of 3-aminobenzamide, 3-hydroxy-1-(4-iodophenyl)-4-(trifluoroacetyl)-5,6-dihydro-2(1H)-pyridinone, chloroacetyl chloride, and dimethylamine.

L3 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:376824 CAPLUS
DN 138:368777
TI Preparation of pyridyl-substituted anthranilic acid amides for treating neoplastic disease
IN Bold, Guido; Furet, Pascal; Manley, Paul William
PA Novartis AG, Switz.; Novartis Pharma Gmbh
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003040101	A1	20030515	WO 2002-EP12445	20021107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
			GB 2001-26901	A 20011108
			GB 2002-12917	A 20020605

OS MARPAT 138:368777
IT **524729-00-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridyl-substituted anthranilic acid amides for treating neoplastic disease)
RN 524729-00-8 CAPLUS
CN Benzamide, 2-[[[3-[(methylamino)carbonyl]phenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; Ar = II (wherein Ra = H, alkyl; and R1 = H, perfluoroalkyl; R2 = H, halo, alkyl, alkenyl, alkynyl); or Ar = 4-pyridyl and R1 = perfluoroalkyl; R2 = Br, I, alkyl, alkenyl, alkynyl; or R1 = H, and R2 = F, Br, I, Et, alkyl, alkenyl or alkynyl] and their N-oxides and salts, useful for the treatment especially of a neoplastic disease, such as a tumor disease, of retinopathy or age-related macular degeneration in the human or animal body, were prepared and formulated. Thus, reductive amination of 4-pyridinecarboxaldehyde with 2-amino-N-(4-bromo-3-trifluoromethylphenyl)benzamide (preparation given) in the presence of NaBH3CN afforded I [Ar = 4-pyridyl; R1 = CF3; R2 = Br]. The IC50 values that can be found for the compds. I are in range of 0.001 to 1 μM in test for activity against VEGF-receptor tyrosine kinase.
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:242305 CAPLUS
DN 138:271675
TI Preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides for the treatment of inflammation
IN Bergmanis, Arija A.; Bonafoux, Dominique; Clare, Michael; Crich, Joyce Z.; Fletcher, Theresa R.; Geng, Lifeng; Hagen, Timothy J.; Hamper, Bruce C.; Hanson, Gunnar J.; Houdek, Stephen C.; Huang, He; Iula, Donna M.; Koszyk, Francis J.; Lennon, Patrick J.; Liao, Shuyuan; Liao, Subo; Metz, Suzanne; Mohler, Scott B.; Nguyen, Maria; Oburn, David S.; Owen, Thomas J.; Partis, Richard A.; Scates, Angela M.; Stealey, Michael A.; Tollefson, Michael B.; Vazquez, Michael L.; Weier, Richard M.; Wolfson, Serge G.; Xu, Xiangdong
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 331 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003024935	A2	20030327	WO 2002-US29774	20020919
WO 2003024935	A3	20030821		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-323423P	P 20010919
			US 2002 379090P	P 20020509
US 2004110741	A1	20040610	US 2002-247096	20020919
			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509
EP 1444207	A2	20040811	EP 2002-775879	20020919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
			US 2001-323423P	P 20010919
			US 2002-379090P	P 20020509
			WO 2002-US29774	W 20020919
WO 2003095430	A1	20031120	WO 2003-US8917	20030319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2002-379090P	P 20020509

L3 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

WO 2002-US29774 A 20020919

PATENT FAMILY INFORMATION:

FAN 2003:913147

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003095430	A1	20031120	WO 2003-US8917	20030319
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2002-379090P	P 20020509
				WO 2002-US29774	A 20020919
	WO 2003024935	A2	20030327	WO 2002-US29774	20020919
	WO 2003024935	A3	20030821		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-323423P	P 20010919
				US 2002-379090P	P 20020509

OS MARPAT 138:271675

IT **503555-09-7P**, 1-(1,3-Benzodioxol-5-yl)-8-[[[2-[(4-methoxybenzyl)amino]pyridin-3-yl]carbonyl]amino]-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(IKK2 inhibitor; preparation of benzo[g]carboxamides as IKK2 inhibitors for
treatment of cancer, inflammation, and inflammation associated disorders)

RN 503555-09-7 CAPLUS

CN 1H-Benz[g]indazole-3-carboxamide, 1-(1,3-benzodioxol-5-yl)-4,5-dihydro-8-[[[2-[[(4-methoxyphenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I II

AB The present invention relates to substituted pyrazolyl deriva., compns. comprising such, intermediates, methods of making substituted pyrazolyl derivs., and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis. Title compds. I [wherein A = (un)substituted (CH2)m; m = 0-3; B = (un)substituted (hetero)aryl; X = N or C; Y and Z = independently N, C, CH, CR3, S, or O; R1 = H, halo, (halo)alkyl, (hetero)aryl, alkenyl, alkynyl, CN, NO2, alkoxy(carbonyl), carbamoyl, acyl, alkylthio, sulfamoyl, ureido, etc.; R2 = H, halo, (halo)alkyl, hydroxyalkyl, alkoxy, CN, NO2, alkylthio, amino, carbamoyl, ureido, CO2H, etc.; R3 = (un)substituted amidine, alkylamino, aminoalkyl, carbamoyl, NH2, or acylamino(methyl); R4 = H, halo, alkylsulfinyl, alkylsulfonyl, CN, alkoxycarbonyl, (halo)alkyl, hydroxyalkyl, haloalkoxy, heterocyclyl, NO2, acylamino, (hetero)aryl, alkenyl, alkoxy, alkylthio, sulfamoyl, acyl, ureido, carbamoyl, etc.; R5 -

L3 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

H, or (un)substituted (aryl)alkyl, (hetero)aryl, heterocyclylalkyl, or heteroarylalkyl; R11 = H, halo, (halo)alkyl, CN, alkoxycarbonyl, alkenyl, alkynyl, alkoxy, carbamoyl, etc.; R12 = H, halo, alkyl, or alkoxy; with provisos; and isomers, tautomers, carriers, esters, prodrugs, and pharmaceutically acceptable salts thereof] were prepd. via conventional and solid phase synthetic methods as IκB protein kinase β (IKKβ or IKK2) inhibitors. For example, reaction of 7-nitro-1-tetralone with Et acetate in the presence of Li bis(trimethylsilyl)amide in ether gave the 1,3-diketone (87%), which was cyclized with 4-sulfonamidophenylhydrazine•HCl with HCl in MeOH to give the Et 1H-dihydrobenzo[g]indazolecarboxylate (69%). Amidation with NH3OH in MeOH provided II. In IKKβ resin enzyme assays, I exhibited IKKβ activity with IC50 values ranging from ≤ 1 μM to > 100 μM. Thus, I are useful for treating cancer, inflammation, and inflammation-assocd. disorders, such as arthritis (no data).

L3 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:42101 CAPLUS

DN 138:106502

TI Preparation of biphenylcarboxylic acid amides as inhibitors of microsomal triglyceride transfer protein (MTP)

IN Priepke, Henning; Hauel, Norbert; Dahmann, Georg; Thomas, Leo; Mark, Michael

PA Boehringer Ingelheim Pharma K.-G., Germany

SO PCT Int. Appl., 193 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003004020	A1	20030116	WO 2002-EP7215	20020629
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DE 2001-10132686	A 20010705
	DE 10132686	A1	20030116	DE 2001-10132686	20010705
	US 2003073836	A1	20030417	US 2002 187860	20020702
				DE 2001-10132686	A 20010705
				US 2001-304584P	P 20010711

OS MARPAT 138:106502

IT **486436-62-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of biphenylcarboxylic acid amides as microsomal
triglyceride transfer protein (MTP) inhibitors)

RN 486436-62-8 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]-4-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I

AB Title compds. I [X1 = CR1; X2 = CR2; X3 = CR3; X4 = CR4; with 1-2 of the groups being a N-atom; R1, R2, R3, R4 = H, halo, alkyl, etc.; A = O, S, NH, etc.; R8 = (un)substituted Ph, 1-naphthyl, 2-naphthyl, etc.; R5 = H, (un)substituted alkyl; R6 = H, alkyl; R7 = (un)substituted alkyl; Y = 1-2 carbon atom(s) bound to (un)substituted 5-membered heteroaryl] and their pharmaceutically acceptable salts were prepared For example, coupling of acid II, e.g., prepared from 4-hydrazinobenzonitrile in 5-steps, and 4-phenylbenzylamine afforded biphenylcarboxylic acid amide III in 86% yield. In triglyceride transfer protein inhibition studies, compds. I exhibited IC50 values ≤ 100μM. Compds. I are claimed useful as inhibitors of microsomal triglyceride transfer protein (MTP) for the treatment of atherosclerosis.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:22869 CAPLUS
DN 138:89806
TI Preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for treatment of cardiovascular disease.
IN Ingraham, Richard H.; Proudfoot, John R.
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003002555	A1	20030109	WO 2002-US18752	20020614
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-302066P	P 20010629
US 2003022929	A1	20030130	US 2002-172457	20020614
			US 2001-302066P	P 20010629
EP 1406892	A1	20040414	EP 2002-739870	20020614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2001-302066P	P 20010629
			WO 2002-US18752	W 20020614
US 2004092567	A1	20040513	US 2003-670668	20030925
			US 2001-302066P	P 20010629
			US 2002-172457	A1 20020614

OS MARPAT 138:89806
IT **483342-21-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for treatment of cardiovascular disease)
RN 483342-21-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[4-[3-(3-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I

AB A method of treating cardiovascular disease comprises administration of title compds. [I; R1, R3 = CF3, halo, cyano, alkyl, alkenyl, alkynyl, (substituted) cycloalkyl, heterocyclyl, etc.; R2 = H, halo, Me; L = NHCO, NHCS, NH, NHCH2, NHCOCO, etc.; R4 = (substituted) alkyl, alkoxy, alkylthio, alkylamino, alkoxyalkyl, alkylthioalkyl, carbocyclyl, heterocyclyl, etc.; R8 = H, NH2] (no data). Thus, 2-chloronicotinic acid in MeCN was treated with EDC and then with 1-(4-aminophenyl)-3-(3-pyridyl)-5-trifluoromethylpyrazole under ice cooling followed by stirring for 1 h to give I (R1 = 3-pyridyl; R2, R8 = H; R3 = CF3; L = NHCO; R4 = 2-chloropyridin-3-yl).

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:658116 CAPLUS
DN 137:201332
TI Preparation of heterocyclylalkylamine derivatives as remedies for angiogenesis mediated diseases
IN Chen, Guoqing; Adams, Jeffrey; Bemis, Jean; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Geuns-meyer, Stephanie; Handley, Michael; Huang, Qi; Kim, Joseph L.; Kim, Tae-seong; Kiselyov, Alexander; Ouyang, Xiaohu; Patel, Vinod F.; Smith, Leon M.; Stec, Markian; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang
PA Amgen Inc., USA
SO PCT Int. Appl., 502 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002066470	A1	20020829	WO 2002-US743	20020111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-261339P	P 20010112
			US 2001-323764P	P 20010919
			US 2002-46681	A 20020110
US 2003125339	A1	20030703	US 2002-46681	20020110
			US 2001-261339P	P 20010112
			US 2001-323764P	P 20010919
BR 2002006435	A	20030923	BR 2002 6435	20020111
			US 2001-261339P	P 20010112
			US 2001-323764P	P 20010919
			US 2002-46681	A 20020110
			WO 2002-US743	W 20020111
EP 1358184	A1	20031105	EP 2002-717325	20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2001-261339P	P 20010112
			US 2001-323764P	P 20010919
			US 2002-46681	A 20020110
			WO 2002-US743	W 20020111
EE 200300324	A	20031215	EE 2003-324	20020111
			US 2001-261339P	P 20010112
			US 2001-323764P	P 20010919
			US 2002-46681	A 20020110
			WO 2002-US743	W 20020111
NO 2003003181	A	20030911	NO 2003-3181	20030711
			US 2001 261339P	P 20010112
			US 2001-323764P	P 20010919
			US 2002-46681	A 20020110
			WO 2002-US743	W 20020111

PATENT FAMILY INFORMATION:
FAN 2003:950057

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PI	US 2003225106	A1	20031204	US 2002-197974	20020717
				US 2001-261339P P	20010112
				US 2001-323764P P	20010919
				US 2002-46681 A2	20020110
	US 2003125339	A1	20030703	US 2002-46681	20020110
				US 2001-261339P P	20010112
				US 2001-323764P P	20010919
	WO 2004007458	A1	20040122	WO 2003-US22417	20030715

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002-197974 A 20020717

OS MARPAT 137:201332

IT **453561-07-4P 453561-08-5P 453561-23-4P**
453561-81-4P, 2-[(2,3-Dihydrobenzofuran-5-ylmethyl)amino]-N-[3,3-dimethyl-1-(piperidin 4-ylmethyl)-2,3-dihydro-1H-indol-6-yl]nicotinamide
453563-25-2P 453563-26-3P 453563-27-4P
453563-28-5P 453563-33-2P 453563-34-3P
453563-35-4P 453563-36-5P 453563-84-3P
453564-40-4P 453564-41-5P 453564-42-6P
453564-46-0P 453564-69-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclylalkylamine derivs. as remedies for angiogenesis mediated diseases)

RN 453561-07-4 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453561-08-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(3,4-dichlorophenyl)-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453561-23-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(4 chlorophenyl)-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453561-81-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[2,3-dihydro-3,3-dimethyl-1-(4-piperidinylmethyl)-1H-indol-6-yl]- (9CI) (CA INDEX NAME)



RN 453563-25-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(6-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453563-26-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(6-quinolinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 453563-27-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 453563-28-5 CAPLUS
CN 3-Pyridinecarboxamide,
2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 453563-33-2 CAPLUS
CN 3-Pyridinecarboxamide,
2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 453563-34-3 CAPLUS
CN 3-Pyridinecarboxamide,
N-(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 453563-35-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[6-[[[2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 453563-36-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[2,3-dihydro-3,3-dimethyl-1-[(1-methyl-4-piperidinyl)methyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453563-84-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[(2,3-dihydro-6-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 453564-40-4 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-[[[2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-3,4-dihydro-4,4-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453564-41-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 453564-42-6 CAPLUS
CN 3-Pyridinecarboxamide,
2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-[(2S)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 453564-46-0 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[(5-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 453564-69-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(7-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I



II

AB Title compds. [I; A1, A2 independently = C, N; A = 5-, or 6-membered partially saturated heterocyclyl, 5-, or 6-membered heterocyclyl, 9-, or 10-membered fused partially saturated heterocyclyl, 9-, 10-, or 11-membered fused heteroaryl, naphthyl, 4-, 5-, or 6-membered cycloalkenyl; X = C:ZNR3, C:ZN(R3)R4; Z = O, S; Y = N:CH, NR5(CR6R7), R8N(R5)(CR6R7), NR5(CR6R7)R8; R = 5-, or 6-membered (un)substituted heterocyclyl, 9-, 10-, 11-membered heterocyclyl; R1 = 6-10-membered (un)substituted aryl, 5-, or 6-membered (un)substituted heterocyclyl, 9-11 membered (un)substituted fused heterocyclyl, cycloalkyl, cycloalkenyl; R2 = H, halo, oxo, SH, COOH, CHO; R3 = H, alkyl, 5-, or 6-membered heterocyclyl; R4 = alkylenyl, alkenylenyl, alkynylenyl; R5 = H, alkyl, aralkyl, C6H5; R6, R7 independently = H, halo, CN, alkyl; R6R7 = cycloalkyl; R8 = alkylenyl; etc.] are prepared and are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compds. as well as to intermediates useful in such processes. Thus, the title compound II was prepared from Me 3-amino-2-thiophenecarboxylate, 4-chloroaniline, and 4-pyridine carboxaldehyde via coupling reaction.

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:637637 CAPLUS
DN 137:185325
TI Preparation of acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenylamines as stimulators of endothelial NO-synthase transcription
IN Strobel, Hartmut; Wohlfart, Paulus
PA Aventis Pharma Deutschland GmbH, Germany
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064546	A2	20020822	WO 2002-EP1449	20020212
	WO 2002064546	A3	20021107		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				EP 2001-102853 A	20010213
	EE 200300370	A	20031015	EE 2003-370	20020212
				EP 2001-102853 A	20010213
				WO 2002-EP1449 W	20020212
	EP 1362027	A2	20031119	EP 2002-722069	20020212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				EP 2001-102853 A	20010213
				WO 2002-EP1449 W	20020212
	JP 2004518720	T2	20040624	JP 2002-564479	20020212
				EP 2001-102853 A	20010213
				WO 2002-EP1449 W	20020212
	BR 2002007197	A	20040706	BR 2002-7197	20020212
				EP 2001-102853 A	20010213
				WO 2002-EP1449 W	20020212
	US 2003008915	A1	20030109	US 2002-73203	20020213
	US 6759412	B2	20040706		
				EP 2001-102853 A	20010213
	NO 2003003566	A	20031013	NO 2003-3566	20030812
				EP 2001-102853 A	20010213
				WO 2002-EP1449 W	20020212

OS MARPAT 137:185325
IT **450368-07-7P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(eNOS transcription stimulator; preparation of acylated tetrahydrobenzocycloheptenylamines as stimulators of endothelial NO-synthase transcription)
RN 450368-07-7 CAPLUS
CN 2-Pyridinecarboxamide, 6-chloro-3-[(phenylmethyl)amino]-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



GI



I II

AB Title compds. I (wherein R1 and R4 = independently H, (pseudo)halo, CF3, NO2, or (un)substituted alkyl, alkenyl, alkynyl, Ph, heteroaryl, amino, alkoxy, sulfamoyl, etc.; R2 and R3 = independently H, (pseudo)halo, OH, PhO, alkoxy, CF3, CN, NO2, or (un)substituted alkyl, amino, acylamino, etc.; A = CH2, CHOH, or CH(alkyl); B, C, and D = independently CH2 or CH(alkyl); R5 = (un)substituted (hetero)aryl; and stereoisomers, mixts., or pharmaceutically acceptable salts thereof] were prepared as stimulators of endothelial NO-synthase (eNOS) transcription, which has a vasodilating effect and inhibits the aggregation of platelets, the adhesion of leukocytes to the endothelium, and the proliferation of intimal smooth muscle cells. For example, amidation of 4-fluorobenzoic acid chloride with 6,7,8,9-tetrahydro-5H-benzocyclohepten-6-ylamine in the presence of TEA in dioxane afforded II. The latter activated eNOS transcription in primary human umbilical vein cord endothelial cells (HUVEC) with EC50 of 0.02 μM. I are useful for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchial, chronic renal failure, cirrhosis of the liver, osteoporosis, or restricted memory performance or for a restricted ability to learn, or the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives (no data).

L3 ANSWER 16 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:603273 CAPLUS
DN 138:122629
TI Synthesis of 1,4-benzodiazepine-2,5-dione derivatives
AU Ho, Tong-Ing; Chen, Wen-Shiong; Hsu, Chi-Wei; Tsai, Yeun-Min; Fang, Jim-Min
CS Dep. of Chem., National Taiwan Univ., Taipei, Taiwan
SO Heterocycles (2002), 57(8), 1501-1506
CODEN: HTCYAM; ISSN: 0385-5414
PB Japan Institute of Heterocyclic Chemistry
DT Journal
LA English
OS CASREACT 138:122629
IT **489446-50-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2,5-dioxo-1H-1,4-benzodiazepine-3-carboxylate derivs.)
RN 489446-50-6 CAPLUS
CN Benzamide, N-(4-methoxyphenyl)-2-[[(3-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



AB A synthesis of a series of 1,4-benzodiazepine-2,5-dione derivs. with a carboxy group at the 3-position is realized in good yields by using Me malonylchloride as a key reagent and intramol. nucleophilic substitution as ring closure reaction. The synthesis of 4-(4-Methoxyphenyl)-1-[(3-methoxyphenyl)methyl]-2,5-dioxo-1H-1,4-benzodiazepine-3-carboxylic acid Me ester was described.
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:539663 CAPLUS
DN 137:109210
TI Preparation of substituted arylamine derivatives and methods of use as antitumor agents
IN Chen, Guoqing; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Huang, Qi; Kim, Joseph L.; Kim, Tae-Seong; Patel, Vinod F.; Smith, Leon M.; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang
PA Amgen Inc., USA
SO PCT Int. Appl., 253 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002055501	A2	20020718	WO 2002-US742	20020111
WO 2002055501	A3	20021219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
			US 2002-46526	A 20020110
US 2002147198	A1	20021010	US 2002-46526	20020110
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
EP 1358161	A2	20031105	EP 2002-717324	20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
			US 2002-46526	A 20020110
			WO 2002 US742	W 20020111

PATENT FAMILY INFORMATION:
FAN 2003:551181

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003134836	A1	20030717	US 2002-197960	20020717
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
			US 2002-46526	A2 20020110
US 2002147198	A1	20021010	US 2002-46526	20020110
			US 2001-261360P	P 20010112
			US 2001-323686P	P 20010919
WO 2004007457	A2	20040122	WO 2003-US22276	20030715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2002-197960 A 20020717
OS MARPAT 137:109210
IT **442847-21-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted aminopyridines as antitumor agents)
RN 442847-21-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl 1-(4 piperidinylmethyl)-1H indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



IT **442845-77-4P 442846-13-1P 442846-17-5P 442846-22-2P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation of substituted aminopyridines as antitumor agents)
RN 442845-77-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-13-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-17-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[6-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro-3,3-dimethyl-1H-indol-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-22-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-acetyl-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[(4-fluorophenyl)methyl]amino] (9CI) (CA INDEX NAME)



IT 442845-71-8P 442845-72-9P 442845-73-0P
442845-78-5P 442845-79-6P 442845-80-9P
442845-81-0P 442845-82-1P 442845-83-2P
442845-84-3P 442845-85-4P 442845-86-5P
442845-87-6P 442845-88-7P 442845-89-8P
442845-90-1P 442845-91-2P 442845-92-3P
442845-93-4P 442845-94-5P 442845-95-6P

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

442845-96-7P 442845-97-8P 442845-99-0P
442846-00-6P 442846-01-7P 442846-02-8P
442846-03-9P 442846-04-0P 442846-05-1P
442846-06-2P 442846-07-3P 442846-08-4P
442846-09-5P 442846-10-8P 442846-11-9P
442846-12-0P 442846-14-2P 442846-15-3P
442846-16-4P 442846-18-6P 442846-19-7P
442846-20-0P 442846-21-1P 442846-23-3P
442846-24-4P 442846-25-5P 442846-26-6P
442846-27-7P 442846-28-8P 442846-29-9P
442846-30-2P 442846-31-3P 442846-32-4P
442846-33-5P 442846-34-6P 442846-35-7P
442846-36-8P 442846-38-0P 442846-39-1P
442846-40-4P 442846-42-6P 442846-44-8P
442846-46-0P 442846-48-2P 442846-50-6P
442846-52-8P 442846-53-9P 442847-23-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of substituted aminopyridines as antitumor agents)

RN 442845-71-8 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 442845-72-9 CAPLUS
CN 2-Pyridinecarboxamide, N-(4-chlorophenyl)-3-[[(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-73-0 CAPLUS
CN 2-Pyridinecarboxamide, N-(3-fluoro-4-methylphenyl)-3-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-78-5 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-79-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(4-fluorophenyl)methyl]amino] N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442845-80-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-81-0 CAPLUS

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, 2-[[(2-bromophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 442845-82-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[[[4-(trifluoromethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-83-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-difluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-84-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[(4-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-85-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[[(2-cyanophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-86-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(2-methylpropyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-87-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442845-88-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-methoxyphenyl)methyl]amino]-N-[4-(1-

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-89-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-aminophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-90-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 442845-91-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-92-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl] (9CI) (CA INDEX NAME)



RN 442845-93-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442845-97-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-99-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3,4-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl] (9CI) (CA INDEX NAME)



L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 442845-94-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-95-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442845-96-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-chlorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 442846-00-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-01-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2-fluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-02-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,6-difluorophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-03-9 CAPLUS

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, 2-[[(3-bromophenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-04-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-05-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[3-(dimethylamino)propyl]-5-(trifluoromethyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-06-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-07-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-08-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-bromo-2-fluorophenyl)-2-[[[3-[3-(dimethylamino)propyl]-4-fluorophenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-09-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-10-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[4-fluoro-3-[3-(4-morpholinyl)-1-propynyl]phenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-11-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(1,3-benzodioxol-5-ylmethyl)amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-12-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-14-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[2-(1,1-dimethylethyl)-5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-15-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-(1-methyl-4-piperidinyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-16-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-[(dimethylamino)acetyl]-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-18-6 CAPLUS
CN Carbamic acid, [2-[6-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2,3-dihydro 3,3-dimethyl-1H-indol-1-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-19-7 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-3,4-dihydro-4,4-dimethyl , 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-20-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[3-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-21-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[2-(1,1-dimethylethyl)-5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-23-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-24-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-27-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-28-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-25-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[(2R)-2-pyrrolidinylmethoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-26-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(4-piperidinylmethoxy)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-29-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-(aminoacetyl)-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-30-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1-(4-piperidinyl)-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-31-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-(4-piperidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846-32-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-6-yl)-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-35-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-[1-methyl-1-(1-methyl-4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 442846-36-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-2-oxo-7-quinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-33-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 442846-34-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-[(1-methyl-4-piperidinyl)methyl]-1H-indol-6-yl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-38-0 CAPLUS
CN 3-Pyridinecarboxamide, N-5-benzofuranyl-2-[[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-39-1 CAPLUS
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-2-[[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 442846-40-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3,4-difluorophenyl)methyl]amino]-N-[4-(1,1-

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 442846-42-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[[2-(1-piperidinyl)ethyl]amino]phenyl]-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 442846-44-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-[(1-piperidinylmethyl)amino]phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-46-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[5-[[[2-[[(4-fluorophenyl)methyl]amino]-3-pyridinyl]carbonyl]amino]-2-(pentafluoroethyl)phenoxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 442846-48-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[4-(pentafluoroethyl)-3-(2-pyrrolidinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-50-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-(2-pyrrolidinylmethoxy)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442846 52-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-(2-pyrrolidinylmethoxy)phenyl]-2-[[(4-fluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 442846-53-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(4-fluorophenyl)methyl]amino]-N-[3-[(1-methyl-2-pyrrolidinyl)methoxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 442847-23-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(3-fluorophenyl)methyl]amino]-N-(4-phenoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 442845 77-4
CMF C25 H20 F N3 O2

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 76 05-1
CMF C2 H F3 O2

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [B1 and B2 independently equal C or N, wherein B1B2 form part of 5-6 membered heteroaryl ring A; R1 = one or more substituents selected from H, halo, oxo, (un)substituted cycloalkyl, phenylalkyl, etc.; R2 = (un)substituted cycloalkyl, cycloalkenyl, 6-10 membered aryl or 5-6 membered heterocyclyl, etc.; R3 = (un)substituted aryl; R4 = H, alkyl, (un)substituted Ph or aralkyl; X1 = bond, alkylenyl, alkenylenyl and alkynylenyl, where one of the CH2 groups may be substituted with O or NH, wherein X1 is optionally substituted with OH; X2 = (un)substituted N containing linker, e.g., -NHCH2], and there pharmaceutically acceptable derivs., are prepared and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. Thus, II was prepared via arylation of 1-dimethylamino-2-propyne with 3-bromo-5-trifluoromethylaniline, hydrogenation, amidation with 2-chloropyridine-3-carbonyl chloride and chloro-substitution with 4-fluorobenzylamine. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

L3 ANSWER 18 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:171853 CAPLUS
DN 136:232201
TI Preparation of cyclic amine derivatives as CCR3 antagonists
IN Morihira, Koichiro; Inami, Hiroshi; Kubota, Hirokazu; Yokoyama, Kazuhiro; Morokata, Tatsuaki; Takeuchi, Makoto; Takahashi, Toshiya; Kaneko, Masayuki; Imaoka, Takayuki; Torii, Yuichi; Iura, Yosuke
PA Yamanouchi Pharmaceutical Co., Ltd., Japan; Toray Industries, Inc.
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002018335	A1	20020307	WO 2001-JP7321	20010827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			JP 2000-257451	A 20000828
AU 2001080187	A5	20020313	AU 2001-80187	20010827
			JP 2000-257451	A 20000828
			WO 2001-JP7321	W 20010827

OS MARPAT 136:232201
IT 403477-79-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic amine derivs. as CCR3 antagonists)
RN 403477-79-2 CAPLUS
CN Benzamide, 2-[[(2-chlorophenyl)methyl]amino]-N-[8-[(6-fluoro-2-naphthalenyl)methyl] 8-azabicyclo[3.2.1]oct 3-yl]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 18 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB The title compds. I [ring A = (un)substituted heterocyclic ring, etc.; X = bond, O, CO, etc.; ring B = Q1, etc.; ring V3 = hydrocarbon ring, etc.; W = CH, N; Y = CO, etc.; R21, R22 = H, halo, etc.; T1 = (CH2)n; n = 0 - 2; ring D = (un)substituted aryl, etc.] are prepared In an in vitro test (for CCR3 antagonism) using cells, compds. of this invention showed IC50 values of 0.001 μM to 0.45 μM.
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:11104 CAPLUS
DN 136:69743
TI Preparation of pyridyl benzamides and related compounds as Factor Xa inhibitors.
IN Zhu, Bing-Yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick A.; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
PA USA
SO U.S. Pat. Appl. Publ., 259 pp., Cont.-in-part of U.S. Ser. No. 663,420.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002002183	A1	20020103	US 2001-794225	20010228
	US 6376515	B2	20020423		
				US 2000-185746P P	20000229
				US 2000-663420 A2	20000915
	US 2003162690	A1	20030828	US 2002-126976	20020422
				US 2000-185746P P	20000229
				US 2000-663420 A2	20000915
				US 2001-794225 A1	20010228
	US 2004097561	A1	20040520	US 2003-687334	20031015
				US 2000-185746P P	20000229
				US 2000-663420 A2	20000915
				US 2001-794225 A1	20010228
				US 2002-126976 A1	20020422

PATENT FAMILY INFORMATION:
FAN 2001:208239

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019788	A2	20010322	WO 2000-US25196	20000915
	WO 2001019788	A3	20010809		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-154332P P	19990917
				US 2000-185746P P	20000229
	AU 2000074867	A5	20010417	AU 2000-74867	20000915
				US 1999-154332P P	19990917
				US 2000-185746P P	20000229
				WO 2000-US25196 W	20000915
	EP 1216228	A2	20020626	EP 2000-963452	20000915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
				US 1999-154332P P	19990917
				US 2000-185746P P	20000229
				WO 2000-US25196 W	20000915

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	BR 2000014076	A	20021015	BR 2000-14076	20000915
				US 1999-154332P P	19990917
				US 2000-185746P P	20000229
				WO 2000-US25196 W	20000915
	JP 2003509406	T2	20030311	JP 2001-523368	20000915
				US 1999-154332P P	19990917
				US 2000-185746P P	20000229
				WO 2000-US25196 W	20000915
	NO 2002001229	A	20020521	NO 2002-1229	20020312
				US 1999-154332P P	19990917
				US 2000-185746P P	20000229
				WO 2000-US25196 W	20000915

FAN 2001:208248

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019798	A2	20010322	WO 2000-US25195	20000915
	WO 2001019798	A3	20011025		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-154332P P	19990917
	AU 2000074866	A5	20010417	AU 2000-74866	20000915
				US 1999-154332P P	19990917
				WO 2000-US25195 W	20000915
	EP 1216231	A2	20020626	EP 2000-963451	20000915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
				US 1999-154332P P	19990917
				WO 2000-US25195 W	20000915
	BR 2000014078	A	20021231	BR 2000-14078	20000915
				US 1999-154332P P	19990917
				WO 2000-US25195 W	20000915
	TR 200201413	T2	20030221	TR 2002-200201413	20000915
				US 1999-154332P P	19990917
	JP 2003509412	T2	20030311	JP 2001-523378	20000915
				US 1999-154332P P	19990917
				WO 2000-US25195 W	20000915
	NZ 517828	A	20031031	NZ 2000-517828	20000915
				US 1999-154332P P	19990917
				WO 2000-US25195 W	20000915
	NO 2002001230	A	20020521	NO 2002-1230	20020312
				US 1999-154332P P	19990917
				WO 2000-US25195 W	20000915

FAN 2001:661391

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064642	A2	20010907	WO 2001-US6247	20010228
	WO 2001064642	A3	20020502		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915

FAN 2001:661392

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064643	A2	20010907	WO 2001-US6255	20010228
	WO 2001064643	A3	20020404		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915
	EP 1259485	A2	20021127	EP 2001-918257	20010228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915
				WO 2001-US6255	W 20010228

FAN 2002:522631

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002091116	A1	20020711	US 2001-794214	20010228
	US 6632815	B2	20031014		
				US 1999-154332P	P 19990917
				US 2000-662807	A2 20000915
	US 6720317	B1	20040413	US 2000-662807	20000915
				US 1999-154332P	P 19990917
	US 6686368	B1	20040203	US 2003-387927	20030312
				US 1999-154332P	P 19990917
				US 2000-662807	A3 20000915
	US 2004116399	A1	20040617	US 2003-600695	20030620
				US 1999-154332P	P 19990917
				US 2000-662807	A2 20000915
				US 2001 794214	A1 20010228

OS MARPAT 136:69743
IT **358659-61-7P 358659-62-8P 358659-63-9P 358659-64-0P 358659-65-1P 358659-66-2P 358659-67-3P 358659-68-4P 358659-69-5P 358659-74-2P 358659-75-3P 358659-76-4P 358659-77-5P 358659-78-6P 358659-79-7P 358659-80-0P 358659-81-1P 358659-82-2P 358659-83-3P 358659-84-4P 358659-85-5P 358659-87-7P 358659-88-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridyl benzamides and related compds. as Factor Xa inhibitors)

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 358659-61-7 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-62-8 CAPLUS
CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)





RN 358659-63-9 CAPLUS
CN Benzamide,
N-(5-chloro-2-pyridinyl)-2-[[[4-(imino(methylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-64-0 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-65-1 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-66-2 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-67-3 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-68-4 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-5-chloro N (5-chloro 2-pyridinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-69-5 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-74-2 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-75-3 CAPLUS
CN Benzamide, N-(5 chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-76-4 CAPLUS

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(4-methyl-1-piperazinyl)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-77-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(hexahydro-1H-azepin-1-yl)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-78-6 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5 fluoro- (9CI) (CA INDEX NAME)



RN 358659-79-7 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-80-0 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-fluoro- (9CI) (CA INDEX NAME)



RN 358659-81-1 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-82-2 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-87-7 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-88-8 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-83-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-84-4 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-methoxy (9CI) (CA INDEX NAME)



RN 358659-85-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R2C(:NRJ), (substituted) Ph, naphthyl, heterocyclyl, etc.; R1-R3 = H, OR5, NR5R6, alkyl, alkenyl, etc.;
R1R2 or R2R3 = atoms to form (substituted) cycloalkyl, heterocyclyl; R5, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) alkylphenyl, alkylnaphthyl; R5R6 = atoms to form a 3-8 membered (substituted) ring; Q = bond, CH2, CO, O, S, SO, SO2, NR7, SO2NR7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, (substituted) alkylphenyl, alkylnaphthyl; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, O, S, SO, SO2, alkylcarbonyl, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, 3-8 membered (fused) (aromatic) heterocyclyl; J = bond, NR9CO, O, S, SO, SO2, CH2, NR9SO2, etc.; X = (substituted) Ph, naphthyl, (fused) heteroaryl], were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-aminophenylcarboxamide (preparation given), 4-cyanobenzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-cyanophenylcarbonyl)amino]phenylcarboxamide. The latter in MeOH at 0° was saturated with HCl and stirred overnight followed by solvent evaporation The residue was refluxed 2 h with NH4OAc in MeOH to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-amidinophenylcarbonyl)amino]phenylcarboxamide.

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:661392 CAPLUS
DN 135:226888
TI Preparation of pyridyl benzamides and related compounds as Factor Xa inhibitors.
IN Zhu, Bing-yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
PA Cor Therapeutics, Inc., USA
SO PCT Int. Appl., 322 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064643	A2	20010907	WO 2001-US6255	20010228
	WO 2001064643	A3	20020404		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915
	EP 1259485	A2	20021127	EP 2001-918257	20010228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915
				WO 2001-US6255	W 20010228

PATENT FAMILY INFORMATION:
FAN 2001:208239

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019788	A2	20010322	WO 2000-US25196	20000915
	WO 2001019788	A3	20010809		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
	AU 2000074867	A5	20010417	AU 2000-74867	20000915
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	EP 1216228	A2	20020626	EP 2000-963452	20000915

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	BR 2000014076	A	20021015	BR 2000-14076	20000915
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	JP 2003509406	T2	20030311	JP 2001-523368	20000915
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	NO 2002001229	A	20020521	NO 2002-1229	20020312
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915

FAN 2001:208248

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019798	A2	20010322	WO 2000-US25195	20000915
	WO 2001019798	A3	20011025		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-154332P	P 19990917
	AU 2000074866	A5	20010417	AU 2000-74866	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	EP 1216231	A2	20020626	EP 2000-963451	20000915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	BR 2000014078	A	20021231	BR 2000-14078	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	TR 200201413	T2	20030221	TR 2002-200201413	20000915
				US 1999-154332P	P 19990917
	JP 2003509412	T2	20030311	JP 2001-523378	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	NZ 517828	A	20031031	NZ 2000-517828	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	NO 2002001230	A	20020521	NO 2002-1230	20020312
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915

FAN 2001:661391

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064642	A2	20010907	WO 2001-US6247	20010228
	WO 2001064642	A3	20020502		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915

FAN 2002:11104

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002002183	A1	20020103	US 2001-794225	20010228
	US 6376515	B2	20020423		
				US 2000-185746P	P 20000229
				US 2000-663420	A2 20000915
	US 2003162690	A1	20030828	US 2002-126976	20020422
				US 2000-185746P	P 20000229
				US 2000-663420	A2 20000915
				US 2001-794225	A1 20010228
	US 2004097561	A1	20040520	US 2003-687334	20031015
				US 2000-185746P	P 20000229
				US 2000-663420	A2 20000915
				US 2001-794225	A1 20010228
				US 2002-126976	A1 20020422

FAN 2002:522631

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002091116	A1	20020711	US 2001-794214	20010228
	US 6632815	B2	20031014		
				US 1999-154332P	P 19990917
				US 2000-662807	A2 20000915
	US 6720317	B1	20040413	US 2000-662807	20000915
				US 1999-154332P	P 19990917
	US 6686368	B1	20040203	US 2003-387927	20030312
				US 1999-154332P	P 19990917
				US 2000-662807	A3 20000915
	US 2004116399	A1	20040617	US 2003-600695	20030620
				US 1999-154332P	P 19990917
				US 2000-662807	A2 20000915
				US 2001-794214	A1 20010228

OS MARPAT 135:226888
IT **358659-61-7P 358659-62-8P 358659-63-9P 358659-64-0P 358659-65-1P 358659-66-2P 358659-67-3P 358659-68-4P 358659-69-5P 358659-74-2P 358659-75-3P 358659-76-4P 358659-77-5P 358659-78-6P 358659-79-7P 358659-80-0P 358659-81-1P 358659-82-2P 358659-83-3P 358659-84-4P 358659-85-5P 358659-87-7P 358659-88-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridyl benzamides and related compds. as Factor Xa inhibitors)
RN 358659-61-7 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-62-8 CAPLUS
CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 358659-63-9 CAPLUS
CN Benzamide,
N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(methylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-64-0 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-65-1 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-69-5 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-74-2 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-75-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-76-4 CAPLUS

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-66-2 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-67-3 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-68-4 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino(4-methyl-1-piperazinyl)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-77-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(hexahydro-1H-azepin-1-yl)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-78-6 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)



RN 358659-79-7 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-80-0 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-fluoro- (9CI) (CA INDEX NAME)



RN 358659-81-1 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-82-2 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-87-7 CAPLUS
CN Benzamide, N-(5-chloro-2 pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-88-8 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-83-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-{[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino}-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-84-4 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-85-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R2C(:NR3), (substituted) Ph, naphthyl, heterocyclyl, etc.; R1-R3 = H, OR5, NR5R6, alkyl, alkenyl, etc.;
R1R2 or R2R3 = atoms to form (substituted) cycloalkyl, heterocyclyl; R5, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) alkylphenyl, alkylnaphthyl; R5R6 = atoms to form a 3-8 membered (substituted) ring; Q = bond, CH2, CO, O, S, SO, SO2, NR7, SO2NR7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, (substituted) alkylphenyl, alkylnaphthyl; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, O, S, SO, SO2, alkylcarbonyl, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, 3-8 membered (fused) (aromatic) heterocyclyl; J = bond, NR9CO, O, S, SO, SO2, CH2, NR9SO2, etc.; X = (substituted) Ph, naphthyl, (fused) heteroaryl], were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl)-2-aminophenylcarboxamide (preparation given), 4-cyanobenzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-cyanophenylcarbonyl)amino]phenylcarboxamide. The latter in MeOH at 0° was saturated with HCl and stirred overnight followed by solvent evaporation The residue was refluxed 2 h with NH4OAc in MeOH to give 70% N-(5-bromo-2-pyridinyl)-[2-(4-amidinophenylcarbonyl)amino]phenylcarboxamide.

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:661191 CAPLUS
DN 135:210946
TI Preparation of pyridylamides as Factor Xa inhibitors.
IN Zhu, Bing-yan; Zhang, Penglie; Wang, Lingyan; Huang, Wenrong; Goldman, Erick; Li, Wenhao; Zuckett, Jingmei; Song, Yonghong; Scarborough, Robert
PA Cor Therapeutics, Inc., USA
SO PCT Int. Appl., 306 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064642	A2	20010907	WO 2001-US6247	20010228
	WO 2001064642	A3	20020502		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915

PATENT FAMILY INFORMATION:

FAN 2001:208239

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019788	A2	20010322	WO 2000-US25196	20000915
	WO 2001019788	A3	20010809		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
	AU 2000074867	A5	20010417	AU 2000-74867	20000915
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	EP 1216228	A2	20020626	EP 2000-963452	20000915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	BR 2000014076	A	20021015	BR 2000-14076	20000915
				US 1999-154332P	P 19990917

				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	JP 2003509406	T2	20030311	JP 2001-523368	20000915
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915
	NO 2002001229	A	20020521	NO 2002-1229	20020312
				US 1999-154332P	P 19990917
				US 2000-185746P	P 20000229
				WO 2000-US25196	W 20000915

FAN 2001:208248

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019798	A2	20010322	WO 2000-US25195	20000915
	WO 2001019798	A3	20011025		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-154332P	P 19990917
	AU 2000074866	A5	20010417	AU 2000-74866	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	EP 1216231	A2	20020626	EP 2000-963451	20000915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	BR 2000014078	A	20021231	BR 2000-14078	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	TR 200201413	T2	20030221	TR 2002-200201413	20000915
				US 1999-154332P	P 19990917
	JP 2003509412	T2	20030311	JP 2001-523378	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	NZ 517828	A	20031031	NZ 2000-517828	20000915
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915
	NO 2002001230	A	20020521	NO 2002-1230	20020312
				US 1999-154332P	P 19990917
				WO 2000-US25195	W 20000915

FAN 2001:661192

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064643	A2	20010907	WO 2001-US6255	20010228
	WO 2001064643	A3	20020404		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				

				LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
				RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
				US 2000-185746P	P 20000229
				US 2000 663420	A 20000915
	EP 1259485	A2	20021127	EP 2001-918257	20010228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-185746P	P 20000229
				US 2000-663420	A 20000915
				WO 2001-US6255	W 20010228

FAN 2002:11104

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002002183	A1	20020103	US 2001-794225	20010228
	US 6376515	B2	20020423		
				US 2000-185746P	P 20000229
				US 2000-663420	A2 20000915
	US 2003162690	A1	20030828	US 2002 126976	20020422
				US 2000-185746P	P 20000229
				US 2000-663420	A2 20000915
				US 2001 794225	A1 20010228
	US 2004097561	A1	20040520	US 2003-687334	20031015
				US 2000-185746P	P 20000229
				US 2000-663420	A2 20000915
				US 2001-794225	A1 20010228
				US 2002-126976	A1 20020422

FAN 2002:522631

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002091116	A1	20020711	US 2001-794214	20010228
	US 6632815	B2	20031014		
				US 1999-154332P	P 19990917
				US 2000-662807	A2 20000915
	US 6720317	B1	20040413	US 2000-662807	20000915
				US 1999-154332P	P 19990917
	US 6686368	B1	20040203	US 2003-387927	20030312
				US 1999-154332P	P 19990917
				US 2000-662807	A3 20000915
	US 2004116399	A1	20040617	US 2003-600695	20030620
				US 1999-154332P	P 19990917
				US 2000-662807	A2 20000915
				US 2001-794214	A1 20010228

OS MARPAT 135:210946
IT **358659-61-7P 358659-62-8P 358659-63-9P 358659-64-0P 358659-65-1P 358659-66-2P 358659-67-3P 358659-68-4P 358659-69-5P 358659-74-2P 358659-75-3P 358659-76-4P 358659-77-5P 358659-78-6P 358659-79-7P 358659-80-0P 358659-81-1P 358659-82-2P 358659-83-3P 358659-84-4P 358659-85-5P 358659-87-7P 358659-88-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN 358659-61-7 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(imino 1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-62-8 CAPLUS
CN Benzamide, 2-[[[4-(aminoiminomethyl)phenyl]methyl]amino]-N-(5-chloro 2-pyridinyl) (9CI) (CA INDEX NAME)





RN 358659-63-9 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[imino(methylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-64-0 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-65-1 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-4-morpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-66-2 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-67-3 CAPLUS
CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-68-4 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-5-chloro-N-(5 chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-69-5 CAPLUS
CN Benzamide, 5-chloro-N (5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-74-2 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl) 2-[[[4-(imino-4-thiomorpholinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-75-3 CAPLUS
CN Benzamide, N-(5-chloro-2 pyridinyl)-2-[[[4-(imino-1-piperazinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-76-4 CAPLUS

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino(4-methyl 1-piperazinyl)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-77-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(hexahydro-1H-azepin-1-yl)iminomethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-78-6 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)



RN 358659-79-7 CAPLUS
CN Benzamide, N-(5-chloro 2-pyridinyl)-2-[[[4 (4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-fluoro- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-80-0 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-fluoro- (9CI) (CA INDEX NAME)



RN 358659-81-1 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 358659-82-2 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-[(dimethylamino)iminomethyl]phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-83-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-84-4 CAPLUS
CN Benzamide, 2-[[[4-(1-azetidinyliminomethyl)phenyl]methyl]amino]-N-(5-chloro-2-pyridinyl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-85-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-piperidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 358659-87-7 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]-5-methoxy- (9CI) (CA INDEX NAME)



RN 358659-88-8 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-5-fluoro-2-[[[4-(imino-1-pyrrolidinylmethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB AQDEGJX [A = alkyl, cycloalkyl, NR1R2, NR1R1C(:NR3), (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl, etc.; R1-R3 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (alkyl)aryl, (alkyl)heteroaryl, etc.; R1R2 or R2R3 = atoms to form a 3-8 membered (substituted) (heterocyclic) ring; Q = bond, CH2, CO, O, NR7, etc.; R7 = H, alkyl, (alkyl)aryl, (alkyl)heteroaryl, etc.; D = bond, (substituted) Ph, naphthyl, mono- or bicyclic heterocyclyl; E = bond, alkyl, S, SO, SO2, alkoxy, etc.; G = (substituted) alkenyl, cycloalkenyl, phenylene, heterocyclyl, fused cyclic system; J = bond, NR9CO, O, S, SO, SO2, SO2NR9, CH2, NR9, etc.; R9 = H, alkyl, (alkyl)aryl, etc.; X = (substituted) Ph, naphthyl, heteroaryl, fused bicyclyl], were prepared as antithrombotics (no data). Thus, N-(5-bromo-2-pyridinyl) 2-aminophenylcarboxamide (preparation given), 4 [(2-tert-butylaminosulfonyl)phenyl]benzoyl chloride, and pyridine were stirred overnight in CH2Cl2 to give 85% N-(5-bromo-2-pyridinyl)-[2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino]phenylcarboxamide.

L3 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:565010 CAPLUS

DN 135:137407

TI Preparation of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors

IN Manley, Paul William; Bold, Guido

PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.

SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001055114	A1	20010802	WO 2001-EP835	20010125
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				GB 2000-1930 A	20000127
	AU 2001028499	A5	20010807	AU 2001-28499	20010125
	AU 771626	B2	20040401		
				GB 2000-1930 A	20000127
				WO 2001-EP835 W	20010125
	BR 2001007805	A	20021022	BR 2001-7805	20010125
				GB 2000-1930 A	20000127
				WO 2001-EP835 W	20010125
	EP 1259487	A1	20021127	EP 2001-946854	20010125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				GB 2000-1930 A	20000127
				WO 2001-EP835 W	20010125
	JP 2003520853	T2	20030708	JP 2001-555056	20010125
				GB 2000-1930 A	20000127
				WO 2001-EP835 W	20010125
	NZ 520005	A	20040227	NZ 2001-520005	20010125
				GB 2000-1930 A	20000127
				WO 2001-EP835 W	20010125
	NO 2002003218	A	20020916	NO 2002-3218	20020702
				GB 2000-1930 A	20000127
				WO 2001-EP835 W	20010125
	US 2003032656	A1	20030213	US 2002-181005	20020711
	US 6624174	B2	20030923		
				GB 2000-1930 A	20000127
				WO 2001 EP835 W	20010125
	ZA 2002005988	A	20030728	ZA 2002-5988	20020726
				GB 2000-1930 A	20000127

OS MARPAT 135:137407

IT **62636-33-3P 352227-86-2P 352227-92-0P 352228-00-3P**

L3 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 352228 00 3 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(4-hydroxyphenyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; n = 1-6; W = O, S; R1, R3 = H, alkyl, acyl; R2 = (un)substituted cycloalkyl, aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S; R, R' = H, alkyl; X = (un)substituted aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S] and their pharmaceutically acceptable salts, useful for therapy of

L3 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors)

RN 62636-33-3 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl] , monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 352227-86-2 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[3-[(methylamino)carbonyl]phenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 352227-92-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[3-hydroxyphenyl]methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

a disease which responds to an inhibition of the VEGF-receptor tyrosine kinase activity (such as neoplastic disease), were prepd. and formulated. Thus, amidation of 3-aminobenzotrifluoride with 2-chloronicotinoyl chloride followed by reacting 4-pyridineethanamine with the resulting carboxamide afforded I [n = 2; R, R' = H; X = 4-pyridyl; W = O; R1, R3 = H; R2 = 3-(F3C)C6H4].

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:457059 CAPLUS
DN 133:89437
TI Preparation of heteroaryl-substituted aromatic amides as factor Xa inhibitors
IN Beight, Douglas Wade; Craft, Trelia Joyce; Denny, Carl Penman; Franciskovich, Jeffry Bernard; Goodson, Theodore, Jr.; Hall, Steven Edward; Herron, David Kent; Joseph, Sajan Pariyadan; Klimkowski, Valentine Joseph; Masters, John Joseph; Mendel, David; Milot, Guy; Pineiro-Nunez, Marta Maria; Sawyer, Jason Scott; Shuman, Robert Theodore; Smith, Gerald Floyd; Tebbe, Anne Louise; Tinsley, Jennifer Marie; Weir, Leonard Crayton; Wikel, James Howard; Wiley, Michael Robert; Yee, Ying Kwong
PA Eli Lilly and Co., USA; Kyle, Jeffrey, Alan; et al.
SO PCT Int. Appl., 403 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000039118	A1	20000706	WO 1999-US29946	19991215
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 1998-113556P	P 19981223
CA 2361149	AA	20000706	CA 1999-2361149	19991215
			US 1998-113556P	P 19981223
			WO 1999-US29946	W 19991215
EP 1140903	A1	20011010	EP 1999-964279	19991215
EP 1140903	B1	20040804		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
			US 1998-113556P	P 19981223
			WO 1999-US29946	W 19991215
JP 2002533454	T2	20021008	JP 2000-591029	19991215
			US 1998-113556P	P 19981223
			WO 1999-US29946	W 19991215
US 6635657	B1	20031021	US 2001-857751	20010608
			US 1998-113556P	P 19981223
			WO 1999-US29946	W 19991215
US 2004029874	A1	20040212	US 2003-629760	20030729
US 6759414	B2	20040706		
			US 1998-113556P	P 19981223
			WO 1999-US29946	W 19991215
			US 2001-857751	A3 20010608

OS MARPAT 133:89437
IT **280769-65-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L3 ANSWER 23 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroaryl-substituted arom. amides as factor Xa inhibitors)
RN 280769-65-5 CAPLUS
CN Benzamide, 2-[[[4-(acetylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)





GI



AB The title compds. [I; A3-A6, together with the two carbons to which they are attached, complete a substituted benzene in which A3 = CR3, A4 = CR4, A5 = CR5, and A6 = CR6 (wherein R3 = H, Me, MeO, etc.; one of R4 and R5 = H, alkyl, halo, etc.; the other of R4 and R5 = H; R6 = H, Me, F, etc.); L1 = CONH; Q1 = 2-pyridinyl (un)substituted at the 5-position, 3-pyridinyl (un)substituted at the 6-position, 2-pyrimidinyl (un)substituted at the 5-position, etc.; R2 = L2Q2 (L2 = NHCO, NHCH2, OCH2, etc.; Q2 = (un)substituted piperidinyl, piperazinyl, Ph, etc.)] and their pharmaceutically acceptable salts, useful as inhibitors of factor Xa (no data), were prepared and formulated. E.g., a multi-step synthesis of II.HCl was given. In general, compds. I are effective at 0.01-1000 mg/kg/day.
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 24 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:335388 CAPLUS
DN 132:347491
TI Preparation of N-aryl(thio)anthranilic acid amides as VEGF receptor tyrosine kinase inhibitors
IN Altmann, Karl-Heinz; Bold, Guido; Furet, Pascal; Manley, Paul William; Wood, Jeanette Marjorie; Ferrari, Stefano; Hofmann, Francesco; Mestan, Jurgen; Huth, Andreas; Kruger, Martin; Seidelmann, Dieter; Menrad, Andreas; Haberey, Martin; Thierauch, Karl-Heinz
PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Schering Aktiengesellschaft
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000027820	A1	20000518	WO 1999-EP8545	19991108
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			GB 1998-24579	A 19981110
CA 2346898	AA	20000518	CA 1999-2346898	19991108
			GB 1998-24579	A 19981110
			WO 1999-EP8545	W 19991108
BR 9915210	A	20010724	BR 1999-15210	19991108
			GB 1998-24579	A 19981110
			WO 1999-EP8545	W 19991108
TR 200101237	T2	20010821	TR 2001-200101237	19991108
			GB 1998-24579	A 19981110
EP 1129075	A1	20010905	EP 1999-971802	19991108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
			GB 1998-24579	A 19981110
			WO 1999-EP8545	W 19991108
JP 2002529453	T2	20020910	JP 2000-581000	19991108
			GB 1998-24579	A 19981110
			WO 1999-EP8545	W 19991108
AU 758230	B2	20030320	AU 2000-13811	19991108
			GB 1998-24579	A 19981110
			WO 1999-EP8545	W 19991108
NZ 511339	A	20030725	NZ 1999-511339	19991108
			GB 1998-24579	A 19981110
			WO 1999-EP8545	W 19991108
NO 2001001894	A	20010704	NO 2001-1894	20010417
			GB 1998-24579	A 19981110
			WO 1999-EP8545	W 19991108
ZA 2001003290	A	20030123	ZA 2001-3290	20010423
			GB 1998-24579	A 19981110
US 2002019414	A1	20020214	US 2001-850434	20010507
US 6448277	B2	20020910		
			GB 1998-24579	A 19981110
			WO 1999-EP8545	W 19991108

L3 ANSWER 24 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	ZA 2001004673		A	20020909	ZA 2001-4673	20010607
					GB 1998-24579 A	19981110
	US 2003064992		A1	20030403	US 2002-180289	20020626
					GB 1998 24579 A	19981110
					WO 1999-EP8545 W	19991108
					US 2001-850434 A3	20010507

PATENT FAMILY INFORMATION:

FAN 2000:335387

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000027819	A2	20000518	WO 1999-EP8478	19991109
	WO 2000027819	A3	20000817		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				GB 1998-24579 A	19981110
				DE 1999-19910396 A	19990303
	DE 19910396	A1	20000907	DE 1999-19910396	19990303
	DE 19910396	C2	20011213		
	BR 9915553	A	20010814	BR 1999-15553	19991109
				GB 1998-24579 A	19981110
				DE 1999-19910396 A	19990303
				WO 1999-EP8478 W	19991109
	EP 1129074	A2	20010905	EP 1999-953967	19991109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				GB 1998-24579 A	19981110
				DE 1999-19910396 A	19990303
				WO 1999-EP8478 W	19991109
	TR 200101307	T2	20020521	TR 2001-200101307	19991109
				GB 1998-24579 A	19981110
				DE 1999-19910396 A	19990303
	JP 2002529452	T2	20020910	JP 2000-580999	19991109
				GB 1998-24579 A	19981110
				DE 1999-19910396 A	19990303
				WO 1999-EP8478 W	19991109
	EE 200100258	A	20021216	EE 2001-258	19991109
				GB 1998-24579 A	19981110
				DE 1999-19910396 A	19990303
				WO 1999-EP8478 W	19991109
	NZ 511413	A	20040130	NZ 1999-511413	19991109
				GB 1998-24579 A	19981110
				DE 1999-19910396 A	19990303
				WO 1999-EP8478 W	19991109
	AU 771180	B2	20040318	AU 2000-10454	19991109
				GB 1998-24579 A	19981110
				DE 1999-19910396 A	19990303
				WO 1999-EP8478 W	19991109
	NO 2001002245	A	20010710	NO 2001-2245	20010507

L3 ANSWER 24 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

					GB 1998-24579 A	19981110
					DE 1999-19910396 A	19990303
					WO 1999-EP8478 W	19991109
	BG 105588		A	20020430	BG 2001-105588	20010611
					GB 1998-24579 A	19981110
					DE 1999-19910396 A	19990303
					WO 1999-EP8478 W	19991109

OS MARPAT 132:347491

IT **269390-99-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-aryl(thio)anthranilic acid amides as VEGF receptor tyrosine kinase inhibitors)

RN 269390-99-0 CAPLUS

CN Benzamide, 2-[(5-quinolinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI



I

AB Use of title compds. I; W = O, S; X = NR8; Y = CR9R10(CH2)n, SO2; R9, R10 = H, alkyl; n = 0-3; R1 = aryl; R2 = mono- or bicyclic heteroaryl with the exception that R2 cannot = 2-phthalimidyl, and when Y = SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; R3-R6 = H, substituent; R7, R8 = H, alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof, for the

L3 ANSWER 24 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

prepn. of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity is claimed. Thus, a mixt. of 4-pyridinecarboxaldehyde and 2-amino-N-(4-trifluoromethylphenyl)benzamide (prepn. given) in MeOH contg. HOAc was treated with NaBH3CN followed by 16 h stirring to give 2-[(4-pyridyl)methyl]amino-N-[4-(trifluoromethyl)phenyl]benzamide. Tested I inhibited Flt-1 VEGF receptor tyrosine kinase with IC50 = 0.18-0.56 μM.

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:409260 CAPLUS

DN 131:73440

TI Preparation of aromatic amide derivatives as ACC inhibitor

IN Igawa, Hiroshi; Nishimura, Masato; Okada, Keiji; Nakamura, Takashi

PA Fujirebio, Inc., Japan

SO Jpn. Kokai Tokkyo Koho, 72 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11171848	A2	19990629	JP 1998-270721	19980925
				JP 1997-277942	19970926

OS MARPAT 131:73440

IT **228580-97-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of aromatic amide derivs. as ACC inhibitor)

RN 228580-97-0 CAPLUS

CN Benzoic acid, 2-[[2-[(2-phenylethyl)amino]-5-(phenylethynyl)benzoyl]amino]- (9CI) (CA INDEX NAME)



IT **228580-60-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aromatic amide derivs. as ACC inhibitor)

RN 228580-60-7 CAPLUS

CN Benzoic acid, 2-[[2-[(phenylmethyl)amino]benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



IT **228580-61-8P 228580-64-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)

L3 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(prepn. of arom. amide derivs. as ACC inhibitor)
RN 228580-61-8 CAPLUS
CN Benzoic acid, 2-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 228580-84-5 CAPLUS
CN Benzoic acid, 2-[[2-[(3-phenylpropyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



GI



I

AB Title compds. [I; R = 3-CF3C6H4, C6H5(CH2)2, C6H5, CH3(CH2)5, CH3(CH2)3, CH3(CH2)2, CH3CH2, CH3, C6H5(CH2)3, etc.; R1 = H, CH3(CH2)4, 5-CH3(CH2)5CC, 5-CH3CH2CC, 5-(CH3)3CCC, 4-C6H5CH2O, 4-C6H5CC, 3-C6H5CC, 3-C6H5CC, 3-(4-NO2C6H4)CC, 3-(4-NCC6H4)CC, 3-(4-HOC6H4)CC, etc.; R2 = 5-OH, 5-Cl, 5-OMe, 5-Me, 5-Br, etc.; R3 = H, CH3, etc.; R4 = CO2H, AcNHSO2, CH3(CH2)4CONHSO2, 4-CF3C6H4CONHSO2, PHCONHSO2, (CH3)3CONHSO2, CH3(CH2)2NHCONHSO2, etc.; X = CH, N; dotted bond = single, double] are prepared and tested as ACC (acetyl-CoA carboxylase) inhibitors in treatment of lipids oxidation related diseases, such as myocardial infarction, cerebral infarction, and diabetes. The title compound I (R = 3-CF3C6H4; R1 = H; R2 =

L3 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
H; R3 = H; X = CH; dotted bonds were double bonds) was prepd. with 72% yield from 3-EtO2CC6H4NH2 and 3-(2-HO2CC6H4NH)C6H4CF3.

L3 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:236274 CAPLUS
DN 128:282780
TI Preparation of heterocyclic inhibitors of microsomal triglyceride transfer protein
IN Biller, Scott A.; Dickson, John K.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Sulsky, Richard B.; Tino, Joseph A.
PA Bristol-Myers Squibb Co., USA
SO U.S., 185 pp., Cont.-in-part of U.S. Ser. No. 391,901, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5739135	A	19980414	US 1995-472067	19950606
				US 1993-117362	A2 19930903
				US 1994-284808	B2 19940805
				US 1995-391901	B2 19950221
	CA 2091102	AA	19930907	CA 1993 2091102	19930305
				US 1992-847503	A 19920306
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503	A 19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503	A 19920306
	EP 584446	A2	19940302	EP 1993-103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1992-847503	A 19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503	A 19920306
	PT 584446	T	20020930	PT 1993-103697	19930308
				US 1992-847503	A 19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308
				US 1992-847503	A 19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992-847503	A 19920306
	US 5595872	A	19970121	US 1993-117362	19930903
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
	US 5789197	A	19980804	US 1995-486924	19950607
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
	US 6492365	B1	20021210	US 1995-486929	19950607
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
	US 5712279	A	19980127	US 1996-648811	19960111
				US 1995-391901	B2 19950221
				US 1995-472067	A2 19950606
	IL 116917	A1	20000831	IL 1996-116917	19960126
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
	TW 486469	B	20020511	TW 1996-85100978	19960126

L3 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
	CA 2213466	AA	19960829	CA 1996-2213466	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
	WO 9626205	A1	19960829	WO 1996-US824	19960201
	W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
	AU 9647631	A1	19960911	AU 1996-47631	19960201
	AU 699865	B2	19981217		
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	CN 1176640	A	19980318	CN 1996-192015	19960201
	CN 1108301	B	20030514		
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
	EP 886637	A1	19981230	EP 1996-903604	19960201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	JP 11500442	T2	19990112	JP 1996-525679	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996 US824	W 19960201
	NZ 302055	A	20000228	NZ 1996-302055	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	PL 185443	B1	20030530	PL 1996-322003	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	ZA 9601340	A	19970911	ZA 1996-1340	19960220
				US 1995-391901	A 19950221
	US 5883099	A	19990316	US 1997-896872	19970721
				US 1993-117362	A2 19930903
				US 1994-284808	B2 19940805
				US 1995-391901	B2 19950221
				US 1995-472067	A3 19950606
	US 6034098	A	20000307	US 1997-898304	19970721
				US 1993-117362	A2 19930903
				US 1994-284808	B2 19940805
				US 1995-391901	B2 19950221
				US 1995-472067	A3 19950606
	US 6066650	A	20000523	US 1997-898303	19970721
				US 1993-117362	A2 19930903
				US 1994-284808	B2 19940805
				US 1995-391901	B2 19950221
				US 1995-472067	A1 19950606
	FI 9703416	A	19970820	FI 1997-3416	19970820
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201

L3 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

NO 9703821	A	19970820	NO 1997-3821		19970820
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
			WO 1996-US824	W	19960201
LT 4367	B	19980825	LT 1997-152		19970919
			US 1995-391901	A	19950221
LV 11951	B	19981120	LV 1997-171		19970919
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
US 2003166590	A1	20030904	US 2001-933593		20010821
			US 1992-847503	B2	19920306
			US 1993-15449	B2	19930222
			US 1993-117362	A3	19930903
			US 1995-486929	A3	19950607

PATENT FAMILY INFORMATION:

FAN 1995:568500

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI EP 643057	A1	19950315	EP 1994-113800		19940902
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
			US 1993-117362	A	19930903
CA 2091102	AA	19930907	CA 1993-2091102		19930305
			US 1992-847503	A	19920306
ZA 9301601	A	19931005	ZA 1993-1601		19930305
			US 1993-117362	A	19930903
HU 67962	A2	19950529	HU 1993-627		19930305
HU 218419	B	20000828			
			US 1992-847503	A	19920306
JP 06038761	A2	19940215	JP 1993-46499		19930308
			US 1992-847503	A	19920306
EP 584446	A2	19940302	EP 1993-103697		19930308
EP 584446	A3	19950426			
EP 584446	B1	20020619			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
			US 1992-847503	A	19920306
AT 219514	E	20020715	AT 1993-103697		19930308
			US 1992-847503	A	19920306
PT 584446	T	20020930	PT 1993-103697		19930308
			US 1992-847503	A	19920306
ES 2178640	T3	20030101	ES 1993-103697		19930308
			US 1992-847503	A	19920306
AU 670930	B2	19960808	AU 1993-34064		19930309
AU 9334064	A1	19930909			
			US 1992-847503	A	19920306
US 5595872	A	19970121	US 1993-117362		19930903
			US 1992-847503	B2	19920306
			US 1993-15449	B2	19930222
CA 2131430	AA	19950304	CA 1994-2131430		19940902
			US 1993-117362	A	19930903
FI 9404048	A	19950304	FI 1994-4048		19940902
			US 1993-117362	A	19930903
NO 9403260	A	19950306	NO 1994-3260		19940902
			US 1993-117362	A	19930903

L3 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AU 9471642	A1	19950316	AU 1994-71642		19940902
AU 690125	B2	19980423			
			US 1993-117362	A	19930903
ZA 9406772	A	19950403	ZA 1994-6772		19940902
			US 1993-117362	A	19930903
JP 07165712	A2	19950627	JP 1994-210057		19940902
			US 1993-117362	A	19930903
CN 1106003	A	19950802	CN 1994-115640		19940902
			US 1993-117362	A	19930903
HU 70613	A2	19951030	HU 1994-2542		19940902
			US 1993-117362	A	19930903
US 5789197	A	19980804	US 1995-486924		19950607
			US 1992-847503	B2	19920306
			US 1993-15449	B2	19930222
			US 1993-117362	A3	19930903
US 6492365	B1	20021210	US 1995-486929		19950607
			US 1992-847503	B2	19920306
			US 1993-15449	B2	19930222
			US 1993-117362	A3	19930903
US 2003166590	A1	20030904	US 2001-933593		20010821
			US 1992-847503	B2	19920306
			US 1993-15449	B2	19930222
			US 1993-117362	A3	19930903
			US 1995-486929	A3	19950607

FAN 1996:641305

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI WO 9626205	A1	19960829	WO 1996-US824		19960201
W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
CA 2091102	AA	19930907	CA 1993-2091102		19930305
			US 1992-847503	A	19920306
HU 67962	A2	19950529	HU 1993-627		19930305
HU 218419	B	20000828			
			US 1992-847503	A	19920306
JP 06038761	A2	19940215	JP 1993-46499		19930308
			US 1992-847503	A	19920306
EP 584446	A2	19940302	EP 1993-103697		19930308
EP 584446	A3	19950426			
EP 584446	B1	20020619			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
			US 1992-847503	A	19920306
AT 219514	E	20020715	AT 1993-103697		19930308
			US 1992-847503	A	19920306
PT 584446	T	20020930	PT 1993-103697		19930308
			US 1992-847503	A	19920306
ES 2178640	T3	20030101	ES 1993-103697		19930308
			US 1992-847503	A	19920306
AU 670930	B2	19960808	AU 1993-34064		19930309
AU 9334064	A1	19930909			
			US 1992-847503	A	19920306

L3 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 5739135	A	19980414	US 1995-472067		19950606
			US 1993-117362	A2	19930903
			US 1994-284808	B2	19940805
			US 1995-391901	B2	19950221
AU 9647631	A1	19960911	AU 1996-47631		19960201
AU 699865	B2	19981217			
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
			WO 1996-US824	W	19960201
EP 886637	A1	19981230	EP 1996-903604		19960201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE					
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
			WO 1996-US824	W	19960201
JP 11500442	T2	19990112	JP 1996-525679		19960201
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
			WO 1996-US824	W	19960201
NZ 302055	A	20000228	NZ 1996-302055		19960201
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
			WO 1996-US824	W	19960201
PL 185443	B1	20030530	PL 1996-322003		19960201
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
			WO 1996-US824	W	19960201
ZA 9601340	A	19970911	ZA 1996-1340		19960220
			US 1995-391901	A	19950221
FI 9703416	A	19970820	FI 1997-3416		19970820
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
			WO 1996-US824	W	19960201
NO 9703821	A	19970820	NO 1997-3821		19970820
			US 1995-391901	A	19950221
			US 1995-472067	A	19950606
			WO 1996-US824	W	19960201
LT 4367	B	19980825	LT 1997-152		19970919
			US 1995-391901	A	19950221

FAN 1998:115356

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI US 5712279	A	19980127	US 1996-548811		19960111
			US 1995-391901	B2	19950221
			US 1995-472067	A2	19950606
CA 2091102	AA	19930907	CA 1993-2091102		19930305
			US 1992-847503	A	19920306
HU 67962	A2	19950529	HU 1993-627		19930305
HU 218419	B	20000828			
			US 1992-847503	A	19920306
JP 06038761	A2	19940215	JP 1993-46499		19930308
			US 1992 847503	A	19920306
EP 584446	A2	19940302	EP 1993-103697		19930308
EP 584446	A3	19950426			
EP 584446	B1	20020619			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
			US 1992-847503	A	19920306
AT 219514	E	20020715	AT 1993-103697		19930308

L3 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

			US 1992-847503	A	19920306
PT 584446	T	20020930	PT 1993-103697		19930308
			US 1992-847503	A	19920306
ES 2178640	T3	20030101	ES 1993-103697		19930308
			US 1992-847503	A	19920306
AU 670930	B2	19960808	AU 1993-34064		19930309
AU 9334064	A1	19930909			
			US 1992-847503	A	19920306
US 5739135	A	19980414	US 1995-472067		19950606
			US 1993-117362	A2	19930903
			US 1994-284808	B2	19940805
			US 1995-391901	B2	19950221
ZA 9601340	A	19970911	ZA 1996-1340		19960220
			US 1995-391901	A	19950221
LT 4367	B	19980825	LT 1997-152		19970919
			US 1995-391901	A	19950221

OS MARPAT 128:282780

IT **182429-79-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic inhibitors of microsomal triglyceride transfer protein)

RN 182429-79-4 CAPLUS

CN 9H Fluorene-9-carboxamide, 9-[4-[4-[[2-[(phenylmethyl)amino]benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L3 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I-V; Q = C(O), S(O)2; X = CHR8, C(O), CHR9CHR10, CR9:CR10 (wherein R8-R10 = H, alkyl, alkenyl, etc.); Y = (CH2)m, C(O) (m = 2-3); R1 = alkyl, alkenyl, alkynyl, etc.; R2-R4 = H, halo, alkyl, etc.; R5 = alkyl, alkenyl, alkynyl, etc.; R6 = H, C1-4 alkyl, C1-4 alkenyl] which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases such as hyperglycemia and obesity, were prepared Thus, reaction of 1-(3,3 diphenylpropyl)-4-piperidinamine.HCl (preparation described) with benzoyl chloride in the presence of Et3N in CH2Cl2 afforded 84% the title compound III.HCl [Q = C(O); R1 = 3,3-diphenylpropyl; R5 = Ph; R6 = H]. Compds. I-V are effective at 5-500 mg/day.

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:641305 CAPLUS
DN 125:275663
TI Preparation of 9-(piperidinoalkyl)fluorene-9-carboxamides and analogs as microsomal triglyceride transfer protein inhibitors
IN Wetterau, John R. II; Sharp, Daru Young; Gregg, Richard E.; Biller, Scott A.; Dickson, John A.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Robl, Jeffrey A.; et al.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 427 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9626205	A1	19960829	WO 1996-US824	19960201
	W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
	CA 2091102	AA	19930907	CA 1993-2091102	19930305
				US 1992-847503 A	19920306
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503 A	19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503 A	19920306
	EP 584446	A2	19940302	EP 1993-103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1992-847503 A	19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503 A	19920306
	PT 584446	T	20020930	PT 1993-103697	19930308
				US 1992-847503 A	19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308
				US 1992-847503 A	19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992-847503 A	19920306
	US 5739135	A	19980414	US 1995-472067	19950606
				US 1993-117362 A2	19930903
				US 1994-284808 B2	19940805
				US 1995-391901 B2	19950221
	AU 9647631	A1	19960911	AU 1996-47631	19960201
	AU 699865	B2	19981217		
				US 1995-391901 A	19950221
				US 1995-472067 A	19950606
				WO 1996-US824 W	19960201
	EP 886637	A1	19981230	EP 1996-903604	19960201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				

L3 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	JP 11500442	T2	19990112	JP 1996-525679	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	NZ 302055	A	20000228	NZ 1996-302055	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	PL 185443	B1	20030530	PL 1996-322003	19960201
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	ZA 9601340	A	19970911	ZA 1996-1340	19960220
				US 1995-391901	A 19950221
	FI 9703416	A	19970820	FI 1997-3416	19970820
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996-US824	W 19960201
	NO 9703821	A	19970820	NO 1997-3821	19970820
				US 1995-391901	A 19950221
				US 1995-472067	A 19950606
				WO 1996 US824	W 19960201
	LT 4367	B	19980825	LT 1997-152	19970919
				US 1995-391901	A 19950221

PATENT FAMILY INFORMATION:

FAN 1995:568500

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 643057	A1	19950315	EP 1994-111800	19940902
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1993-117362	A 19930903
	CA 2091102	AA	19930907	CA 1993-2091102	19930305
				US 1992-847503	A 19920306
	ZA 9301601	A	19931005	ZA 1993-1601	19930305
				US 1993-117362	A 19930903
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503	A 19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503	A 19920306
	EP 584446	A2	19940302	EP 1993-103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1992-847503	A 19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503	A 19920306
	PT 584446	T	20020930	PT 1993-103697	19930308
				US 1992-847503	A 19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308
				US 1992-847503	A 19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309
	AU 9334064	A1	19930909		
				US 1992-847503	A 19920306

L3 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	US 5595872	A	19970121	US 1993-117362	19930903
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
	CA 2131430	AA	19950304	CA 1994-2131430	19940902
				US 1993-117362	A 19930903
	FI 9404048	A	19950304	FI 1994-4048	19940902
				US 1993-117362	A 19930903
	NO 9403260	A	19950306	NO 1994-3260	19940902
				US 1993-117362	A 19930903
	AU 9471642	A1	19950316	AU 1994-71642	19940902
	AU 690125	B2	19980423		
				US 1993-117362	A 19930903
	ZA 9406772	A	19950403	ZA 1994-6772	19940902
				US 1993-117362	A 19930903
	JP 07165712	A2	19950627	JP 1994-210057	19940902
				US 1993-117362	A 19930903
	CN 1106003	A	19950802	CN 1994-115640	19940902
				US 1993-117362	A 19930903
	HU 70613	A2	19951030	HU 1994-2542	19940902
				US 1993-117362	A 19930903
	US 5789197	A	19980804	US 1995-486924	19950607
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
	US 6492365	B1	20021210	US 1995-486929	19950607
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
	US 2003166590	A1	20030904	US 2001-933593	20010821
				US 1992-847503	B2 19920306
				US 1993-15449	B2 19930222
				US 1993-117362	A3 19930903
				US 1995-486929	A3 19950607

FAN 1998:115356

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5712279	A	19980127	US 1996-548811	19960111
				US 1995-391901	B2 19950221
				US 1995-472067	A2 19950606
	CA 2091102	AA	19930907	CA 1993-2091102	19930305
				US 1992-847503	A 19920306
	HU 67962	A2	19950529	HU 1993-627	19930305
	HU 218419	B	20000828		
				US 1992-847503	A 19920306
	JP 06038761	A2	19940215	JP 1993-46499	19930308
				US 1992-847503	A 19920306
	EP 584446	A2	19940302	EP 1993-103697	19930308
	EP 584446	A3	19950426		
	EP 584446	B1	20020619		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1992-847503	A 19920306
	AT 219514	E	20020715	AT 1993-103697	19930308
				US 1992-847503	A 19920306
	PT 584446	T	20020930	PT 1993-103697	19930308
				US 1992-847503	A 19920306
	ES 2178640	T3	20030101	ES 1993-103697	19930308
				US 1992-847503	A 19920306
	AU 670930	B2	19960808	AU 1993-34064	19930309

L3 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	AU 9334064	A1	19930909			
				US 1992-847503	A	19920306
	US 5739135	A	19980414	US 1995-472067		19950606
				US 1993-117362	A2	19930903
				US 1994-284808	B2	19940805
				US 1995-391901	B2	19950221
	ZA 9601340	A	19970911	ZA 1996-1340		19960220
				US 1995-391901	A	19950221
	LT 4367	B	19980825	LT 1997-152		19970919
				US 1995-391901	A	19950221

FAN 1998:236274

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 5739135	A	19980414	US 1995-472067		19950606
				US 1993-117362	A2	19930903
				US 1994-284808	B2	19940805
				US 1995-391901	B2	19950221
	CA 2091102	AA	19930907	CA 1993-2091102		19930305
				US 1992-847503	A	19920306
	HU 67962	A2	19950529	HU 1993-627		19930305
	HU 218419	B	20000828			
				US 1992-847503	A	19920306
	JP 06038761	A2	19940215	JP 1993-46499		19930308
				US 1992-847503	A	19920306
	EP 584446	A2	19940302	EP 1993-103697		19930308
	EP 584446	A3	19950426			
	EP 584446	B1	20020619			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

				US 1992-847503	A	19920306
	AT 219514	E	20020715	AT 1993-103697		19930308
				US 1992-847503	A	19920306
	PT 584446	T	20020930	PT 1993-103697		19930308
				US 1992-847503	A	19920306
	ES 2178640	T3	20030101	ES 1993-103697		19930308
				US 1992-847503	A	19920306
	AU 670930	B2	19960808	AU 1993-34064		19930309
	AU 9334064	A1	19930909			
				US 1992-847503	A	19920306
	US 5595872	A	19970121	US 1993-117362		19930903
				US 1992 847503	B2	19920306
				US 1993-15449	B2	19930222
	US 5789197	A	19980804	US 1995-486924		19950607
				US 1992-847503	B2	19920306
				US 1993-15449	B2	19930222
				US 1993-117362	A3	19930903
	US 6492365	B1	20021210	US 1995 486929		19950607
				US 1992-847503	B2	19920306
				US 1993-15449	B2	19930222
				US 1993-117362	A3	19930903
	US 5712279	A	19980127	US 1996-548811		19960111
				US 1995-391901	B2	19950221
				US 1995-472067	A2	19950606
	IL 116917	A1	20000831	IL 1996-116917		19960126
				US 1995-391901	A	19950221

L3 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1995-472067	A	19950606
	TW 486469	B	20020511	TW 1996-85100978		19960126
				US 1995-391901	A	19950221
				US 1995-472067	A	19950606
	CA 2213466	AA	19960829	CA 1996-2213466		19960201
				US 1995-391901	A	19950221
				US 1995-472067	A	19950606
	WO 9626205	A1	19960829	WO 1996-US824		19960201

W: AU, BG, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, UA

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

				US 1995-391901	A	19950221
				US 1995-472067	A	19950606
	AU 9647631	A1	19960911	AU 1996-47631		19960201
	AU 699865	B2	19981217			
				US 1995-391901	A	19950221
				US 1995-472067	A	19950606
				WO 1996-US824	W	19960201
	CN 1176640	A	19980318	CN 1996-192015		19960201
	CN 1108301	B	20030514			
				US 1995-391901	A	19950221
				US 1995-472067	A	19950606
	EP 886637	A1	19981230	EP 1996-903604		19960201

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE

				US 1995-391901	A	19950221
				US 1995-472067	A	19950606
				WO 1996-US824	W	19960201
	JP 11500442	T2	19990112	JP 1996-525679		19960201
				US 1995-391901	A	19950221
				US 1995-472067	A	19950606
				WO 1996-US824	W	19960201
	NZ 302055	A	20000228	NZ 1996-302055		19960201
				US 1995-391901	A	19950221
				US 1995-472067	A	19950606
				WO 1996-US824	W	19960201
	PL 185443	B1	20030530	PL 1996-322003		19960201
				US 1995-391901	A	19950221
				US 1995-472067	A	19950606
				WO 1996-US824	W	19960201
	ZA 9601340	A	19970911	ZA 1996-1340		19960220
				US 1995-391901	A	19950221
	US 5883099	A	19990316	US 1997-896872		19970721
				US 1993-117362	A2	19930903
				US 1994-284808	B2	19940805
				US 1995-391901	B2	19950221
				US 1995-472067	A3	19950606
	US 6034098	A	20000307	US 1997-898304		19970721
				US 1993-117362	A2	19930903
				US 1994-284808	B2	19940805
				US 1995-391901	B2	19950221
				US 1995-472067	A3	19950606
	US 6066650	A	20000523	US 1997-898303		19970721
				US 1993-117362	A2	19930903
				US 1994-284808	B2	19940805

L3 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1995-391901	B2	19950221
				US 1995-472067	A1	19950606
	FI 9703416	A	19970820	FI 1997-3416		19970820
				US 1995-391901	A	19950221
				US 1995-472067	A	19950606
				WO 1996-US824	W	19960201
	NO 9703821	A	19970820	NO 1997-3821		19970820
				US 1995-391901	A	19950221
				US 1995 472067	A	19950606
				WO 1996-US824	W	19960201
	LT 4367	B	19980825	LT 1997-152		19970919
				US 1995 391901	A	19950221
	LV 11951	B	19981120	LV 1997-171		19970919
				US 1995-391901	A	19950221
				US 1995-472067	A	19950606
	US 2003166590	A1	20030904	US 2001-933593		20010821
				US 1992-847503	B2	19920306
				US 1993-15449	B2	19930222
				US 1993-117362	A3	19930903
				US 1995-486929	A3	19950607

OS MARPAT 125:275663

IT **182429-79-4P 182433-96-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 9-(piperidinoalkyl)fluorene-9-carboxamides and analogs as microsomal triglyceride transfer protein inhibitors)

RN 182429-79-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[[2-[(phenylmethyl)amino]benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L3 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A



RN 182433-96-1 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[1-oxido-4-[[2-[(phenylmethyl)amino]benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



GI

L3 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB R5Z3NRR6 [R = piperidyl group Q1; R5 = alkyl, alkoxy, (hetero)aryl, etc.; R6 = H, alk(en)yl; R5R6 = atoms to form a benzanellated ring; Z3 = CO or SO2; 1 of Z4,Z5 = NR1 and the other = CH2; R1 = e.g., (un)substituted aryl group Q2; R12 = H, (halo)alkyl, heteroaryl, etc.; Z = bond, O, S, alkylimino, etc.; Z1,Z2 = bond, O, SO0-2, CO, etc.; Z11 = bond, alkylene, arylene, etc.] were prepared as microsomal triglyceride transfer protein inhibitors (no data). Thus, N-propyl-9-fluorenecarboxamide (preparation given) was alkylated by I(CH2)4OSiMe2CMe3 (preparation given) and the deprotected and iodinated product aminated by 2-(4-piperidinyl)-2,3-dihydro-1H-isoindol-1-one (preparation given) to give title compound I.

L3 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139602-68-9 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-2-[[(2,4-dimethoxyphenyl)methyl]amino]-(9CI) (CA INDEX NAME)



RN 139602-69-0 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 139602-71-4 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)-(9CI) (CA INDEX NAME)



L3 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:571361 CAPLUS
DN 117:171361
TI Synthesis of biologically active 4(3H)-quinazolinonium perchlorates
AU Chernobrovin, N. I.; Kozhevnikov, Yu. V.; Morozova, G. E.; Chernobrovina, T. A.
CS Perm. Farm. Inst., Perm, Russia
SO Khimiko-Farmatsevticheskii Zhurnal (1992), 26(3), 48-51
CODEN: KHFZAN; ISSN: 0023-1134
DT Journal
LA Russian
IT **139602-64-5P 139602-66-7P 139602-67-8P**
139602-68-9P 139602-69-0P 139602-71-4P
139602-72-5P 139602-73-6P 143424-22-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acetylation of)
RN 139602-64-5 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 139602-66-7 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)-(9CI) (CA INDEX NAME)





RN 139602-67-8 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)-(9CI) (CA INDEX NAME)

L3 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 139602-72-5 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)-(9CI) (CA INDEX NAME)



RN 139602-73-6 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-2-[[(3,4-dimethoxyphenyl)methyl]amino]-(9CI) (CA INDEX NAME)



RN 143424-22-0 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)



GI

L3 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB Title salts I (R = H, 3-Me, 4-Me, 4-MeO, 4-Cl; R1 = OMe, R2 = H; R1 = H, R2 = OMe) were prepared by condensation of anthranilanilides with dimethoxybenzaldehydes, followed by borohydride reduction of the imine group, N-acetylation, and acid cyclization. The acute toxicity and anticonvulsant, analgesic, and antimicrobial activities of some I were tested.

L3 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)





RN 139602-67-8 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino] N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 139602-68-9 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-2 [[(2,4-dimethoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 139602-69-0 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)

L3 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:128388 CAPLUS
DN 116:128388
TI Arylamides of N-(p-2',4'- or -3',4'-dimethoxybenzyl)anthranilic acid
IN Chernobrovin, N. I.; Kozhevnikov, Yu. V.; Zalesov, V. S.; Semenova, Z. N.
PA Perm Pharmaceutical Institute, USSR
SO U.S.S.R.
From: Otkrytiya, Izobret. 1991, (28), 258.
CODEN: URXXAF
DT Patent
LA Russian
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI SU 1156362	A1	19910730	SU 1983-3573020	19830217
			SU 1983-3573020	19830217

IT **139602-64-5 139602-65-6 139602-66-7 139602-67-8 139602-68-9 139602-69-0 139602-70-3 139602-71-4 139602-72-5 139602-73-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(intermediate for quinazolinonium perchlorate derivs.)

RN 139602-64-5 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 139602-65-6 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 139602-66-7 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139602-70-3 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)





RN 139602-71-4 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 139602-72-5 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139602-73-6 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-2-[[(3,4-dimethoxyphenyl)methyl]amino]-(9CI) (CA INDEX NAME)



GI



AB The title compds. (I; R = H, Me, p-Cl; R1 o-OMe, m-OMe) are intermediates for biol. active 1-(2',4'- or -3',4'-dimethoxybenzyl)-2-methyl-3-aryl-4(3H)-quinazolinonium perchlorates.

L3 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:514559 CAPLUS
DN 115:114559
TI Preparation of 5,11-dihydro-6H-dipyrido [3,2-b:2',3'-e](1,4) diazepines and their use in the prevention or treatment of HIV infection
IN Hargrave, Karl D.; Schmidt, Guenther; Engel, Wolfhard; Trummlitz, Guenther; Eberlein, Wolfgang
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl, G.m.b.H.
SO Eur. Pat. Appl., 42 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 429987	A2	19910605	EP 1990-121954	19901116
	EP 429987	A3	19920122		
	EP 429987	B1	19990317		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	CA 2030056	AA	19910518	CA 1990-2030056	19901115
	CA 2030056	C	19951017		
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
	FI 9005674	A	19910518	FI 1990-5674	19901116
	FI 94529	B	19950615		
	FI 94529	C	19950925		
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	NO 9004986	A	19910521	NO 1990-4986	19901116
	NO 175478	B	19940711		
	NO 175478	C	19941019		
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	HU 56103	A2	19910729	HU 1990-7186	19901116
	HU 208139	B	19930830		
				US 1989 438923 A	19891117
	JP 04178386	A2	19920625	JP 1990-311230	19901116
	JP 2912007	B2	19990628		
				US 1989 438923 A	19891117
	IL 96367	A1	19970218	IL 1990-96367	19901116
				US 1989-438923 A	19891117
				IL 1990 94883 A0	19900627
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	AT 177744	E	19990415	AT 1990-121954	19901116
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	ES 2130114	T3	19990701	ES 1990-121954	19901116
				US 1989-438923 A	19891117

L3 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	AU 9066732	A1	19910523	AU 1990-66732	19901119
	AU 630251	B2	19921022		
				US 1989 438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	ZA 9009246	A	19920729	ZA 1990-9246	19901119
				US 1989-438923 A	19891117
	JP 04257584	A2	19920911	JP 1991-211068	19910822
	JP 2539116	B2	19961002		
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	HU 59407	A2	19920528	HU 1991 2865	19910904
	HU 214595	B	19980428		
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	RU 2040527	C1	19950725	RU 1992-5011559	19920506
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
	US 5620974	A	19970415	US 1994-279464	19940722
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
				US 1993-91418 A3	19930713
	HK 1011025	A1	20000420	HK 1998-112090	19981117
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019

PATENT FAMILY INFORMATION:

FAN 1991:102069

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 393529	A1	19901024	EP 1990-107098	19900412
	EP 393529	B1	19930630		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1989-340970 A	19890420
	AT 91128	E	19930715	AT 1990-107098	19900412
				US 1989-340970 A	19890420
				EP 1990-107098 A	19900412
	ES 2058656	T3	19941101	ES 1990-107098	19900412
				US 1989-340970 A	19890420
	CA 2014771	AA	19901020	CA 1990-2014771	19900418
	CA 2014771	C	20000801		
				US 1989-340970 A	19890420
	JP 03063276	A2	19910319	JP 1990-104379	19900419
	JP 2851913	B2	19990127		
				US 1989-340970 A	19890420

L3 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970	B2 19890420
				US 1989-372974	B2 19890628
				US 1989-438923	B2 19891117
				US 1990-579001	B2 19900906
				US 1990-600390	B2 19901019
				US 1991-740828	B1 19910805
	US 5620974	A	19970415	US 1994-279464	19940722
				US 1989-340970	B2 19890420
				US 1989-372974	B2 19890628
				US 1989-438923	B2 19891117
				US 1990-579001	B2 19900906
				US 1990-600390	B2 19901019
				US 1991-740828	B1 19910805
				US 1993-91418	A3 19930713

FAN 1991:449732

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 410148	A1	19910130	EP 1990-112072	19900626
	EP 410148	B1	19940406		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1989-372974 A	19890628
	CA 2019812	AA	19901228	CA 1990-2019812	19900626
	CA 2019812	C	20001121		
				US 1989-372974 A	19890628
	DD 295849	A5	19911114	DD 1990-342100	19900626
				US 1989-372974 A	19890628
	AT 103918	E	19940415	AT 1990-112072	19900626
				US 1989-372974 A	19890628
				EP 1990-112072 A	19900626
	ES 2063202	T3	19950101	ES 1990-112072	19900626
				US 1989-372974 A	19890628
	NO 9002851	A	19910102	NO 1990-2851	19900627
	NO 174468	B	19940131		
	NO 174468	C	19940518		
				US 1989-372974 A	19890628
	HU 55017	A2	19910429	HU 1990-4021	19900627
	HU 206504	B	19921130		
				US 1989-372974 A	19890628
	JP 03115283	A2	19910516	JP 1990-169663	19900627
	JP 2911967	B2	19990628		
				US 1989-372974 A	19890628
	ZA 9004991	A	19920325	ZA 1990-4991	19900627
				US 1989-372974 A	19890628
	FI 92828	B	19940930	FI 1990 3225	19900627
	FI 92828	C	19950110		
				US 1989-372974 A	19890628
	IL 94883	A1	19941007	IL 1990-94883	19900627
				US 1989-372974 A	19890628
	AU 9057921	A1	19910103	AU 1990-57921	19900628
	AU 620724	B2	19920220		
				US 1989-372974 A	19890628
	RU 2024522	C1	19941215	RU 1992-5011432	19920427
				US 1989-372974 A	19890628
	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970	B2 19890420
				US 1989-372974	B2 19890628
				US 1989-438923	B2 19891117
				US 1990-579001	B2 19900906

L3 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1990-600390	B2 19901019
				US 1991-740828	B1 19910805
US 5620974	A	19970415		US 1994-279464	19940722
				US 1989-340970	B2 19890420
				US 1989-372974	B2 19890628
				US 1989-438923	B2 19891117
				US 1990-579001	B2 19900906
				US 1990-600390	B2 19901019
				US 1991-740828	B1 19910805
				US 1993-91418	A3 19930713

OS MARPAT 115:114559
IT **132312-45-9P 132362-76-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antiviral dihydrodipyridodiazepines)
RN 132312-45-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)





RN 132362-76-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



GI



AB Title compds. I (Z = O, S, :NCN, :NOR9; R1-R8 = various subsets of groups selected from H, alkyl, cycloalkyl, fluoroalkyl, aryl, tetrahydrofuryl, alkanoyl, trihalomethyl, alkoxycarbonyl, halo, amino, and many more; R9 = C1-3 alkyl; numerous provisions and exceptions) were prepared for prevention and treatment of HIV-1 infection. For example, 2-hydroxy-4-methyl-3-nitropyridine was converted by chlorination with POCl3 and reduction to 3-amino-2-chloro-4-methylpyridine, which underwent amidation with 2-chloronicotinoyl chloride and condensation with EtNH2 to give (chloromethylpyridinyl)(ethylamino)pyridinecarboxamide II. Cyclization of II by NaH in DMF at reflux temperature gave I (Z = O, R1 = R3 = R4 = R6-R8 = H, R2 = Et, R5 = Me) (III). At 3 μg/mL, III gave 100% inhibition of HIV-1 replication in a human T-cell culture assay. III also gave 100% inhibition of HIV-1 reverse transcriptase at 10 μg/mL in vitro; no activity was seen for I against 2 related enzymes, indicating high specificity. Three formulations, 77 synthetic examples, and addnl. test results including cytotoxicity are given.

L3 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:449732 CAPLUS
DN 115:49732
TI Preparation of 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-ones and thiones and their use in the prevention or treatment of AIDS
IN Schmidt, Guenther; Engel, Wolfhard; Trummlitz, Guenter; Eberlein, Wolfgang; Hargrave, Karl D.
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl, G.m.b.H.
SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 410148	A1	19910130	EP 1990-112072	19900626
EP 410148	B1	19940406		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
			US 1989-372974	A 19890628
CA 2019812	AA	19901228	CA 1990-2019812	19900626
CA 2019812	C	20001121		
			US 1989-372974	A 19890628
DD 295849	A5	19911114	DD 1990-342100	19900626
			US 1989-372974	A 19890628
AT 103918	E	19940415	AT 1990-112072	19900626
			US 1989-372974	A 19890628
			EP 1990-112072	A 19900626
ES 2063202	T3	19950101	ES 1990-112072	19900626
			US 1989-372974	A 19890628
NO 9002851	A	19910102	NO 1990-2851	19900627
NO 174468	B	19940131		
NO 174468	C	19940518		
			US 1989-372974	A 19890628
HU 55017	A2	19910429	HU 1990-4021	19900627
HU 206504	B	19921130		
			US 1989-372974	A 19890628
JP 03115283	A2	19910516	JP 1990-169663	19900627
JP 2911967	B2	19990628		
			US 1989-372974	A 19890628
ZA 9004991	A	19920325	ZA 1990 4991	19900627
			US 1989-372974	A 19890628
FI 92828	B	19940930	FI 1990-3225	19900627
FI 92828	C	19950110		
			US 1989-372974	A 19890628
IL 94883	A1	19941007	IL 1990-94883	19900627
			US 1989-372974	A 19890628
AU 9057921	A1	19910103	AU 1990-57921	19900628
AU 620724	B2	19920220		
			US 1989-372974	A 19890628
RU 2024522	C1	19941215	RU 1992-5011432	19920427
			US 1989-372974	A 19890628
US 5366972	A	19941122	US 1993-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990 600390	B2 19901019
			US 1991-740828	B1 19910805

L3 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

US 5620974	A	19970415	US 1994 279464	19940722
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713

PATENT FAMILY INFORMATION:

FAN 1991:102069

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 393529	A1	19901024	EP 1990-107098	19900412
EP 393529	B1	19930630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
			US 1989-340970	A 19890420
AT 91128	E	19930715	AT 1990-107098	19900412
			US 1989-340970	A 19890420
			EP 1990-107098	A 19900412
ES 2058656	T3	19941101	ES 1990-107098	19900412
			US 1989-340970	A 19890420
CA 2014771	AA	19901020	CA 1990-2014771	19900418
CA 2014771	C	20000801		
			US 1989-340970	A 19890420
JP 03063276	A2	19910319	JP 1990-104379	19900419
JP 2851913	B2	19990127		
			US 1989-340970	A 19890420
US 5366972	A	19941122	US 1993-91418	19930713
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
US 5620974	A	19970415	US 1994-279464	19940722
			US 1989-340970	B2 19890420
			US 1989-372974	B2 19890628
			US 1989-438923	B2 19891117
			US 1990-579001	B2 19900906
			US 1990-600390	B2 19901019
			US 1991-740828	B1 19910805
			US 1993-91418	A3 19930713

FAN 1991:514559

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 429987	A2	19910605	EP 1990-121954	19901116
EP 429987	A3	19920122		
EP 429987	B1	19990317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
			US 1990-600390	A 19901019
CA 2030056	AA	19910518	CA 1990-2030056	19901115
CA 2030056	C	19951017		
			US 1989-438923	A 19891117
			US 1990-579001	A 19900906
FI 9005674	A	19910518	FI 1990-5674	19901116
FI 94529	B	19950615		
FI 94529	C	19950925		

L3 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	NO 9004986	A	19910521	NO 1990-4986	19901116
	NO 175478	B	19940711		
	NO 175478	C	19941019		
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	HU 56103	A2	19910729	HU 1990-7186	19901116
	HU 208139	B	19930830		
				US 1989-438923	A 19891117
	JP 04178386	A2	19920625	JP 1990-311230	19901116
	JP 2912007	B2	19990628		
				US 1989-438923	A 19891117
	IL 96367	A1	19970218	IL 1990-96367	19901116
				US 1989-438923	A 19891117
				IL 1990-94883	A0 19900627
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	AT 177744	E	19990415	AT 1990-121954	19901116
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	ES 2130114	T3	19990701	ES 1990 121954	19901116
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	AU 9066732	A1	19910523	AU 1990-66732	19901119
	AU 630251	B2	19921022		
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	ZA 9009246	A	19920729	ZA 1990-9246	19901119
				US 1989-438923	A 19891117
	JP 04257584	A2	19920911	JP 1991-211068	19910822
	JP 2539116	B2	19961002		
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	HU 59407	A2	19920528	HU 1991-2865	19910904
	HU 214595	B	19980428		
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	RU 2040527	C1	19950725	RU 1992-5011559	19920506
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019
	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970	B2 19890420
				US 1989-372974	B2 19890628
				US 1989-438923	B2 19891117
				US 1990-579001	B2 19900906
				US 1990-600390	B2 19901019
				US 1991-740828	B1 19910805
	US 5620974	A	19970415	US 1994-279464	19940722

L3 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1989-340970	B2 19890420
				US 1989-372974	B2 19890628
				US 1989-438923	B2 19891117
				US 1990-579001	B2 19900906
				US 1990-600390	B2 19901019
				US 1991-740828	B1 19910805
				US 1993-91418	A3 19930713
	HK 1011025	A1	20000420	HK 1998-112090	19981117
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990 600390	A 19901019

OS MARPAT 115:49732

IT **132312-45-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of drug for treatment of AIDS)

RN 132312-45-9 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)





GI



I

AB The title compds. I [Z = O, S; R1 = H, (substituted) alkyl, arylmethyl,

L3 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

etc.; R2 = H, (substituted) alkyl, alkenyl, etc.; R3-R8 = H, or 1 of R3-R8 is alkyl, alkoxy, alkylthio, etc., and the remaining 5 of R3-R8 are each H, or R3-R5 are H, alkyl with the proviso that at least one is H or 1 of R3-R5 is Bu with the remaining 2 being H; and R6-R8 are H, alkyl with the proviso that at least 1 is H, or 1 of R6-R8 is Bu with the remaining 2 being H; with the proviso that when R1 and R2 are H, alkyl and R3-R8 are all H then Z is S] were prepd. A mixt. of 5,11-dihydro-11-ethyl 5-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one and Lawesson's reagent in toluene was refluxed for 2.5 h to give I (R1 = Me; Z = S; R2 = Et; R3 = R4 = R5 = R6 = R7 = R8 = H), which at 10 μg/mL gave 100% in vitro inhibition of reverse transcriptase.

L3 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:449642 CAPLUS

DN 115:49642

TI Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones

AU Hargrave, Karl D.; Proudfoot, John R.; Grozinger, Karl G.; Cullen, Ernest; Kapadia, Suresh R.; Patel, Usha R.; Fuchs, Victor U.; Mauldin, Scott C.; Vitous, Jana; et al.

CS Boehringer Ingelheim Pharm., Inc., Ridgefield, CT, 06877, USA

SO Journal of Medicinal Chemistry (1991), 34(7), 2231-41
CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

OS CASREACT 115:49642

IT **132312-45-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and reductive intramol. cyclocondensation of, dipyridodiazepinone from)

RN 132312-45-9 CAPLUS

CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)





GI



I II

AB Novel pyrido[2,3-b][1,4]benzodiazepinones, pyrido[2,3-b][1,5]benzodiazepinones, and dipyrido[3,2-b:2',3'-e][1,4]diazepinones e.g., I (X = N, X1 = CH; X = CH; X1 = N) and II inhibited human immunodeficiency virus type 1 reverse transcriptase in vitro at concns.

L3 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

low as 35 nM. In all three series, small substituents (e.g., Me, Et, Ac) are preferred at the lactam nitrogen, whereas slightly larger alkyl moieties (e.g., Et, cyclopropyl) are favored at the other (N-11) diazepinone nitrogen. In general, lipophilic substituents are preferred on the A ring, whereas substitution on the C ring generally reduces potency relative to the corresponding compds. with no substituents on the arom. ring. Max. potency is achieved with Me substitution at the position

ortho to the lactam nitrogen atom; however, in this case an unsubstituted lactam nitrogen is preferred. Addnl. substituents on the A ring can be readily tolerated. II (BI-RG 587) is a potent (IC50 = 84 nM) and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, and has

been chosen for preclin. development. II is noncytotoxic except at high doses and effective against all clin. isolates of HIV-1, including those which are AZT-resistant. It is specific for HIV-1, ineffective against HIV-2, inactive against simian and feline reverse transcriptase, and does not inhibit DNA polymerases.

L3 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:102069 CAPLUS
DN 114:102069
TI Preparation of 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-ones as drugs for prevention or treatment of AIDS
IN Schmidt, Guenther; Engel, Wolfhard; Trummlitz, Guenter; Eberlein, Wolfgang; Hargrave, Karl D.
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl, G.m.b.H.
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 393529	A1	19901024	EP 1990-107098	19900412
	EP 393529	B1	19930630		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1989-340970 A	19890420
	AT 91128	E	19930715	AT 1990-107098	19900412
				US 1989-340970 A	19890420
				EP 1990-107098 A	19900412
	ES 2058656	T3	19941101	ES 1990-107098	19900412
				US 1989-340970 A	19890420
	CA 2014771	AA	19901020	CA 1990-2014771	19900418
	CA 2014771	C	20000801		
				US 1989-340970 A	19890420
	JP 03063276	A2	19910319	JP 1990-104379	19900419
	JP 2851913	B2	19990127		
				US 1989-340970 A	19890420
	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
	US 5620974	A	19970415	US 1994-279464	19940722
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
				US 1993-91418 A3	19930713

PATENT FAMILY INFORMATION:
FAN 1991:449732

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 410148	A1	19910130	EP 1990-112072	19900626
	EP 410148	B1	19940406		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1989-372974 A	19890628
	CA 2019812	AA	19901228	CA 1990-2019812	19900626

L3 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

	CA 2019812	C	20001121		
				US 1989-372974 A	19890628
	DD 295849	A5	19911114	DD 1990-342100	19900626
				US 1989-372974 A	19890628
	AT 103918	E	19940415	AT 1990-112072	19900626
				US 1989-372974 A	19890628
				EP 1990-112072 A	19900626
	ES 2063202	T3	19950101	ES 1990-112072	19900626
				US 1989-372974 A	19890628
	NO 9002851	A	19910102	NO 1990-2851	19900627
	NO 174468	B	19940131		
	NO 174468	C	19940518		
				US 1989-372974 A	19890628
	HU 55017	A2	19910429	HU 1990-4021	19900627
	HU 206504	B	19921130		
				US 1989-372974 A	19890628
	JP 03115283	A2	19910516	JP 1990-169663	19900627
	JP 2911967	B2	19990628		
				US 1989-372974 A	19890628
	ZA 9004991	A	19920325	ZA 1990-4991	19900627
				US 1989-372974 A	19890628
	FI 92828	B	19940930	FI 1990-3225	19900627
	FI 92828	C	19950110		
				US 1989-372974 A	19890628
	IL 94883	A1	19941007	IL 1990-94883	19900627
				US 1989-372974 A	19890628
	AU 9057921	A1	19910103	AU 1990-57921	19900628
	AU 620724	B2	19920220		
				US 1989-372974 A	19890628
	RU 2024522	C1	19941215	RU 1992-5011432	19920427
				US 1989-372974 A	19890628
	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
	US 5620974	A	19970415	US 1994-279464	19940722
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
				US 1993-91418 A3	19930713

FAN 1991:514559

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 429987	A2	19910605	EP 1990-121954	19901116
	EP 429987	A3	19920122		
	EP 429987	B1	19990317		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	CA 2030056	AA	19910518	CA 1990-2030056	19901115
	CA 2030056	C	19951017		
				US 1989-438923 A	19891117

L3 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1990-579001 A	19900906
	FI 9005674	A	19910518	FI 1990-5674	19901116
	FI 94529	B	19950615		
	FI 94529	C	19950925		
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	NO 9004986	A	19910521	NO 1990-4986	19901116
	NO 175478	B	19940711		
	NO 175478	C	19941019		
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	HU 56103	A2	19910729	HU 1990-7186	19901116
	HU 208139	B	19930830		
				US 1989-438923 A	19891117
	JP 04178386	A2	19920625	JP 1990-311230	19901116
	JP 2912007	B2	19990628		
				US 1989-438923 A	19891117
	IL 96367	A1	19970218	IL 1990-96367	19901116
				US 1989-438923 A	19891117
				IL 1990-94883 A0	19900627
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	AT 177744	E	19990415	AT 1990-121954	19901116
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	ES 2130114	T3	19990701	ES 1990-121954	19901116
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	AU 9066732	A1	19910523	AU 1990-66732	19901119
	AU 630251	B2	19921022		
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	ZA 9009246	A	19920729	ZA 1990-9246	19901119
				US 1989-438923 A	19891117
	JP 04257584	A2	19920911	JP 1991-211068	19910822
	JP 2539116	B2	19961002		
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	HU 59407	A2	19920528	HU 1991-2865	19910904
	HU 214595	B	19980428		
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	RU 2040527	C1	19950725	RU 1992-5011559	19920506
				US 1989-438923 A	19891117
				US 1990-579001 A	19900906
				US 1990-600390 A	19901019
	US 5366972	A	19941122	US 1993-91418	19930713
				US 1989-340970 B2	19890420
				US 1989-372974 B2	19890628
				US 1989-438923 B2	19891117
				US 1990-579001 B2	19900906
				US 1990-600390 B2	19901019
				US 1991-740828 B1	19910805
	US 5620974	A	19970415	US 1994-279464	19940722

L3 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

				US 1989-340970	B2 19890420
				US 1989-372974	B2 19890628
				US 1989-438923	B2 19891117
				US 1990-579001	B2 19900906
				US 1990-600390	B2 19901019
				US 1991-740828	B1 19910805
				US 1993-91418	A3 19930713
	HK 1011025	A1	20000420	HK 1998-112090	19981117
				US 1989-438923	A 19891117
				US 1990-579001	A 19900906
				US 1990-600390	A 19901019

OS MARPAT 114:102069
IT **132312-45-9P 132362-76-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for dipyridodiazepinone reverse transcriptase inhibitor)
RN 132312-45-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)





RN 132362-76-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-chloro-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



GI

L3 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I



II

AB The title compds. (I; R1, R2 = H, C1-5 alkyl), were prepared Thus, N-(2-chloro-3-pyridinyl)-2-[[(4-methoxyphenyl)methyl]amino]-3-pyridinecarboxamide (preparation given) was refluxed 8 h with NaH in DMF to give 50% 5,11-dihydro-11-[(4-methoxyphenyl)methyl]-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, which was converted to title compound II in 3 steps.
II at 10 μg/mL gave 100% inhibition of HIV-I reverse transcriptase. Dosage formulations were prepared containing I (R1 = H, R2 = Pr).

L3 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1984:611088 CAPLUS
DN 101:211088
TI Studies of 4[3H]-quinazolone. XII. Synthesis and biological activity of 1-benzyl(4'-nitrobenzyl)-2-methyl-3-alkyl(aryl)-4(3H)-quinazolinone perchlorates
AU Chernobrovin, N. I.; Kozhevnikov, Yu. V.; Zalesov, V. S.; Gradel, I. I.
CS Perm. Farm. Inst., Perm, USSR
SO Khimiko-Farmatsevticheskii Zhurnal (1984), 18(7), 830-3
CODEN: KHFZAN; ISSN: 0023-1134
DT Journal
LA Russian
IT **92944-76-8P 92944-77-9P 92944-78-0P**
92944-79-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acetylation of)
RN 92944-76-8 CAPLUS
CN Benzamide, N-(2,4-dimethylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 92944-77-9 CAPLUS
CN Benzamide, N-(4-methoxyphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 92944-78-0 CAPLUS
CN Benzamide, N-(4-methoxyphenyl)-2-[[(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 92944-79-1 CAPLUS
CN Benzamide, N-(4-ethoxyphenyl)-2-[[(4-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



GI



I

L3 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
AB The title compds. I (R = 2,4-xylyl, 4-MeOC6H4, Bu, hexyl, R1 = H; R = 4-MeOC6H4, 4-EtOC6H4, R1 = NO2) were prepared in 58.6-83.4% yields by acetylation of o-RNHCOC6H4NR2CH2C6H4R1-p (II, R2 = H) to give 61.3-98.1% II (R2 = Ac) which were cyclized by refluxing in MeOH containing 57% HClO4. I (R = 4-MeOC6H4, R1 = NO2) was an effective antispasmodic for white mice at 150 mg/kg dosage.

L3 ANSWER 35 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1984:34516 CAPLUS
DN 100:34516
TI New synthesis of 11-acyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones and related studies
AU Kovac, T.; Oklobdzija, M.; Comisso, G.; Decorte, E.; Fajdiga, T.; Moimas, F.; Angeli, C.; Zonno, F.; Toso, R.; Sunjic, V.
CS Chem. Res. Co., San Giovanni, Italy
SO Journal of Heterocyclic Chemistry (1983), 20(5), 1339-49
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 100:34516
IT **88369-73-7P 88369-74-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 88369-73-7 CAPLUS
CN Benzamide, N-(2-chloro-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 88369-74-8 CAPLUS
CN Benzamide, N-(2-chloro-1-oxido-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI)
(CA INDEX NAME)



GI

L3 ANSWER 35 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I

AB 11-Acyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones I (R = 4-methylpiperazino, imidazolo, 2-methylimidazolo) were prepared via N-α-chloroacetylation and aminolysis. Other attempts at cyclization to form I are also reported.

L3 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1977:171214 CAPLUS
DN 86:171214
TI Synthesis and pharmacological properties of 2-aminonicotinamide derivatives
AU Zhmurenko, L. A.; Borisenko, S. A.; Salimov, R. M.; Glozman, O. M.; Zagorevskii, V. A.
CS Nauchno-Issled. Inst. Farmakol., Moscow, USSR
SO Fiziologicheski Aktivnye Veshcheatva (1976), 8, 89-92
CODEN: FAVUAI; ISSN: 0533-1153
DT Journal
LA Russian
IT **62636-33-3P 62636-39-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and pharmacol. properties of)
RN 62636-33-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(phenylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 62636-39-9 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-methoxyphenyl)-2-[(phenylmethyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

GI



I

AB The title compds. I [R = H, m-F3CC6H4, o-MeOC6H4, NR21 = HOCH2CH2NH,

L3 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
PhCH2NH, 4-methyl-1-piperazinyl, 4-(2-hydroxyethyl)-1-piperazinyl, piperidino], useful as sedatives and muscle relaxants, were obtained in 56-98% yields by amination of chloronicotinamides with R21NH.

L3 ANSWER 37 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Et3N; after 30 min, ice-cold 6-aminopenicillanic acid and Et3N in CHCl3 was added and the soln. kept 12 hr to give, after alk. addn., Na 6 (3-benzyloxy-2-picolinamido)penicillanate. Prepd. similarly were: Na 7-(3-benzyloxy 2-picolinamido)cephalosporanate, Na 6-(3-hydroxy-2-picolinamido)penicillanate, and Na 7-(3-hydroxy 2-picolinamido)-cephalosporanate.

L3 ANSWER 37 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1971:76431 CAPLUS
DN 74:76431
TI 3-Substituted picolinyl penicillins and cephalosporins, useful as animal feed supplements and in germicidal preparations employed as surface disinfectants
IN Schwarz, J. S. Paul; Sheehan, John T.
PA E. R. Squibb and Sons, Inc.
SO U.S., 11 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3553203	A	19710105	US 1969-834157	19690617
	BR 6915314	A0	19730419	BR 1969-215314	19691219
				US 1969-834157	19690617
	CA 963003	A1	19750218	CA 1970-85025	19700609
				US 1969-834157	19690617
	DE 2028830	A	19710107	DE 1970 2028830	19700611
				US 1969-834157	19690617
	CH 517116	A	19711231	CH 1970-517116	19700616
				US 1969 834157	19690617
	FR 2052982	A1	19710416	FR 1970-22345	19700617
	FR 2052982	A5	19710416		
				US 1969 834157	19690617

IT **30861-03-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 30861-03-1 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[3-(benzylamino)picolinamido]-3,3-dimethyl-7 oxo-, monosodium salt (8CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

AB The title compds. were prepared Thus, ClCO2Et was added to an ice-cold solution of 3-benzyloxy-2-picolinic acid-HCl sesquihydrate in CHCl3 containing

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	297.84	453.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-27.20	-27.20

STN INTERNATIONAL LOGOFF AT 10:07:02 ON 14 AUG 2004

L Number	Hits	Search Text	DB	Time stamp
1	5221	("514/183,188,277,352,354,356").CCLS	USPAT	2003/07/02 09:57
2	1355	("546/304,315,345").CCLS	USPAT	2003/07/02 09:58
3	189	(("514/183,188,277,352,354,356").CCLS) and (("546/304,315,345").CCLS)	USPAT	2003/07/02 09:58
4	37	((("514/183,188,277,352,354,356").CCLS) and (("546/304,315,345").CCLS)) and cancer	USPAT	2003/07/02 09:58

SBC
8/12/04

8/12/04

L Number	Hits	Search Text	DB	Time stamp
1	5373	("514/183,188,277,352,354,356").CCLS	USPAT	2003/11/06 14:34
2	1372	("546/304,315,345").CCLS	USPAT	2003/11/06 14:35
3	194	(("514/183,188,277,352,354,356").CCLS) and (("546/304,315,345").CCLS)	USPAT	2003/11/06 14:35
4	12075	((("514/183,188,277,352,354,356").CCLS) and (("546/304,315,345").CCLS)) and 2-amino-pyridine-3 carboxamide	USPAT	2003/11/06 14:36
5	0	L:3 and ((((("514/183,188,277,352,354,356").CCLS) and (("546/304,315,345").CCLS)) and 2-amino-pyridine-3 carboxamide) and KDR	USPAT	2003/11/06 14:37
6	7	((("514/183,188,277,352,354,356").CCLS) and (("546/304,315,345").CCLS)) and ((((("514/183,188,277,352,354,356").CCLS) and (("546/304,315,345").CCLS)) and 2-amino-pyridine-3 carboxamide) and cancer	USPAT	2003/11/06 14:38
7	0	((("514/183,188,277,352,354,356").CCLS) and (("546/304,315,345").CCLS)) and ((((("514/183,188,277,352,354,356").CCLS) and (("546/304,315,345").CCLS)) and 2-amino-pyridine-3 carboxamide) and KDR	USPAT	2003/11/06 14:39